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THE DEVELOPMENT AND APPLICATION OF PROTEOMICS TO THE ANALYSIS OF 
CHLAMYDIA TRACHOMATIS 
 
Paul James Stuart Skipp 
 
The  bacterial  pathogen  Chlamydia  trachomatis  causes  Trachoma,  the  worlds  leading  cause  of  preventable 
blindness and is also responsible for the most common curable sexually transmitted disease in the UK and 
United States. C. trachomatis is an obligate intracellular organism characterised by a unique and complex growth 
cycle. Its study presents many challenges since it has historically been recalcitrant to genetic manipulation and 
growth in the absence of a host cell. Nevertheless, the sequencing of the C. trachomatis genome and its relatively 
small size by comparison to genomes from other bacterial pathogens, has paved the way for studies at the 
proteomic level. 
 
This thesis describes the development and application of proteomic approaches to study C. trachomatis L2. To 
survey the expressed chlamydial proteome, a combination of the qualitative approaches, 2-DGE, MudPIT and 
GeLC-MS/MS;  and  the  quantitative  approaches  AQUA,  iTRAQ  and  LC-MS
E  were  used.  Collectively,  the 
approaches efficiently identified 648 expressed proteins, representing ~72% of the predicted proteome of C. 
trachomatis L2, from both the infectious (elementary body, EB) and replicating (reticulate body, RB) form of the 
pathogen. In the infectious EB, the entire set of predicted glycolytic enzymes were detected, indicating that 
metabolite flux rather than de novo synthesis of this pathway is triggered upon infection of host cells. Further, 
proteomic analysis of the RB form also uncovered biosynthetic enzymes for chlamydial cell wall synthesis, 
indicating that peptidoglycan is produced in some form during growth in host cells. 
 
Comparison of the quantitative approaches iTRAQ and LC-MS
E demonstrated that LC-MS
E quantitative data 
was significantly more robust and extensive relative to iTRAQ data. In addition to information on relative 
amounts  of  these  proteins  between  the  two  forms,  LC-MS
E  data  also  yielded  the  cellular  concentration 
(molecules per cell) for 489 proteins. 
 
This extensive set of absolute quantitation data permits estimates of the energy invested in the synthesis of 
various classes of proteins. The results indicate that C. trachomatis devotes most of its energy into maintenance 
of the translational machinery. However, it also expends significant amounts of energy into making cell envelope 
components and a set of hitherto hypothetical proteins. These proteins, which account for the bulk of the energy 
invested by the intracellular RB form of the pathogen as it converts to the extracellular EB form, highlight the 
importance of absolute quantitation data for understanding the biological processing status of the cell. 
 
The datasets also revealed a large number of proteins that were differentially expressed between replicating RBs 
and  infectious  EBs,  ranging  from  8.4-fold  down-regulation  to  3.5-fold  up-regulation.  Consistent  with 
transcriptomic studies (Belland et al., 2003), proteins involved in protein synthesis, ATP generation, central 
metabolism, secretion and nutrient uptake were predominant in the metabolically active RB at 15 h PI. Although 
many of the proteins in these functional categories were down-regulated in EBs, proteins required for glycolysis, 
central  metabolism,  protein  synthesis,  and  type  III  secretion  were  present  in  significant  amounts  in  EBs 
suggesting that the infectious EB is primed ‘ready-to-go’ upon contact with the host cell. 
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1.  GENERAL INTRODUCTION 
 
1.0 Introduction 
 
1.1 Infection and Immunity – the global prospective 
From the common cold to tuberculosis, malaria and AIDS, infectious diseases are found all over the 
world and in many cases present a life-threatening risk. Infectious disease remains the world's No. 1 cause of 
death, with around 17 million people dying every year – almost one third of all deaths worldwide. A major 
contributing factor to these deaths is the lack of appropriate vaccines and treatments against these diseases. 
However, the idea that these deaths are only a consequence of poor socioeconomic conditions and as such are 
restricted to third world countries would be incorrect. For example, over the past decade the increasing 
resistance of pathogens to antibiotics has become a major cause for concern. The Centre for Disease Control 
(Klevens et al., 2002) estimates that each year, nearly 2 million people in the United States acquire an 
infection while in a hospital, resulting in 99,000 deaths. As life expectancy increases and we spend longer in 
our old age with a weakened immune system, there is a high probability we will fall ill to an infectious 
disease. As well as direct mortality and morbidity, research indicates that there are many indirect connections 
between infections and diseases such as asthma, rheumatic arthritis, allergies, and certain forms of diabetes. 
Bacteria, viruses and parasites are also linked with triggering cancer and diseases of the heart. It is therefore 
quite clear that finding effective treatments and prevention regimes against infectious diseases provides an 
enormous and important challenge for science. 
 
The chronic ocular disease trachoma, caused by the bacterial pathogen Chlamydia trachomatis is one 
of the oldest and commonest infectious diseases known to mankind, dating back several thousand years and 
being first documented as early as the pharaonic era in Egypt (Ebers & Stern, 1875). Trachoma is the leading 
cause of preventable blindness and represents a major public health problem. The causative agent is the 
bacterial  pathogen  Chlamydia  trachomatis.  The  World  Health  Organisation  (WHO)  estimates  that  146 
million people have trachoma due to ocular infection by C. trachomatis serovars A to C and that 4.9 million 
of these are totally blind (Whitcher et al., 2001). In some parts of the developing world, over 90% of the 
population are infected and is attributed to poor socioeconomic environment where limited access to water 
and sanitation leads to poor personal and environmental hygiene. Where improvements in the socioeconomic 
status of a population in an endemic country have been made, trachoma can and has been eliminated.  
 
Although trachoma has been eliminated from the western world, Chlamydial infection also represents 
the most common form of curable sexually transmitted disease (STD) in the UK and the United States. Since 
1995, there has been a sustained increase in STDs with over 448 million new infections each year (WHO, 
2005).  Indeed,  genital  chlamydial  infections  in  the  UK  have  almost  reached  epidemic  proportions  with 
~215,000  cases  reported  in  2010  (Health  Protection  Agency,  2010).  This  represents  the  most  reported Chapter 1    General introduction 
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sexually transmitted disease, overtaking genital warts, and is the first time that a bacterial infection has held 
such a title.  
 
This  thesis  describes  the  development  and  application  of  a  potentially  powerful  technology  – 
proteomics – to the study of C. trachomatis.  Before describing the technology and how it has been used in 
this area to date, it is pertinent to review certain aspects of the biology of Chlamydia, in order to give a more 
rounded  perspective  on  the  studies.  Thus,  the  following  sections  describe  the  classification  of  these 
organisms, a synopsis of what is known about their physiology and developmental cycles, and an overview of 
their pathogenic properties, before going on to discuss areas of more immediate relevance such as chlamydial 
genomics and proteomics.  
 
1.2 The genus Chlamydia 
 
The virus-like obligate intracellular life cycle of chlamydiae and factors such as their inability to grow 
on conventional media has caused much confusion in the terminology that surrounds them and their grouping 
taxonomically. The genus Chlamydia is defined by many distinct characteristics and these are shown in 
Table 1.1. 
 
Table 1.1. Defining characteristics of the genus Chlamydia (Moulder, 1984; Everett et al.,1999). 
 
! Obligate intracellular habitat 
! Unique developmental cycle 
! Gram negative envelope without peptidoglycan 
! Genus specific lipopolysaccharide 
! Patches of hexagonally arrayed cylindrical 
projections 
! Utilisation of host ATP for protein synthesis 
! Small genome 
! Glycogen producing 
 
 
  1.2.1 Classification 
Chlamydia has been known by a number of names including Ehrlichia, Chlamdoza, Rickettsiaformis, 
Bedsonia  and  Colesiota  and  by  terms  such  as  PLV  (psittacosis-lymphogranuloma  venereum)  and  TRIC 
(Trachoma-inclusion-conjunctivitis). In 1966, Moulder (1966) reported the bacterial nature of chlamydiae. 
Shortly  after,  Page  (1966)  established  the  genus  Chlamydia  and  later  created  two  species  in  the  genus 
Chlamydia: C. trachomatis & C. psittaci (Page, 1968), representing the group A (inclusions of chlamydiae 
containing  glycogen)  and  group  B  (non-glycogen  containing  inclusions  of  chlamydiae)  groupings 
respectively,  of  Gordon  &  Quan  (1965).  Based  on  observational  differences  of  their  life  cycles  and Chapter 1    General introduction 
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metabolism,  Storz  and  Page  (1971)  created  the  separate  order  Chlamydiales,  moving  from  the  order 
Rickettsiales. The development of DNA-based classification methods during the 1980s provided tools for 
distinguishing species (>70% homology) and genera (>20% homology). Using these data led to the creation 
of two additional species: Chlamydia pneumoniae in 1989 (Grayston,1989) and Chlamydia percorum in 1992 
(Fukushi & Hirai, 1992), creating a total of four species, C. trachomatis, C. psittaci, C. pneumoniae and C. 
percorum. 
 
In 1999, a new taxonomy was proposed (Everett et al., 1999) introducing more genera and species 
based  on  phylogenetic  relationships.  This  requires  members  of  the  order  Chlamydiales  to  be  obligate 
intracellular  bacteria  with  a  chlamydia-like  developmental  cycle  of  replication  and  have  >80%  rDNA 
sequence identity with Chlamydiales 16S rRNA genes and/or 23S rRNA genes. Included in this order are the 
families  Chlamydiaceae,  Skimkaniacea  and  Parachlamydiacea.  To  be  identified  as  a  member  of  the 
Chlamydiaceae family, new chlamydia-like isolates require >90% identity with the 16S rRNA gene of the 
strain B577 from Chlamydiaceae. This increased the number of species in the family Chlamydiaceae to nine 
and grouped these species into two genera, Chlamydia and Chlamydophila.  Two new species, Chlamydia 
muridarum  and  Chlamydia  suis  joined  Chlamydia  trachomatis  and  Chlamydophila  acquired  the  current 
species  Chlamydia  psittaci,  Chlamydia  pneumoniae  and  Chlamydia  percorum  to  form  Chlamydophila 
psittaci,  Chlamydophila  pneumoniae  and  Chlamydophila  percorum,  respectively.  For  both  genera,  new 
species are required to be ≥ 97% identical. Three new Chlamydophila species are derived from C. psittaci: 
Chlamydophila abortus, Chlamydophila caviae and Chlamydophila felis. 
 
Uptake of the new taxonomy has not been generally accepted by the scientific community and it has 
been suggested that it causes confusion. A diagram of the relationship between the old and the new system is 
represented in Figure 1.1. Discussions within this thesis will refer to the emended taxonomy.  
 
Prior  to  the  emended  nomenclature,  C.  trachomatis  was  divided  into  three  biovars  (biological 
variants),  closely  related  trachoma,  Lympho-Granuloma  Venereum  (LGV)  and  the  antigenically  distinct 
murine biovar. Under the emended nomenclature, only strains from human biovars of trachoma and LGV are 
retained in Chlamydia trachomatis. These have been further subdivided into 19 serovars (Batteiger, 1996). 
Serovars A-K, Ba, Da, Ia, Ja are known as the trachoma biovar and are largely confined to infections of 
mucosal epithelial surfaces. Serovars A to C cause the hyperendemic ocular disease trachoma and Serovars D 
to K are associated with sexually transmitted genitor-urinary tract infections, conjunctivitis and neonatal 
pneumonia. The LGV biovar comprises of serovars L1, L2, L2a, L2b and L3, which are more invasive than 
disease  caused  by  the  urogenital  serovars  (D-K).  LGV  serovars  infect  predominantly  monocytes  and 
macrophages and pass through the epithelial surface to regional lymph nodes, often resulting in systemic 
infection. 
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Figure 1.1. Comparison of the old and new classification nomenclature for the order Chlamydiales 
 
The  current  classification  of  C.  trachomatis  is  based  on  serological  differentiation  of  antigenic 
epitopes on the Major Outer Membrane Protein (MOMP), encoded by the gene ompA (Wang and Grayston, 
1991a; Wang and Grayston, 1991b; Wang et al., 1985). According to the amino acid sequence homology of 
these epitopes, these serovars have been placed in the following serogroups or class: B class (B, Ba, D, Da, 
E, L1, L2 and L2a), C class (A, C, H, I, Ia, J, Ja, K, and L3) and intermediate class (F and G) (Yuan et 
al.,1989).  
 
The perceived limited diversity of chlamydiae as closely related obligate intracellular bacteria causing 
a wide range of disease in human and animal hosts has changed in recent years with the isolation of several 
‘chlamydia-like’  organisms.  These  include  endosymbionts  of  free-living  amoebae  (Michel  et  al.,  1994; 
Fritsche,  1993),  which  have  been  grouped  in  the  family  Parachlamydiaceae;  a  bacterium  growing  in 
‘cytoplasmic  phagosomes’  contaminating  a  cell  culture  (Kahane,  1993),  which  has  been  grouped  in  the 
family Skimikaniacea; and an isolate from an aborted bovine foetus (Dilbeck et al.,1990; Kocan et al., 1990) 
which was placed in a newly proposed family Waddliaceae,  within the order Chlamydiales (Rurangirwa et 
al.,  1999).  The  families’  Parachlamydiaceae,  Simkaniaceae  and  Waddliaceae  are  sister  taxons  to 
Chlamydiaceae because they have a Chlamydia-like cycle of replication and their ribosomal genes are 80-
90% identical to ribosomal genes in the Chlamydiaceae. The type genera are Parachlamydia and Simkania, 
respectively, and new members of these genera should have 16S rRNA or 23S rRNA genes that are 95% 
identical to the type species Parachlamydia, Acanthamoebae and Skimkania negevenisis, respectively. 
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1.3 Physiology and the developmental cycle 
 
Chlamydiales  differ from the other main order of intracellular bacteria, the Rickettsiales,  in  their 
characteristic unique biphasic growth cycle, which has been extensively described (Ward, 1988; Moulder, 
1991;  reviewed  by  AbdelRahman  and  Belland,  2005).  A  representation  of  the  developmental  cycle  of 
Chlamydia is shown in Figure 1.2. The cycle starts with the attachment of a small infectious, extracellular 
form,  the  elementary  body  (EB)  to  the  host  cell  membrane.  Through  an  invagination  of  the  host  cell 
membrane, the EB is ingested by the cell and becomes enclosed within an inclusion. These small EBs 
subsequently undergo differentiation into the larger obligate intracellular replicating form, the reticulate body 
(RB). These are considered to be metabolically active, but non-infectious; in contrast, infectious EBs are 
considered metabolically inactive. Cell division then occurs prior to the second differentiation stage, where 
RBs are transformed to EBs, which are subsequently released from the cell, and so the infectious cycle 
continues. 
 
 
Figure 1.2. Graphical representation of the developmental cycle of C. trachomatis 
 
1.3.1 Attachment   
The first and most critical stage in the chlamydial development cycle is attachment of EBs to the host 
cell surface. The intracellular nature of chlamydial development and its specificity for its restricted host and 
cell types argues for the existence of a specific adhesion mechanism, although currently the receptors are not 
clearly defined.  Isoelectric focusing of whole cells has shown that EBs of both the LGV and trachoma 
serovars of C. trachomatis carry a negative surface charge at physiological pH (Kraaipoel and Duin, 1979); 
similarly, the host cell also carries a net negative surface charge. Penetration of this electrostatic barrier is Chapter 1    General introduction 
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therefore necessary to facilitate attachment of EBs to the host cell. Evidence supporting this requirement is 
provided by positively charged macromolecules such as DEAE-dextran or poly-L-lysine, which enhance 
attachment and inclusion formation of the trachoma, but interestingly, are not required for LGV strains (Kuo 
et al., 1976; Kuo et al., 1973). Additionally, for in vitro studies, it is necessary to centrifuge isolates from the 
trachoma biovar onto the surface of host cells such as Buffalo Green Monkey Kidney (BGMK) cells to 
achieve adequate infectivity, whereas, this is not required to achieve good infectivity of the LGV biovar. 
Although  it  is  unclear  why  LGV  strains  are  more  efficient  at  attaching  to  the  host  cell,  one  possible 
explanation is that while there are no marked differences in net surface charge between the two biovars, there 
may be differences in charge at the local or molecular levels.  
 
There are most likely multiple adhesins on the EB surface for interaction with the host cell (Campbell 
et al., 2006). The Major Outer Membrane Protein (MOMP) has been proposed as a potential adhesin (Su et 
al., 1990) and two proteins of 18 and 32 kDa in C. trachomatis have been shown to bind to host cells, 
depending upon serotype (Wenman and Meuser, 1986). Heparin, which inhibits the attachment of Chlamydia 
to host cells, has also been shown to affect these proteins. MOMP and these two smaller proteins have been 
identified as glycoproteins (Swanson and Kuo, 1990) with N-linked glycans (Swanson and Kuo, 1991a; 
Swanson and Kuo, 1991b). These structures, which rarely occur in bacteria, have been demonstrated to play 
an essential role in attachment and entry (infectivity) to the host cell (Kuo et al.,1996). OmcB from C. 
pneumoniae,  a  major  component  of  the  outer  membrane  complex,  has  also  been  shown  using  a  yeast 
adhesion display system to adhere to HEp-2 epithelial cells. Further, blocking of the protein OmcB on the 
surface  of  C.  pneumoniae  EBs  using  anti-OmcB  antibodies,  reduced  infection  of  HEp-2  cells  by  60% 
(Moelleken  and  Hegemann,  2008).  Similarly,  the  polymorphic  membrane  protein  PmpD,  has  also  been 
proposed to function as an adhesin (Wehrl et al., 2004).  
 
1.3.2 Entry 
Following attachment, uptake occurs such that the EBs are ingested by the host cell. Ingestion can 
occur via two routes: (i) the microfilament independent uptake of chalmydiae into clathrin-coated vesicles, or 
(ii) by the microfilament and energy-dependent process of phagocytosis or via both mechanisms (reviewed 
by Ward, 1988). This is dependent upon important factors such as strain, host cell and method of inoculation. 
Escalante-Ochoa, (2000) showed that, although Chlamydophila psittaci can use the microfilament-dependent 
and -independent entry pathways in both cell types, internalization and development of Chlamydophila in 
fibroblast cells mainly concerned processes mediated by microfilaments. In contrast, in epithelial cells, the 
internalisation mechanisms predominantly involved microtubule motor proteins. 
 
   A number of studies have demonstrated that the cytoskeleton of the host cell can be remodelled by 
microbial pathogens to facilitate their efficient uptake by eukaryotic cells. For example, enteropathogenic 
Escherichia coli (E. coli) recruit actin to form pedestal-like structures for attachment (Francis et al., 1991) 
and Salmonella induces membrane ruffles for internalisation (Finlay et al., 1991; Francis et al., 1993).  A 
similar entry mechanism was demonstrated by Carabeo et al. (2002) in C. trachomatis. Attachment of EBs to 
the host cell elicited a localised concentration of actin, resulting in distinct microvillar reorganisation through Chapter 1    General introduction 
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the cell surface, and the formation of pedestal-like structures at the site of attachment. Interestingly, a mutant 
cell  line  unable  to  support  internalisation  by  C.  trachomatis  serovar  L2  did  not  induce  microvillar 
hypertrophy. In contrast, serovar D was able to be internalised, producing the pedestal-like structures. It is 
uncertain whether this cell line is defective in a specific receptor as it has not yet been fully characterised 
(Carabeo and Hackstadt, 2001). However, other studies have demonstrated that serovars L2 and D do not 
compete  for  attachment,  indicating  that  different  receptors  may  be  involved  (Davis  and  Wyrick,  1997). 
Although there maybe distinct receptors for different serovars, similar signals appear to be relayed to the host 
as both serovars D and L2 elicit microvillar hypertrophy in normal cell lines. These results are consistent 
with those involving receptor-mediated phagocytosis of C. trachomatis EBs by epithelial cells. A key protein 
involved in this cytoskeletal remodelling is the protein TARP (translocated actin recruiting phosphoprotein), 
a predicted type III effector protein that is present in all chlamydial species. Once translocated into the host 
cell, TARP induces rapid formation and polymerisation of actin filaments promoting EB entry (Clifton et al., 
2004; Jewett et al., 2006). However, a consensus exists that Chalmydia is likely to use multiple mechanisms 
for entry (Moulder, 1991). 
 
For survival within the host cell, chlamydiae at a very early stage (1-3hrs) must avoid the host cell’s 
defence mechanisms. This is accomplished in part by separating themselves from the endocytic vesicular 
trafficking  pathway.  The  bacteria  ensure  that  no  endocytic  markers  are  accumulated  on  or  within  the 
chlamydial  inclusion  membrane  (CIM)  and  hence  they  inhibit  fusion  with  host  cell  lysosomes.  While 
avoiding fusion with lysosomes, the chlamydial inclusion expands by fusion with sphingomyelin-containing 
lipids derived from the Golgi apparatus (Hackstadt et al., 1995; Hackstadt et al., 1997; Scidmore et al., 
1996).  Additionally,  other  glycerophospholipids  and  lipids  from  the  Golgi,  mitochondria,  endoplasmic 
reticulum and lipid droplets are modified and incorporated into the inclusion membrane (Wylie et al., 1997; 
Cocchiaro et al., 2008). By intercepting this lipid traffic, chlamydiae are able to mimick the phospholipid 
composition of the host cell. This confirms observations that the phospholipid composition of chlamydiae, 
are closer to those found in eukaryotic cells than in prokaryotes (Wylie et al., 1997). 
 
There  are  several  encoded  proteins  that  are  associated  with  the  CIM  (Bannantine  et  al.,  1998a; 
Bannantine et al., 1998b; Rockey et al., 1995; Belland et al., 2003). These and the discovery of a contact-
dependent type III secretion (TTSS) pathway, similar to those found in other bacterial systems (Hsia et al., 
1997;  Stephens  et  al.,1998;  reviewed  by  Beeckman  and  Vanrompay,  2010),  represent  an  important 
development in the understanding of the host-pathogen relationship. The probable function of the type III 
secretion system is to modify host processes that may be necessary for host invasion, remodelling of the 
inclusion membrane, or affecting regulatory or host pathways. Already in the late 70s and early 80s, Gregory 
et al. (1979) and Matsumoto et al. (1976) observed the outer cell wall of the EB as having a hexagonal array 
of cylindrical projections of approximately 5 nm in size with ‘rosettes’ or fine holes. It was shown that one 
end of each projection was anchored into the cytoplasmic membrane while the other end of the projection 
protruded  beyond  the  cell  wall  into  the  cytoplasm.  These  were  later  suggested  to  represent  visual 
confirmation of a TTSS (Fields et al., 2003). 
 Chapter 1    General introduction 
   
10 
Rockey  and  co-workers  have  isolated  and  characterised  several  of  the  CIM  associated  proteins 
(Bannantine et al., 1998a; Bannantine et al., 1998b; Rockey et al., 1995; Scidmore-carlson et al., 1999). 
These proteins, Inc proteins, have been shown to be candidates for secretion by the TTSS (Subtil et al., 2001) 
and it is implied that they are secreted within the inclusion or through the CIM mediating communications 
with  the  cytosol.  One  particular  protein,  IncA,  located  on  the  cytoplasmic  side  of  the  CIM,  undergoes 
phosphorylation  by  host  cell  kinases  (Rockey  et  al.,  1997)  and  has  been  proposed  to  be  involved  in 
subverting the signal transduction pathways in the host cell, to the advantage of the pathogen (Bavoil et al., 
2000). However, a recent study demonstrates another role for IncA. IncA-laden fibres of C. trachomatis are 
used to create secondary inclusions (Figure 1.3), which are subsequently used to transport chlamydiae to 
these secondary inclusions and so actively expand the environment for development (Suchland et al., 2005). 
The Inc proteins are characterized by a hydrophobic bilobed motif containing 50-80 amino acid residues 
(reviewed  by  Kostryukova  et  al.,  2008).  Interestingly,  although  only  about  10  have  been  shown  to  be 
localised to the inclusion membrane, Bannantine et al. (2000) identified through screening all predicted 
protein sequences within genomes of C. trachomatis and C. Pneumoniae, over 40 such sequences. As such, 
these chlamydial specific proteins are likely to play a vital role in the CIM development.  
 
Expansion of this inclusion displaces the host cell nucleus and within two hours EBs are localised to 
the peri-nuclear region of the host cell. Dynein, part of the microtubule-organising centre has been implicated 
in the localisation of EBs to the peri-nuclear region because it co-localises with chlamydial early inclusions. 
Clausen et al. (1997) demonstrated that sodium vanadate, an inhibitor of dynein and tyrosine kinases, is 
detrimental to chlamydial development. 
 
 
 
Figure 1.3. Chlamydial developmental forms within fibers linking primary and secondary inclusions. 
C. trachomatis G/UW-57-infected HeLa cells (MOI, 0.1) were fixed 28 h PI and labeled with anti-IncA 
(green) and anti-MOMP (red). Confocal microscopy was then used to identify and document the presence of 
chlamydial developmental forms within IncA-laden fibers. (A and B) Two infected cells are shown, one Chapter 1    General introduction 
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containing an inclusion lacking a fiber and one containing primary and secondary inclusions connected by a 
fiber. (A) The MOMP labeling identifies RBs that are found within the primary inclusion and within a fiber 
pointing to the right. (B) IncA and MOMP labeling within the same cells, demonstrating that the RBs outside 
the primary inclusion are present within an IncA-laden fiber. (C to E) A serial confocal Z-section showing an 
inclusion and associated fibers. (D) The secondary inclusion (arrow) is connected to the primary inclusion 
with at least two IncA-laden fibers (asterisk), and an RB (arrowhead) is found within one fiber. Scale bar, 10 
µm.  Reproduced  with  permission  of  the  American  Society  for  Microbiology  (License  number 
2841450471563).  
 
1.3.3 Differentiation, replication and lysis 
Shortly after ingestion, the main differentiation process is initiated. The processes that trigger this 
intracellular interconversion of EBs to RBs are unknown. One proposal is that although protein synthesis in 
extracellular EBs is undetectable, initial translation of early phase proteins may be directed from stable 
transcripts present in infectious EB forms. Further, control of protein synthesis is through the existence of a 
series of promoters that are functional at specific times during the developmental life cycle (Plaunt and 
Hatch, 1988). At approximately 9 hrs the process of differentiation from EBs to RBs reaches its maximum. 
EBs lose their rigidity through the reduction of disulphide-linked MOMP to its monomeric form (Hatch et 
al., 1986), and are transformed to the RB phenotype, increasing in size from 0.3 µm to 1.0 µm and becoming 
flexible and fragile in nature (Hackstadt et al., 1985). Infection, ingestion and initiation of EB reorganisation 
occurs in minutes and reorganisation of EB to RB is completed within 8-24hrs. 
 
Division of the RB occurs by binary fission at approximately 2-3 hours per generation and is complete 
in C. trachomatis by 24 hrs post infection, at which time, some RBs have commenced conversion to EBs 
while others continue dividing. The factors that initiate conversion of RBs to EBs are unclear and conflicting. 
Evidence suggests that growth of chlamydiae within the inclusion depends on their interaction with the CIM 
and  consequently  on  TTSS  activity  in  the  area  of  contact.  Contact-dependent  replication  of  RB  may 
ultimately  lead  to  overcrowding  and  detachment  resulting  in  TTSS  inactivation.  This  may  be  part  of  a 
signalling cascade leading to the initiation of late differentiation (Hackstadt et al., 1997; Bavoil and Hsia, 
1998; Bavoil et al., 2000). Although this may conflict with the previously proposed temporally regulated 
developmental cycle hypothesis (Plaunt and Hatch, 1988), it is consistent with the lack of synchronicity 
observed in chlamydial biology, i.e. whilst the development within the inclusion is relatively synchronous 
early on, it becomes asynchronous at later times.  
 
At  around  18-22  hrs  post  infection,  RBs  reorganise  into  EBs.  Through  several  divisions  of 
intermediate forms they undergo a reduction in size, genomic DNA condenses with the aid of histone-like 
proteins and sulphydryls of the bacterial cysteine-rich outer membrane proteins are crosslinked forming a 
rigid cell wall (Hatch et al., 1986). Eventually, infectious EBs and amorphous non-infectious intermediate 
forms  are  released  either  by  lysis  (C.  Psittaci)  or  the  inclusion  is  extruded  by  reverse  endocytosis  (C. 
trachomatis and C. pneumoniae). The resulting inclusions may contain 100 - 500 progeny that are free to 
infect more cells.  Chapter 1    General introduction 
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1.4 Human diseases induced by Chlamydia 
 
1.4.1 Chlamydia trachomatis infections 
1.4.1.2 Ocular infections – Trachoma 
Trachoma, derived from the ancient Greek word meaning ‘rough eye’, is one of the oldest known human 
diseases and is the leading infectious cause of ocular morbidity. The disease is a chronic keratoconjunctivitis 
caused by the ocular serovars A, B, Ba and C of Chlamydia trachomatis.  
 
Once  a  worldwide  disease,  trachoma  is  now  confined  to  developing  countries.  The  World  Health 
Organisation (WHO) estimates that despite long-established control efforts, more than 500 million people are 
at high risk of infection (Polack et al., 2005). Recent estimates are that over 40 million people are infected, 
and about 1.3 million are blind in Africa, the Middle East, Central and Southeast Asia, and Latin America 
(Burton and Mabey, 2009). Generally, trachoma is associated with poor personal and environmental hygiene 
with transmission mainly by contact, although eye-seeking flies and gnats are also considered a major factor 
in the spread of the disease. It occurs most frequently in children with those in endemic areas typically being 
infected before 2 years of age (Dawson et al., 1976).  
 
The disease begins with a mucopurulent conjunctivitis, developing into a follicular keratoconjunctivitis. 
Repeated episodes of infection cause superficial vascularization of the cornea (pannus) and conjunctival 
scarring which increase with the severity and duration of the disease. Severe scarring of the conjunctiva 
distorts the eyelid, a condition called entropion. This causes the eyelashes to turn into the eye (trichiasis) 
causing abrasion of the orb of the eye resulting in ulceration, secondary infection with other bacteria and 
ultimately scarring causing opacity and blindness (Jones, 1975). 
 
1.4.1.2.3 Ocular infections – Paratrachoma 
Clinically indistinguishable from trachoma, the genital strains of C. trachomatis  serovars D to K 
ocassionally cause a chronic follicular conjunctivitis. This type of infection, termed paratrachoma or adult 
inclusion conjunctivitis follows a similar course of disease to trachoma, including follicular conjunctivitis 
with pannus and often conjunctival scarring. However, they are not associated with chronic disease, are not 
sight-threatening  and  are  rarely  associated  with  stable  transmission  cycles  within  a  given  community. 
Occurring generally in sexually active young adults (50% of men with paratrachoma also have a genital 
infection) (Darougar et al., 1972), it is usually transferred by the hands from the infected site to the eyes. It 
has an incubation period of 1 to 2 weeks, is usually self-limiting and is mono-ocular. 
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1.4.1.3 Genital tract infections 
Chlamydia trachomatis causes more cases of sexually transmitted diseases (STDs) than any other 
bacterial pathogen, and make gential infections caused by Chlamydia a major public health problem. In the 
UK it is the most common Sexually Transmitted Infection (STI), with 215,501 diagnoses in Genito-Urinary 
Medicine clinics in 2010 (Health Protection Agency, 2010), and in the United States it is the most commonly 
reported notifiable disease (Centre for Disease Control and prevention, 2010). Highest rates are seen in 
young  people,  especially  men  and  women  under  24  years.  Of  the C. trachomatis  genital  tract  infecting 
serovars D to K, serovars D to G are the most common (Oriel and Ridgway, 1982; Bax et al., 2011). 
 
1.4.1.4.1 Genital tract infections in men 
Non-gonococcal urethritis (NGU) is caused by C. trachomatis in 30 – 50% of cases (Horner et al., 
2005).  These  can  be  asymptomatic,  but  in  symptomatic  patients  it  manifests  itself  as  a  mucopurulent 
discharge with dysuria. Post-gonococcal urethritis (PGU) is defined as persistent NGU following treatment of 
a gonoccocal urethritis infection. This is attributed to a mixed infection of N. gonorrhoeae and an organism 
responsible for NGU such as C .trachomatis (Oriel and Ridgway, 1982). There is also supporting evidence 
for the reactivation of latent genital chlamydial infection by concurrent gonorrhoea infections (Batteiger et 
al., 1989). 
 
C. trachomatis is responsible for 30 - 60% of cases of epididymitis in men less than 30 - 35 years of 
age, while N. gonorrhoeae is the second most common organism in such cases (Oriel, 1992). Inflammation 
of the reproductive tubes that carry sperm from the testis (epididymitis) presents as pain in the affected 
testicle; when severe, the condition may be accompanied by abdominal pain, fever and malaise. In chronic 
epididymitis,  blockage  of  the  epididymis  may  occur,  causing  infertility  due  to  reduced  sperm  numbers. 
Occasionally, a scrotal mass is observed, mimicking a testicular malignancy (Ward et al., 1999). Although 
proctitis is generally attributed to infection with LGV, other chlamydial serovars have been isolated from 
anoreceptive intercourse-practising homosexual men (Munday and Taylor-Robinson, 1983). 
 
1.4.1.4.2 Genital tract infections of women 
Cervicitis 
The two most regularly identified pathogens that may cause inflammation of the cervix (cervicitis) are 
gonococci  and  C.  trachomatis.  Presentation  of  cervicitis  includes:  pain  passing  urine,  soreness,  cervical 
discharge, swelling and erythema. Occasionally, lymphoid follicles similar to those found in trachoma are 
observed. Approximately 80 percent of infections are asymptomatic; however, if left untreated, infection can 
spread causing pelvic inflammatory disease (PID).  
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It has also been recognised that chlamydial and other infections may play a role in the aetiology of 
cervical and other cancers (Quirk and Kupinski, 2001). In particular, large serological studies have suggested 
evidence linking C. trachomatis infection with an associated risk of developing cervical cancer (Wallin et al., 
2002; Lehtinen et al., 2011). 
 
Endometritis and Salpingitis 
Forty percent of women with untreated chlamydia go on to develop Pelvic Inflammatory Disease 
(PID), a general term referring to infection of the upper genital tract. Sequelae include, infection of the 
fallopian  tube  (salpingitis),  uterine  lining  (endometritis),  ovaries  and  surrounding  tissues.  Clinical 
manifestations range from asymptomatic endometritis to severe symptomatic salpingitis with mucopurulent 
discharge  (Paavonen,  1998).  Acute  and  chronic  salpingitis  leads  to  fibrosis  and  scarring  creating  major 
complications. These include chronic pelvic pain, damage to the fallopian tubes, affecting egg transport 
leading to ectopic pregnancy or causing blockage preventing transport and fertilization of the egg, leading to 
infertility (Brunham et al., 1986; Kosseim and Brunham, 1986; Barrett and Taylor, 2005). 
 
1.4.1.5 Lymphogranuloma venereum (LGV) 
The  lympho-granuloma  venereum  (LGV)  biovar  comprises  serovars  L1  to  L3.  Although  more 
uncommon, they are more invasive than those caused by the urogenital serovars (D-K) and transmission is 
almost exclusively by sexual contact. LGV is endemic in the West Indies, Africa, India, Southeast Asia, and 
the Caribbean. Although uncommon in Europe and North America, a new LGV variant designated L2b was 
thought to be responsible for outbreaks in the Netherlands, neighbouring European countries, the United 
Kingdom  and  the  United  States,  causing  proctitis  rather  than  genital  ulceration  and  the  typical  inguinal 
buboes (Nieuwenhuis et al., 2003; Spaargaren et al., 2005a; Spaargaren et al., 2005b). Observed variations in 
the gene used to genotype Chlamydia strains, ompA, supported speculation of a new variant representing a 
newly emerging infection. Recently, the genomes of both the L2 and the ‘epidemic’ LGV isolate (L2b) have 
been sequenced. Comparison of these genomes found no additional genes in the L2b strain, however, there 
was some evidence of gene loss and regions of heightened variation, which have previously been important 
sites for inter-strain variation. It has therefore been suggested that this is unlikely to be a newly emerged 
strain, but is an old strain with relatively new clinical manifestations (Thomson et al., 2008). More recently, 
deep genome sequencing of a clinical isolate revealed a recombinant of the L2 and D strain. Regions of 
genetic exchange in this strain (L2c) included the toxin gene, which interestingly, after ~20 passages in 
laboratory culture was lost. Deletions and insertions were also observed for the genes ftsK, tarp, hctB, whose 
functions are associated with replication, chlamydial host cell entry and DNA compaction in the later stages 
of the chlamydial developmental cycle. These findings are likely to have important implications for the 
evolution  and  emergence  of  new  chlamydial  strains,  highlighting  the  importance  of  applying  new  high-
throughput sequencing technologies to understand the phenotypes of such clinical recombinants and their 
influence on pathogenicity (Somboonna et al., 2011). 
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LGV  has  a  specific  tropism  for  lymphoid  cells  and  spreads  through  the  inguinal  lymph  nodes 
becoming systemic. There are three stages of infection. The first stage normally begins after an incubation 
period of 1 - 3 weeks with a small painless lesion that appears at the site of infection, normally the penis or 
the vagina. This may be accompanied by headache and fever. After 2 to 6 months, progression to the second 
stage is indicated by lymphadenopathy. The lymph nodes become enlarged ‘buboes’ that eventually rupture 
and drain causing variable courses of disease. If left untreated, the third stage of infection can lead to fistulas, 
stictures, genital elephantiasis, frozen pelvis, and infertility (Mabey and Peeling, 2002).  
 
1.4.1.6 Neonatal infections 
Chlamydial  exposure  through  the  birth  canal  leads  to  60%  of  infants  born  acquiring  infection 
(reviewed by Schachter and Grossman, 1981). About one third of those infants exposed develop neonatal 
conjunctivitis, while approximately one in six develops pneumonia. 
 
Neonatal conjunctivitis caused by C.  trachomatis  has an incubation period of around 10-14 days 
causing inflammation and mucopurulent discharge. The condition is not considered to be sight-threatening 
and  is  self-limiting,  resolving  itself  within  a  few  months  without  treatment.  Scarring  of  the  cornea  is 
uncommon, although in more severe cases some keratitis and micropannus can develop. Infection sites can 
also  include  the  nasopharyx,  middle  ear,  trachea,  lungs,  rectum  and  vagina  with  no  obvious  disease 
pathology. In untreated cases, 10 – 20% of neonates will go on to develop C. trachomatis pneumonia (Beem 
and Saxon, 1977). Most infants do not require hospital treatment, but in severe cases hospitalization may be 
required. 
 
1.4.2 Chlamydophila infections in humans 
1.4.2.1 Chlamydophila pneumoniae 
Chlamydophila pneumoniae, originally called the TWAR strain from the name of the original two 
isolates. (Taiwan (TW-183), isolated from an ocular site and an acute respiratory isolate designated AR-39) 
is now considered a separate species of Chlamydia (Grayston et al., 1989) and are described within the genus 
Chlamydophila under the revised nomenclature (Everett et al., 1999). 
 
Infecting  the  mucosal  surfaces  of  the  respiratory  tract,  C.  pneumoniae  displays  a  wide  range  of 
disease. It is one of the most common human pathogens and causes acute infections such as pneumonia, 
bronchitis, sinusitis and pharyngitis. It is estimated that C. pneumoniae is the cause of 10% of community-
acquired pneumonia cases and 5% of bronchitis and sinusitis cases in the United States (Kuo et al., 1995a). 
Infection is most prevalent in children from 5 -14 years of age and 50 to 70% of the adult population 
worldwide is seropositive for this pathogen (Grayston, 1992). However, since the antibody response is time-
limited to 3-5 years, infection may occur several times during a persons lifetime (Kuo et al., 1995a). 
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Respiratory infections caused by C. pneumoniae are often mild with no symptoms or only symptoms 
of  extended  cough  (Miyashita  et  al.,  2003)  and  in  most  cases  they  probably  remain  undiagnosed. 
Nevertheless,  some  infections  cause  severe  illness  and  may  cause  pneumonia  and  bronchitis.  C. 
pneuomoniae, has so far only been shown to infect humans and transmission appears to be via person- -
person, although this route appears to be relatively inefficient (Grayston et al., 1993). 
 
Chlamydial infections that are asymptomatic and thereby untreated may become persistent and lead to 
chronic conditions. The association of C. pneumoniae with chronic human diseases was first shown in sero-
epidemiological  studies,  which  demonstrated  the  association  of  antibodies  to  C.  pneumoniae  with  acute 
myocardial infarction (Saikku et al., 1988; Arcari et al., 2005). Further, links with other chronic diseases 
such as asthma, chronic bronchitis and chronic obstructive pulmonary disease have also been suggested to be 
associated  with  C. pneumoniae  infection,  based  upon  sero-epidemiological  evidence  (Hahn  et  al.,  1991; 
Azzouzi et al., 2005). An association of C. pneumoniae with coronary artery disease has also been supported 
by detection of either antigens by immunohistochemistry or nucleic acids of the organism by the polymerase 
chain reaction in the affected tissues (Kuo et al., 1993a; Kuo et al.,1993b; Kuo et al., 1995b; Ouchi et al., 
1998; Leinonen and Saikku, 2002; Belland et al., 2004).  
 
1.4.2.3 Chlamydophila psittaci 
Chlamydophila psittaci, previously Chalmydia psittaci, is the causative agent of psittacosis (parrot 
fever). Although the disease was first found in the psittacine, the natural reservoir for C. psittaci occurs in a 
wide range of domesticated and feral birds, but is also incidentally transmissible to humans. Historically, 
psittacosis was used to describe the infection in psittacine birds and ornithosis in feral birds. Both have been 
shown to cause the same infections (Page, 1966) and so the use of the term Chlamydiosis for chlamydial 
infections in all species including birds, animals and humans has become universally accepted. 
 
Chlamydial infection in birds is both a major economic problem and an occupational health hazard for 
those working in the poultry and pet bird industries. Infection in birds occurs primarily in the gastro-intestinal 
tract with transmission of infection by the shedding of chlamydiae in the faeces or by discharge from the 
respiratory  tract.  Exposure  to  dead  or  living  infected  birds  or  droppings  also  provides  a  method  of 
transmission among all the aforementioned species. Person- -person transmission can occur, but is rare. 
 
The most common human C. psittaci infections cause acute respiratory tract infections that may have 
systemic manifestations. Presentation is extremely variable - some patients having only a mild cough while 
others can develop severe or fatal pneumonia. The incubation period of the disease is highly variable between 
1 to 4 weeks with presentations of fever, chills and headache in both mild and severe disease states. The 
alternative more severe disease state has similarities to typhoid, general feverish state without respiratory 
involvement  and  bradycardia.  Primary  diagnosis  is  often  made  after  confirming  the  existence  of  bird 
exposure (Schachter, 1988). C. psittaci diseases can show surprising persistence, lasting up to ten years with 
very few symptoms (Meyer and Eddie, 1951). Chapter 1    General introduction 
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1.4.2.4 Other human infections 
There are several reports of human abortion, or severe respiratory disease in non-pregnant humans 
caused by the ovine abortion strain Chlamydophila abortus, previously from the taxon C. psittaci (Mare, 
1994). Generally, reported cases are during the lambing season when there is a higher risk of exposure to 
chlamydiae from aborting ovine foetuses. Chronic conjunctivitis caused by infection with feline C. felis has 
also been reported (Hartley et al., 2001).  
 
1.4.2.5 Non-human infections 
Chlamydia has been isolated from a large number of feral and domesticated mammals, as well as many avian 
species  and  frogs  (reviewed  by  Storz,  1988).  Diseases  include  ocular  disorders,  pneumonias,  arthritis, 
abortion,  intestinal  infection,  meningitis,  mastitis  and  hepatitis  (reviewed  by  Storz,  1988).  Of  particular 
importance is Chlamydophila abortus, a major cause of abortion in sheep, cattle and goats. In Britain it is 
estimated to cost the sheep industry in excess of £20 million per annum (Aitken et al., 1990). 
  
1.4.2.6 Persistent infections 
Although not clearly understood, Chlamydia can persist in a viable, but non-cultivable growth stage resulting 
in a long-term relationship with the host cell (reviewed by Beatty et al., 1994a; Wyrick, 2010). For instance, 
the  ability  of  C.  pneumoniae  to  cause  persistent  respiratory  infections  in  humans  is  well-documented 
(Hammerschlag et al., 1992;!Miyashita et al., 1996).!Distinguishing between this persistent state and a re-
infection  causing  chronic  disease  presents  difficulties.  Nonetheless,  multiple  lines  of  evidence  support 
persistent infections both in vitro and in vivo.  
   
Abnormal  chlamydial  development  in  vitro  has  been  induced  by  a  number  of  different  methods 
including antibiotic treatment, low nutrient induction, cytokine exposure (particularly IFN-γ), induction by 
phage, during monocyte infections and when maintained in continuous culture (reviewed by Hogan et al., 
2004). These result in persistent states which show many similarities to each other such as the development 
of small inclusions, loss of infectivity, enlarged aberrant RB that do not undergo binary fission and inhibition 
of differentiation at different stages, i.e. EB to RB or RB to EB. When inhibitory growth pressure is removed, 
the normal developmental cycle is often resumed. The persistent state of this well-adapted pathogen may 
represent an important mechanism for intracellular survival (Hogan et al., 2004). It is likely that differences 
in persistent forms between strains may have subtly evolved to enhance the pathogens survival to specific 
environmental cues and different host niches.  
 
Fehlner-Gardiner (2002) and Caldwell (2003) provided an explanation for specific tissue tropisms or 
niches based upon indole-rescuable phenotypes in C. trachomatis. Genital serovars (D - K and L1 and L3), 
but not ocular (A - C) serovars growing in tryptophan-deficient medium, are able to synthesize tryptophan Chapter 1    General introduction 
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from exogenous indole and therefore recover their normal infective cycle. Interestingly, tryptophan depletion 
by induction of the tryptophan degrading enzyme indoleamine 2,3-dioxygenase (IDO) by IFN-γ has been 
shown  to  be  the  major  mechanism  for  IFN-γ-mediated  persistence  in  C.  trachomatis  serovar  A  and  C.  
pneumoniae  A-03  in  aortic  smooth  muscle  cells  (Beatty  et  al.,  1994b;  Pantoja  et  al.,  2000).  These 
observations  together  suggest  the  persistence  of  a  chlamydial  infection  in  vivo  maybe  governed  by  the 
interplay  between  IFN-γ  mediated  tryptophan  depletion  and  other  factors  such  as  the  availability  of 
exogenous indole, the strains ability to synthesis tryptophan, the susceptibility of specific strains to IFN-γ or 
other cytokines and IDO induction levels. Adding to this complexity, it is likely that there will be many other 
processes in addition to tryptophan catabolism, such as iron depletion, the nitric oxide synthase effector 
pathway, that could also be attributable to IFN-γ. Taking into account the wide host range of Chlamydia, the 
importance of each mechanism and their interplay, it is likely that persistent states will vary between species 
and reflect their requirements for survival within a specific niche. 
 
   
1.5 Diagnosis of chlamydial infections 
 
Confirmation  of  a  chlamydial  infection  depends  upon  obtaining  a  clinical  sample  for  a  suitable 
laboratory diagnostic test. Historically, intrusive procedures that may not be acceptable to people who are 
asymptomatic have been necessary to obtain the required cervical and urethral specimens. The development 
of new detection methods has facilitated the use of urine samples, which are more acceptable.  
 
1.5.1 Cell culture  
For many years, the method of choice for confirming a chlamydial infection was the inoculation of 
clinical material into cell culture. A variety of cell lines including McCoy cells, mouse L929, BHK21 (Baby 
hamster kidney), HeLa and BGMK (Buffalo Green Monkey Kidney) cells have been used (Hobson et al., 
1982). Infected cells are examined for the presence of the characteristic chlamydial inclusion bodies by either 
staining with Iodine, staining with Giemsa stain, fluorochrome-labelled poly- or mono-clonal antibody or by 
enzyme immunohistochemistry.  
 
1.5.2 Immunofluorescence 
Direct  detection  of  chlamydial  elementary  bodies  using  immunofluorescence  provided  the  first 
commercially available test. This test was based upon a fluorescein-conjugated, species specific monoclonal 
antibody to the major outer membrane protein of C. trachomatis. When compared to tests carried out in cell 
culture, good results were obtained with values of 96.3% sensitivity and 99.5% specificity (Uyeda et al., 
1984).  Other  manufacturers  subsequently  produced  similar  tests  based  upon  monoclonal  antibodies  of 
lipopolysaccharide  (LPS)  extending  the  methodology  to  the  detection  of  all  Chlamydophila  species. 
Although the test is relatively fast, it requires careful examination by skilled microscopists and is subjective. 
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1.5.4 Immunoassays  
Introduction of a range of enzyme-linked immunosorbant assays (ELISA) based upon chlamydial 
antigens  and  cognate  monoclonal  antibodies  provided  a  less  subjective  automatable  test.  For  example, 
NovaLisa™ is a diagnostic ELISA assay for the qualitative measurement of IgA, IgG and IgM antibodies 
against C. trachomatis. 
 
1.5.5 Nucleic acid amplification based tests 
Nucleic  acid  amplification-based  methods  are  now  of  prime  importance  for  the  diagnosis  of 
chlamydial  infections  (Lisby  et  al.,  1999)  and  have  been  considered  the  most  important  advance  in 
chlamydial detection since cell culture (Stary et al., 1998). 
 
The polymerase chain reaction (PCR) or ligase chain reaction (LCR), are highly sensitive and specific 
methods  for  the  detection  of  Chlamydia  using  multiple-copy  gene  targets,  e.g.  those  on  the  cryptic 
chlamydial  plasmid.  Detection  of  C.  trachomatis  in  genital  specimens  of  infected  symptomatic  and 
asymptomatic men and women has been increased by 30% using these types of amplification technologies 
(Dille et al.,1993; Schachter et al.,1994; Ostergaard et al.,1990). The true sensitivity of PCR and LCR is of 
the order of 90 to 97% (Cheng et al., 2001). Improved performance in terms of reproducibility and suitability 
for automation has enabled testing in populations of low prevalence, thereby providing a method that informs 
infection control strategies. However, new rRNA-based tests have been reported to offer further increases in 
sensitivity, allowing the detection of infections previously missed by PCR (Yang et al., 2007). 
 
1.5.5.1 Serological detection of antibody 
Serological tests used for the detection of current or prior exposure to chlamydial infections, or for 
comparisons between infected sample populations, are clearly useful. There are wide variations between 
various tests and their correlation to anti-chlamydial titre. So, while a single serum sample showing raised 
anti-chlamydial titre maybe useful for diagnosing entrenched infections (Taylor-Robinson, 1992), it may not 
indicate an active infection, as elevated levels can exist in the absence of the pathogen. The considered Gold 
Standard  of  serological  diagnosis  of  C.  trachomatis  infections  has  been  the  serotype-specific  micro-
immunofluorescence test (MIF) (Wang and Grayston, 1991b), providing classification of C. trachomatis into 
15 serotypes. However, the observation of cross reactivity with C. pneumoniae leading to false positives 
(Gijsen et al., 2001) in combination with other issues such as lack of objectivity, reproducibility has limited 
the suitability of this assay for routine use. An evaluation of two species-specific enzyme immunoassays 
(EIA) against MIF and were found to be less laborious, more specific and less expensive (Bax et al., 2003). 
Although,  serological  tests  fall  short  of  providing  diagnoses  on  an  individual  basis,  their  high  negative 
predictive value may be of use in identifying patients where C. trachomatis is unlikely to play a role in 
infection. 
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1.6 Chlamydial genomics 
 
The restricted and obligate intracellular nature of chlamydiae and until recently, the lack of any gene 
transfer system (Wang et al., 2011), has hindered the understanding of chlamydiae at both the cellular and 
molecular  level.  Therefore,  the  sequencing  of  several  chlamydial  genomes  has  been  very  important  in 
furthering Chlamydia research. 
 
Fortunately, the size of the genomes of chlamydiae are relatively small (~ 1 Mb) and so sequencing of 
these genomes is easily achieved. At the initiation of these studies, eight genomes representing five strains of 
chlamydiaceae had been sequenced, annotated and published (Stephens et al.,1998; Kalman et al., 1999; 
Read  et  al.,  2000;  Read  et  al.,  2003;  Shirai  et  al.,  2000;  Carlson  et  al.,  2005;  Thomson  et  al.,  2005). 
However,  recent  advances  in  high-throughput  genome  sequencing  technologies  now  facilitate  the  rapid 
sequencing of many isolates from different strains. Therefore, for the practical purposes of this thesis, an 
overview of these sequences representing a single strain and serovar is shown in Table 1.2. Two isolates of 
C. trachomatis serovar B have also been sequenced, but are not contained within the table since they are yet 
to  be  published.  Draft  sequences  of  these  genomes  can  be  obtained  at  the  following 
URL:http://www.sanger.ac.uk/sequencing/Chlamydia/trachomatis/CTA_CTB/). C. trachomatis, serovar A, D 
and C. muridarum also contained a plasmid, and in C. caviae and C. pneumoniae AR39 a bacteriophage. 
These were also sequenced and are associated with the relevant genome sequences. The primary description 
of these genome sequences has provided thorough and valuable information that has expanded our previous 
perspectives of chlamydiae. 
 
Table 1.2 Genome sizes of sequenced chlamydiaceae 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.6.1 Genome comparison 
Different strains of chlamydiae share similarities in terms of their unique biphasic developmental 
cycle and morphology. However, as previously discussed, they show differences in tissue tropism, infectivity 
Genome    Size (Mb)  Plasmid/Phage  Reference 
C. trachomatis, D/UW-3/CX  1.042  7493 bp plasmid  Stephens et al., 1998 
C. pneumoniae, CWL029  1.230    Kalman et al., 1999 
C. pneumoniae, AR39  1.234  4524 bp phage  Read et al., 2000 
C. pneumoniae, J138  1.226    Shirai et al., 2000 
C. muridarum MoPn  1.080  7501 bp plasmid  Read et al., 2000 
C. caviae (GPIC)  1.173  7966 bp phage  Read et al., 2003 
C. trachomatis, A/Har-13  1.051  7510 bp plasmid  Carlson et al., 2005 
C. abortus  1.144    Thomson et al., 2005 
C. trachomatis, L2/434/Bu  1.039  7499 bp plasmid  Thomson et al., 2008 
C.trachomatis L2/UCH-1/proctitis  1.039  7499 bp plasmid  Thomson et al., 2008 
C. trachomatis E/11023  1.043    Jeffrey et al., 2010 
C. trachomatis F/70  1.048    Jeffrey et al., 2010 
C. trachomatis G/9301  1.043    Jeffrey et al., 2010 
C. trachomatis J/6276  1.043    Jeffrey et al., 2010 Chapter 1    General introduction 
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and inclusion morphology. The varying levels of DNA homology between strains, suggests that comparative 
analyses  of  chlamydial  genomes  may  reveal  differences.  These  differences  can  be  used  to  formulate 
hypotheses to explain the observed differences in pathogenicity and tissue/host specificity. 
 
Seven hundred and ninety eight genes were conserved in all the published chlamydiae sequences prior 
to the sequencing of the C. abortus genome in 2005, representing the possible minimal set of genes required 
for the development and intracellular survival of Chlamydia. One hundred and eighty three of these genes 
could not be found in any of the 70 other microbial organisms published in the TIGR database (Read et al., 
2003). 
 
Comparative analysis of the C. caviae genome (Read et al., 2003) showed that 68 out of 1009 C. 
caviae genes were not found in any of the other chlamydial genome sequences up to this date. Similarly, 
comparative analysis of C. pneumoniae contained 168 genes of unknown function (Read et al., 2003). These 
niche-specific genes are not likely to be required for primary functions and are more likely to be necessary 
for virulence and survival of chlamydiae in specific sites or hosts. C. caviae possesses an almost complete 
tryptophan biosynthesis operon, indicating the ability of C. caviae, to synthesise tryptophan from the early 
precursor anthranilate. In comparison, C. trachomatis only possess a limited set of these genes (Stephens et 
al.,1998). Ocular-gential and LGV serovars are able to synthesise tryptophan from indole, whereas the ocular 
serovars A to C contain a truncated trpA gene and serovar B lacks the trpA operon and hence are unable to 
synthesis tryptophan (Shaw et al., 2000b), confirming the findings of Fehlner-Gardinier et al. (2002) and 
Caldwell et al. (2003). These niche-specific genes are also absent in the sequenced strains of C. pneumoniae 
suggesting they are also unable to synthesise tryptophan (Kalman et al., 1999). Differences in tryptophan 
requirements and sensitivity to IFN-γ –mediated growth inhibition (Beatty et al., 1994b) are likely to reflect 
some  of  the  strain  differences  observed  in  host  specificity,  virulence,  persistence  and  transmission  of 
chlamydiae. 
 
A  tox  gene,  similar  to  cytotoxic  genes  from  enterobacteria,  is  also  present  in  C.  caviae  with 
orthologues in C. muridarum. It has been suggested that these products may be secreted by the type III 
secretion system, in order to inhibit actin polymerisation (Read et al., 2003). Truncated ORFs of these genes 
were found in both the L2 and D serovars, but no orthologues were identified in C. pneumoniae (Read et al., 
2003; Thomson et al., 2008). Again, the absence or presence of these niche-specific genes may account for 
the different sites of infection between chlamydiae as they may influence trafficking and ultimately affect the 
degree of systemic infection (Belland et al., 2001). 
 
Eighty percent of the predicted proteins from C. pneumoniae have a corresponding orthologue in C. 
trachomatis (Kalman et al., 1999). A major difference between these two species is the increased number of 
genes  encoding  for  the  polymorphic  membrane  proteins  (pmps)  similar  to  those  found  in  C.  psittaci, 
increasing from nine pmp genes in C. trachomatis to 21 in C. pneumoniae. Several of the pmp genes contain 
frame shifts that vary between isolates (Grimwood and Stephens, 1999). The C. pneumoniae genomes are 
more than 99.9% identical and the small differences are mainly found in pmps and the polymorphic protein Chapter 1    General introduction 
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(ppp) family of C. pneumoniae (Daugaard et al., 2001; Rocha et al., 2002). Pmp genes represent a major area 
of variability between strains. The fact that chlamydiae with such a small genome has maintained these 
paralogs, suggests that they play a pivotal role in structural, functional or antigenic polymorphism. 
 
The size of all the C. trachomatis genomes sequenced to date are similar in size. Comparison of the C. 
trachomatis serovars D/UW-3/CX, A/Har-13 and L2/434/Bu (Stephens et al., 1998; Carlson et al., 2005; 
Thomson et al., 2008), have 846 genes common to all three genomes. Differences in the coding sequences 
between these genomes could be accounted for by in-silico prediction differences or as a result of functional 
loss, indicating that differences in disease aetiology was not attributable to gene acquisition (Thomson et al., 
2008). 
 
1.6.2 Highlights of chlamydial genome sequencing studies 
For the first time, genomic data has provided a putative list of gene products that informs us of the 
metabolic capabilities of chlamydiaceae. The functional assignment of these genes cannot however be taken 
for granted. Assignments are made on the basis of sequence homology, the levels of which can be somewhat 
arbitrary. Chlamydiaceae lineage is deeply separated from that of other eubacteria and so many of their 
proteins  show  only  low  levels  of  homology  with  known  proteins.  Nonetheless,  when  supported  by 
biochemical characterisation, confident functional assignments can be made. The vast number of genes and 
their products makes discussion of each gene product in turn an impractical task. Therefore, the following 
discussion focuses on key subsets of these genes. 
 
In terms of central metabolism, the pathways that appear to be present in C. trachomatis suggest that it 
is  an  aerobic  organism  utilising  glutamate  as  the  primary  carbon  source  with  glucose  and  oxoglutarate 
playing supplementary roles during different stages of the development cycle. Genes encoding the proteins 
for  an  intact  glycolytic  pathway  were  identified,  although  controversy  concerning  the  presence  of  the 
predicted enzyme fructose-1,6-diphosphate aldolase has led to the proposal of an alternative route via the 
pentose-phosphate  pathway  (also  called  the  hexose  monophosphate  shunt)  to  circumvent  this  enzyme 
(Stephens et al., 1998). An incomplete tricarboxylic acid (TCA) cycle was identified. In light of the absence 
of the genes encoding the enzymes citrate synthase, aconitase, and isocitrate dehydrogenase, it has been 
suggested that the pathway operates via an aspartate shunt. No genes encoding glyoxylate-bypass enzymes 
were  identified,  indicating  that  chlamydiae  are  unable  to  use  fatty  acids  or  acetate  as  carbon  sources 
(Stephens et al., 1998). Consistent with the observation of accumulation and storage of glycogen within 
chlamydiae, a complete glycogen synthesis and degradation system was identified, supporting a role for 
glucose as a carbon source at different stages of the developmental cycle. Genes encoding essential functions 
in aerobic respiration were also well represented in the chlamydial genome (Stephens et al., 1998). 
 
Traditionally, chlamydiae have been considered ‘energy parasites’ obtaining ATP from their host cells 
(Moulder, 1991; Hatch et al., 1982). Two ATP transporting proteins with sequence identity to those from 
Rickettsia prowazekii were identified in both the C. trachomatis and C. pneumoniae genomes supporting this 
accepted hypothesis (Andersson, 1998). It was therefore surprising when genes encoding a wide range of Chapter 1    General introduction 
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ATPases as well as phosphoglycerate kinase, pyruvate kinase, and succinate thiokinase were also identified 
via genomics. This finding suggests that chalmydia may have the capability to produce ATP themselves and 
hence may not be strict ATP auxotrophs (Stephens et al., 1998). However, it remains to be seen if these 
compounds  are  actually  expressed  at  the  protein  level  and  if  so  when.    The  ability  to  synthesise  ATP 
autonomously may be important when Chlamydia is unable to obtain ATP from the host cell such as in the 
early and late stages of development (Hatch et al., 1982). 
 
Several groups of chlamydial encoded proteins can be considered of special interest. These include (i) 
proteins involved in making peptidoglycan (ii) type III secretion proteins; (iii) inclusion membrane proteins 
(incs); and (iv) the polymorphic membrane proteins (pmps) previously discussed. 
 
It has previously been proposed that chlamydiae lack peptidoglycan because muramic acid, one of the 
major components has not been biochemically detected in any significant amounts (Fox et al., 1990). The 
presence  of  nearly  a  full  set  of  genes  involved  in  peptidoglycan  synthesis  was  therefore  unexpected. 
Peptidoglycan  has  also  been  suggested  to  play  a  role  in  the  division  of  RB.  This,  combined  with  the 
sensitivity of Chlamydia to cyclo serine and beta-lactam antibiotics such as penicillin (Chopra et al., 1998), 
strongly  supports  the  hypothesis  that  chlamydiae  synthesise  peptidoglycan  or  a  peptidoglycan–like 
component (Stephens et al., 1998). 
 
Orthologous genes that are predicted to encode a type III secretion system were also found in their 
entirety, first in C. caviae and subsequently in C. trachomatis (Hsia et al., 1997; Stephens et al., 1998). The 
TTSS  is  found  in  many  gram-negative  bacteria  and  their  genes  are  typically  linked  with  ‘pathogenicity 
islands’ with a relatively high A+T content. The genes encoding the chlamydial TTSSs have an A+T content 
similar to the rest of the genome and are found in three loci on the chromosome (Stephens et al., 1998). The 
TTSS in Chalmydia is likely to play a role in modifying the host cell processes that may be necessary for host 
cell invasion, restructuring of the inclusion membrane, or affecting host cell regulatory pathways (reviewed 
by Beeckman and Vanrompay, 2010). As previously noted, surface projections on both RB and EB have 
been observed using electron microscopy (Matsumoto, 1982). Originally thought to be involved in nutrient 
uptake before the discovery of the TTSS genes, these projections are now considered to be type III needles 
(Bavoil and Hsia, 1998; Hatch, 1998). 
 
Homologous proteins associated with the chlamydial inclusion membrane termed inclusion membrane 
proteins (incs), have been identified in all sequenced chlamydiae, but have not been found in any other 
sequenced organism. The first of these were identified in C. psittaci and termed incA, B and C (Rockey et 
al.,1995;  Bannantine  et  al.,  1998a).  Several  incs  have  now  been  identified  and  all  of  these  have  a 
characteristic  bilobed  hydrophobic  region.  In  total,  33  genes  encoding  proteins  with  this  hydrophobicity 
pattern have been identified in the C. trachomatis genome and 93 in the C. pneumoniae CWL029 genome 
(reviewed by Vandahl et al., 2004; Kostryukova et al., 2008). The likely role of this class of protein is in 
inclusion  membrane  remodelling  and  transport.  This  was  demonstrated  by  Suchland  et  al,  (2005),  who Chapter 1    General introduction 
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showed that IncA was involved in the expansion of the inclusion membrane by creating secondary inclusions 
and transporting chlamydiae to those inclusions. 
 
1.6.3 Genetic transformation 
Towards the end of these studies, a genetic transformation system in C. trachomatis was developed 
and reported, representing a major advance for the field of Chlamydia research (Wang et al., 2011). The 
developed system used a constructed shuttle vector based on the 7.5 kb chlamydial plasmid of C. trachomatis 
L2/434/BU  and  the  E.coli  plasmid  pBR325,  with  transformation  achieved  by  simple  calcium  chloride 
treatment of EBs. Selection of transformants was achieved by taking advantage of the penicillin-induced RB 
phenotype, which forms non-dividing aberrant RBs, where further development to the EB form is arrested. 
Genetically stable, penicillin resistant transformants are selected from the aberrant RBs by the isolation of 
penicillin  resistant  EBs  over  successive  passages.  The  author’s  demonstrate  this  genetic  transformation 
system by producing a penicillin resistant C. trachomatis strain, expressing the green fluorescent protein 
within  chlamydial  inclusions.  They  also  substantiate  the  associated  link  that  the  chlamydial  plasmid  is 
necessary for the synthesis and accumulation of glycogen in chlamydiae. By transforming the chlamydial 
plasmid into a non-glycogen producing, plasmid-free strain of C. trachomatis L2, glycogen production and 
accumulation was restored, confirming a role for the plasmid in glycogen biosynthesis. If this transformation 
system can be applied routinely, it will represent an important milestone and has the potential to advance our 
understanding of chlamydial pathogenesis substantially. 
 
 
1.7 Transcriptional profiling of Chlamydia 
 
Comparative sequence analysis of genomes can help formulate hypotheses based upon the presence or 
absence of a particular gene or group of genes. However, it is likely that a substantial fraction of a chlamydial 
genome is differentially regulated and co-ordinately transcribed providing critical functional and regulatory 
roles and mediating  the  phenotypic changes observed  during the developmental cycle (Nicholson et al., 
2003). The development of microarray hybridisation techniques (reviewed by Lander, 1999; Brown and 
Botstein, 1999) provides a technology able to measure the relative levels of mRNA between two cellular 
states. Advances in microarray technology (alternatively termed transcriptional profiling) have made this a 
popular technique for global gene expression analysis. 
 
Two elegant studies have used transcriptional profiling to analyse two C. trachomatis strains, serovar 
D and L2 (Nicholson et al., 2003; Belland et al., 2003). These studies have provided powerful new insights 
into the temporal expression of genes that control the different stages of the developmental cycle and those 
that determine the nature of the host-pathogen interaction. 
 
3.2%  of  the  chlamydiae  genome  (29  genes)  was  transcriptionally  active  as  early  as  1  hour  post-
infection  (PI).  By  3  h  PI,  an  additional  200  genes  were  transcriptionally  active.  This  corresponded  to Chapter 1    General introduction 
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microscopic observations of the differentiation of EB to RB by chromatin decondensation. At 8 h PI there 
was significant amounts of intense transcriptional activity, which was maintained through the period of the 
developmental cycle when RB replicate by binary fission. During this period (16-24 h PI), almost every gene 
was  transcribed  highlighting  the  fact  that  chlamydiae,  with  its  small  genome,  has  very  little  facultative 
capacity. During the late stages of development, a subset of 28 genes were specifically expressed (Belland et 
al., 2003). Since genes were classified according to the moment their transcript was observed, and owing to 
some asynchronicity in the cycle, the comparison of gene transcripts expressed very early or late in the cycle 
will be the most informative. 
 
1.7.1 Immediate - Early genes 
Among the Immediate -Early genes, seven had been previously described. These included the first 
early stage protein to be cloned and sequenced called the early upstream ORF gene (Wichlan and Hatch, 
1993), a family of inc genes (incD, E, F and G) and the chaperonin genes groEL and groES (Shaw et al., 
2000a).  Newly  identified  immediate  early  genes  included  ADP/ATP  translocase,  nucleotide  phosphate 
transporter,  oligopeptide  permease,  a  D-alanine/glycine  permease,  malate  dehydrogenase,  methionine 
aminopeptidases  and  nucleoside  phosphohydrolase.  These  components  are  involved  in  translocation  and 
interconversion of metabolites within the bacterial cell. At 1 h PI two further inc proteins were transcribed. 
The number of inc-like proteins predicted to be expressed reiterates the important role that these proteins 
must play in modifying the chlamydial inclusion membrane to support growth and survival.  
 
A novel predicted 162 kDa transcript encoded by CT147 (CT denotes the gene prefix Chlamydia 
trachomatis, serovar D) with a significant level of homology to the early endosomal antigen 1 (EEA1) was 
confirmed by immunofluorescence and radiolabelling to colocalise with the inclusion membrane. EEA1 is 
involved in endosomal trafficking and fusion in mammalian cells (Christoforidis et al., 1999; Mu et al., 1995; 
Simonsen et al., 1998). The transcript of CT147 was first detected at 1 h PI, reaching a maximum expression 
at 8 h PI. Expression of the protein was first detected at 8 h PI using immunofluorescence where it was 
localised to the periphery of the chlamydiae inclusion and detected at 16 h PI using immunoprecipitation. 
The temporal difference in detection of protein expression was attributed to the different sensitivities of the 
two assays. Between 24 and 40 h PI, the protein disappears with the concomitant appearance of several lower 
molecular mass immunoreactive species, indicating post-translational  modification  of  CT147  by  either  a 
chlamydial or a host protease (Belland et al., 2003).  
 
1.7.2 Late genes 
Twenty six genes were expressed in the late stages of development, including previously characterised 
genes  such  as  those  encoding  the  histone-like  proteins  HctA  and  HctB,  which  mediate  chromosomal 
condensation in the differentiation of RB to EB (Brickman et al., 1993; Barry et al., 1993). The secondary 
differentiation process (RB to EB) is characterised by the formation of a highly disulphide cross-linked outer 
membrane (OM) complex. Two late genes encoding for cysteine rich OM proteins (omcA and omcB) and the 
major outer membrane protein (OmpA) form this OM complex. It is proposed that these extensive intra- and 
inter- disulphide linkages are formed by two thioredoxin disulfide isomerases (CT780 and CT783), also Chapter 1    General introduction 
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expressed late in the cycle. The expression of two highly conserved membrane thio-proteases may also have 
a  proteolytic  function  in  the  formation  and  maturation  of  this  OM  complex.  These  two  proteases  show 
homology to adenoviral proteases that have been shown to play a role in the maturation of virus particles 
(Greber, 1998). 
 
The application of microarray technology to study the temporal gene expression of chlamydiae has 
proved to be invaluable. The identification of a number expressed genes with novel functions, has provided 
fresh insights into the biology of the chalmydiae and may even have provided new potential targets for 
therapeutic agents. 
 
To  date,  however,  it  has  been  difficult  to  correlate  the  patterns  of  mRNA  expression  with  the 
corresponding patterns of protein expression. This is due in large part to the technical difficulties associated 
with studying the latter. These difficulties, together with recent proteomic advances that overcome some of 
them, are described in the next section. 
 
 
1.8 Proteome analysis 
 
The completion of a genome sequence is frequently insufficient to determine the biological function 
of a gene. Measurement of the genes at the mRNA level can provide valuable information, as demonstrated 
by Belland et al., (2003). However, no simple correlation exists between changes in mRNA expression levels 
(transcriptomics) and those at the protein level (proteomics), with several studies reporting disparity between 
the relative expression of mRNAs and the corresponding expressed protein (Anderson and Seilhamer, 1997; 
Gygi et al 1999a; Cox et al., 2005). This is unsurprising in view of the fact that many regulatory processes 
impact  on  gene  expression  after  transcription.  For  example,  mRNAs  may  be  translated  with  different 
efficiencies and may also have different half-lives. Similarly, proteins undergo different rates of degradation 
and may also require post-translational modifications in order to be active. However, by exploiting new 
technologies to measure some of these parameters more precisely, closer correlation between mRNA and 
protein expressions are observed (Schwanhausser et al., 2011). 
 
The original dogma of one gene producing one protein, we know, no longer stands true. In eukaryotic 
cells, it has been suggested that each gene can specify an average of 6 to 8 proteins, although the precise 
number is uncertain (Strohman, 1994). The mechanisms responsible for this diversity include: alternative 
splice variants, post-translational modifications, proteolytic cleavage, differences in protein conformation, 
and changes in oligomeric state (protein-protein interactions). Different forms of a protein may reside in one 
or several cellular locations, each performing a specific biological function. Collectively, therefore, there are 
compelling reasons for undertaking direct analysis of proteins, even if the task is markedly more difficult 
than working at the mRNA level. 
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Proteomics  can  be  defined  as  the  systematic,  large-scale  analysis  of  proteins,  protein-protein 
interactions and their post-translational modifications. As such, the ideal proteome study would provide the 
absolute quantitative measurement of every protein; its isoforms, modifications and complexes within a given 
sample. Although not routine in the majority of proteomic laboratories, the application of new proteomic 
technologies  are  beginning  to  achieve  proteome  coverage  comparable  to  those  of  deep  transcriptome 
sequencing technologies. For example, Nagaraj et al. (2011) quantified 9230 proteins encoded by 9207 genes 
in HeLa cells, matching nearly all those transcripts identified by deep transcriptome sequencing of the same 
sample. 
 
There are two essential steps in a proteomic analysis: the separation of the proteins in a sample 
derived from tissue or cells and the identification of the proteins in that mixture. Historically, the high-
resolution  separation  of  complex  mixtures  of  proteins  has  been  performed  using  two-dimensional  gel 
electrophoresis  (2-DGE),  in  which  hundreds  or  even  thousands  of  proteins  are  separated  orthogonally, 
according to their charges (pI) and molecular masses using polyacrylamide gels (O’Farrell, 1975). Once 
separated, the proteins in the gel are visualised by staining (e.g. with coomassie brilliant blue, silver stains or 
fluorescent dyes such as Sypro Ruby), and quantitated by image analysis to pinpoint the spots of interest. 
Spots  of  interest  are  then  picked  for  protein  identification.  These  days,  the  approaches  used  for  the 
subsequent identification of these proteins are generally based on biological mass spectrometry. The current 
main  approaches  of  protein  separation,  protein  identification,  modern  mass  spectrometry  (MS) 
instrumentation and advancements in the context of proteomics will be discussed later; however, to maintain 
continuity, previous chlamydiae proteomic studies are first discussed. 
 
1.8.1 Proteome analysis of Chlamydiae 
1.8.1.1 Early Chlamydia proteome studies 
Early proteome studies focused on the Chlamydial Outer Membrane Complex (COMC) from EBs. 
Batteiger (1985), compared lymphogranuloma venereum and ocular strains of C. trachomatis and identified 
three major outer membrane proteins (MOMP) within this complex, a protein of variable molecular mass, 42 
– 45 kDa, (OmpA), a 60 kDa protein (OmcB) and a 12 kDa protein (OmcC). The 60 kDa protein in C. 
trachomatis L2 was found to be more basic and was only observed after analysis by non-equilibrium pH 
gradient electrophoresis. This provided the first evidence of structural differences between the LGV and 
ocular strains, supporting their classification into separate biovars. 
 
Moroni et al. (1996) compared the COMC from different C. trachomatis serovars, as well as from C. 
pneumoniae  and  C.  caviae  using  2-DGE.  OmcB  from  C.  trachomatis  L2  was  resolved  in  the  gels,  but 
migrated one pH unit more basic than OmcB of C. trachomatis  F, and two pH units more basic than that of 
C. trachomatis  D. No further proteins were identified in these studies.  
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1.8.1.2 More recent C. trachomatis proteome studies 
The  first  proteomic  study  of  whole  cell  lysates  of  C.  trachomatis  was  aimed  at  identifying  the 
synthesis of early proteins from C. trachomatis serovar L2 using pulse-label experiments in combination with 
2-DGE (Lundemose et al., 1990). Seven proteins were observed at 2 to 8 h PI. Four of these proteins were 
labelled  at  2  to  4  h  PI,  three  of  which  were  identified  using  colocalisation  with  proteins  detected  by 
immunoblotting with known antibodies. These three proteins of 75, 62, and 45 kDa were identified as the S1 
ribosomal protein, the GroEL-like protein, and DnaK-like protein, respectively. The remaining four proteins 
were not identified. Early transcription of the groEL gene was recently confirmed by transcriptional profiling 
(Shaw et al., 2000a; Slepenkin et al., 2003). Interestingly, the transcript for GroES, a 20 kDa protein that has 
been shown to be co-transcribed with GroEL in C. psittaci (Morrison et al., 1989) was not detected. This was 
probably attributable to its small size and hence, the reduced number of amino acids available for label 
incorporation, a limitation of these types of radiolabelling experiments. 
  
Improved resolution of 2D gels attributed to immobilised pH gradient (IPG) strips enabled Bini et al. 
(1996)  to  generate  one  of  the  first  reference  maps  for  C.  trachomatis.  Approximately  600  spots  were 
separated in silver stained gels. A combination of immunoblotting with known antibodies and N-terminal 
protein  sequencing  was  used  to  identify  nine  known  proteins.  Seven  sequences  were  obtained  from  yet 
uncharacterised proteins. These analyses were carried out prior to the availability of chlamydial genome 
sequences and hence information and technology for the identification of proteins was limited. 
1.8.1.3 C. pneumoniae proteome studies 
The first comprehensive map of Chlamydia following the publication of genome sequences for the 
chlamydiae was that of elementary bodies separated by 2-DGE (Vandahl et al., 2001). One hundred and sixty 
seven  different  proteins  were  identified  by  mass  spectrometry  from  samples  labelled  with  [
35S] 
methionine/cysteine, constituting 15% of the genome. Samples were pooled from different stages of the 
developmental cycle aimed at increasing proteome coverage. This qualitative study provided important new 
findings, including: the first report indicating the expression of the type III secretion system in EBs; 8 new 
pmps; confirmation of 31 out of 167 previously hypothetical proteins; validation of a high number of proteins 
involved in metabolism, transcription and translation (Vandahl et al., 2001).  
 
A quantitative proteomic study using [
35S] pulse-labeling in combination with 2-DGE, examined the 
global protein expression profile of C. pneumoniae from 24 to 48 h PI during the transition from reticulate to 
elementary bodies. Of the 35 proteins identified in this study, 31 of these proteins increased in expression 
during the transition from RB to EB and only 4 proteins showed an observed decrease. These included 
proteins  associated  with  amino  acid  and  cofactor  biosynthesis,  maintenance  of  cytoplasmic  function, 
modification  of  the  bacterial  cell  surface  and  energy  metabolism.  The  results  of  this  study  infer  that 
metabolic pathways may be involved in the transition from RB to EB (Mukhopadhyay et al., 2006). 
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1.8.1.4 The chlamydial secretome 
Orthologues of type I-IV secretion systems similar to those of other Gram-negative bacteria have been 
identified  in  the  chlamydiae  (Hsia  et  al.,  1997;  Stephens  et  al.,  1998;  Kalman  et  al.,  1999),  and  the 
expression of several proteins from the type III secretion apparatus were observed in proteome studies of C. 
pneumoniae (Vandahl et al., 2001) and C. trachomatis (Shaw et al., 2002b). However, the identification of 
chlamydial secreted proteins from the cytoplasm of host cells has been complicated by the fragility of the 
inclusion and RBs. Shaw et al. (2002b) compared the protein content of whole lysates of infected cells to 
purified chlamydiae using 2-DGE to identify chlamydial proteins that are found outside the bacterium. Using 
this subtractive proteomic approach resulted in the identification of two proteins, CT858 of C. trachomatis 
and Cpn1016 of C. pneumoniae. These were orthologues of the protein known as the Chlamydia protease-
like activity factor (CPAF), which has been shown to down-regulate host cell transcription factors required 
for MHC class I and II presentation and subsequently confirmed to be secreted (Zhong et al., 2001a). 
1.8.1.5 Further proteomic studies on the outer membrane complex  
In  addition  to  earlier  studies,  further  proteome  analysis  of  the  COMC  identified  several  proteins 
including a predicted membrane component of the TTSS, YscC, indicating that the apparatus is assembled in 
EBs  and  is  membrane-associated  in  Chalmydia  (Vandahl  et  al.,  2002).  Other  type  three  III  secretion 
components identified in the C. pneumoniae study were not observed in the COMC (Vandahl et al., 2001). In 
addition to the major outer membrane proteins (OmpA, OmcB, OmcC), other major constituents of the 
COMC  included  the  Pmps,  as  characterised  by  Vandahl  et  al,  (2002)  using  2-DGE.  Pmps  have  been 
confirmed to be part of the family of exported Gram-negative bacterial proteins designated autotransporters 
(Wehrl  et  al.,  2004).  Further  confirmation  of  Pmps  in  the  COMC  came  from  Birkelund  et  al.  (2009), 
identifying 7 out of the 9 C. trachomatis Pmps in the COMC (PmpB, C, D, E, F, G and H), using combined 
fractional  diagonal  chromatography  (COFRADIC).  In  addition  to  previously  identified  proteins  of  the 
COMC, they also reported a putative membrane protein (CTL0541), a putative exported protein (CTL0887), 
a  hypothetical  protein  (CTL0626)  and  the  low  calcium  response  protein  D  (SctV),  a  bacterial  inner 
membrane component of the type III secretion system. Further in-silico analysis of the hypothetical protein 
CTL0626, identified a conserved domain motif for a carbohydrate-selective porin, OrpB. This motif was also 
found to be present in other sequenced chlamydial genomes. Further evidence of OrpB as a component of the 
COMC  was provided using immunblotting and immunofluorescence microscopy. The COMC was more 
recently characterised by Liu et al. (2010) using differential proteomics, confirming the COMC proteins 
reported by Birkelund et al. (2009). The authors also identified an additional three previously unreported 
proteins,  CTL0493  (Omp85),  CTL0645  and  a  peptidoglycan  associated  lipoprotein  (Pal),  as  probable 
components of the COMC.  
 
1.8.1.6 Proteomic comparison of the serovars of C. trachomatis 
2-DGE reference maps of EBs from C. trachomatis A, D and L2 were published in 2002 (Shaw et al., 
2002a). The findings were similar to those reported in the study of C. pneumoniae with ~16% of the ORFs 
identified in the C. trachomatis serovars. From the 144 protein species identified in all serovars, 55 migrated Chapter 1    General introduction 
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differently in serovars D and L2, 52 differed between A and L2 whereas only 26 differed between A and D. 
This reflects the greater similarity between the serovars A and D than between LGV, serovar L2 and A/D. 
Twenty five ORFs expressing hypothetical proteins were identified in C. trachomatis D including CT579, the 
orthologue of the chlamydial-like protease factor (CPAF) identified in the COMC study. Serovar specific 
differences  in  the  pmp  proteins  were  observed  and  may  reflect  differences  in  mechanisms  of  host  cell 
attachment and/or chlamydial virulence between serovars. In particular, the detected N-terminal fragment of 
PmpF identified in L2 were not observed in the same area on C. trachomatis A or D gels indicating serovar-
specific differences in the PmpF amino acid sequence, expression levels or processing (Shaw et al., 2002a). 
The majority of the differences observed between serovars are likely to be attributable to the substitution of 
charged amino acid with non-charged (or vice versa) and hence may not have major biological implications 
(Vandahl et al., 2004).  
1.8.1.7 Summary of chlamydiae proteomic studies 
Table 1.3 presents a summary of the chlamydiae proteomic studies discussed in this Chapter. 
 
Table 1.3 Summary of proteomic studies of Chlamydiae 
 
 
Study type  Sample 
type 
Technique used  Chlamydial 
species 
Serovar  Reference 
Qualitative  COMC  2-DGE  C. trachomatis  L1, L2, L3 
A, B, Ba, C to K  
Batteiger et al., 1985 
Quantitative  EB, RB  Pulse-labeling, 2-DGE  C. trachomatis  L2  Lundemose et al., 1990 
Qualitative  COMC  Pulse-labeling, 2-DGE  C. trachomatis  
C. pneumoniae 
C. psittaci 
L2, D, F 
IOL-207 
6BC 
Moroni et al., 1996 
Qualitative  EB  2-DGE  C. trachomatis  L2  Bini et al., 1996 
Quantitative  EB, RB 
(IFN-γ 
treatment) 
Pulse-labeling, 2-DGE  C. trachomatis  A, L2  Shaw et al., 1999 
Qualiitative  EB  1-DGE  C. trachomatis  L2  Mygind et al., 2000 
Qualitative  EB  Pulse-labeling, 2-DGE  C. pneumoniae  VR1310  Vandahl et al., 2001 
Qualitative  EB  2-DGE  C. pneumoniae  VR1310  Vandahl et al., 2002 
Qualitative  EB  Pulse-labeling, 2-DGE  C. trachomatis  A, D, L2  Shaw et al., 2002a 
Qualitative  Secreted 
proteins 
Pulse-labeling, 2-DGE  C. trachomatis 
C. pneumoniae 
A, D, L2 
VR1310 
Shaw et al., 2002b 
Quantitative  EB, RB  Pulse-labeling, 2-DGE  C. pneumoniae  VR1452  Mukhopadhyay et al., 
2006 
Qualitative  COMC  COFRADIC  C. trachomatis  L2  Birkelund et al., 2009 
Qualitative  COMC  LC-MS/MS  C. trachomatis  L2  Liu et al., 2010 Chapter 1    General introduction 
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1.9 Proteomic techniques 
 
The complex nature of the proteome has presented researchers with major challenges in terms of its 
analysis, even for relatively simple expressed proteomes, such as those of microbes (O’Connor et al., 2000). 
These major challenges include suitable protein separation strategies, the determination of protein expression 
levels and the subsequent identification of those proteins of interest. The following section focuses on these 
major challenges and recent methods to resolve them using present day proteomics.  
 
1.9.1 Protein separation strategies  
1.9.1.1 Two-dimensional polyacrylamide gel electrophoresis 
The  classical  method  for  quantitative  and  qualitative  expression  proteomics  has  combined  high-
resolution  separation  of  proteins  using  two  dimensional  polyacrylamide  gel  electrophoresis  (2-DGE) 
(O’Farrell, 1975; Klose, 1975; Gorg et al., 1988) with mass spectrometry (MS) or tandem mass spectrometry 
(MS/MS)  approaches  for  the  identification  of  the  protein  spots.  As  mentioned  previously,  2-DGE  can 
separate  hundreds  or  even  thousands  of  proteins  orthogonally  according  to  their  charge  (pI)  in  the  first 
dimension and by their molecular masses in the second dimension. 
 
In the first dimension, termed isoelectric focussing, proteins migrate through a pH gradient formed 
within a polyacrylamide gel until they reach their isoelectric point (the point at which their charge is the same 
as the surrounding pH). With the development of immobilised pH gradient (IPG) gels (Bjellqvist et al., 
1982),  in  which  the  pH  gradient  is  maintained  by  acrylamido  buffers  that  are  co-polymerised  and  so 
‘immobilised’ into the gel, the overall sample to -sample reproducibility has greatly improved (Gorg et 
al.,1988).  
 
In  the  second  dimension,  IPG  strips  containing  the  focussed  proteins  are  soaked  in  a  denaturing 
solution containing sodium dodecylsulphate (SDS). The strong negatively charged SDS binds to all of the 
proteins within the strip making them essentially have the same charge. This strip is placed at the cathode of 
a second polyacrylamide gel. When an electric field is applied to this second dimension gel, proteins migrate 
from the cathode (IPG strip) towards the anode. Although all the proteins move in the direction of the anode, 
smaller proteins move faster through the gel than larger ones, hence, proteins are separated according to their 
size.  This  second  dimension  separation  is  essentially  the  same  as  conventional  one  dimensional 
polyacrylamide gel electrophoresis (1-DGE), which is also used in many proteomic approaches for protein 
separation. 
 
After separation, the proteins need to be visualised using a protein specific stain. There are a number 
of different stains available with a range of sensitivities and dynamic ranges. The most commonly used 
staining techniques are coomassie blue, silver staining, and fluorescent stains such as Sypro Ruby. For a 
detailed review on staining techniques, see Patton (2002). All proteins appear as spots on the gel indicating 
their location. The intensity of the spot can subsequently be used to quantify the amount of protein between Chapter 1    General introduction 
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samples separated on different gels. This can usually be achieved using commercial gel image quantitation 
packages such as PDQuest (BioRad, Hercules, CA). 
 
Because even the best 2-DGE can separate no more than 1500 proteins, the dynamic range of protein 
expression that can be measured is limited to only the most abundant proteins of a crude protein mixture. 
Relative to DNA microarrays, the number of induced proteins observed in 2-DGE can be underestimated by 
2 to 4 fold (Eymann et al., 2002; Hommais et al., 2001; Conway and Schoolnik, 2003). It is also now evident 
that there are many other challenges faced when utilizing this technology with proteins that have extreme 
physico-chemical  properties  such  as  very  acidic,  very  basic,  very  small,  very  large,  or  low  abundance 
proteins (Gygi et al., 2000). 
1.9.1.2 Multidimensional chromatography 
Faced  with  the  limitations  of  2-DGE  technology,  there  has  been  a  major  thrust  to  alternative 
technologies.  One  approach  that  has  generated  a  notable  amount  of  interest  is  multidimensional  liquid 
chromatography (Link et al., 1999; Opiteck et al., 1997). 
 
Multidimensional chromatography allows separation of complex mixtures by using multiple columns 
with different stationary phases. These columns are coupled orthogonally, which means that fractions from 
the first column can be selectively transferred to other columns for additional separation using an alternative 
physio-chemical principle. This enables separation of complex mixtures that cannot be separated using a 
single column. This technology coupled on-line to MS/MS, provides a powerful method for resolving and 
identifying peptides/proteins from complex mixtures and thus has also been termed multidimensional protein 
identification technology (MudPIT). An example of this was developed in the Yates laboratory using strong 
cation exchange (SCX) and reverse phase nanocapillary columns arranged in series to provide high resolution 
separation and concentration of tryptic peptides derived from protein samples, prior to their identification by 
MS/MS. In this study they were able to resolve and identify 1,484 proteins from 5540 peptides in bakers 
yeast  (S.  cerevisiae),  in  comparison  to  around  300  previously  identified  by  2-DGE,  thus  significantly 
improving  proteome  coverage.  Included  in  these  proteins  were  low  abundance  proteins,  proteins  with 
extreme pI and molecular mass, and integral membrane proteins (Washburn et al., 2001; Wolters et al., 
2001). By combining two or even more orthogonal separations based on different physiochemical properties, 
samples of increasing complexity, over wide dynamic ranges can be resolved (Garbis et al., 2011).  
1.9.1.3 GeLC-MS/MS 
Another technically simpler alternative to both 2-DGE and MudPIT has been termed GeLC-MS/MS. 
Like MudPIT, significant gains in proteome coverage have been found using this technology by essentially 
boosting peak and load capacity. GeLC-MS/MS uses conventional 1-DGE for protein separation. Slices of 
the gel, containing fractionated proteins, are then subjected to in-gel digestion with a site-specific endo-
protease such as trypsin, prior to further fractionation with nanocapillary LC columns and on-line peptide 
identification via tandem MS (Schirle et al., 2003). Although, the good separation ability of GeLC-MS/MS 
has been applied to relatively simple mixtures, it has also been demonstrated to be capable of separating Chapter 1    General introduction 
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relatively complex mixtures by resolving and identifying 1289 plasmodium proteins (Lasonder et al., 2002). 
The  technique  has  found  particular  application  in  qualitative  proteomics,  alternatively  referred  to  as 
‘shotgun’proteomics’ (Skipp and O’Connor, 2011).  
 
Although not a true quantitative technique, several empirical indications can be used to estimate the 
relative abundance of a protein in a mixture using this technique. In general, the higher the amount of protein, 
the  greater  the  MS  signal  intensity  of  their  corresponding  peptide  ions.  Also  the  number  of  sequenced 
peptides recovered for each protein and the number of spectra obtained for each peptide are proportional to 
the  abundance  of  the  protein  in  question.  These  are  refered  to  as  ‘spectral  counting’  or  ‘exponentially 
modified peptide abundance index’ (Rappsilber et al., 2002; Liu et al., 2004; Ishihama et al., 2005; Lu et al., 
2007).  
 
1.10 Protein Identification 
 
In  the  past  decade,  a  major  limitation  has  been  the  lack  of  sensitive  methods  to  unambiguously 
identify the separated proteins of interest. A number of methods for protein identification have been explored 
during this time and these are discussed below. 
 
1.10.1 Co-localisation 
In co-localisation, unknown proteins are identified by comparison to previously identified proteins for 
identification. For example, in 2-DGE, the molecular weights and pI’s of previously identified proteins are 
compared to those of unknown proteins analysed under identical conditions. Proteins that migrate to the same 
position as the previously identified known proteins on the gel are considered to be the same proteins. Co-
localisation  is  clearly  limited  in  its  use  for  large-scale  protein  identification  experiments,  but,  in  small 
focused analyses, it can play an important role.  
 
1.10.2 Protein sequencing by the Edman degradation technique 
Ideally, the ultimate protein identification would consist of the entire sequence of a protein including 
its  post-translational  modifications.  Although  modern  N-terminal  protein  sequenators  using  Edman 
degradation (Edman and Begg, 1967) are able to assign the identity of a protein with sufficient confidence 
when >10 amino acid residues are obtained, they are limited to a maximum analysis of around 70 amino acid 
residues per peptide/protein and have high sample concentration requirements to achieve such coverage. 
Additionally,  80%  of  eukaryotic  proteins  cannot  be  N-terminally  sequenced  due  to  post-translational 
modifications at the N-terminus (Nokihara, 1998). To circumvent this problem of short read-lengths and N-
terminal blocking, internal peptides can be sequenced following digestion of proteins with an endo-protease 
or by chemical cleavage and then peptide separation. Proteomic studies require sensitive, high throughput 
identification strategies whereas these types of approaches require significant (pmol) amounts of protein and 
are costly. Further, the determination of each amino acid residue using an N-terminal sequencer takes around 
23 minutes Thus, for the 10 amino acids required for a confident assignment, approximately 4 hours per Chapter 1    General introduction 
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peptide would be required. Sequence analysis via the C- terminus is even more difficult and requires more 
starting material. 
 
1.10.3 Protein Mass and pI 
Experimentally  determined  mass  and/or  the  pIs  of  proteins  from  2-DGE  have  been  compared  to 
theoretical values of proteins for identification. However, the masses and pIs of proteins determined by 2-
DGE  are  of  low  accuracy  making  assignment  of  proteins  based  on  these  measurements  impossible.  In 
addition, post-translational modifications that are not indicated in the theoretical sequence will not be taken 
into account in the molecular mass and pI calculation, which further complicates identification. However, the 
use of mass as an identification feature in proteomics is appealing. Developments in the area of biological 
mass spectrometry (MS) now allow the measurement of intact proteins and their proteolytic fragments to a 
very high accuracy (Kelleher et al., 1999; Biemann and Papayannopoulos, 1994; Shevchenko et al., 1996) 
There has therefore been a major push to devise new techniques to exploit these improvements in mass 
spectrometry technology. 
 
1.11 Biological Mass spectrometry 
 
Advances in biological MS, together with similar advances in bioinformatics, have enabled the rapid, 
unambiguous identification of proteins that are present in the sub-picomolar range. MS is now the method of 
choice for protein identification and also forms the basis of many new approaches for the simultaneous 
quantitation  of  proteins  within  a  biological  sample.  For  clarity  in  the  explanation  of  these  MS-based 
approaches, it is first relevant to discuss the elements and types of instrumentation used in biological mass 
spectrometry. 
 
A mass spectrometer consists of three essential elements: 
1. An ionization source, which converts molecules in either solution or solid form into gas phase ions. 
2. One or more mass analysers, to separate the gas phase ions according to their mass-to-charge ratios (m/z). 
3. An ion detector to count the ions emerging from the last mass analyser. 
Most mass spectrometers use the same type of ion detector, but use different ion sources and mass analysers. 
Conventionally a mass spectrometer is named after the type of its ion source and the type of mass analyser. 
 
1.11.1 Ion sources 
One of the most important advances in biological mass spectrometry has been the innovation of robust 
techniques for ionising biomolecules such as peptides, thereby allowing their efficient introduction into mass 
analysers for analysis. The two key techniques matrix-assisted laser desorption ionisation (MALDI) and 
electrospray ionisation (ESI) have revolutionised such analyses, allowing the analysis of proteins in excess of 
1 MDa, and have been combined with a variety of mass analysers.  
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1.11.1.1 Matrix-assisted laser desorption ionization (MALDI) 
MALDI (Karas and Hillenkamp, 1988; Beavis and Chait, 1996) is achieved in two steps. In the first 
step, the compound to be analysed is mixed in a solvent containing small organic molecules, called a matrix, 
and that has an absorbtion wavelength that closely matches that of the MALDI source laser. This mixture is 
then dried onto a surface to form a heterogeneous layer containing analyte embedded in matrix crystals. The 
second step involves ablation of bulk portions of this crystalline matrix by intense, short pulses of laser. The 
irradiation  by  the  laser  causes  rapid  heating  of  the  crystals,  which  in  turn  causes  local  sublimation  and 
expansion of the matrix into the gas phase. Ionisation reactions can occur at any time during this process, but 
the origin of ions in MALDI is still not fully understood (Zenobi and Knochenmuss, 1998). The rationale for 
the matrix is that it has a different absorbance wavelength to the analyte thereby minimising laser-mediated 
fragmentation of the latter. The analyte embedded in this matrix co-desorbs, achieving ionisation without 
directly receiving the laser light energy. 
 
Matrix selection and optimization of the sample preparation are the most important factors in this type 
of analysis. The choice of matrix is based on the laser wavelength used and the class of compound to be 
analysed. Currently there are two main MALDI sources that deliver energy on different wavelengths. UV is 
more common and delivers the energy electronically using either an N2 or frequency tripled Nd:YAG laser 
with a wavelength of 337 nm or 355 nm respectively. IR-MALDI delivers energy vibrationally to the matrix 
using wavelengths around 3 µm. Common UV-MALDI matrices used for peptide analysis include α-Cyano-
4-hydroxycinnamic acid and 2,5-Dihydroxybenzoic acid. 
 
The  MALDI  technique  is  relatively  insensitive  to  contamination  (salts,  buffers,  detergents,  etc) 
compared to other ionisation techniques and produces mainly singly charged molecular species with very few 
multiply charged or fragment ions, producing simpler mass spectra. Historically, certain types of source / 
mass analyser have been used in combination. Although MALDI, a pulsed ion source, has been linked to 
other types of analyser, the most important has been the time-of-flight (TOF) analyser. The introduction of 
the MALDI source has led to considerable development and innovation in the area of TOF technology.  
1.11.1.2 Electrospray ionisation 
The success of the continuous ion source, electrospray (ESI), started when Fenn et al. (1989) showed 
that multiply charged ions could be obtained from proteins, allowing their molecular masses to be determined 
on instruments, whose mass range was limited to 2000 Da. At the beginning, ESI was thought to only have 
application for the analysis of proteins, but later, was extended not just to the analysis of polymers and 
biopolymers, but also to the analysis of small polar molecules. The source was easy to couple to high-
performance  liquid  chromatography  (HPLC),  nano-  and  capillary-  LC  and  capillary  electrophoresis,  and 
became the source of choice for such applications. 
 
In ESI, gas phase ions are generated by applying a potential to a flowing liquid, containing both the 
analyte and solvent molecules. A strong electric field is applied to a liquid passing through a capillary tube 
(normally at 0.2 – 10 µl/min). The electric field is obtained by applying a potential difference (2 – 5kV) Chapter 1    General introduction 
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between this capillary and the counter-electrode (Figure 1.4). This electric field at the spray tip creates a 
charge separation by, in positive ion mode, attracting anions to the capillary tip and repelling cations to the 
solution surface. The field pulls the surface towards the sampling aperture, but is opposed by the surface 
tension of the liquid. These forces balance forming a Taylor cone from which a spray appears. The solvent 
contained in the droplets evaporates causing them to shrink to the point where coulombic forces cause them 
to divide into smaller droplets. This process continues, producing smaller and smaller droplets, until the field 
strength on their surface becomes great enough to cause ions to be desorbed from the surface. The detection 
limits  that  can  be  achieved  with  ESI  have  improved  dramatically  by  reducing  the  flow  rates  to  the 
nanolitre/minute range using microspray (Andren et al., 1994) and nanospray inlets (Wilm and Mann, 1996). 
Andren et al. (1994) were able to detect 320 zeptomole/µL of a neuropeptide using a microspray inlet. ESI 
has typically been used in conjunction with quadrupole or ion-trap mass analysers to produce information by 
tandem  mass  spectrometry  (MS/MS).  However,  the  use  of  continuous  ion  sources,  such  as  ESI  with 
orthogonal acceleration time of flight mass (OaTOF) analysers is now commonplace. 
 
 
 
Figure 1.4. Representation of the Electrospray ionisation (ESI) process. 
 
1.11.2 Mass analysers 
Once the ions have been generated, they need to be separated according to their m/z ratio. Mass 
analysers use time (e.g., TOF) or an electric or magnetic field (e.g., quadrupole or ion trap) to separate ions 
of a particular m/z before their detection by the ion detector. There are many types of analyser. However, 
only  four  will  be  covered:  quadrupole  mass  filters  (Q),  TOF  analysers,  Fourier-transform  ion  cyclotron 
resonance and Orbitrap, the first two of which, have been used during the course of the research described in 
this thesis. 
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1.11.2.1 Quadrupole mass filters 
Quadrupole analysers (Paul and Steinwegen, 1953; Ferguson et al., 1965), consist of four parallel rods 
(Figure 1.5) with circular or, ideally, hyperbolic section. Oscillating and constant voltages are applied to 
these rods to generate a field that allows ions of a particular m/z to pass down between the rods, that is, to 
have a stable trajectory through the quadrupole to an ion detector. By scanning through a range of voltages, 
the field can be altered to select for ions of different m/z values. Ions that have unstable trajectories discharge 
themselves against the rod and are not detected. 
 
As a scanning instrument, the quadrupole is more amenable to continuous ion sources such as ESI. 
However, although the stream of ions is continuous, only ions within a specified m/z window are allowed 
through; the remainder are wasted resulting in a low duty cycle (i.e. the number of ions detected in one scan). 
Quadrupoles are considered to be low-resolution instruments and are generally operated at unit resolution, 
i.e. a resolution that is sufficient to separate two peaks one mass unit apart. 
 
 
Figure 1.5. Layout of a quadrupole mass filter. The red arrow represents an ion with a stable trajectory, blue 
an unstable trajectory of the ion. Reproduced with permission from www.chem.vt.edu/chem-
ed/ms/graphics/quad-sch.gif. 
1.11.2.2 Time of Flight mass analysers 
Stephens in 1946 (Stephens, 1946) described the principle of the time of flight analyser. Since the end 
of the 1980s there has been renewed interest, in part, due to advances in electronics to handle the dataflow, 
but mainly because of the development of pulsed ion sources like MALDI, to which TOF analysers have 
been particularly suited. Chapter 1    General introduction 
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A time-of-flight analyser uses the differences in flight time through a field-free drift region to separate 
ions of different m/z values. Ions are produced in pulses and an electric field accelerates them into a field- 
free region at very low pressure (~10
-7 Torr), with a kinetic energy qV, where q is the ion charge and V is the 
applied accelerating voltage. Since the ions kinetic energy is ½ mv
2, lighter ions have a higher velocity than 
heavier ions and reach the detector at the end of the drift region sooner. Their m/z value can be calculated 
using the following equation. 
m / z = 2eVobs(t/d)
2    
e = charge of an electron, Vobs = accelerating potential, d=length of flight tube and t = time taken to traverse 
the flight tube. 
 
Initially, one of the limiting factors in the development of TOF analysers was poor resolution. This 
could be attributed in part to Wiley and MacLaren’s (1955) observation that ions of a particular m/z would 
reach the detector with a spread in arrival times. This is due to the effects of uncertainty in the time of ion 
formation,  location  in  the  extraction  field  and  differences  in  initial  kinetic  energy,  resulting  in  reduced 
resolution. Using a pulsed two-grid ion source, Wiley and McLaren developed an approach termed delayed 
extraction, which compensates for temporal, spatial and differences in kinetic energy distribution providing 
improvements in resolution (Wiley and MacLaren, 1955). In brief, all the ions are given the same initial 
kinetic energy by the extraction pulse and then drift along the field free region where they are separated, so 
that all ions of the same m/z arrive at the detector simultaneously. However, because the pulse energy is not 
felt by all ions with equal intensity, a kinetic energy spread for each m/z exists. This lowers the resolution by 
creating a time-of-flight spread for each m/z. Differences in these kinetic energies can be compensated by 
incorporation of a reflectron at the end of the flight tube. This is in essence an electrostatic mirror and 
consists of a series of electric fields that deflect ions back along the flight tube, resulting in a re-focusing of 
ions with the same m/z value on the ion detector. ‘The development of the reflectron represents one of the 
most important advances in increasing resolution of the TOF analyser’ (Mamyrin, 2001). Some modern 
commercial TOF analysers boast resolutions of up to 60,000. 
 
The requirement of TOF analysers for discrete packets of ions (pulses of ions, i.e. from MALDI 
source) prohibited the use of continuous ion sources such as ESI, until the introduction of the orthogonal 
acceleration Time-of-Flight analyser (OaTOF) (Guilhaus et al., 2000). In an OaTOF analyser, an accelerating 
potential is applied at right angles to the continuous ion beam generated from the ion source. The ion beam is 
then chopped using a pulsed voltage supply coupled to the orthogonal accelerator to provide repetitive pulses 
at a frequency of a few kilohertz. These packets of ions are then allowed to drift into the flight tube where the 
ions separate according to their flight time. 
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In a TOF analyser, since all ion times (m/z) are measured on the micro-second time scale, the duty 
cycle is much shorter than scanning instruments, such as the quadrupole and hence offer increased sensitivity 
at full scan. The development of the OaTOF analyser has provided the advantage of being able to couple 
liquid chromatography, capillary electrophoresis, etc. through ESI sources. 
 
Accurate mass measurement, coupled with sufficient resolution, greatly restricts the enormous number 
of possible molecular formulas that might be represented by a particular molecular mass. The technological 
advances of TOF in terms of resolution and hence mass accuracy make TOF analysers a powerful tool for 
proteomic  analysis.  Mass  measurement  accuracy  of  10  ppm  allows  useful  measurements  of  molecular 
formulas, although 1 to 2 ppm is preferable. TOF mass spectrometers are now providing better than 2 ppm 
mass accuracy routinely.  
1.11.2.3 Fourier transform ion cyclotron resonance 
The Fourier-transform ion cyclotron resonance (FT-ICR) analyser (Comisarow and Marshall, 1974a; 
Comisarow and Marshall, 1974b) is also an analyser that has been used for proteomic analysis. The analyser 
has extremely high sensitivity and resolution (up to 1,000,000) with mass accuracy that can exceed 1 ppm.  
 
It has been proven to be particularly useful for the analysis of complex mixtures, i.e., tryptic digests of 
proteins, where it has been shown that the accurate mass of certain single peptides measured by FT-ICR, 
along  with  easily  obtainable  constraints,  can  be  used  to  identify  proteins  unambiguously  by  sequence 
database searching (Goodlett et al., 2000).  
 
In FT-ICR (reviewed by Marshall, 1998), ions are injected into a penning trap. These ions are then 
excited using a resonant excitation pulse where they begin to cycle (orbit). Once this excitation pulse is 
removed, the ions continue in their orbit. Within the trap, detector plates are located at fixed positions. As the 
ions move near these plates, they induce an image (electrical signal) on the detector plates. This image 
current will oscillate at the ions resonant frequency and can be amplified, digitised and recorded. Since ions 
with the same m/z will rotate at the same frequency, a fourier transformation on the signal can be used to 
deconvolute the data and obtain a mass spectrum.  
 
FT-MS  has  the  advantage  of  improved  sensitivity  as  well  as  much  higher  resolution  and  thus 
precision. However, there are a number of disadvantages that has limited their wide acceptance in proteomic 
laboratories.  For  example,  as  the  speed  of  front-end  separations  increases,  the  analysis  time  is  reduced, 
reducing sensitivity and space-charge-related mass shifts limit dynamic range and mass accuracy. This has 
provided impetus for research into new types of 
 high resolution mass analyzers. 
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1.11.2.4 Orbitrap 
A  fundamentally  new  type  of  mass  analyser,  the  Orbitrap  (Makarov,  2000)  has  recently  been 
introduced, offering high-resolution (typically 60,000 – 240,000 fwhm), sub- ppm mass accuracy (Olsen et 
al., 2005), high sensitivity, increased dynamic range and reduced running costs. (commercially available 
since 2005). Ions are electrostatically trapped in an orbit around a central, spindle-shaped electrode. They 
perform  two  kinds  of  movements  in  parallel:  First,  they  cycle  in  an  orbit  around  the  central  electrode. 
Second, they also move back and forth along the axis of the central electrode. Thus, the ion movement 
resembles a ring that oscillates along the axis of the spindle. This oscillation generates an image current in 
detector plates that is recorded. The frequencies of these image currents are dependant upon the m/z of the 
ions and mass spectra are obtained by Fourier transformation of the recorded image currents. As such, these 
instruments are routinely used within proteomic laboratories (Scigelova and Makarov, 2006).  
 
1.11.3 Tandem mass spectrometry 
Tandem mass spectrometry (MS/MS) or multistage mass spectrometry (MS
n) allows more structural 
information  to  be  obtained  on  a  particular  ionic  species.  This  is  particularly  the  case  if  soft  ionisation 
techniques, which produce very little fragmentation, such as MALDI or ESI are used.  
 
In the most common MS/MS experiment, a first analyser is used to isolate a precursor ion, which then 
undergoes  fragmentation  to  yield  product  ions  (also  known  as  daughter  ions),  which  are  measured  in  a 
second spectrometer. It is possible to increase the number of stages. For example, one can fragment an ion of 
a particular mass to produce product ions and then select one of those product ions for further fragmentation 
and measure the resulting fragment ions. This would be termed MS/MSMS or MS
3. The number of steps can 
be increased further to yield an MS
n experiment (where n refers to the number of generations of the ions 
being analysed).  
 
Tandem mass spectrometry can be achieved in two ways: in space by the coupling of two physically 
distinct instruments, or in time by performing an appropriate sequence of events in an ion storage device. 
Conventionally, for tandem in space methods, two transmissive mass analysers with an ion manipulation 
stage between them have been used. The most common instrument of this type is the triple quadrupole mass 
spectrometer (QqQ). The coupling of a quadrupole analyser to a TOF analyser, commonly known as Q-TOF, 
provided a major advancement for the area of proteomics allowing analysis using high resolution tandem 
mass spectrometry of peptides in complex mixtures using both MALDI and ESI ionisation (Morris et al., 
1996; Shevchenko et al., 2000). However, obtaining higher order MS
n spectra requires n analysers to be 
combined in series and as such is difficult to implement because of the technical challenges and potential 
cost.  
 
Tandem-in-time methods such as the ion trap, ICR and FT-ICR are able to achieve MS
n successively 
by analysing, reacting and reanalysing in the same instrument. A significant difference between an ion trap 
and FT-ICR is that in the former, ions are expelled from the trap to be analysed. In the Fourier transform Chapter 1    General introduction 
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mass spectrometer, they can be observed non-destructively and are therefore measured at each step in the 
sequential  fragmentation  process.  Ion  traps  have  also  been  coupled  with  TOF  analysers  to  remove  the 
limitation of low m/z detection associated with ion trap instruments. 
1.11.3.1 Collision Induced Dissociation fragmentation 
In MS/MS and MS
n studies, a precursor ion is selected and generally fragmented in a collision cell 
generating  product  ions  before  the  mass  spectrum  is  acquired.  Using  this  fragmentation  data,  structural 
information can be obtained for different types of molecules such as peptides, proteins, sugars and small 
molecules. One of the most common methods of fragmentation currently used in proteomics is collision 
induced dissociation (CID), also known as, collisionally activated decomposition (CAD) (Hayes and Gross, 
1990; McLuckey, 1992). In CID, a precursor ion undergoes repeated collisions with a collision gas at a 
pressure,  bringing  the  ion  into  an  excited  state.  Once  the  fragmentation  threshold  is  reached,  the  ion 
undergoes  unimolecular  decomposition  forming  product  ions.  The  types  of  product  ions  generated  are 
dependent upon the energy used and the precursor ion. At lower energies, neutral losses such as H2O, CO, 
CO2, etc are observed. At higher energies more structurally significant product ions are obtained and often 
result in cleavage of the molecule at characteristic positions such as those found in peptide fragmentation. 
The fragmentation of protonated peptides follows a defined nomenclature as shown in Figure 1.6. Product 
ions resulting from the backbone cleavage of the αC-C, the C-N amide linkage, or N-αC bond are called a-, 
b-, and c-type ions, if the charge is retained on the amino-terminal fragment, or x-, y-, and z-type ions, 
respectively,  if  the  charge  is  retained  on  the  C-terminal  fragment  ion.  The  product  ions  are  numbered 
according to their positions from their respective terminal end. In general, the most commonly observed 
product ions are b- and y-type ions in low-energy CID. In high-energy CID conditions, d-, v-, and w-type ions 
corresponding  to  side  chain  cleavages  may  also  be  formed.  Although  there  are  alternative  types  of 
fragmentation techniques, CID was used during the course of the studies presented in this thesis. 
 
Figure 1.6.  The nomenclature for ions derived from backbone fragmentation of a peptide by CID (Biemann, 
1988).    Chapter 1    General introduction 
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There are four different types of scan in MS/MS and these are outlined below and in Figure 1.7. Even 
though these are based on scanning modes of a triple quadrupole, most can be applied to other instruments 
with very little modification. 
 
 
1.  Product ion scan - In this case, the precursor ion is focussed in the first mass spectrometer, fragmented 
in the collision cell and the resulting product ions measured in the second spectrometer. 
 
2.  Precursor ion scan - In this case the second mass spectrometer is held to measure the occurrence of a 
particular fragment ion and the first mass spectrometer is scanned. This results is a spectrum of 
precursor ions that arise from that particular product ion. 
 
3.  Neutral loss scan - In this case the first mass spectrometer is scanned as in (2) but this time the second 
mass spectrometer is also scanned but at a defined mass offset to produce a spectrum of precursor ions 
that undergo a particular neutral loss. 
 
4.  Selected reaction monitoring – In this case, both the first and second analysers are focused on selected 
masses so that the masses in the first mass spectrometer are only selected if a fragment ion of the correct 
mass is also observed. 
 
 
 
 
 
Figure 1.7. The four main scan modes in tandem mass spectrometry. 
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1.11.4 Peptide mass fingerprinting 
MALDI-TOF-MS is high-throughput, sensitive and has traditionally been used as a primary screen for 
the identification of proteins from 2-D gels using a peptide mass fingerprinting approach (PMF). In PMF, a 
protein sample is digested with a site-specific protease, such as trypsin and the peptide masses determined by 
MS (Yates et al., 1993; James et al., 1993; Henzel et al., 1993). The measured peptide masses obtained 
provide a fingerprint of the protein under analysis. Using readily available genomic data, the masses of the 
measured proteolytic peptides are compared to predicted proteolytic peptides generated ‘in- silico’ from the 
genomic data (Figure 1.8). In detail, a protein sequence entry from a genomic database is theoretically 
digested according to the specificity of the protease used for digestion, taking into account user-specified 
parameters such as number of missed cleavage sites and known modifications (e.g., cysteine modifications). 
Essentially, a theoretical mass  spectrum  is  constructed  for  each  protein  within  the  database,  statistically 
analysed and the best match to the submitted list of peptides obtained. 
 
This type of approach is dependent on obtaining a sufficient number of peptides that match the protein 
being identified.  However, the presence of unknown post-translational modifications or a reduced number of 
peptides as a consequence of low sample amounts, may result in some theoretical masses being unaccounted 
for, and hence reduce the statistical confidence of the identification. Other disadvantages are the requirement 
for the protein sequence to be present in the database of interest (i.e., a genome sequence is required) and that 
the presence of a mixture of proteins can significantly complicate the analysis and potentially compromise 
the results. 
 
The comparison or scoring can be simple (i.e., number of matching peptide ions) or more complex. 
The  problem  with  using  the  number  of  matches  for  assignment  is  that  it  does  not  show  how  well  the 
theoretical  match  fits  the  experimental  data  (i.e.,  quality  of  match)  or  whether  sufficient  data  has  been 
provided to identify a hit above the background (i.e., significance match) (Eriksson and Fenyö, 2002). There 
are a number of scoring systems now available based upon a range of different scoring characteristics from 
heuristic to probalistic, all of which have their advantages and disadvantages. Several software packages have 
been  developed,  but  the  most  commonly  used  are:  MASCOT  (Perkins  et  al.,1999),  PepIdent  (Gras  et 
al.,1999), Profound (Zhang et al., 2000), SEQUEST (Eng et al., 1994), X!Tandem (Craig and Beavis. 2004) 
ProteinLynx  (Waters,  Manchester,  UK)  and  more  recently  Andromeda  (Cox  et  al.,  2011).  Peptide 
fragmentation patterns from MS/MS experiments may also be used in a similar approach to identify peptides. 
As  described  earlier,  peptides  fragment  in  a  predictable  manner,  this  property  can  be  used  to  obtain 
theoretical  fragmentation  patterns  for  individual  peptides,  which  can  then  be  matched  to  the  observed 
fragmentation patterns using similar matching and scoring algorithms.  
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Figure 1.8.  Representation of a peptide mass fingerprinting experiment. Workflow (A) outlines a process 
for generation of the experimental data. Workflow (B) outlines the ‘in silico’ process for matching and 
scoring of the experimental data to a genomic database to obtain a protein ID. 
      
1.11.5 LC-MS/MS 
Peptide  mass  fingerprinting  can  allow  the  identification  of  a  single  protein  or  in  some  cases  the 
components of a simple mixture. However, the analysis of complex mixtures or the identification of a protein 
from a single peptide is not possible. In contrast, combining liquid chromatography with tandem MS (LC-
MS/MS), allows the identification of proteins from complex mixtures and can also provide identification of a 
protein from a single peptide. Universally, most LC-MS/MS experiments are accomplished by coupling on-
line reversed phase high performance liquid chromatography (RP-HPLC) to an MS/MS instrument. Protein 
digests can be loaded onto the RP-HPLC column, separated and fragmentation information for each peptide 
obtained by MS/MS. Selection criteria for the acquisition of fragmentation data can be defined. The speed 
and complexity of these types of separations often prevents the collection of MS/MS data of all components 
within a mixture. A method called data-dependent-acquisition (DDA) allows criteria such as intensity and 
charge state to be used in an intelligent way to interrogate samples. As part of these criteria, exclusion lists 
can be used to eliminate previously analysed ions for a defined period of time, thereby forcing the pursuit of 
low abundance precursors and hence increasing coverage of the sample (Davis et al., 2001 and Spahr et al, 
2001). The replacement of large bore columns by nano and capillary columns for LC-MS/MS, has vastly 
increased sensitivity by reducing the volume of solvent sprayed (between 50 and 400 nl/min) and effectively 
concentrating the sample as it enters the source, allowing the identification of proteins at the low femtomole 
level (Emmett and Caprioli et al., 1994; Natsume et al., 2002). Chapter 1    General introduction 
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1.11.6 Qualitative analysis 
In MS/MS, a specific peptide ion is selected and fragmented. Theoretically, this makes the complexity 
of the original digest irrelevant. However, in practice, one-dimensional peptide chromatography often does 
not  provide  sufficient  peak  capacity  to  separate  peptides  from  complex  mixtures  to  allow  current  mass 
spectrometers to ‘keep up’ with MS/MS demands (Michalski et al., 2011). To address this problem, various 
different combinations of protein and peptide separation  schemes have been explored involving two-  or 
three-dimensional chromatography and/or one-dimensional gel electrophoresis as discussed earlier in this 
Chapter.  Alternative  MS  strategies  have  also  been  employed.  Utleg  et  al.  (2003),  utilised  gas  phase 
fractionation to assign 128 previously unknown proteins, from a total of 139 from the human proteasome by 
repeated  experiments  using  narrow  but  overlapping  m/z  ranges.  Using  a  combination  of  these  different 
fractionation strategies, including 1D-GE, peptide isoelectric focusing and gas phase fractionation, essentially 
complete proteome coverage of the yeast, Saccharomyces cerevisiae has been achieved (de Godoy et al., 
2008). Nonetheless, the combinatorial nature of using multiple fractionation steps requires extensive MS 
instrument time (~1000 hrs) and are likely to prohibit the use of such strategies on a routine basis, even for 
relatively small proteomes. However, more recently, one-dimensional LC separations using long columns 
combined with orbitrap analysers, have afforded proteome coverage on a microarray scale within a single 
analytical run (Iwasaki et al., 2010; Nagaraj et al., 2012). These ‘single-shot’ approaches are very attractive 
since  they  reduce  analysis  time,  minimise  sample  requirements,  and  potentially  improve  reproducibility 
between  analytical  runs.  While  at  present  they  may  not  be  suitable  for  in-depth  characterisation  of  a 
proteome, e.g. isoforms or sites of post-translational modifications, with advances in both separation and MS 
technologies, ‘single-shot’ approaches could be applied to more complex proteomes. 
 
1.11.7 Quantitative approaches 
The concentration of an analyte and its relationship to the measured signal intensity depends upon a 
number of factors that are difficult to control and are not fully understood (Aebersold and Mann, 2003). As a 
result,  without  internal  standards,  mass  spectrometers  are  poorly  quantitative.  To  provide  quantification, 
whilst utilising the speed and sensitivity of LC-MS/MS, strategies based upon stable isotopes have been 
employed. The difference in mass between pairs of chemically identical analytes of different stable isotope 
composition can be measured in a mass spectrometer. The measured ratio of the signal intensities between 
these pairs indicates the abundance ratio of the two analytes. It is on this basis that a number of strategies 
centred on stable isotope tags have been introduced. 
 
Metabolic labelling of samples using isotopically labelled amino acids provides certain advantages. 
Stable isotope labelling with amino acids in cell culture, or SILAC (reviewed by Ong et al., 2003), utilises 
the incorporation of essential amino acids such as [
13C]-labelled arginine and/or lysine into proteins within a 
particular cell state. This can then be compared to a cell state where the proteins contain native [
12C] arginine 
and a differential expression ratio obtained. The early combination of samples from cells in the two states 
eliminates errors due to subsequent handling steps, such as the use of multi-step purification strategies. As Chapter 1    General introduction 
   
46 
discussed  in  the  previous  section,  de  Godoy  et  al.  (2008),  made  the  landmark  advance  of  essentially 
identifying the entire yeast proteome. Further, this study was a comparison of haploid and diploid yeast 
proteomes using SILAC, quantifying 4,399 proteins, demonstrating that relative quantitation data can also be 
obtained for complete proteomes. 
 
As  elegantly  demonstrated  above,  SILAC  is  well  suited  to  cells  grown  in  culture;  however,  the 
application of the approach to intact multicellular organisms presents additional complexities. Nonetheless, 
the approach has been extended to nematode worms  (Krijgsveld et al., 2003), human tissue (Geiger et al., 
2010a)  and  even  mice  (Krüger  et  al.,  2008).  But,  for  many  organisms,  particularly  animals,  difficulties 
associated with isotope incorporation means that in vivo labelling is not an option (Beynon and Pratt, 2005). 
In such cases, post-isolation chemical isotope tagging of proteins, is currently the most commonly used 
labelling method. A number of isotope tagging chemistries have been described, although probably the most 
commonly used are ICAT (Gygi et al., 1999b) and iTRAQ (Ross et al., 2004; Choe et al., 2007), both of 
which are available from ABSciex (formerly available from Applied Biosystems). 
 
The ICAT reagent contains a biotin affinity tag, a linker that contains stable isotopes and a thiol-
specific reactive group. The method relies on tagging cysteine residues at the protein level and isolating 
peptides  containing  these  tagged  residues  by  affinity  chromatography,  after  proteolytic  digestion.  This 
reduces the number of peptides isolated from the pool of peptides, thus providing the advantage of reducing 
sample complexity. Large-scale evaluation of the reproducibility of the ICAT approach, resulted in a median 
coefficient of variation of 18.6%. However, the technique was biased towards acidic proteins (pI<7), under 
represented small proteins (< 10kDa) and surprisingly showed no superiority over 2D-PAGE for the analysis 
of hydrophobic proteins (Molloy et al., 2005). 
 
In the iTRAQ tagging method, the dependence on cysteine containing peptides is eliminated through 
the use of amine-specific tags, thus potentially allowing the tagging of most tryptic peptides (Ross et al., 
2004; Choe et al., 2007). There are currently eight possible tags, which permit multiplexing of up to eight 
samples in a single experiment. The tags have an identical mass as a result of differences in other parts of the 
iTRAQ  tag  structure  (Figure  1.9).  Relative  quantification  is  achieved  using  MS/MS  via  eight  strong 
diagnostic product ions, m/z =113, 114, 115, 116, 117, 118, 119 and 121 Da, produced during fragmentation 
of the labelled peptide. A comparative study looking for markers of endometrial cancer using both iTRAQ 
and ICAT suggests that data obtained by the two approaches are complementary (Desouza et al., 2005). 
ICAT analyses were more selective and provided better detection of lower abundance peptides and proteins, 
conversely, iTRAQ analysis identified a larger percentage of abundant proteins by a number of multiple 
peptides, providing improved statistical confidence in the quantification data. Other potential advantages of 
the iTRAQ approach include, retaining post-translational modifications, which may be otherwise lost if using 
ICAT. Peptide lysates generated by digestion with trypsin are labelled via their N-termini using one of the 
eight different iTRAQ tags. Tagged peptides are selected and fragmented in the mass spectrometer, releasing 
a reporter ion whose intensity reflects the quantity of the peptide. Comparison of reporter ion ratios allows Chapter 1    General introduction 
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differential expression analysis to be performed. The peptide backbone fragment ions are used to identify the 
peptide. 
 
 
 
 
 
Figure 1.9. Structure of the iTRAQ tag and workflow for a 2-plex experiment (after Ross et al., 2004). 
 
The quantification approaches discussed so far have been concerned with the relative amounts of a 
protein between two cellular states. A targeted approach termed AQUA, described by Gerber et al., (2003), 
allows the measurement of targeted proteins in absolute amounts. An internal peptide standard is synthesised 
with incorporated stable isotopes, based upon a predicted tryptic peptide corresponding to the target protein 
of interest. In the method described by Gerber et al., protein lysates are separated by 1-DGE and bands 
corresponding to the molecular mass of the protein of interest are excised (Figure 1.10). The gel band is 
subjected to in-gel tryptic digestion in the presence of known amounts of the internal peptide standard and an 
LC-MRM experiment performed. By comparing the peak area of a specific MS/MS fragment ion from the 
heavily  labelled  internal  peptide,  to  the  corresponding  fragment  ion  of  the  native  peptide,  the  absolute 
concentration of the protein of interest can be calculated (discussed in detail in Chapter 3). Although still 
relatively low throughput, multiplexing strategies and the elimination of the 1-DGE separation step, has 
allowed precise measurement of 10’s to 100’s of proteins in a single assay, with high sensitivity. (Kuzyk et 
al., 2009). The approach is very attractive for validation studies and is more routinely being used as a better 
alternative to immune-based assays such as ELISA. 
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Figure 1.10. AQUA Workflow (after Gerber et al., 2003). 
 
‘Label-free’ strategies for quantitation are increasingly being used since they require no labeling and 
can therefore be applied to almost any biological sample (reviewed by Neilson et al., 2011). These strategies 
take  advantage  of  the  accurate  mass  capabilities  of  high-resolution  mass  spectrometers  and  highly 
reproducible  chromatography.  Nearly  all  label-free  approaches  involve  the  integration  of  peptide  ion 
abundances into chromatographic peak areas from LC-MS or LC-MS/MS runs. The integrated peaks for each 
peptide ion can then be aligned and compared across multiple LC-MS or LC-MS/MS experiments. However, 
for label-free acquisition using LC-MS/MS, there is a trade-off between acquisition of MS survey scans for 
precise peptide quantitation and the number of MS/MS scans required for peptide assignment. This balance 
can often be difficult to achieve, especially in complex mixtures, leading to precursor ions detected in MS, 
but with no corresponding MS/MS fragmentation spectra for identification. One way of resolving this is to 
perform multiple runs of the same sample, performing LC-MS for quantitation and then a separate LC-
MS/MS  experiment  for  identification.  Integrated  peptide  intensities  can  then  be  associated  with  their 
respective peptide identity using an Accurate Mass Retention Time (AMRT) pair (Conrads et al., 2000; Page 
et al., 2004; Silva et al., 2005). For each peptide ion within an analytical run, an Accurate Mass Retention 
Time  (AMRT)  pair  is  generated  consisting  of  a  precise  mass  and  the  LC  elution  time  of  the  peptide, 
providing a unique identifier. Using these AMRT pairs, the intensites of the same AMRTs can be compared 
across  many  LC-MS  and  LC-MS/MS  chromatograms,  providing  both  a  relative  measure  of  peptide 
abundance and peptide identity. 
 
A label-free approach that allows the simultaneous quantitation and identification of proteins within a 
single analytical run is based upon the MS acquisition strategy LC-MS
E
 (Silva et al., 2005; Silva et al., 
2006a; Silva et al., 2006b). Data is acquired using a Q-ToF MS, where the quadrupole is operated in RF 
mode (the quadrupole is only used to focus, but not select the ions). As the peptides are separated by RP 
chromatography and electrosprayed into the MS, the collision cell is alternated between low and elevated Chapter 1    General introduction 
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collision  energies  at  ~1  second  intervals  to  obtain  ion  intensities  from  both  precursor  (low  energy)  and 
fragment ions (elevated energy) simultaneously. Using sophisticated software, each fragment ion is aligned 
with its corresponding precursor ion by exploiting subtle differences in the retention time maxima of each 
eluting precursor. Since there is no disruption to the MS signal by quadrupole switching, the precursor ion 
intensity  can  be  used  to  compare  ion  abundances  between  different  analytical  runs,  whilst  the  elevated 
fragmentation  data  is  used  to  identify  each  peptide  precursor.  Using  this  data-independent  approach, 
improvements in protein and proteome coverage are observed, increasing confidence in peptide assignment. 
This  mode  of  acquisition  has  also  recently  been  applied  using  alternative  MS  platforms  (Geiger  et  al., 
2010b). 
 
An extension of this approach allows the MS peptide intensities identifying a particular protein to be 
used to determine their absolute concentration within a sample. Silva et al. (2006), showed that the average 
MS signal response for the top three most intense peptides from an internal protein standard, could be used as 
a universal response factor (counts/mol) that can be applied to the average of the top 3 most intense peptides 
of  any  other  protein  measured  within  that  sample.  The  authors  successfully  used  these  absolute 
concentrations  to  determining  the  stoichiometry  of  functional  complexes  within  Escherichia  coli. 
Modifications  of  this  Top3  strategy  have  also  been  successfully  employed.  Malmstrom  et  al.  (2009), 
determined  the  absolute  quantity  of  19  proteins  using  targeted  LC-MRM  and  heavily  labelled  peptide 
isotopes. These 19 anchor proteins were used as internal standards to apply the Top3 strategy, obtaining 
estimates of absolute protein abundance for 51% of the human pathogen Leptospira interrogans, ranging 
from 40,000 copies/cell to >10 copies/cell. 
 
 
1.12 Aims and objectives 
 
1. To establish, develop and apply both qualitative and quantitative proteomic techniques for the proteomic 
analysis of the intracellular bacterial pathogen C. trachomatis L2 in both isolated EB and RB forms. 
 
2. To compare using qualitative proteomic techniques the protein expression profiles of EBs and RBs from C. 
trachomatis L2, to provide an insight into the biology of chlamydiae during its unique developmental cycle. 
The dataset generated will also provide a baseline for further quantitative studies. 
 
3.  To  compare  the  protein  expression  profiles  of  EBs  and  RBs  from  C.  trachomatis  using  quantitative 
proteomic techniques developed and established in the earlier part of the work in this thesis. Complementing 
existing transcriptomic data (Belland et al., 2003), the quantitative data generated will further increase our 
biological understanding of chlamydiae. 
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2.0 MATERIALS AND METHODS 
 
2.1 Materials 
The following HPLC grade solvents were obtained from Sigma-Aldrich (Poole, UK): acetonitrile, 
methanol. The following chemicals and reagents were purchased from Sigma-Aldrich: formic acid, acetic 
acid, trifluoroacetic acid, sodium chloride, potassium chloride, sodium dihydrogen phosphate (NaH2PO4), 
sodium  monohydrogen  phosphate  (Na2HPO4),  ammonium  bicarbonate  (NH4HCO3),  triethylammonium 
bicarbonate, DTT (dithiothreitol), iodoacetamide, α-cyano-4-hydoxycinnamic acid, sodium dodecyl sulphate 
(SDS), copper sulphate (CuSO4.5H2O), bicinchoninic acid. Immobilised pH gradient (IPG) strips, pH 4-7 
(Amersham-Pharmacia  Biotech),  ExcelGel,  12-14%  SDS-acrylamide  precast  gels  (Amersham-Pharmacia 
Biotech),  4-12%  NuPAGE  precast  gels  (Invitrogen,  Paisley,  UK),  Sypro  Ruby  protein  stain  (Biorad, 
Hercules, CA), RapiGest™ (Waters corporation, Milford, USA). 
 
Standard  protein  and  peptides  [Glu
1]-fibrinopeptide  B  (ACTH  fragment  18-39),  L-(tosylamido-2-
phenyl) ethyl chloromethyl ketone (TPCK)-treated bovine trypsin, bovine serum albumin (BSA), horse heart 
myoglobin were purchased from Sigma-Aldrich. Alcohol dehydrogenase  reference  digest  was  purchased 
from  Waters  corporation  (Milford,  USA).  Proteomic  grade  trypsin  was  obtained  from  Promega 
(Southampton,  UK).  Unless  otherwise  stated,  all  other  reagents  were  acquired  from  Fisher  Scientific 
(Loughborough, UK) and Promega (Southampton, UK). 
 
Custom synthetic peptides were purchased from Peptide Research Products (Southampton, UK). [
13C] 
labelled isotopic Leucine was obtained from Cambridge Isotopes (Cambridge, UK).  
 
Water for HPLC and all buffer and reagent preparations was produced using an in-house MilliQ™ 
water purification system (Millipore, Billerica, MA) 
 
2.2 General techniques 
 
2.2.1 Bacterial strains 
The strains of Chlamydia trachomatis, Salmonella Typhimurium, Escherichia coli K-12 used in this 
study are listed below: 
 
Bacteria  Strain 
Salmonella Typhimurium  SL1344 
E. Coli K-12  MG1655 
Chlamydia trachomatis  L2/343/Bu (VR902B) Chapter 2    Materials and Methods 
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2.2.2 Bacterial growth media 
S. Typhimurium (SL1344) cells were cultured using Luria-Bertani (LB) medium consisting of 10 g 
tryptone, 5 g yeast extract, 5 g NaCl per litre of deionised water. The pH was adjusted to 7.2 using NaOH. 
LB plates were produced by supplementation of LB media with 1.5% Bacto-agar No.3. 
 
E.coli K-12 were cultured using 2YT medium consisting of 16 g tryptone, 10 g yeast extract, 5 g NaCl 
per litre of deionised water. The pH was adjusted to 7.4 using NaOH. All solutions were autoclaved at 121ºC 
for 20 min prior to use. 
 
2.2.3 Growth of Salmonella Typhimurium SL1344 
S. Typhimurium SL1344 were cultured in LB medium overnight at 37
oC with shaking. The culture 
was diluted 1 in 40 into fresh pre-warmed LB media and grown at 37
oC with agitation.  At  an  A600  of 
approximately 0.5, the culture flask was cooled by incubation in ice water for 20 min prior to harvesting of 
the cells by centrifugation at 4,000 x g at 4°C for 20 min, using a JA21 rotor in a Beckman Avanti centrifuge. 
The cells were washed with pre-cooled 0.9% (w/v) sodium chloride solution (~250 ml), re-pelleted and 
stored at -80ºC. 
 
2.2.4 Growth of Salmonella Typhimurium under conditions of osmotic stress 
Overnight cultures of Salmonella Typhimurium were diluted 1:40 into fresh pre-warmed LB media 
and grown with gentle agitation at 37ºC. Sodium chloride in LB was added to a final concentration of 0.5 M. 
The cultures were incubated for a further 60 min at 37ºC with gentle agitation. When the cells had reached 
mid-exponential growth (A600 = 0.5), the culture flask was cooled for 20 min in ice water, prior to harvesting 
of the cells by centrifugation at 4,000 x g at 4°C for 20 min, using a JA21 rotor in a Beckman Avanti 
centrifuge.  The  cells  were  washed  with  pre-cooled  0.9%  (w/v)  sodium  chloride solution (~250 mls) re-
pelleted and stored at -80ºC. 
 
2.2.5 Growth and preparation of E. coli K-12 (MG1655) for AQUA analysis 
Overnight cultures of E. coli K-12 (MG1655) were diluted 1:6 into fresh pre-warmed 2YT broth and 
grown aerobically with gentle agitation at 37ºC to an absorbance at 600nm (A600) of 1.0. The culture was 
diluted 1:6 into pre-warmed 2YT broth and 35 ml samples dispensed into 250 ml flasks and incubated at 
37ºC with gentle agitation. At each time point, a 35 ml sample was transferred to a Falcon tube whereupon 
500 µl of culture was removed and added to 500 µl of 60 mM sodium azide for determination of cell 
numbers  using  A600  and  haemocytometer  measurements,  as  described  below.  The  remaining  cells  were 
harvested by centrifugation at 12,000 x g for 5 min at 4ºC. Pellets were re-suspended in 2 X Final Sample 
Buffer (as detailed in section 2.4.2) in the ratio of 100 µl per 0.1 A600, incubated at 70ºC for 3 min and stored 
at -20ºC until use. 
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2.2.5.1 Cell counting 
The absorbance at 600 nm (A600) of 1 ml of culture containing sodium azide was measured against a 
suitable blank using a UV spectrophotometer (Hitachi, UK). For haemocytometer measurements, bacterial 
cells  were  counted  using  a  standard  counting  chamber  (Depth  0.1  mm,  1/400  mm
2,  Hawksley,  UK)
  in 
conjunction with a Carl Zeiss phase contrast binocular microscope fitted with a x60 objective lens. 100 µl of 
the diluted cells containing sodium azide were added to the counting chamber, covered with a cover slip and 
counted by visual inspection.  
 
2.2.6 Growth of C. trachomatis 
C. trachomatis L2/434/Bu (VR902B) was obtained from the American Type Culture Collection and 
cultured at 37ºC in Buffalo Green Monkey Kidney Cells (BGMK) in Dulbecco Minimal Essential Medium 
(MEM) (Sigma-Aldrich, Poole, UK) supplemented with 1 µg/ml of cycloheximide (Sigma-Aldrich) and 25 
µg/ml of gentamicin (Sigma-Aldrich) as described by Pickett et al. (2005). For each purified preparation of 
EBs or RBs, Chlamydia were cultured in 14 x T-175 cm
2 flasks per preparation. Cells were harvested at 15 h 
post-infection  for  RBs  and  48  h  post-infection  for  EBs.  Growth  of  C.  trachomatis  was  performed  in 
collaboration with Dr. Joanne Spencer and Mrs Leslie Cutcliffe at Southampton General Hospital. 
 
2.2.7 Purification of EBs and RBs 
Infected monolayers were detached with phosphate buffered saline (PBS) containing 0.125% (w/v) 
trypsin, 0.02% (w/v) EDTA. Individual cell suspensions were pooled and the total cells pelleted in Dulbecco 
MEM supplemented with 10% foetal calfs serum by centrifugation (Allegra 6R, Beckman Coulter, High 
Wycombe, UK) at 3,000 x g for 10 min. The infected cell pellet was re-suspended in 6 mls of PBS:H2O 
(1:10) and homogenised for 6 min using a Dounce homogeniser to break open cells and release RBs and EBs. 
The homogenate was centrifuged at 250 x g to pellet the cell debris. The supernatant, which contained 
partially purified Chlamydia, was mixed with an equal volume of PBS.  
 
Further purification of partially pure RBs and EBs was achieved using two cycles of density gradient 
centrifugation. The partially pure mixture was layered onto 35 mls of 20% (v/v) Urografin 370 (Schering 
Healthcare, UK) in PBS and centrifuged using an Optima L-80 XP Ultracentrifuge (Beckman Coulter) at 
100,000 x g for 2 h in a pre-chilled Beckman SW28 rotor. After centrifugation, the supernatant was discarded 
and the cell pellet containing EBs and/or RBs, were resuspended in 2 mls of PBS. The chlamydial pellet was 
further  purified,  by  layering  onto  a  discontinuous  urografin  gradient  consisting  of  34%,  44%  and  54% 
Urografin 370 in PBS layers. The gradient was prepared as follows: Three percentages of Urografin were 
prepared, 34% (11.9 ml PBS + 6.1 ml Urografin), 44% (6.2 ml PBS + 4.8 ml Urografin) and 54% (3.7 ml 
PBS + 4.3 ml Urografin). To an ultra clear centrifuge tube (Beckman Coulter), 18 mls of 34% Urografin was 
added. Using a syringe with a large metal needle, 10 mls of 44% Urografin was added by placing the needle 
tip to the bottom of the 34% Urografin and adding slowly. A clear interface between the gradients was 
observed. This was then repeated with 7 ml of the 55% Urografin. The 2 mls of resuspended EBs and/or RBs 
were gently layered onto the gradient cushion and centrifuged at 100,000 x g for 2 h in a Beckman SW28 Chapter 2    Materials and Methods 
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rotor. After centrifugation, EBs banded at the 44%/54% interface and RBs banded at the 34%/44% interface. 
The collected bands were centrifuged at 35,000 x g for 30 min in a Beckman 55.2 rotor and pelleted. Each 
pellet was resuspended in ~ 500 µl of PBS and stored in aliquots at -80ºC. Purification of EBs and RBs was 
performed  in  collaboration  with  Dr.  Joanne  Spencer  and  Mrs  Leslie  Cutcliffe  at  Southampton  General 
Hospital. 
 
2.2.8 Host-free Protein Synthesis 
Urografin purified RBs were immediately incubated in a host-free reaction mixture (100 mM Tris-
HCl pH 7.0, 50 mM KCl, 5 mM MgCl2, 7.8mM creatine phosphate, 1.5 mg of phosphocreatine kinase per 
ml, 19 unlabelled amino acids, 1 mM ATP and 10 mCi of L-[
35S] methionine) as described (Stephens et al., 
1998). After incubation at 37ºC, samples were solubilised in SDS-PAGE final sample buffer and SDS-PAGE 
was performed using the discontinuous buffer system method (Laemmli, 1970) with 10% acrylamide gels 
(acrylamide:bisacrylamide 38.5:1 w/w). Gels were stained and prepared for autoradiography by treatment 
with 1 M sodium salicylate - 50% methanol for 30 min at room temperature, then dried under vacuum and 
exposed to Kodak XAR-5 film at -70ºC. This procedure was performed courtesy of Mrs Leslie Cutcliffe at 
Southampton General Hospital. 
 
2.2.9 Estimation of protein concentration 
2.2.9.1 Bicinchoninic acid protein assay  
Protein  concentration  was  determined  using  the  bicinchoninic  acid  (BCA)  method  (Smith  et  al., 
1985). Protein standards were prepared using bovine serum albumin in the range 100 to 1000 µg/ml in the 
same buffer as the sample. 200 µl of 4% (w/v) CuSO4.5H2O was added to 10 ml of bicinchoninic acid 
(BCA). 200 µl of BCA working reagent was added to 20 µl of each protein standard and 20 µl of each 
sample contained in a 300 µl 96 well microtitre plate. Samples and standards were measured in duplicate. 
After incubation at room temperature for 30 min, plates were read at 570 nm using a Dynex plate reader and 
analysed with Revelation 3.2 software (Dynex Technologies Limited, Worthing, UK) 
2.2.9.2 Bradford protein assay 
Protein  concentration  was  determined  using  the  Bradford  protein  assay  (Bradford,  1976).  Protein 
standards were prepared using bovine serum albumin in the range 50 µg/ml to 500 µg/ml in the same buffer 
as the sample. A working dye reagent was prepared by diluting 1 part dye reagent concentrate (BioRad, 
Hercules, CA) with 4 parts MilliQ H2O (v/v). 200 µl of the diluted Bradford dye reagent was added to 10 µl 
of each protein standard and 10 µl of each sample contained in a 300 µl 96 well microtitre plate. Samples and 
standards were measured in duplicate. After incubation at room temperature for 10 min, plates were read at 
570 nm using a Dynex plate reader and analysed with Revelation 3.2 software (Dynex Technologies Limited, 
Worthing, UK) 
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2.2.10 Genome quantification by real-time qPCR 
A single copy of the omcB gene is located on the C. trachomatis  L2 chromosome. The absolute 
number  of  genomes  in  both  EB  and  RB  preparations  were  accurately  determined  by  performing  5′-
exonuclease (TaqMan) assays with unlabelled primers and carboxyfluorescein/carboxytetramethylrhodamine 
(FAM/TAMRA) dual-labelled probes based on the omcB gene as previously described (Pickett et al., 2005). 
5 µl of sample was added to 20 µl reaction mixture containing forward primer (300 nM), reverse primer (300 
nM), probe (100 nM) and TaqMan Universal PCR Master Mix (Applied Biosystems). Real-time PCR cycles 
were performed in an ABI PRISM 7700 Sequence Detection System (Applied Biosystems) according to the 
manufacturer’s  instructions.  Genome  determination  was  performed  courtesy  of  Mrs  Leslie  Cutliffe  at 
Southampton General Hospital. 
 
2.3 Protein preparation and separation techniques 
 
2.3.1 Two-dimensional gel electrophoresis 
2.4.1.1 Preparation of EB and RB whole cell lysates 
EB and RB cell pellets were centrifuged at 6,000 x g for 10 min in a bench-top centrifuge (Heraeus, 
Hanau, Germany) and the supernatant removed and discarded. Cell pellets were resuspended and extracted 
using  lysis  buffer  (2%  (v/v)  Triton  X-100,  2.5%  (v/v))  IPGphor  buffer,  (range:  pH  4-7),  2.5%  (v/v)  β-
mercaptoethanol. Extracts were then treated with the Plus-one 2-D Clean-Up Kit (Amersham Biosciences, 
Little Chalfont, Bucks, UK) according to the manufacturer’s instructions. Samples were snap-frozen in liquid 
N2 and stored at -80ºC. 
2.3.1.2 Immobiline DryStrip gel rehydration 
Approximately 50 µg of EB or RB protein extracts were mixed with rehydration solution (containing 
per 5 ml: 8 M urea, 0.1 g CHAPS, 25 µl pH 4-7 IPG buffer, 15 mg dithiothreitol, and a few grains of Orange 
G) to give a final sample volume of 400 µl. The sample-buffer solution was added to an 18 cm IPG strip 
holder. An 18 cm pH 4-7 IPG gel strip “Immobilised DryStrip” was placed into the sample-buffer facing gel-
side  down.  The  lid  was  placed  on  the  IPG  strip  holder  and  placed  into  the  IPG-phor  unit  (Amersham 
Biosciences, Little Chalfont, Bucks, UK), in accordance with the manufacturer’s instructions. The unit was 
programmed to allow rehydration of the strips for 20 h before isoelectric focusing (IEF) was performed as 
follows: 1 h at 300 V, 2 h at 500 V, 1 h at 1000 V, 2 h at 2000 V, 3 h at 3500 V followed by a sixth step at 
5000 V for 24 h. 
2.3.1.3 Equilibration of Immobiline DryStrips 
The IPG strip of focused proteins was transferred to a glass tube ~ 10 ml volume (Fisher Scientific) 
and 10 ml of equilibration buffer 1 added (containing per 10 ml: 0.05 M Tris-HCl (pH 6.8), 6 M urea, 30% 
(v/v) glycerol, 1% (w/v) SDS, 25 mg dithiothreitol). The tube was sealed and incubated at room temperature 
with rocking for 10 min. After this time, the solution was discarded and replaced with equilibration buffer 2 Chapter 2    Materials and Methods 
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(containing the same as buffer 1, but replacing the 25 mg of dithiothreitol with 0.45 g of iodoacetamide per 
10 ml and a few grains of Bromophenol Blue to aid monitoring of the second dimension electrophoresis). 
After a further incubation of 10 min at room temperature with rocking, the IPG strip was removed and 
drained on filter paper for 15 min each side to remove excess liquid. 
2.3.1.4 Second dimension polyacrylamide gel electrophoresis 
The Multiphor II Electrophoresis unit was prepared and maintained at 15ºC in accordance with the 
manufacturer’s  instructions.  The  equilibrated  IPG  strip  was  placed  gel  side  down  onto  a  12  -14% 
polyacrylamide  gel  (ExcelGel  XL,  Amersham  Pharmacia  Biotech)  as  detailed  in  the  manufacturer’s 
instructions. Electrophoresis was performed at 20 mA for 45 min and then at 40 mA until the dye front had 
reached the bottom of the gel.  2-D gel electrophoresis of EBs and RBs was performed in collaboration with 
Dr. Joanne Spencer at Southampton General Hospital. 
2.3.1.5 Staining 
Following electrophoresis, proteins were visualised using the fluorescent protein stain Sypro Ruby. 
The gel was washed with a small volume of fixing solution (containing 7% (v/v) acetic acid in 10% (v/v) 
methanol) to remove excess mineral oil. Once washed, the gel was placed in 300 ml of fixing solution and 
incubated at room temperature with gentle rocking for 30 min. After 30 min the fixing solution was replaced 
with 300 ml of Sypro Ruby stain and incubated for 16 h at room temperature with gentle rocking in a covered 
container to eliminate light. The Sypro Ruby stain was replaced with MilliQ H2O and the gel incubated for a 
further 3 h in the container at room temperature with rocking. 
2.3.1.6 Imaging 
The  Sypro  Ruby  stained  gel  was  washed  with  MilliQ  H2O  and  placed  gel  facing  up  onto  the 
transilluminator  of  a  VersaDoc  3000  Imager  (BioRad,  Hercules,  CA,  USA).  The  imager  was controlled 
through the 2-D gel image analysis software PDQuest (BioRad). The gel was imaged using a Sypro Ruby 
filter (462 nm excitation and 610 nm emission wavelengths) using an exposure time of between 15 and 30 
sec, depending upon the intensity of the protein spots.  
2.3.1.7 Image analysis and Gel spot excision 
Spot detection, alignment and selection of gel spots for excision, were performed using the 2-D gel 
analysis software PDQuest (BioRad). Gel spots were excised using a Biorad ProteomeWorks™ spot cutter 
integrated and controlled through PDQuest. Alignment of the spot cutter with the high resolution gel image 
acquired using the VersaDoc was obtained by acquiring a low-resolution image using the on-board spot 
cutter camera to locate landmark spots to align the spot cutter to the high resolution gel image. Because the 
spot cutter used epi-illumination for excitation as opposed to trans-illumination used to acquire the high-
resolution image on the VersaDoc, the sensitivity of the spot cutter camera was insufficient for detection of 
fluorescent protein spots for alignment of the cutter. Gels were therefore stained using Colloidal Coomassie 
Brilliant Blue (Colloidal CBB, BioRad) to allow visualisation using white light trans-illumination. Sypro 
Ruby stained gels were transferred into 300 ml of colloidal CBB and incubated for 1 h at room temperature Chapter 2    Materials and Methods 
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with gentle rocking. After 1 h, the stain was replaced with MilliQ H2O and incubated for a further 3 h at 
room temperature with rocking. Gels were placed onto the cutting platform (gel side facing upward) of the 
spot cutter and imaged with white light trans-illumination for 1 second. This image was used to align the spot 
cutter to the high-resolution image acquired using the VersaDoc according to the manufacturer’s instructions. 
Spots were cut using a 1.5 mm cutting tip and dispensed into 50 µl of MilliQ H2O in a 96 well microtitre 
plate. The cutting tip was washed between each spot cut using 50% (v/v) methanol. The 96 well microtitre 
plates were sealed and stored at +4ºC until in-gel digestion was performed. 
 
2.3.2 One-dimensional SDS gel electrophoresis 
Protein samples were solubilised using 2 x Final Sample Buffer (FSB) (0.125 M Tris-HCl (pH 6.8), 
4% (w/v) SDS, 20% (v/v) glycerol, 200 mM dithiothreitol, 0.05% (w/v) bromophenol blue). Samples were 
heated at 70ºC for 10 min and allowed to cool to room temperature prior to loading; 10 µL of Precision plus 
All Blue prestained markers (BioRad) were used for size approximation. Separation was performed using 4–
12% NuPAGE Novex Bis-Tris gels (Invitrogen) with NuPAGE MOPS running buffer (Invitrogen) with an 
XCell SureLock apparatus (Invitrogen) at 200 V for 50 minutes. Gels were stained with 50 ml of Colloidal 
Coomassie Brilliant Blue (BioRad) for 1 h at room temperature with rocking and destained using analytical 
grade water for 16 h at room temperature with rocking. 
 
2.3.3 Manual In-gel digestion 
2.3.3.1 Reduction, alkylation and digestion 
In-gel digestion was performed following the method of Shevchenko et al. (1996). Gel bands were cut 
into 1 mm x 1 mm pieces using a sterile scalpel blade and placed in a 0.5 ml microcentrifuge tube with 150 
µl of MilliQ water. The water was removed and replaced with  ~ 300 µl acetonitrile (approximately 3-4 times 
the volume of the gel pieces). The gel pieces were allowed to dehydrate for approximately 10 min before 
removing the acetonitrile and replacing with ~ 50 µl of 10 mM DTT in 0.1 M NH4HCO3 (enough liquid to 
cover the gel pieces). The gel pieces were incubated for 30 min at 56ºC to reduce proteins and subsequently 
dehydrated with acetonitrile as described above and the supernatant discarded. Alkylation of the proteins was 
achieved by addition of 40 µl of 55 mM iodoacetamide in 0.1 M NH4HCO3 and incubation for 20 min at 
room temperature in the dark. Gel pieces were then washed with ~300 µl of 0.1 M NH4HCO3 for 15 minutes 
and  the  supernatant  discarded.  The  gel  pieces  were  dehydrated  using  acetonitrile  and  the  supernatant 
discarded. Where the gel pieces still retained Coomassie Blue stain, the samples were further incubated 
overnight  in  1:1  (v/v)  0.1M  NH4HCO3:acetonitrile,  prior  to  removal  of  the  solution,  dehydration  with 
acetonitrile and the supernatant discarded. Protein digestion was accomplished by the addition of enough 
trypsin (1.5 ng/µl trypsin in 50 mM NH4CO3, 5 mM CaCl2) to cover the gel pieces and incubated at 37ºC for 
45 min. After incubation, 5-25 µl of the trypsin buffer without trypsin (50 mM NH4CO3, 5 mM CaCl2) was 
added to keep the gel pieces wet during enzyme cleavage. The samples were then incubated for 16 h at 37ºC. 
For AQUA experiments 500 fmol of the relevant stable isotopic reference peptide was added in 50 mM 
NH4CO3 to the gel pieces at the trypsin addition stage. 
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2.3.3.2 Peptide Extraction 
After 16 h digestion, 15 µl of 25 mM NH4HCO3 was added to the gel pieces and incubated at 37ºC for 
15 minutes with vigorous shaking. The gel pieces were briefly centrifuged to bring them to the bottom of the 
tube, acetonitrile added (~ 2 times the volume of the gel pieces) and incubated for a further 15 min at 37ºC 
with vigorous shaking. The gel pieces were centrifuged at 9,000 x g in a microcentrifuge (Heraeus) for 1 min 
and the supernatant collected into a 0.5 ml microfuge tube. 50 µl of 5% (v/v) formic acid was added to the 
gel pieces and after incubation at 37ºC for 15 min, acetonitrile added (~2 times the volume of the gel pieces) 
and the samples incubated for a further 15 min at 37ºC. The gel pieces were centrifuged at 9,000 x g and the 
supernatants  pooled.  Supernatants  were  lyophilised  in  vacuo  using  an  Eppendorf  Concentrator  plus 
(Eppendorf, Hamburg, Germany) and stored at +4ºC until use. 
 
2.3.4 Automated in-gel digestion 
Automated in-gel digestion and peptide extraction was performed using an automated MassPREP™ 
workstation (Waters, UK). Gel pieces in a 300 µl 96 well microtitre plate were subjected to the following 
steps: 
 
Destain 
Two Coomassie Blue destain steps were performed consisting of the addition of 50 µl of 100 mM NH4HCO3 
and 50 µl acetonitrile followed by incubation for 10 min at 40ºC and then the supernatant removed and 
discarded. 
 
Dehydration 
50  µl  of  acetonitrile  was  added  to  the  gel  pieces,  incubated  for  5  min  at  40ºC  and  then  removed  and 
discarded. 
 
Reduction 
50 µl of 10 mM dithiothreitol in 100 mM NH4HCO3 was added to the gel pieces incubated at 40ºC for 30 min 
and then removed and discarded. 
 
Alkylation 
50 µl of 55 mM iodoacetamide in 100 mM NH4HCO3 was added to the gel pieces, incubated at 40ºC for 20 
min and then removed and discarded 
 
Wash 
50  µl  of  100  mM  NH4HCO3  was  added  to  the  gel  pieces  and  incubated  for  10  min  at  40ºC.  50  µl  of 
acetonitrile was then added, incubated for 5 min and then removed and discarded. 
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Dehydration 
50 µl acetonitrile was added to the gel pieces and incubated for 5 min at 40ºC. The liquid was removed and 
replaced with a further 50 µl acetonitrile, removed and allowed to evaporate for 15 min. 
 
Digestion 
25 µl of trypsin at a concentration of 6 ng/µl in 50 mM NH4HCO3 was added to the gel pieces and incubated 
for 15 min at 37ºC. 10 µl of 50 mM NH4HCO3 was added and the gel pieces incubated for 5 h at 37ºC. 
 
First Extraction 
30 µl of extraction buffer was added to the gel pieces (2% acetonitrile (v/v) containing 1% formic acid (v/v)) 
and incubated for 30 min at 37ºC.  
 
MALDI target spotting 
1.6 µl of matrix (2 mg of α-cyano-4-hydroxycinnamic acid in 50% acetonitrile:H2O (v/v), containing 0.1% 
trifluoroacetic acid (v/v)) was added to a steel MALDI target plate (Waters). 2.0 µl of extracted peptide 
solution was added onto the target and allowed to air dry at room temperature for 15 min. 
 
Peptide transfer 
15 µl of the remaining peptide solution was transferred to a clean 200 µl 96 well microtitre plate (ABgene, 
UK) 
 
Second Extraction 
12 µl of extraction buffer and 12 µl of acetonitrile was added to the gel pieces and incubated for 30 min at 
37ºC. 15 µl of supernatant was removed and combined with the previously extracted peptides. Microtitre 
plates were lyophilised in vacuo and stored at +4 ºC until use. 
 
2.3.5 In-solution digestion 
Proteins  were  solubilised  in  50  mM  NH4CO3  containing  0.1%  Rapigest.  Tris[2-carboxyethyl] 
phosphine  (TCEP)  was  added  to  a  final  concentration  of  5  mM  and  incubated  for  60  min  at  60°C. 
Iodoacetamide was then added to a final concentration of 55 mM and incubated at room temperature in the 
dark  for  15  min.  Digestion  was  performed  using  TPCK-modified  trypsin  (Sigma-Aldrich),  at  an 
enzyme:substrate ratio (w/w) of 1:25 and incubated for 16 h or overnight at 37ºC. 
 
2.3.6 Amino acid analysis 
Amino acid analysis was performed by Alta Biosciences, Birmingham, UK. 
 
2.3.7 GeLC – MS/MS of EBs and RBs 
One-dimensional SDS polyacrylamide gel electrophoresis coupled with Nano-liquid chromatography-
tandem mass spectrometry (GeLC-MS/MS) was used as previously described (Schirle et al., 2003) to identify 
proteins from Chlamydia trachomatis, serovar L2. Chapter 2    Materials and Methods 
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Purified  elementary  and  reticulate  bodies  were  re-suspended  in  200  µl  of  50  mM  NH4HCO3 
containing 0.1% (v/v) RapiGest, incubated for 10 min on ice and sonicated for 10 min in a sonication bath 
containing chilled water (~4ºC). Samples were centrifuged at 9,000 x g for 15 min to remove cell debris, the 
supernatant removed and the protein concentration determined using the BCA assay as detailed in section 
2.2.9. Preparations containing 130 µg of whole cell lysate were solubilised in 30 µl of 2 x Final Sample 
Buffer, fractionated using a NuPAGE 4-12% gradient SDS-polyacrylamide gel and stained as described in 
section 2.3.2. After visualisation with colloidal Coomassie Blue, each gel lane (length: 7cm) was excised, cut 
into 29 equal-sized pieces, and each band subjected to in-situ trypsin digestion using a modified automated 
method of Shevchenko et al., (1996), as described in section 2.3.4. MALDI-ToF MS as detailed in section 
2.5.2 was used to confirm the presence of proteolytic peptides from gel bands excised and digested from the 
top, middle and bottom of the gel. Samples were lyophilised in-vacuo using an Eppendorf Concentrator plus 
(Eppendorf) and resuspended in 30 µl of acetonitrile:water (v/v) containing 0.1% (v/v) formic acid. NanoLC-
MS/MS was performed on each of the peptide extracts as described in sections 2.3.9.5 and 2.6.1 and the data 
processed and searched against a protein translation of the C. trachomatis, serovar D genome and NCBI 
human genome as described in section 2.7. 
 
2.3.8 MudPIT 
Purified  elementary  and  reticulate  bodies  were  re-suspended  in  200  µl  of  50  mM  NH4HCO3 
containing 0.1% (v/v) RapiGest, incubated for 10 min on ice and sonicated for 10 min in a sonication bath 
containing chilled water (~4ºC). Samples were centrifuged at 9,000 x g for 15 min to remove cell debris, the 
supernatant removed and the protein concentration determined using the BCA assay as detailed in section 
2.2.9. ~100 µg of protein lysate was reduced, alkylated and digested as detailed in section 2.3.5. The resulting 
peptide digest was adjusted to pH 2 with 1 mM HCl and incubated at 70ºC to precipitate the Rapigest. The 
solution was clarified by centrifugation at 9,000 x g prior to MudPIT analysis. 
 
A workflow of the procedure used for MudPIT analysis and a plumbing schematic are shown in 
Figures 2.1 and 2.2, respectively. ~100 µg of a protein digest of either EBs or RBs were diluted 1:1 with 5 
mM KH2PO4 pH 3.0 containing 10% (v/v) acetonitrile and 10 µl injected using a low volume autosampler 
(Waters corporation) onto a 5 mm x 0.35 mm i.d. Optipak SCX trap column (Waters corporation), connected 
to a StreamSelect 10-port valve (Waters corporation). With the valve set at position 1 (Figure 2.2), sample 
was introduced onto the column and washed with aqueous 1% (v/v) acetic acid using a CapLC, nanoLC 
system (Waters corporation) for 5 min at a flow rate of 10 µl/min. Uncharged peptides that did not bind to the 
SCX trap column were washed onto the in-series PepMap C18 RP trap column, 5 µm, 100Å, 300 µm i.d. x 1 
mm (Dionex, Sunnyvale, CA, USA). The 10-port valve was then switched to valve position 2 (Figure 2.2), 
allowing elution of the uncharged peptides from the RP trap onto an Atlantis C18 analytical column, (3 µm 
particle size, 75 µm i.d. x 150 mm, Waters corporation), where the peptides were separated and introduced 
on-line  into  a  Q-Tof  Global  Ultima  mass  spectrometer.  Data  directed  acquisition  experiments  were 
performed (see section 2.6.1) using the following linear RP gradient at a flow rate of ~200 nl/min: 5% 
Solvent A (acetonitrile/water, 5:95 (v/v); 0.1% (v/v) formic acid) to 60% Solvent B (acetonitrile/water, 97:3 Chapter 2    Materials and Methods 
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(v/v); 0.1% (v/v) formic acid) formed over 40 min, before a steeper 15 min gradient to 80% solvent B. The 
column was maintained at 80% solvent B to remove remaining material and then re-equilibrated over 10 min 
to the initial starting conditions, and the 10-port valve switched back to valve position 1. 10 column volumes 
of 25 mM KCl was injected onto the SCX trap column, eluting released peptides onto the RP trap column. To 
remove salts, the RP trap was washed for 25 min with 1% (v/v) acetic acid at a flow rate of 10 µl/min and 
then the 10-port valve switched to valve position 2 to allow analytical separation and analysis of the eluted 
peptide fraction. This process was repeated using the following concentrations of KCl; 25 mM, 35 mM, 50 
mM, 60 mM, 75 mM, 100 mM, 200 mM. Data was processed and searched against a protein translation of 
the C. trachomatis serovar D, C. trachomatis L2/434/Bu and human NCBI genomes as described in section 
2.7. 
 
 
 
 
Figure 2.1. Experimental workflow of the proteomic analysis technique MudPIT used in this study. 
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Figure 2.2. Plumbing schematic of the 10-port valve used for MudPIT analyses. 
 
Initially, with the StreamSelect 10-port valve set to position 1, samples are introduced onto the SCX trap 
column via the sample injector using 1% acetic acid. Charged peptides bind to the SCX trap column and 
uncharged peptides pass through the SCX column onto the RP trap column. After a period of washing, the 
10-port valve is switched to valve position 2. Peptides bound to the RP trap column are eluted onto the C18 
RP analytical column and separated using a RP gradient developed using the LC system. When the analytical 
separation is complete, the 10-port valve is switched back to position 1. This process is repeated using 
increasing  incremental  concentrations  of  salt  introduced  via  the  sample  injector  to  release  fractions  of 
peptides from the SCX column onto the analytical RP column. 
 
2.3.9 iTRAQ  
2.3.9.1 Preparation of EBs and RBs from C. trachomatis for iTRAQ labelling  
400 µl of 0.5 M triethylammonium bicarbonate buffer containing 5 mM dithiothreitol and 0.1% (w/v) 
SDS was added to cell pellets of EBs (two biological replicates) or RBs (two biological replicates) and 
incubated on ice for 2 h. The resulting solution was transferred to a FastPrep lysis vessel containing ‘Lysing 
matrix  D’  (Q-Biogene,  CA).  Samples  were  lysed  using  the  Savant  FastPrep  system  (Thermo  Scientific, 
Langenselbold, Germany) for 3 cycles of 30 seconds at a speed setting of 6. The vessel was removed, chilled 
on ice for 3 min and the process repeated. The FastPrep vessel was then centrifuged in a bench-top centrifuge 
(Heraeus) at 9,000 x g for 5 min and the supernatant removed. A further 100 µl of dissolution buffer was 
added to the FastPrep vessel, vortexed, centrifuged for a further 4 min and the supernatant collected. The 
supernatants were pooled and the protein concentration determined using the Bradford protein assay (see 
section 2.2.9). Remaining supernatant was flash frozen using liquid nitrogen and stored at -80ºC. 
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2.3.9.2 Preparation of S. Typhimurium for iTRAQ analysis 
Cell pellets, prepared as detailed in sections 2.2.3 and 2.2.4 were re-suspended in 1.6 ml of 20 mM 
HEPES pH 8.0, transferred to a 5 ml sonication vessel and sonicated in a salt ice bath for 6 cycles (cycle: 15 
sec ON followed by 1 min off) using an MSE Soniprep 150 (Sanyo) fitted with an exponential microprobe. 
The cell lysate was then centrifuged at 25,681 x g using a JA21 in a Beckman Avanti centrifuge for 20 min at 
4ºC to remove cell debris and the supernatant collected. The protein concentration of the supernatant was 
determined using the BCA assay (section 2.2.9) prior to flash freezing the samples using liquid nitrogen and 
storage at -80ºC. 
 
2.3.9.3 Preparation of samples for iTRAQ analysis from whole cell lysates of 
Chlamydia trachomatis and Salmonella Typhimurium 
Samples for iTRAQ labelling were carried using the supplied kit and according to manufacturer’s 
instructions,  Chemistry  Reference  Guide.  Part  Number  4351918  Rev.  A.  05/2004  (Applied  Biosystems, 
Foster City, USA). 
 
To  each  of  up  to  four  sample  tubes  containing  ~100  µg  of  sample  in  0.5  M  triethylammonium 
bicarbonate buffer (where the final volume of dissolution buffer was no more than 34 µl), 1 µl of 2% (w/v) 
SDS (except for chlamydial protein lysates, since these already contained 0.1% (w/v) SDS) and 2 µl of the 
reducing agent, 50 mM TCEP (tris-(2-carboxyethyl) phosphine (TCEP) were added and vortexed. Samples 
were incubated at 60°C for 1 h. After incubation, 1 µl of the cysteine blocking reagent, 200 mM methyl 
methane-thiosulfonate (MMTS) in isopropanol was added, prior to incubation for a further 10 min at room 
temperature. Proteins were digested by adding 10 µl of 1 mg/ml trypsin containing 88.8 µg CaCl2. Samples 
were incubated overnight at 37ºC. 
 
After digestion, each vial of iTRAQ reagent was brought to room temperature and 70 µl of ethanol 
added to each reagent vial. Each vial was vortexed for 1 min to dissolve the iTRAQ reagent and centrifuged 
at 9,000 x g for 1 min. The contents of one iTRAQ reagent vial was added to one sample tube, vortexed for 1 
minute and centrifuged at 9,000 x g for 1 min. For example, for a duplex-type experiment, the contents of the 
iTRAQ reagent 114 vial was added to the control sample, and the contents of the iTRAQ reagent 117 vial 
was  added  to  the  test  sample.  Sample  tubes  containing  the  iTRAQ  reagents  were  incubated  at  room 
temperature for 1 h prior to combining them together into a 0.5 ml tube and lyophilizing in vacuo using an 
Eppendorf Concentrator plus (Eppendorf). 
 
2.3.9.4 Fractionation of iTRAQ labelled peptides using strong cation exchange 
chromatography 
The  combined  iTRAQ  peptide  mixture  was  separated  by  strong  cation  exchange  (SCX) 
chromatography on a Dionex Ultimate nano-LC system using a Polysulfoethyl A column (4.6 mm i.d. x 150 
mm, 5 µm, 300Å, Phenomenex, Cheshire, UK) or a ProPac
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Samples were dissolved in 500 µl of buffer A (Buffer A: 25% (v/v) acetonitrile, 10 mM phosphoric acid) and 
loaded onto the column using a 500 µl loop. The loaded sample was washed with buffer A for 20 min at 200 
µl/min to remove excess reagent. Peptides were eluted with a linear gradient of 0 – 500 mM KCl in 25% 
(v/v) acetonitrile, 10 mM phosphoric acid, at 200 µl/min with fractions collected at 1 min intervals. Peptide 
elution was monitored using UV absorbance at 214, 235 and 280 nm. Fractions were lyophilised and re-
suspended in 50 µl of MilliQ H2O prior to analysis by nanoLC – MS/MS as detailed in sections 2.3.9.5.2 and 
2.6.1) 
2.3.9.5 Reversed phase NanoLC-MS/MS 
NanoLC separations were performed using a CapLC system (Waters Corporation, Manchester, UK), 
consisting of a µHPLC pump and low volume autosampler coupled to a Streamselect µ-column switching 
module (Waters Corporation).  
 
Samples were stored in microtitre plates in a chilled area at 10ºC. Samples were loaded via a low 
volume autosampler (Waters Corporation) onto a PepMap C18 guard column (5 mm x 300 µm i.d., Dionex) 
for pre-concentration and desalting using 100% solvent C (acetonitrile/water, 3:97; (v/v) 0.1% (v/v) formic 
acid) at a flow rate of 20 µl/min. The eluent was diverted to waste. After 6 min of washing, the nano- 
reversed phase C18 PepMap analytical column (150 mm x 75 µm i.d., Dionex) was switched into line using 
the Streamselect µ-column switching module and a separation gradient performed as detailed below. For all 
experiments performed, a flow rate of 200 nl/min was set. The 75 µm i.d., 360 µm o.d analytical capillary LC 
column was coupled to 20 µm i.d., fused silica of the nanoLC sprayer (Waters Corporation) using a teflon 
zero dead volume connector.  
2.3.9.5.1 NanoLC of Gel extracts 
Separation of gel extracted peptides were performed using a linear RP gradient at a flow rate of ~200 
nl/min:  5%  Solvent  A  (acetonitrile/water,  5:95  (v/v);  0.1%  (v/v)  formic  acid)  to  60%  Solvent  B 
(acetonitrile/water, 97:3 (v/v); 0.1% formic acid (v/v)) formed over 40 min, before a steeper 15 minute 
gradient to 80% solvent B. The column was maintained at 80% solvent B to remove remaining material and 
then re-equilibrated over 10 min to the initial starting conditions. MS/MS data dependent acquisitions were 
performed on a Q-Tof Global Ultima as described in section 2.6.1. 
 
2.3.9.5.2 NanoLC of iTRAQ samples 
Separation  of  iTRAQ  samples  were  achieved  using  a  slow  linear  gradient  of  7%  solvent  A 
(acetonitrile/water, 3:97 (v/v); 0.1% (v/v) formic acid) to 80% solvent B (acetonitrile/water, 97:3 (v/v); 0.1% 
(v/v) formic acid) formed over 145 min, maintained at 80% B for a further 10 min and returned to the initial 
starting conditions over a period of 8 min. MS/MS data dependent acquisitions were performed on a Q-Tof 
Global Ultima as described in section 2.6.1  
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2.4. AQUA 
 
2.4.1 AQUA analysis of BipA protein from E. coli  
Samples of E. coli K-12 (MG1655) taken at 15, 30, 45, 60, 120, 180 and 240 min intervals during 
growth were prepared as described in section 2.2.5, separated using a 4-12% NuPAGE SDS polyacrylamide 
gel, and stained using Colloidal CCB as detailed in section 2.3.2. Gel bands were excised from the gel, 
corresponding to the approximate molecular mass of BipA ± 15 kDa (actual molecular mass = 67355 Da) and 
in-gel digested in the presence of 500 fmol of the BipA reference peptide, corresponding to residues 440 – 
446, (Leu *– Asp – Tyr – Val – Ileu – Pro – Ser – Arg, where * indicates a leucine contaning 6 x [
13C] 
atoms) as detailed in section 2.3.3. The concentration of the BipA peptide was determined by amino acid 
analysis (Alta Biosciences). The lyophilised samples were re-suspended in 10 µl of 10% (v/v) acetonitrile 
containing 1% (v/v) formic acid, injected onto the nanoLC and separated as described in section 2.3.9.5 for 
the  analysis  of  gel  extracts.  Mass  spectrometry  was  performed  using  a  Q-Tof  Global  Ultima  (Waters 
Corporation). An MS/MS experiment in positive ion mode was performed isolating and fragmenting the 
doubly  charged  precursor  ions,  m/z  =  481  and  484,  corresponding  to  the  native  and  reference  peptide, 
respectively, using a collision energy of 15 eV. Data was collected from 50 to 1200 m/z at 1.0 scan/sec over 
the 65 min LC gradient. All other MS settings were as detailed in section 2.6.1. Ion chromatograms were 
reconstructed for the [M+H]
+ y4
 ion, m/z = 472.28 for both the native and reference peptide. The peak areas 
of each extracted ion chromatogram were calculated using MassLynx 4.0 (Waters Corporation) and used to 
calculate an abundance ratio. Using the previously determined concentration of the BipA reference peptide, 
the concentration of the protein BipA was determined. This process was repeated for each sampled time 
point.  
 
2.4.2 AQUA analysis of the Major Outer Membrane Protein and a Metalloprotease 
from C. trachomatis 
Purified  elementary  and  reticulate  bodies  were  re-suspended  in  200  µl  of  50  mM  NH4HCO3 
containing 0.1% (v/v) RapiGest, incubated for 10 min on ice and sonicated for 10 min in a sonication bath 
containing chilled water (~4ºC). Samples were centrifuged at 9,000 x g for 15 min to remove cell debris, the 
supernatant removed and the protein concentration determined using the BCA assay as detailed in section 
2.2.9. 30 µg of both EB and RB protein lysates were separated using a 4-12% NuPAGE SDS polyacrylamide 
gel and stained using Colloidal CBB as detailed in section 2.3.2.  Gel  bands  were  excised  from  the  gel 
corresponding to the approximate molecular mass of the Major Outer Membrane Protein (CTL0050) and the 
Metalloprotease (CTL0328) ± 15 kDa (actual molecular masses = 42,400 and 69,200 Da, respectively) and 
in-gel digested in the presence of 500 fmol of the MOMP and Metalloprotease reference peptides G-Y-V-G-
Q-E-F-P-L*-D-L-K  (MOMP)  and  I-S-L*-G-I-P-L-K  (Metalloprotease),  where  *  indicates  a  leucine 
contaning 6 x [
13C] atoms) as detailed in section 2.3.3. Peptide concentration was determined by amino acid 
analysis (Alta Biosciences). The lyophilised samples were re-suspended in 10 µl of 10% (v/v) acetonitrile 
containing 1% (v/v) formic acid, injected onto the nanoLC and separated as described in section 2.3.9.5 for Chapter 2    Materials and Methods 
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the  analysis  of  gel  extracts.  Mass  spectrometry  was  performed  using  a  Q-Tof  Global  Ultima  (Waters 
corporation). MS/MS experiments were performed in positive ion mode isolating and fragmenting the doubly 
charged precursor ions corresponding to the native and reference peptides of both MOMP (m/z = 683.4 and 
m/z = 686.4) and the metalloprotease (m/z = 420.7 and m/z = 423.7), using collision energies of 22 eV and 17 
eV, respectively. Data was collected from 50 to 1500 m/z at 1.0 scan/sec over the 65 min LC gradient. All 
other MS settings were as detailed in section 2.6.1. Ion chromatograms were reconstructed for the y ions of 
the native and reference peptides for both MOMP (y6  native m/z = 586.4; y6  reference m/z = 591.4) and the 
metalloprotease  (y7native  m/z  =  727.6;  y7reference  m/z  =  733.6).  The  peak  areas  of  each  extracted  ion 
chromatogram were calculated using MassLynx 4.0 (Waters Corporation) and used to calculate abundance 
ratios. Using the previously determined concentrations of the reference peptides, the concentration of the 
metalloprotease and MOMP were determined. 
 
2.4.3 Absolute quantitation of horse heart myoglobin using infusion 
1 mg of horse heart myoglobin was reduced, alkylated and digested with trypsin in 1 ml of 50 mM 
NH4CO3 containing 0.1% (w/v) Rapigest as described in section 2.3.5. Samples were prepared containing a 
myoglobin digest at a range of concentrations from 500 amol to 15 pmol, each containing 1 pmol of the [
13C] 
labelled  myoglobin  reference  peptide  (A-L-E-L*-F-R,  where  *  indicates  a  leucine  containing  6  x  [
13C] 
atoms). The final volume was 10 µl and all dilutions were prepared in 50% methanol (v/v) containing 1% 
acetic acid (v/v). The concentration of the labelled reference peptide was determined by amino acid analysis 
(Alta Biosciences, Birmingham, UK). Each sample was centrifuged at 9,000 x g for 5 min and transferred to 
a 200 µl 96 well microtitre plate. 10 µl of sample was aspirated using the Nanomate system and an infusion 
MS/MS experiment performed as detailed in section 2.6.3. Samples were sprayed for 30 min at a chip voltage 
of +1.7 kV and a gas pressure of 0.6 psi. MS/MS data was acquired for 2 min from 50 to 1500 m/z at 5 
scan/sec, isolating and fragmenting the doubly charged precursor ion for the native peptide and isotopically 
labelled reference peptide (m/z = 375.2 and 378.2, respectively). A collision energy of 14 eV was applied, a 
value previously determined by infusion of 10 µl of 1 pmol of the isotopically labelled myoglobin reference 
peptide prepared in 50% (v) methanol containing 1% (v/v) acetic acid as detailed in section 2.6.3. Tuning of 
the collision energy was performed to maximise the signal response for the [M+H]
+ y4 ion of the reference 
peptide, m/z = 570.2, corresponding to the native peptide [M+H]
+ y4 ion, m/z = 564.2. After data collection, 
ion chromatograms were reconstructed for the m/z transitions [M+2H]
+2→ y4 for the native and reference 
peptide, respectively (378.2 → 570.2 and 375.2 → 564.2), and the intensities used to obtain an abundance 
ratio. The previously determined concentration of the myoglobin reference peptide was used to calculate the 
concentration of the native reference peptide and hence the myoglobin concentration. This was repeated for 
each time point.  
 
2.4.4 Absolute quantitation of myoglobin in human serum by infusion 
Human serum (A kind gift from Prof. Swee Lay Thein, Kings College, London) at a concentration of 
~75 mg/ml was diluted 1 in 200 with 50 mM ammonium bicarbonate containing 0.1% (v/v) Rapigest and 
digested as described in section 2.3.5. Digested serum was diluted 1:1 with 50% (v/v) methanol containing 
1% (v/v) acetic acid. Samples were spiked with 1 pmol of the myoglobin reference peptide and the native Chapter 2    Materials and Methods 
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horse heart myoglobin digest at a range of concentrations (1 fmol - 30 pmol) in a final volume of 10 µl. 
Samples were centrifuged at 9,000 x g for 5 min and transferred to a 200 µl 96 well microtitre plate. Infusion 
and  MS/MS  were  performed  as  described  in  section  2.6.3.  Myoglobin  protein  concentrations  were 
determined as detailed in section 2.4.3. 
 
2.5 Label-free 
 
2.5.1 Preparation of EB and RB samples for 2D-RPLC-MS
E 
Protein lysates of EBs (two biological replicates) and RBs (two biological replicates) were prepared as 
described in section 2.3.9.1. Each sample containing 100 µg of EB and RB protein lysates (four samples) 
were made up to 100 µl using 0.5 M TEAB. 2 µl of the reducing agent, 50 mM (tris-(2-carboxyethyl) 
phosphine [TCEP] was added and incubated for 1 h at 60ºC. After incubation, 1 µl of the alkylation reagent, 
200  mM  methyl  methane-thiosulfonate  in  isopropanol  was  added  and  incubated  for  10  min  at  room 
temperature. Samples were proteolytically digested by the addition of 10 µl of trypsin at 1 mg/ml containing 
88.8 µg of CaCl2 and incubated overnight at 37ºC. Digested protein lysates were lyophilized in vacuo and re-
suspended in 50 µl of 100 mM ammonium formate containing 8% (v/v) acetonitrile and a tryptic digest of the 
protein alcohol dehydrogenase from Saccharomyces cerevisiae (Waters Corporation), used as an internal 
standard at a final concentration of 20 fmol/µl. Each sample was analysed using 2D-RPLC-MS
E as described 
in section 2.6.4 and the data processed according to sections 2.7.3 and 2.8.3. 
 
2.6 Mass Spectrometry 
 
2.6.1 ESI – Q-ToF MS and MS/MS 
Except the infusion studies and label-free quantitative analyses, described in section 2.6.3 and 2.6.4, 
all  data  were  acquired  using  a  Q-Tof  Global  Ultima  fitted  with  a  Z-spray  and  nanoLockSpray  source 
(Waters). [Glu
1]-fibrinopeptide B ([M+ 2H]
+2 = 785.8426) was used as the internal lockmass calibrant for the 
nanoLockSpray source.  For automated Data Directed Acquisitions (DDA), a survey scan was acquired from 
m/z 375 to 1800 (1.0 scan/sec, 0.1 sec inter-scan delay) in positive ion mode with the switching criteria for 
MS to MS/MS including (i)  ion  intensity  (15  counts  per  second);  (ii)  charge  state (
+2, 
+3, 
+4) and (iii) 
exclusion list (see section 2.6.1). Product ion spectra were acquired from m/z 50 to 1800 at 1 scan/sec until 
the ion intensity fell below a threshold of 5 counts per second or data had been collected for 12 s, which ever 
occurred first. Six channels for product ion acquisition were used. The collision energy used to perform 
MS/MS was automatically varied according to the mass and charge state of the eluting peptide using a 
collision energy profile. For all experiments performed the general parameters shown in Table 2.2 were used 
unless otherwise stated. In MS mode, the quadrupole is operated in RF mode, transmitting a wide range of 
ions. To increase the m/z range transmitted, this transmission window can be moved during a scan. This 
movement is called the MS profile and is controlled by 5 variables: m/z 1, m/z 2, the dwell time at m/z 1, the 
ramp time between m/z 1 and m/z 2 and the dwell time at m/z 2. These three variables are given values as a 
percentage of the total scan time. Typically, these values were maintained at m/z 1 = 400 and m/z 2 = 600 Chapter 2    Materials and Methods 
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with a dwell time of 30% and a ramp rate of 20% for both. This allows detection of ions at 0.6 of the lower 
boundary m/z (0.6 x 400 = 240 m/z) and 4 x the upper m/z value (4 x 600 = 2400 m/z). However, for iTRAQ 
experiments it was found necessary to lower m/z 1 to 100 m/z to allow for transmission of the low mass 
reporter ions in the range 114 – 117 m/z. The RF lens value was also decreased from 1.0 to 0.6 to further 
provide improved signal response in the low mass region. 
  
Instrument  control  and  data  acquisition  were  provided  by  the  software  MassLynx  4.0  (Waters 
Corporation).  The  instrument  was  calibrated  daily  using  the  fragment  ions  of  [Glu
1]-fibrinopeptide  B 
([M+2H]
+2  (m/z  =  785.8426)  as  shown  Table 2.1.  Additionally,  180  fmol  of  an  enolase  digest  (Waters 
Corporation) was used routinely to check the nanoLC-MS/MS analysis process. 
 
Table 2.1.  List of product ion masses from [Glu
1]-fibrinopeptide B, ([M+2H]
+2 = 785.8426 m/z) used for the 
calibration of the Q-Tof Global Ultima and Q-Tof Micro.  
 
m/z 
72.081 
120.081 
175.119 
187.071 
246.156 
333.188 
480.257 
627.325 
684.346 
813.389 
942.432 
1056.475 
1171.502 
1285.544 
 
 
Table 2.2. General parameters used for mass spectrometry performed using a Q-ToF Global Ultima and Q-
ToF Micro. 
 
Parameter  Q-Tof Global Ultima  Q-Tof  Micro 
Capillary voltage (V)  +3.00  Applied via Nanomate 
Cone voltage (V)  100  20 
Extraction cone (V)  n/a  1.5 
Source temperature (ºC)  50  40 
Desolvation temperature (ºC)  0  0 
Cone gas flow (l/h)  20  20 
Resting Collision energy (eV)  10  7 
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2.6.2 MALDI-ToF MS 
MALDI-ToF experiments were performed using a M@LDI HT (Waters, Manchester, UK) in positive 
ion mode. 
 
Samples  were  spotted  onto  stainless  steel  lockmass  target  plates  (Waters)  according  to  the  dried 
droplet method (Karas and Hillenkamp, 1988). Samples were mixed 1:1 with matrix and then 1 µl was 
spotted on to the target plate and allowed to air dry. The matrix used for peptide analysis comprised of 2 
mg/ml α-cyano-4-hydoxycinnamic acid in 50:50 (v/v) acetonitrile:water containing 0.1% (v/v) trifluoroacetic 
acid. External calibration was performed using monoisotopic masses of a bovine serum albumin protein 
digest  at  the  beginning  of  each  day.  All  analyses  were  performed  using  a  lockmass  correction.  [Glu
1]-
fibrinopeptide B [M+H2]
2+ (m/z = 785.8426) prepared in 2 mg/ml α-cyano-4-hydoxycinnamic acid in 50:50 
(v/v) acetonitrile:water containing 0.1% (v/v) trifluoroacetic acid and was used for lockmass correction at a 
concentration of 200 fmol/µl on target.  
 
All samples were analysed using positive ion reflectron mode with delayed extraction. The pulse and 
source voltages were set at 2,340 V and 15,000 V, respectively. A low or medium coarse laser setting was 
used and fine laser energy tuning was provided under software control. Data was collected from m/z 800 – 
3500. Data was processed using MassLynx 4.0 (Waters Corporation). 
 
2.6.3 Infusion MS and MS/MS 
Infusion of samples was achieved using an automated chip infusion system (TriVersa™ Nanomate, 
Advion Biosciences, NY, USA) coupled to a Q-Tof Micro mass spectrometer fitted with a z-spray source 
(Waters Corporation). Lyophilised samples were re-suspended in 10 µl 50% (v/v) methanol containing 1% 
(v/v) acetic acid, otherwise samples were infused as prepared, without further solvent addition. Samples were 
maintained at 4ºC in a 200 µl 96 well microtitre plate. Initially, to generate the nanoelectrospray, a voltage of 
+1.7 kV with a gas back pressure of 0.6 psi was applied to the samples in a conductive tip applied to the back 
of a nozzle on the chip (Figure 2.3). Depending upon the MS signal response, the voltage was fine-tuned in 
the range +1.6 to +2.2 kV and the gas pressure from 0.6 to 1.5 psi to maximise the signal intensity. Flow 
rates vary between ~50 and 300 nl/min depending upon the voltage and gas pressure used. For each analysis, 
a new tip and nozzle were used preventing carryover. The Nanomate system was controlled using ChipSoft 
7.0 software (Advion Biosciences, NY, USA). The Q-Tof micro was operated in positive ion mode using an 
MS scan range of 300 to 1700 m/z (1.0 scan/sec, 0.1 sec inter-scan delay) and an MS/MS scan range of 50 to 
1700 m/z (1.0 scan/sec, 0.1 sec inter-scan delay). Other MS parameters were set according to Table 2.2.  
Collision energies were tuned for each precursor ion and were dependant upon the fragmentation profile 
required. Data acquisition and instrument control was achieved using MassLynx 4.0. The instrument was 
calibrated daily using the fragment ions of [Glu
1]-fibrinopeptide B [M+2H]
+2 (m/z = 785.8426) as shown in 
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2.6.4 2D-RPLC-MS
E 
Two-dimensional  separations  were  performed  using  a  nanoAcquity  2D  UPLC  system  (Waters 
Corporation). For the first dimension separation, 4.5 µl (9.0 µg) of the prepared EB and RB protein lysates 
containing 90 fmol of an ADH digest (see section 2.5.1) were injected onto a 5µm, Xbridge BEH130 C18, 
300 µm i.d. x 50 mm (Waters Corporation) column equilibrated in 20 mM ammonium formate, pH 10 (buffer 
A). The first dimension separation was achieved by increasing the concentration of acetonitrile (buffer B) in 
11 steps consisting of 8.2%, 11.7%, 13%, 14.5%, 15.9%, 17.4%, 18.9%, 20.8%, 23.6%, 45%, 65%. At each 
step the programmed percentage composition was held for 1 min at a flow rate of 2 µl/min and the eluant 
diluted by buffer C (H2O + 0.1% (v/v) formic acid) from the second dimension pump at a flow rate of 20 
µl/min. This effectively dilutes the ammonium formate and acetonitrile, allowing trapping of the eluting 
peptides onto a Symmetry C18, 180 µm i.d. x 20mm trapping cartridge (Waters Corporation). After 15 min 
washing of the trap column, peptides were separated using an in-line second dimension analytical separation 
performed on a 75 µm i.d. x 200 mm, 1.7 µm, BEH130 C18, column (Waters Corporation) using a linear 
gradient of 5 to 40% B  (buffer A = 0.1% (v/v) formic acid in water, buffer B = 0.1% (v/v) formic acid in 
acetonitrile) over 90 min with a wash to 85% B at a flow rate of 300 nl/min. All separations were automated 
and performed on-line to the mass spectrometer. 
 
All  mass  spectrometry  was  performed  using  a  Synapt  Q-Tof  mass  spectrometer  fitted  with  a 
nanolockspray source operating in MS
E mode (Waters Corporation). Data was acquired from 50 to 1990 m/z 
using alternate low and elevated collision energy (CE) scans. Low CE was 5V (Trap), 4V (Transfer) and 
elevated  was  12-35V  ramp  (Trap),  10V  (transfer).  The  lock  mass  Glu-fibrinopeptide,  ([M+2H]
+2,  m/z  = 
785.8426) was infused at a concentration of 100 fmol/µl at 250 nl/min and acquired every 60 seconds. 
Operation of the Waters Synapt mass spectrometer was performed in collaboration with Dr Chris Hughes 
from Waters Corporation. 
 
Figure 2.3. The Triversa Nanomate chip system (Advion Biosciences). Panel A shows 
a photograph of a 400 nozzle chip, while Panel B provides a schematic representation 
of spray production. 
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2.7 Data processing 
 
2.7.1 Exclusion list generation 
In both the MudPIT (section 2.3.8) and GeLC-MS/MS (section 2.3.7) analyses performed in this 
study,  the  technique  of  real-time  database  searching  (RTDS)  was  implemented.  This  was  established  in 
collaboration with the Waters Corporation who provided a developmental version of a real-time database-
searching algorithm. 
 
In this process, EB and RB samples were first analysed using a nanoLC-MS/MS experiment without 
any RTDS as described in sections 2.3.9.5 and 2.6.1. In the next stage, the same samples were analysed a 
second and third time utilising the RTDS algorithm. Exclusion lists were generated ‘on the fly’ using the 
RTDS algorithm within the ProteinLynx Global Server 2.05 software suite (Waters Corporation). Once an 
MS/MS spectrum had been acquired, it was processed to generate a peak list and searched against a protein 
translation of the Chlamydia trachomatis, serovar D genome. This process occurs on a ~30 to 60 sec time 
scale.  During the LC-MS/MS experiment, when three peptides matching a specific protein are assigned, a 
peptide exclusion list is generated. This exclusion list consists of peptide masses generated ‘on the fly’ from 
the in-silico trypsin digestion of those proteins meeting the three peptide criteria. The mass spectrometer is 
automatically updated with the new exclusion lists, excluding the MS/MS analysis of any further peptides 
from those proteins already assigned by three peptides and so allowing the analysis of further low abundant 
peptides and hence potentially improving proteome coverage. 
 
2.7.2 Data processing of GeLC-MS/MS, iTRAQ and MudPIT data 
MS/MS spectra collected using DDA were processed using either ProteinLynx Global Server (PLGS) 
version 2.05 for GeLC-MS/MS and MudPIT data, or PLGS version 2.2.5 for iTRAQ data. The following 
parameters were used for the processing of MS/MS spectra; normal background subtraction with a 25% 
threshold and medium de-isotoping with a threshold of 1%, no smoothing of the data was performed. Peak 
lists were generated in a .pkl format ready for database searching.  
 
2.7.3 Data processing of Label-free data 
LC-MS
E  data  were  processed  using  PLGS  version  2.3  for  submission  to  the  IDENTITY
E  search 
engine (Waters corporation, Milford, MA). The ion detection, clustering and normalization procedures have 
been  described  in  detail  previously  (Geromanos  et  al.,  2009).  Briefly,  LC-MS
E  spectra  were  lockmass-
corrected,  centroided,  deisotoped  and  charge  state  reduced  and  intensity  measurements  adjusted.  Each 
detected component is expressed as an AMRT (accurate mass retention time) pair. These AMRT pairs are 
used to associate fragments ions with their corresponding precursor ions using the embedded time alignment 
algorithm. AMRT pairs are then clustered and matched with the same AMRTs across all experiments based 
upon mass precision and a retention deviation threshold. Once processed, the 11-peak list files corresponding 
to the LC-MS
E acquisitions performed for each of the 11 fractionation steps were merged. The eight merged Chapter 2    Materials and Methods 
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files created, correspond to the two biological and two technical replicates of both EB and RB samples. 
These were subsequently submitted for database searching to IDENTITY
E (section 2.8.3). 
 
2.8 Database searches 
 
2.8.1 Database searches of GeLC-MS/MS and MudPIT data 
Peak lists in .pkl format were submitted to PLGS version 2.05 and the data searched against a protein 
translation of a concatenated database consisting of the C. trachomatis, serovar D genome (May, 2004) and 
the NCBI human genome (May, 2004). The data was also subsequently searched against the C. trachomatis 
L2/434/Bu genome (September 2007). Early access to this completed genome sequence was kindly provided 
by Dr Nicholas Thomson, Wellcome Trust Sanger Institute, Cambridge, UK. The database was publically 
released in January 2008 (Thomson et al., 2008). 
 
A  maximum  of  one  missed  cleavage  for  tryptic  digestion,  a  fixed  modification  for 
carbamidomethylation of cysteine and a variable modification for the oxidation of methionine were allowed. 
Precursor and fragment ion tolerances were set at 100 ppm and 0.25 Da, respectively. Protein identifications 
required the assignment of ≥ 2 different peptides or where identified by only a single peptide, spectra were 
manually inspected and assigned. Proteins were only assigned if, for each peptide ion, greater or equal to 
three consecutive experimentally derived y or b ions could be matched to the predicted spectra. Data was 
imported into Microsoft Excel 2000. The data was checked for homologous chlamydial and human peptides. 
No homologous peptides were detected in these datasets. 
 
2.8.2 Protein identification and quantification of iTRAQ data 
Peak lists in .pkl format were submitted to the Mascot search engine (Matrix Science, London, UK). 
Mascot version 2.0 was used to search iTRAQ labeled S. Typhimurium samples for the iTRAQ optimisation 
and  iTRAQ  parser  development  studies  described  in  Chapter  3.  Mascot  version  2.2.1  was  used  for  the 
chlamydial iTRAQ studies presented in chapter 5. S. Typhimurium iTRAQ peak lists were searched against a 
protein translation of the Salmonella enterica, Serovar Typhimurium genome (December 2005). For the 
chlamydial  iTRAQ  studies,  peak  lists  were  searched  against  a  protein  translation  of  the  C.  trachomatis 
L2/434/BU genome including L2 plasmid genes (January, 2008) and a concatenated database consisting of 
the C. trachomatis L2/434/BU genome and the NCBI human genome (January, 2008). 
 
A maximum of one missed cleavage for trypsin digestion and fixed modifications for methyl methane-
thiosulphonation (MMTS) of cysteine and the N-terminus and lysine side chains using the 4-plex iTRAQ 
label  were  allowed.  Variable  modifications  for  the  oxidation  of  methionine  and  iTRAQ  modification  of 
tyrosine  were  also  allowed.  Precursor  and  fragment  ion  tolerances  were  set  at  100  ppm  and  0.25  Da, 
respectively. Protein identifications required the assignment of ≥ 2 different peptides with a significance 
threshold for accepting a match of p < 0.03 (≥ 98% confidence). Using Mascot 2.2.1, the chlamydial MS data Chapter 2    Materials and Methods 
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was searched against a decoy database of the C. trachomatis L2 genome including the L2 plasmid. The FDR 
of peptides above the identity threshold was estimated to be 3.23%. 
 
For the chlamydial data, .pkl files were merged and protein ratios calculated using Mascot 2.2.1. 
Peptide ratios were weighted and median normalization performed, automatic outlier removal was chosen 
and the peptide threshold was set to ‘at least homology’. False discovery rates were calculated by searching 
all spectra against a decoy database using the Mascot software. For the S. Typhimurium iTRAQ data, protein 
assignments were exported as a comma separated values (.csv) file for association to their respective reporter 
ion ratios generated by the iTRAQ parser. For chlamydial iTRAQ data, merged protein assignments and 
quantitative data were exported as a .csv file for data curating. 
 
2.8.3 Protein identification and quantification of label-free data 
LC-MS
E data was processed as described in section 2.7.3 and submitted to the PLGS database search 
algorithm IDENTITY
E version 2.3. In IDENTITY
E, data is further correlated based upon physiochemical 
properties of peptides in the liquid and gas phase. The search strategy is a three stage iterative process, where 
each successive iteration incrementally increases the selectivity, specificity and sensitivity of each search. 
The outline of this process is described briefly in section 5.3.2 and has been described in detail previously 
(Geromanos et al., 2009; Li et al., 2009). Each processed file was searched against a protein translation of the 
C. trachomatis L2/434/Bu genome sequence, including the L2 plasmid sequence and the internal standard 
alcohol dehydrogenase from Saccharomyces cerevisiae. A full 1x reverse database was also appended as a 
decoy search to determine the peptide false discovery rate. To account for possible host peptides that were 
homologous to chlamydial peptides, data was also searched against the C. trachomatis L2/434/BU database 
appended  with  the  UniProt  human  database  (http://www.uniprot.org,  February  2009).  Search  parameters 
were  as  follows:  Precursor  and  product  ion  tolerance  were  10  ppm  and  15  ppm  respectively.  Enzyme 
specificity  was  set  to  tryptic;  fixed  modifications  included  MMTS;  variable  modifications  included 
deamidated asparagine and glutamine, acetylation at the N-terminus and oxidized methionine. A maximum 
of two missed tryptic cleavages were allowed. A false discovery rate of 4% was applied. Each protein was 
identified with ≥ 3 different peptides and each peptide was assigned with a minimum of at least 3 fragment 
ions per peptide.  
 
2.8.3.1 Data normalization and protein quantification of the label-free data 
Normalization to obtain absolute concentrations was performed within IDENTITY
E.  The average 
intensity measurement for the three most abundant tryptic peptides for each assigned protein, including the 
internal protein standard ADH were determined. The average intensity of the ‘Top3’ most abundant peptides 
of the internal standard were used to calculate a universal response factor (counts/mol of protein). This 
response factor was applied to the average intensity of the ‘Top3’ abundant peptides from all other assigned 
proteins to determine their absolute concentration, expressed as fmol on column (Silva et al., 2006b). The 
results for each of the 8 samples were exported as a .csv file for further manipulation in Microsoft Excel. 
Peptides identified as being homologous between Chlamydia and human (closest genome with homology to Chapter 2    Materials and Methods 
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the African green monkey) were identified and removed using a script written by Dr Richard Edwards. Data 
was further filtered for protein quantitation by only considering proteins that were identified in at least two 
replicates of the same chlamydial development form, i.e., EBs or RBs. These could be either technical or 
biological replicates or both. Proteins assigned in a single replicate present in both EB and RB, were not 
considered for quantitation, but are reported for qualitative purposes. Protein identifications present in a 
single replicate are reported for qualitative purposes and reach the criteria of being matched by ≥ 3 different 
peptides. By using the replication of protein assignments across different injections, the false positive rate is 
minimized, since chemical noise is random in nature and so does not tend to replicate across injections, so 
reducing the false positive rate and improving confidence in protein assignment (Vissers et al., 2007). 
 
2.8.3.2 Normalization to the number of bacterial cells 
Label-free  
For the label-free analysis, each sample was normalized on a per bacterium basis. The number of 
bacteria per µl of EB and RB suspensions used to prepare protein lysates were determined by measuring the 
number of copies of the omcB gene using quantitative PCR, as described in section 2.2.10. The chlamydial 
genome has a single copy of the omcB gene. Based upon the assumption that one omcB gene is equivalent to 
one genome, and that one genome is equivalent to a single bacterium, the number of bacterial cells equivalent 
to the 4.5 ul of digested protein lysate(s) injected on column were determined. Using the Avogadro’s number, 
the number of molecules of each protein were calculated and divided by the number of bacterial cells loaded 
on column to provide quantitative values for each protein expressed as molecules per cell. Values were 
calculated  for  the  entire  dataset  using  Microsoft  Excel.  Protein  ratios  were  calculated  and  the  standard 
deviation between biological and technical replicates determined for each developmental form. These data 
are shown in Appendix 1, Table 5.2. 
 
iTRAQ 
  iTRAQ  protein  ratios  for  each  biological  replicate  were  normalized  according  to  the  number  of 
bacterium contained within each sample preparation. The number of bacterial  cells in each EB and RB 
biological replicate were used to calculate a correction factor ratio, which was applied to each protein ratio 
before calculating the mean ratio and the standard deviation for each protein. 
 
2.8.4 Functional protein categories 
Proteins assigned for the chlamydial studies were grouped into functional categories according to the 
classification originally described by Stephens et al, (1998). Proteins were only classified within a single 
functional group and assigned to each protein via their loci using Microsoft Excel.  
 
2.8.5 Protein identifiers 
Using the ID mapping tool within UniProt (http://www.uniprot.org/), gi numbers were mapped to 
UniProt identifiers and exported as an Excel file. CTL (C. trachomatis L2 loci) and CT (C. trachomatis, Chapter 2    Materials and Methods 
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serovar D loci) numbers were mapped using a loci translation table kindly provided by Dr Nicholas Thomson 
(Wellcome Trust Sanger Institute).  
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3.0 DEVELOPMENT OF QUANTITATIVE 
PROTEOMIC TECHNOLOGIES 
3. 1 Introduction 
 
3.1.1 Relative quantitation  
The ability to compare protein expression levels in cells or tissues in different biological states 
is an important and fundamental aspect of proteomic research. Traditionally, such measurements have 
been achieved using 2-D gel electrophoresis coupled with densitometry, providing a relative measure 
of protein abundance between two different cellular states. However, the approach lacks the required 
dynamic range, representing only the most abundant proteins, and is not applicable to the analysis of 
proteins  with  extreme  physio-chemical  properties  (Gygi  et  al.,  2000;  Tannu  and  Hemby,  2006). 
Further, the relative nature of the comparison means that it is difficult to place a quantitative value on 
the expression level of a protein when it is not detected in cells in one particular state. It is these 
limitations that have led to the development of alternative, non-gel based, quantitative technologies. 
 
The majority of these non-gel based methodologies use stable isotope labelling strategies. In 
these types of proteomic analyses, the difference in mass between pairs of chemically identical analytes 
of different stable-isotope compositions, are measured in a mass spectrometer. The measured ratio of 
the signal intensities between the pairs indicates the abundance ratio of the two analytes.  
 
Such methodologies can be divided into two categories. The first called SILAC (Stable Isotope 
Labelling by Amino acids in Cell culture), is an‘in-vivo’ labelling method (Ong et al., 2003; Mann, 
2006), utilizing the incorporation of essential amino acids such as [
13C]-arginine and [
13C]-lysine into 
proteins  within  a  particular  cellular  state.  By  comparing  the  relative  amounts  of  heavy  and  light 
peptides in test and control samples, respectively, it is possible to estimate the protein abundance ratio 
between the two conditions. Because samples are combined at an early stage, the methodology has the 
advantage  of  eliminating  errors  due  to  any  subsequent  downstream  processing.  However,  the 
requirement  for  the  incorporation  of  essential  amino  acids  restricts  its  application;  for  example,  it 
would be too impractical and expensive to achieve in humans. The second category, the use of external 
stable-isotope labelling strategies, requires the differential labelling or modification of specific amino 
acid residues in proteins or peptides. A well-characterised approach is the Isotope-Coded Affinity Tag 
(ICAT) method. Developed by Gygi and co-workers (1999b), differentially labelled heavy and light 
tags specific for cysteine residues are used to provide relative quantification of cysteine-containing 
peptides. Additionally, these tags contain biotin, allowing the selective retrieval of cysteine-containing 
peptides  from  non-cysteine  containing  peptides  using  affinity  purification,  greatly  reducing  the Chapter 3    Development of Proteomic Technologies 
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complexity of the sample and so providing increases in the dynamic range of the mass spectrometric 
analysis. 
 
All  of  these  methods  are  based  upon  an  incorporated  mass  difference  to  support  relative 
quantification by measurement of the corresponding relative peak areas in either MS or MS/MS (Pan 
and Aebersold, 2007). Because of this requirement, they are restricted to experiments looking at the 
difference between two-to-three conditions (3-plex), (Hilger and Mann, 2011). This limits the types of 
experiments that can be performed; for example, it precludes time-course studies. Although 2-plex 
studies can be combined post-analysis, not all of the same peptides will be identified in every sample, 
making comparison and statistical interpretation of the data difficult.  
 
An alternative method, initially allowing the multiplexing of up to four samples (Ross et al., 
2004) and then subsequently extended to the multiplexing of up to eight samples (Choe et al., 2007) 
has been described. The methodology, termed iTRAQ, is based upon a multiplexed set of isobaric 
reagents that are specific for primary amines (Figure 3.1). Proteins from up to eight different cellular 
states are first reduced, alkylated and digested with trypsin before labelling with one of eight different 
tags.  The  labelled  peptides  from  each  cellular  state  are  then  combined  and  nanoLC–tandem  mass 
spectrometry performed. Since the iTRAQ tags are isobaric, in MS mode the masses of the iTRAQ 
labelled peptides from the eight states are indistinguishable from one another. However, when the 
labelled peptides are isolated and fragmented in tandem MS mode, each tag generates a unique m/z 
reporter ion in a relatively quiet region of the mass spectrum from 113 – 119 and 121 m/z. Protein 
quantification is achieved by comparing the relative intensities of these reporter ions in the MS/MS 
spectrum.  The  corresponding  peptides  are  identified  using  the  fragment  ions  from  the  peptide 
backbone.  Because  there  is  potentially  a  contribution  of  signal  from  all  eight  labelled  peptides, 
improvements in signal to noise ratio are observed leading to more confident peptide identifications. 
Although the technique produces peptide mixtures that are more complex than those obtained using the 
cysteine  specific  ICAT  approach.  The  increased  number  of  peptides  improves  protein  coverage, 
leading to increased statistical confidence in both protein identification and quantification, outweighing 
the extra fractionation steps required. Furthermore, as essentially all peptides are labelled, the approach 
lends itself to the detection of post-translational modifications. An alternative to iTRAQ reagents, are 
Tandem Mass Tags (TMT), which are based upon the same principle, but have different reporter ion 
masses (Thompson et al., 2003). 
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Figure 3.1 iTRAQ tag structure and workflow (after Ross et al., 2004). 
 
3.1.2 Absolute quantitation 
The majority of routinely used quantitative technologies provide only a relative measure of 
protein abundance between two cellular states. It is now apparent that this places restrictions on the 
comparisons that can be made across different experiments. There is therefore a requirement to be able 
to express the quantity of each protein of a complex system in terms of the number of copies per cell, 
as opposed to -fold changes obtained in a differential expression type of experiment. Such information 
represents the ‘gold standard’ in quantification, allowing quantitative comparisons to be made between 
different proteins within the same and/or different systems. 
 
   Absolute quantification of small organic molecules is considered relatively routine (reviewed by 
Hoke et al., 2001), and is well established in the pharmaceutical industry. The type of experiment often 
performed is termed multiple reaction monitoring (MRM), and is traditionally performed on a triple 
quadrupole mass spectrometer, because of the maximum sensitivity achieved when operated in this 
mode. Here, the first quadrupole (Q1) and the last quadrupole (Q3) are used as a mass filter, isolating a 
specific precursor m/z and monitoring one or more of its corresponding fragment ions. Using prior 
knowledge  about  a  drugs  structure,  for  example,  can  be  used  to  predict  the  precursor  m/z  and  a 
corresponding  fragment  m/z  (MRM  transition).  The  fragment  ion  is  then  monitored  during  the 
chromatographic elution, providing both maximum selectivity and sensitivity. By using an isotopically 
labelled version of the drug as an internal standard, the ratio of drug to internal standard can be used to 
calculate the absolute amount of the drug present in the sample. This same approach has in recent 
years, been applied to the absolute quantification of proteins. Chapter 3    Development of Proteomic Technologies 
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The  application  of  the  isotope-dilution  method  for  the  quantification  of  proteins,  was  first 
described by Barr (1996), as a solution to replacing immunoassays. This was re- introduced to the 
proteomics  community  by  Gerber  et  al.  (2003).  Here  they  demonstrated  that  1-D  SDS-PAGE  in 
combination with stable isotope labelled peptide standards and LC-MS/MS, can be used to fractionate 
and  obtain  absolute  quantitative  measurements  of  proteins  and  phosphoproteins  from  complex 
proteomes such as those of HeLa cells. The procedure, termed AQUA (Absolute QUAntitation of 
proteins), involved the separation of whole cell lysates of HeLa cells using 1-D SDS-PAGE. Peptides, 
corresponding to specific tryptic fragments from proteins of interest, were chemically synthesized with 
an incorporated stable isotope such as [
13C]. Samples containing the protein of interest (e.g. slices 
excised from SDS-polyacrylamide gels) were subjected to limit digestion with trypsin, following the 
addition  of  a  known  amount  of  the  isotopically  labelled  peptide.  NanoLC-MS/MS  using  Multiple 
Reaction Monitoring (MRM), was then used to measure the amount of the native tryptic peptide from 
the protein of interest by comparison with the corresponding internal standard. They demonstrated the 
approach  to  be  precise  (±  5%)  and  highly  specific.  For  example,  they  were  able  to  discriminate 
between phosphorylated and non-phosphorylated protein isoforms. It was also markedly more sensitive 
than many existing proteomic approaches, demonstrating that <20 µg of HeLa cell lysates was required 
to quantify the protein separase and its phosphorylation state. 
 
Although conceptually simple, the implementation of such quantitative approaches in a lab with 
different mass spectrometers is not trivial. Accordingly, this chapter focuses on the establishment and 
validation  of  such  technologies  for  quantitative  proteomic  analysis  in  Southampton.  The 
implementation of the iTRAQ strategy for quantitative analysis of the proteome from the intracellular 
bacterium Chlamydia trachomatis has required considerable method development. These developments 
have required the optimisation of sample preparation and fractionation procedures; the optimisation of 
MS analysis using alternative, as apposed to recommended instrumentation; and the processing of raw 
iTRAQ data to obtain qualitative and quantitative information.  
 
The second part of this chapter considers the development of absolute quantification methods 
and their application to the analysis of the Chlamydia trachomatis proteome. Initial studies focus on the 
implementation and validation of the AQUA strategy developed by Gerber et al. (2003) using the more 
accessible and characterised system, Escherichia coli (MG1655). Establishing this technology using E. 
coli has allowed the technique to be extended to allow preliminary data for the absolute quantification 
of proteins expressed in elementary bodies (EBs) and reticulate bodies (RBs), the two developmental 
forms of Chlamydia trachomatis.  
 
As  with  the  completion  of  a  genome  sequence,  the  measurement  of  absolute  quantities  of 
proteins on a proteome-wide scale would represent a major advance. However, to achieve such an 
ambitious goal requires a substantially increase in throughput. One of the limitations of the AQUA 
strategy in this respect is the requirement for lengthly chromatography prior to MS analysis. Typically, Chapter 3  Development of Quantitative Proteomic Technologies 
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the  analysis  time  is  ~  1  h  per  sample  and  can  take  several  hours  of  chromatography  method 
development to establish conditions for each reference or set of reference peptides. The direct analysis 
of samples within complex mixtures, without recourse to on-line chromatography, would therefore 
offer several advantages in terms of speed and development time. Accordingly, this chapter also reports 
a proof of concept strategy developed using automated nanoelectrospray infusion, using a chip-based 
electrospray system (Nanomate system, Advion Biosciences) in combination with high-resolution mass 
spectrometry,  for  the  absolute  quantification  of  proteins  within  simple  and  potentially  complex 
mixtures, eliminating the requirement for on-line RP chromatography. To demonstrate the potential of 
this approach, the biological fluid human serum and the model protein myoglobin are used. 
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3.2 Results 
 
3.2.1 Development and implementation of iTRAQ technology 
As  a  prerequisite  to  the  quantitative  analysis  of  Chlamydia  using  iTRAQ,  a  suitable 
experimental workflow for the quantitative analysis of protein lysates using the iTRAQ reagents from 
Applied  Biosystems  was  implemented  using  protein  lysates  from  Salmonella  Typhimurium. 
Salmonella was selected as it offered an easily obtainable source of protein lysates from cells that are 
readily cultured, compared to the more difficult chlamydial cells, which require a host for growth. 
 
3.2.2 Fractionation of iTRAQ labelled peptide mixtures 
Whole cell lysates of Salmonella Typhimurium SL1344 were prepared as described in Chapter 
2. In brief, 4 x 100 µg samples of protein lysates were reduced, alkylated, proteolytically digested using 
trypsin and labelled using the 4-plex iTRAQ reagents as described in section 2.3.9.3. Lysates from two 
batches  of  unstressed  cells  were  labelled  using  the  114  and  116  iTRAQ  reagents,  respectively. 
Similarly, lysates from two batches of cells osmotically stressed using 0.5 M NaCl were labelled with 
the 115 and 117 reagents. Preliminary mass spectrometric analysis (data not shown) indicated that the 
labelled peptide extract was highly complex, requiring fractionation to increase proteome coverage. 
Therefore, as part of the iTRAQ workflow, two fractionation columns were evaluated. 
 
Strong-cation-exchange (SCX) chromatography is a commonly used fractionation technique for 
proteomics and was chosen for fractionation of the iTRAQ labelled peptide mixture. Initial separations 
were performed using the ProPac
® 250 mm x 1 mm ID SCX column (Dionex), in conjunction with a 
sodium phosphate buffer pH 3.0 and NaCl gradient (0 – 500 mM) as described in section 2.3.9.4.  
Figure 3.2 shows a UV absorbance chromatogram of 400 µg (4 x 100 µg) of iTRAQ labelled peptides 
loaded on column. With the exception of the large UV absorbance signal obtained between 0 and 12 
min, no peptide elution was observed during the 50 min separation gradient. This suggested either no 
effective binding of the labelled peptides to the column and hence the peptides were eluted along with 
the injection artefact, or that peptides were bound with high affinity to the column, with up to 500 mM 
NaCl not being of sufficient ionic strength to elute peptides from the column. Subsequent MS analysis 
revealed that the iTRAQ labelled peptides were contained within the injection artefact. Maintaining the 
pH of the mobile phase buffers at pH 3.0 is essential to ensure that the peptides are positively charged, 
allowing effective binding to the sulphonic acid groups of the SCX column packing material. To be 
certain that the pH was maintained at 3.0 during the separation gradient, the experiment was repeated 
using 10 mM phosphoric acid in combination with a 0 – 500 mM NaCl gradient. Similarly, no peptide 
separation was observed.  
 
In light of the results obtained using the Dionex ProPac column, an alternative SCX column 
from the manufacturer Phenomenex was evaluated. iTRAQ labelled peptides were separated using a Chapter 3    Development of Proteomic Technologies 
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Luna, 5 µm, SCX, 100 Å, 250 x 4.6 mm ID column (Phenomenex), equilibrated in 10 mM phosphoric 
acid. Peptide elution was achieved using a NaCl gradient (0-500 mM) as detailed in section 2.3.9.4. 
Using this column and buffer system, iTRAQ labelled peptides were separated to provide sufficient 
fractionation of the sample for further downstream analysis. A UV absorbance chromatogram of the 
separated iTRAQ peptides is shown in Figure 3.3. Since this column provided sufficient fractionation 
of the iTRAQ labelled peptides, all subsequent iTRAQ experiments, as presented in Chapter 5 were 
performed using the Phenomenex Luna SCX column. 
 
Figure 3.2. A UV chromatogram of a SCX separation of an iTRAQ labelled peptide extract from 
Salmonella Typhimurium using a ProPac® 250 mm x 1mm ID SCX-10 column (Dionex). Separation 
was achieved using sodium phosphate pH 3 and a NaCl gradient (0-500 mM) at 0.2ml/min over 50 
min. UV absorbance was monitored at 235 nm. 
 
 
Figure 3.3. A UV absorbance chromatogram of a SCX separation of an iTRAQ labelled peptide extract 
from  Salmonella  Typhimurium  using  a  250  mm  x  4.6  mm  ID  Luna  SCX  column  (Phenomenex). 
Separation was achieved using 10 mM phosphoric acid and a NaCl gradient (0-500 mM) at 0.2 ml/min. 
UV absorbance was monitored at 235 nm. The inset provides an expansion of the region where peptide 
elution occurred. Fractions were collected at 1 min intervals. Chapter 3  Development of Quantitative Proteomic Technologies 
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3.2.3 Extraction of quantitative information from iTRAQ data 
At the initiation of these studies, the iTRAQ™ approach had been developed primarily for use 
with mass spectrometry instrumentation and software developed by Applied Biosystems (ABI) (Ross et 
al., 2004). The ABI software package ProQuant (ABI), provided both quantitation and identification of 
iTRAQ labelled samples using MS data submitted in proprietary ABI formats. As such, the analysis of 
iTRAQ  labelled  samples  using  MS  instrumentation  and  software  from  the  manufacturer  Waters 
(formerly,  Micromass),  presented  some  challenges.  These  included  the  optimisation  of  instrument 
parameters, peptide assignment and in particular, the extraction of iTRAQ reporter ion information. 
  
The  assignment  of  proteins  from  iTRAQ  labelled  peptides  using  alternative  protein 
identification tools such as, ProteinLynx Global Server and Mascot, can easily be achieved. However, 
obtaining quantitative information using iTRAQ, at the time, was restricted to ProQuant (ABI). In 
collaboration with the School of Electronics and Computer Science (James Rodger, Dr Simon Miles, 
University of Southampton), a parser, written in Java™ was developed to extract the reporter ion 
intensities from the MS/MS spectrum of each fragmented iTRAQ labelled peptide ion. 
 
Before raw MS/MS data can be submitted to PLGS or Mascot for searching, they require pre-
processing to generate a peak list. As part of the PLGS software suite, peak lists can be generated in the 
.pkl file format. This .pkl file contains on one line, the m/z value of a peptide ion, along with its 
corresponding ion intensity and charge state. This is followed by a list of fragment ion m/z’s and their 
corresponding ion intensity values, including the reporter ion m/z and intensities. 
 
The input of the iTRAQ parser is a .pkl file, which parses the following information into a 
comma-separated-variable (CSV) file: .pkl filename, charge state, peptide ion m/z, the reporter ion m/z 
of 114.1 0.1, 115.1 0.1, 116.1 0.1, 117.1 0.1 and their corresponding ion intensities. The mass 
window of  0.1 was established to ensure that the reporter ion peak was captured. This was achieved 
using an iterative process, by manual inspection of the reporter ions in the spectra and output file. The 
Graphical User Interface (GUI) of the iTRAQ parser is shown in Figure 3.4.  
 
 
Figure 3.4. iTRAQ Parser - Screenshot of the Graphical User Interface. Chapter 3    Development of Proteomic Technologies 
90 
Peptides are assigned by submission of the same set of .pkl files to the Mascot search engine 
and the results exported as a .CSV file. This reporter ion intensity information can then be integrated 
with the peptide assignment data using the .pkl filename and corresponding peptide ion mass (to 4 
decimal places) by manipulation in Microsoft Excel. The data is then filtered and processed as follows: 
 
Thresholding 
Ratios with intensities <20 counts were removed since low ion counts close to background can 
cause  errors.  A  value  of  20  was  chosen,  since  this  is  about  10  x  the  ion  counts  obtained  from 
background in this reporter ion region. 
 
Corrections for isotope overlap 
Although small (< 3% for 4-plex; <1% for 8-plex), correction factors to account for isotope 
overlap from the natural isotope abundance (+1, +2 Da) and from incomplete enrichment at any carbon 
or nitrogen (-1, -2) were applied. The information for these purity correction values is provided with 
the iTRAQ reagent kit. 
 
Intensity weighting  
An intensity weighting was applied by summing the reporter ion intensities in any given channel 
(114, 115, 116, 117, etc.) from all peptides arising from a given protein. This provides a natural way of 
the most intense spectra contributing more to the protein ratio, whereas contributions from weaker ions 
closer to background are minimized. 
 
To test the ability of the parser to successfully extract iTRAQ reporter ion data, Salmonella 
protein lysates were labelled with the 114 and 116 iTRAQ reagents. 100 µg of a Salmonella protein 
lysate was labelled with the 114 iTRAQ reagent and 50 µg of the same sample labelled with the 116 
iTRAQ  reagent  (section  2.3.9.3)  and  LC-MS/MS  analysis  performed  without  SCX  fractionation 
(section 2.3.9.5). Using the iTRAQ parser, the reporter ion intensities were extracted and plotted as 
shown in graphs A and B of Figure 3.5. Correlation of the data with the expected 2:1 differential 
expression ratio was reasonable with the exception for a few outlying values (Figure 3.5, A). Upon 
further analysis these outliers were identified as peptide autolysis products from the protease bovine 
trypsin,  used  for  digestion  of  the  protein  lysates.  Exclusion  of  these  data  points  from  the  dataset 
showed that there was a good correlation with the expected 2:1 labelling ratio (Figure 3.5, B). 
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A 
 
B 
 
Figure 3.5. iTRAQ reporter ion intensities of peptides from Salmonella lysates labelled with the 114 
and 116 iTRAQ reagents in a 2:1 ratio. 114 reagent = 100 µg of lysate, 116 reagent = 50 µg of lysate. 
Graph A represents the labelled Salmonella lysates including the data points for the autolysis products 
of trypsin; Graph B represents the labelled Salmonella lysates excluding data points from the trypsin 
autolysis products. This data was in good agreement with the expected 2:1 ratio with a correlation 
coefficient of 0.9372. Data was extracted using the iTRAQ parser written at Southampton University. 
 
3.3 Implementation and validation of the AQUA strategy 
 
To establish and validate a methodology for the absolute quantitation of proteins, the AQUA 
strategy (Gerber et al., 2003) was used to determine the expression levels of the regulatory protein 
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BipA during the growth of the bacterium Escherichia coli. The AQUA strategy has two stages. The 
first of these is the design and synthesis of an internal peptide standard and its validation; the second is 
development of the assay and implementation. 
 
3.3.1 Internal peptide standard selection and validation 
Peptide selection is based upon a number of criteria which includes: the length of the peptide, 
normally selected to be between approximately 5 and 15 amino acids for the ease of synthesis; the 
presence  of  an  amino  acid  that  can  easily  and  cost  effectively  be  replaced  with  a  stable  isotopic 
equivalent  such  as  leucine,  isoleucine  or  phenylalanine;  and  the  lack  of  cysteine  or  methionine 
residues, since these are easily modified by chemical groups or oxidised within the mixture, leading to 
uncharacterised mass shifts. There is also a preference for the amino acid arginine at the C-terminus, as 
these peptides tend to have improved ionisation efficiencies over peptides with a C-terminal lysine. 
Importantly,  peptides  should  be  unique  to  the  protein  under  study  in  their  respective  organism. 
However,  synthesising  peptides  targeted  at  conserved  regions  of  a  protein  can  be  valuable  when 
studying the same protein in several different organisms, thereby reducing the number of peptides 
required to be synthesised. 
 
The following peptide, L*-D-Y-V-I-P-S-R (where * indicates a Leucine containing 6 x [
13C] 
atoms) targeted for the measurement of the protein BipA (residues 440 to 446), was selected according 
to the above criteria and chemically synthesised (Peptide Research Products). This provided a peptide 
that was chemically identical to its native counterpart, but was six actual mass units heavier. Amino 
acid analysis was performed to determine the absolute concentration of the synthetic peptide (Alta 
Biosciences). 
 
An MS/MS infusion experiment of the internal peptide was performed as described in section 
2.5.3 to identify a suitable fragment ion that could be used for monitoring the abundance of the BipA 
peptide. The signal intensity of the y4 fragment ion from the doubly charged precursor ion, m/z = 484 
(Figure 3.6), was maximised by optimisation of the collision energy. Using this optimised collision 
energy,  an  LC-MS/MS experiment was performed using 500 fmol of the peptide to determine its 
retention time (rt = 16.30 min) and MS/MS profile. 
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Figure 3.6. MS/MS fragmentation spectrum of the AQUA peptide standard selected for the absolute 
quantitation of the protein BipA from E. coli. Collision energy was tuned to 15 eV to maximise the 
signal intensity for the y4 ion, m/z = 472.28. Residues 440 to 446. L* indicates a Leucine containing 6 
x [
13C]. 
 
3.3.2 Absolute quantification of the protein BipA during growth of E. coli K-12 
Samples of culture were taken at set time intervals during the growth of E. coli K-12 (MG1655) 
and the number of cells estimated using a haemocytometer and A600 as detailed in section 2.2.5. The 
harvested cells were separated by 1D SDS-PAGE, gel bands excised corresponding to the molecular 
mass of the BipA protein ± 15 kDa (molecular mass = 67355 Da) (Figure 3.7) and in-gel digested in 
the presence of 500 fmol of the BipA isotopically labelled reference peptide, as detailed in section 
2.4.1.  An  LC-MS/MS  experiment  was  performed  isolating  the  precursors  m/z  484  and  481  ions, 
corresponding  to  the  doubly  charged  ion  of  the  reference  peptide  and  native  peptide,  respectively 
(Figure 3.8). Using reconstructed ion chromatograms of the y4 fragment ion (m/z = 472.28), the peak 
areas were used to calculate the concentration of the native peptide and hence the BipA protein (Figure 
3.9). Using the calculated number of cells loaded onto the SDS-PAGE gel, the number of molecules of 
BipA per cell, at each time point during the growth of E. coli K-12 was determined.  
 
BipA  expression  was  maximal  in  cells  in  the  early  exponential  phase  of  growth  (~18,000 
molecules/cell),  but  decreased  over  25-fold  (to  ~700  molecules/cell)  as  cells  progressed  into  the 
stationary  phase.  These  changes  correlated  well  with  immunoblotting  experiments  conducted  in 
parallel, where BipA was also shown to decrease with progressive cell growth (see inset Figure 3.8). 
These immunoblotting experiments were performed in collaboration with Mrs Karen Platt. 
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It was concluded that the AQUA strategy accurately reflected the growth profile of the BipA 
protein. Further, in this particular case, the limit of detection was 700 molecules per cell and was 
comparable  to  the  detection  limits  of  the  semi-quantitative  immunoblotting  procedure  used  for 
comparison. 
 
 
 
Figure 3.7. SDS-PAGE image of crude cell extracts from E. coli (MG1655) extracted at different time 
points during growth and separated for subsequent AQUA analysis of BipA. Colloidal Coomassie blue 
staining; molecular weight markers are indicated on the right hand side. 
 
 
Figure 3.8. AQUA analysis of the protein BipA from E. Coli (MG1655) after 15 min of growth. A = 
LC-MS/MS ion chromatogram of the native BipA peptide ion, m/z = 481.  B = Reconstructed ion 
chromatogram of the y4 ion (m/z = 472.2) from MS/MS of the [M+2H]
2+,6 x [
13C] labelled reference 
peptide ion (m/z = 484) . C = Reconstructed ion chromatogram of the y4 ion (m/z  = 472.2) from 
MS/MS of the [M+2H]
2+, native peptide ion (m/z = 481). Chapter 3  Development of Quantitative Proteomic Technologies 
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Figure 3.9. BipA synthesis is growth regulated. The number of molecules of BipA per cell measured 
using the AQUA approach during growth of E. coli (MG1655). Inset: Immunoblot of samples from the 
same time points probed with BipA-specific antibodies. 
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3.3.3 Absolute quantification of the Major Outer Membrane protein and a putative 
metalloprotease from C. trachomatis. 
As a further test of the AQUA strategy, it was used to quantify two proteins from C. trachomatis, 
serovar L2, identified from qualitative proteomic analyses performed and reported in Chapter 4 of this thesis. 
These two proteins were found to be present in both EBs and RBs, the two developmental forms of C. 
trachomatis.  The  first  of  these  was  the  Major  Outer  Membrane  Protein  (MOMP)  (CTL0050/CT681),  a 
protein that has been reported to be in relatively high abundance in both EBs and RBs (Hatch et al., 1981; 
Salari and Ward, 1981; Caldwell et al., 1981). The second protein selected (CTL0328/CT072) was originally 
annotated  as  a  putative  protease  (Stephens  et  al.,  1998),  and  has  subsequently  been  re-annotated  as  a 
metalloprotease (YaeL) in the C. trachomatis L2 genome (Thomson et al., 2008).  
 
In brief, 30 µg of protein lysates from both EBs and RBs were separated using SDS-PAGE and gel 
slices corresponding to the molecular mass of MOMP (42,550 kDa) and the metalloprotease (69,271 kDa) 
excised ± 15 kDa. AQUA analysis was performed for both proteins in EBs and RBs as detailed in section 
2.4.2 and spiked with 500 fmol of the relevant isotopically labelled reference peptides (Figure 3.10). The 
sequences  of  the  reference  peptides  were  G-Y-V-G-Q-E-F-P-L*-D-L-K  (MOMP)  and  I-S-L*-G-I-P-L-K 
(metalloprotease) (where * indicates a Leucine containing 6 x [
13C]), corresponding to amino acid residues 
242 to 251 and 479 to 486, respectively. These peptides were selected based upon the proteotypic data 
generated in the qualitative studies presented in Chapter 4. 
  
Figures 3.11 and 3.12 show LC-MS/MS ion chromatograms of the [M+2H]
2+ precursor ion from the 
native metalloprotease peptide (m/z = 423.7) along with reconstructed ion chromatograms for the selected y 
fragment ions of both native and reference peptides (y7, m/z = 727.6 and y7*, m/z = 733.6, respectively) (see 
Figure 3.10) for both EBs and RBs. Peak areas from the reconstructed ion chromatograms for both the native 
and  reference  peptide  were  used  to  calculate  the  protein  concentrations.  The  concentration  of  the 
metalloprotease in EB samples was 210 fmol per 30 µg of protein loaded onto an SDS-PAGE gel and more 
than  3.3  -fold  greater  in  RBs,  with  a  concentration  of  693  fmol  per  30  µg  of  protein  confirming  the 
expression of this protein in both EBs and RBs.  
 
In contrast, the concentration of the highly abundant MOMP was unable to be determined in either 
EBs  or  RBs  due  to  effects  caused  by  column  overloading  and  possible  saturation  of  the  MS  detector.  
Therefore, a repeat analysis of the sample at a diluted concentration would be required. Since these analyses 
consume significant amounts of the isolated EB and RB preparations, the analysis was not repeated and the 
samples were retained for the studies presented in Chapter 5.  
 
 
 
 
 Chapter 3    Development of Proteomic Technologies 
 
97 
 
Figure  3.10.  MS/MS  fragmentation  spectra  of  the  AQUA  reference  peptides  selected  for  absolute 
quantitation  of  the  metalloprotease  (CTL0328/CT072)  and  the  Major  Outer  Membrane  Protein 
(CTL0050/CT681) from C.trachomatis L2. A collision energy of 17 eV was used to maximise the intensity 
of the y7 ion (m/z = 733.6) for the Metalloprotease peptide, and 22 eV for maximising the intensity of the y6 
ion (m/z = 591.4) of the Major Outer Membrane Protein. L* indicates a Leucine containing six x [
13C]. 
 
Figure 3.11. AQUA analysis of the metalloprotease protein in EBs from C. trachomatis, serovar L2. 
A = Reconstructed ion chromatogram of the y7 ion (m/z  = 727.4) from MS/MS of the [M+2H]
2+, native 
peptide ion (m/z = 420.4). B = Reconstructed ion chromatogram of the y7 ion (m/z = 733.4) from MS/MS of 
the [M+2H]
2+ [
13C] labelled reference peptide ion (m/z = 423.4). C = LC-MS/MS total ion chromatogram of 
the native metalloprotease peptide ion, m/z = 420.4. Using the peak areas of the native and reference peptide, 
a  calculated  expression  level  of  210  fmol  per  30  µg  of  protein  was  obtanined.  L*  indicates  a  leucine 
containing 6 x [
13C]. Chapter 3    Development of Proteomic Technologies 
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Figure 3.12. AQUA analysis of the metalloprotease protein in RBs from C. trachomatis, serovar L2. 
A = Reconstructed ion chromatogram of the y7 ion (m/z  = 727.43) from MS/MS of the [M+2H]
2+ native 
peptide ion (m/z = 420.4). B = Reconstructed ion chromatogram of the y7 ion (m/z = 733.4) from MS/MS of 
the [M+2H]
2+ [
13C] labelled reference peptide ion (m/z = 423.4) . C = LC-MS/MS total ion chromatogram of 
the metalloprotease reference peptide ion, m/z = 420.4. Using the peak areas of the reference and native 
reference peptide, a calculated expression level of 693 fmol per 30 µg of protein was obtained. L* indicates a 
leucine containing 6 x [
13C]. 
 
3.3.4 Development of an infusion based approach for absolute quantification 
To  increase  the  throughput  of  the  absolute  quantitation  studies,  it  was  of  interest  to  explore  the 
possibility of using an infusion based approach that circumvents the requirement for lengthy LC separations. 
This possibility has become more realistic with the introduction of the Nanomate chip technology (Advion 
Biosciences), which allows efficient infusion of small volumes of samples via nanoelectrospray into a mass 
spectrometer in an automated fashion. The signal averaging that accrues as a result of infusing sample over 
time, results in improved S/N ratios and hence increases the sensitivity and precision with which peptides can 
be measured. As a pre-requisite to the analysis of more complex mixtures (section 3.3.6), the approach was 
first evaluated using a relatively simple mixture, across a wide concentration range.  
 
3.3.5 Absolute quantitation of a protein in a simple mixture 
An internal reference peptide corresponding to a tryptic peptide of horse heart myoglobin, A-L-E-L*-
F-R (residues 135 to 140) was chemically synthesised, replacing the amino acid leucine (indicated by *) with 
a stable isotope of leucine containing 6 x [
13C] (Peptide Research Products). The concentration of this peptide 
was determined by amino acid analysis (Alta Biosciences).  Digests of the protein myoglobin from horse 
heart were prepared in the concentration range from 500 amol to 15 pmol with the myoglobin internal Chapter 3    Development of Proteomic Technologies 
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reference standard added to a final concentration of 1 pmol in a volume of 10 µl as detailed in Chapter 2. The 
sample was infused using the Triversa Nanomate (Advion Biosciences) into a Q-TOF Micro fitted with a z-
spray source (Waters) at a flow rate of ~ 200 nl/min. The samples were each infused over 30 minutes and 
tandem mass spectrometry performed as described in section 2.4.3. Figure 3.13 shows an MS spectrum of 
the myoglobin digest at a concentration of 500 fmol and an expanded region of the native peptide m/z under 
measurement. A typical MS/MS spectrum for the native (A) and internal reference peptide (B) is shown in 
Figure 3.14.  The peak intensities of the y4 fragment ions m/z = 564.3 and 570.2, corresponding to the native 
and reference peptides, respectively, were used to calculate ratios for quantitation. The x and y values used 
for the linear regression analysis in Figure 3.15 represent the expected concentration of myoglobin (x-axis) 
and the observed concentration of myoglobin (y-axis). The statistics associated with the linear regression are 
indicated on the calibration curve. For an ideal system, the slope of the line should be equal to unity and 
intersect through the origin. The observed slope of the line was 1.0807 with an intercept of +0.1058. The r
2 
value calculated for the linear regression was 0.9977 indicating a linear response over the concentration range 
evaluated. The inset graph represents the lower concentrations of the response curve (500 amol to 250 fmol) 
and had an observed slope of 1.2104 and an intercept of -0.0008, r
2= 0.9989, demonstrating linearity at low 
concentrations. The lower limit of detection (LOD) was 500 amol for the quantification of the purified 
myoglobin. 
 
 
Figure 3.13 An MS spectrum from summed scans over a 2 min infusion of 500 fmol of a horse heart 
myoglobin digest using the Nanomate system (Advion Biosciences). The inset shows an expanded region of 
the m/z spectrum indicating (*) the native peptide ion used for quantitation by MS/MS ([M+H]
2+ m/z = 
375.3). Chapter 3    Development of Proteomic Technologies 
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Figure 3.14. MS/MS spectra of (A) the AQUA reference peptide for horse heart Myoglobin and (B) the 
corresponding native peptide from myoglobin. A collision energy of 14 eV was used to obtain maximum 
signal intensity for the y4 fragment ion (A) [M+2H]2+ 378.2 m/z to y4 570.2 m/z; (B) [M+2H]2+ 375 m/z to 
y4 564.2 m/z. 
 
 
Figure 3.15. Observed vs. expected response curve for the quantification of myoglobin from 500 amol 
to 15 pmol by nanoESI-infusion using the Triversa Nanomate. Inset = the low concentration range (500 
amol–250 fmol). 
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3.3.6 Absolute quantitation of a protein in a complex mixture 
To test the approach with a significantly more complex mixture, human serum was spiked with 1 
pmol of myoglobin reference peptide and a digest of horse heart myoglobin at a range of concentrations (1 
fmol - 15 pmol) in a final volume of 10 µl. Samples were infused over 30 min and tandem mass spectrometry 
performed as described in section 2.4.4. An MS spectrum of digested human serum in 50% methanol + 1% 
acetic acid is shown in Figure 3.16.  The observed vs. expected response curve for the quantitation of 
myoglobin in a background of human serum is shown in Figure 3.17. The r
2 value = 0.9972 across the full 
concentration range evaluated with a value of 0.995 in the low concentration range from 10 fmol to 500 fmol. 
The LOD for myoglobin in the complex mixture human serum was 10 fmol. 
 
 
 
 
Figure 3.16. An MS spectrum from summed scans over a 2 min infusion of a human serum digest using the 
Nanomate system (Advion Biosciences). 
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Figure 3.17. Observed vs. expected response curve for the quantification of myoglobin in a background 
of human serum by infusion using the Triversa Nanomate for the concentration range 10 fmol to 15 pmol. 
Inset = the low concentration range (10 fmol–250 fmol). 
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3.4 Discussion 
 
A major aspect of proteome research is the concurrent identification and quantitation of proteins 
within a complex mixture. At the beginning of the studies presented in this thesis, 2-DGE and the ICAT 
approach,  were  the  most  widely  used  gel-based  and  LC-based  proteomic  techniques  used  for  relative 
quantitation, respectively. However, the commercialisation of iTRAQ reagents from Applied Biosystems, 
allowed the Southampton proteomics laboratory to become early adopters of the iTRAQ methodology (Ross 
et al., 2004). To achieve this required overcoming a number of hurdles, since ABI instrumentation and the 
associated  iTRAQ  identification  and  quantitation  software,  were  unavailable  within  the  Southampton 
laboratory.  As  such,  the  first  part  of  this  Chapter  describes  the  implementation  and  optimisation  of 
methodologies for peptide fractionation and quantitation of iTRAQ labelled peptides. Table 3.1 provides a 
comparison of the advantages and disadvantages of the three technologies 2-DGE, ICAT and iTRAQ. 
 
 The  second  part  focuses  on  the  development  and  application  of  technologies  for  the  absolute 
quantification of proteins. Here, preliminary data using the AQUA approach is obtained using the model 
system E. Coli, before measuring proteins from the C. trachomatis proteome. The Chapter also reports a 
proof-of-concept application using nanoelectrospray infusion (nanoESI-infusion) MS/MS for the absolute 
quantification of proteins in complex mixtures. Even when using two orthogonal approaches such as SCX 
and RP-LC, the complexity of a proteome such as Chlamydia, although modest in size when compared to the 
human proteome, still presents a major challenge in achieving complete proteome coverage. It is therefore 
clear that alternative more effective methods of fractionation maybe required if complete proteome coverage 
of an organism such as Chlamydia is to be realised. There are a number of methodologies that have been 
successfully used for the efficient fractionation of complex mixtures. These include, COFRADIC (Gevaert et 
al.,  2002),  gas  phase  fractionation  (section  1.11.6),  SCX  using  pH  gradient  elution,  SDS-PAGE  gel 
electrophoresis, RP-HPLC, high-pH RP-HPLC and OFFGel. Nonetheless, studies directly comparing these 
technologies are limited. Dowell et al (2008), compared the 2-D methodologies, SCX using salt gradients, 
SCX using pH gradients, RP-HPLC and high-pH RP-HPLC (pH 10). When applied to the analysis of an 
E.Coli peptide lysate, they reported that RP-HPLC and high-pH RP-HPLC were more effective than SDS-
PAGE and SCX using pH gradients, identifying 281 and 261 proteins, respectively. Separation using SCX 
with pH gradients and SDS-PAGE performed better than SCX with salt gradients, identifying 178 and 139 
proteins, respectively. Separations using SCX with salt gradients were poor by comparison, with only 81 
proteins identified. Further, High-pH RP has also been shown to be more effective at identifying peptides and 
proteins in membrane preparations, than both SCX with pH gradients and the isoelectric focusing technique 
OFFGel (Manadas et al., 2009). Nevertheless, OFFGel has been effectively used in many studies, including 
the separation of iTRAQ labelled peptides (de Godoy et al., 2008; Chenau et al., 2008). One particular study 
used OFFGel in combination with a label-free quantitative MS approach to measure the absolute cellular 
concentrations of 51% of the proteins encoded by the human pathogen, Leptospira interrogans (Malmstrom 
et al., 2009). Studies can also employ multiple orthogonal stages of separation. Garbis et al. (2011) used a 
combination  of  high-pressure  size  exclusion  chromatography  (SEC),  Zwitterion  –Ion  Hydrophillic Chapter 3    Development of Proteomic Technologies 
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Interaction Chromatography (HILIC), and RP-nanoLC to assign 1955 proteins spanning a dynamic range of 
12 orders of magnitude in blood serum. 
  
 
Table 3.1. Pros and Cons of 2-DGE, ICAT and iTRAQ 
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PROS  CONS 
Allows easy visualisation of post-translational 
modifications 
Co-migration of proteins can cause errors 
in quantitation and protein assignment 
Allows Peptide Mass Fingerprinting to be used 
for identification purposes 
Poor representation of proteins with 
extreme physio-chemical properties, e.g. 
hydrophobic, very basic or acidic and very 
large or small 
Molecular mass and pI information retained  Sampling is biased towards highly 
abundant proteins 
  Difficult to automate 
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T
 
An LC-based method offering flexibility of 
choosing a wide range of stationary and mobile 
phases available to resolve complex biological 
samples at the protein and peptide level 
Reliance on the presence of cysteine 
residues reduces protein coverage, 
potentially misses certain proteins and post-
translational modifications 
Reduces complexity of sample by affinity 
selecting peptides only containing cysteine 
residues 
Labelling at the protein level, potentially 
reduces the efficiency of labelling as a 
result of steric hindrance. 
Extra information provided for database 
searching, that is, the knowledge that each 
peptide must contain a cysteine 
Poor recovery of biotin tagged peptides 
reduces sensitivity 
  Increased complexity of MS spectra 
  Interpretation of fragmentation spectra can 
be complicated by the attached biotin label 
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Tagging of potentially all peptides increases 
protein coverage improving statistical 
confidence in identification and quantitation 
Increases complexity of sample requiring 
further fractionation procedures 
An LC-based method offering flexibility of 
choosing a wide range of stationary and mobile 
phases available to resolve complex biological 
samples at the protein and peptide level 
Labelling at the peptide level can cause 
potential sources of error in earlier sample 
handling or variable degrees of trypsin 
digestion. 
Multiplexing of up to 8 samples and good 
technical reproducibility  
Problems identifying the same peptides in 
replicate experiments 
Allows the detection of post-translational 
modifications 
Poor precursor ion selection can cause 
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3.4.1. Extraction of quantitative reporter ion information 
The instrumentation and software for high-throughput proteomic technologies have been improving 
and developing at a rapid rate. The large-scale proteomic datasets generated from these high-throughput 
technologies, require effective methodologies to process extract and report, both qualitative and quantitative 
information. However, it can be difficult to exploit such innovative methodologies, when their access is 
restricted to a single commercial supplier and often requires considerable financial resource to implement. At 
the time of these studies, although iTRAQ reagents were becoming freely available, software for performing 
quantitative  analysis  of  iTRAQ  data  was  limited  to  the  commercial  software  ProQuant  from  Applied 
Biosystems. 
 
In the absence of the ProQuant software, a Java parser was written to extract quantitative reporter ion 
information from iTRAQ peptide MS/MS spectra into a format, where the reporter ion ratios could easily be 
calculated and integrated with protein identifications generated from PLGS or Mascot. Although quite basic 
in function, the iTRAQ parser provided a useful tool to extract this otherwise inaccessible information. The 
results demonstrated that the parser was able to successfully extract reporter ion intensities from centroided 
peak lists in the .pkl format. Relative quantitation data obtained using iTRAQ labelled peptide extracts from 
Salmonella, showed good correlation with the expected 2:1 labelling ratio. The reporter ion intensities were 
extracted into a .CSV file format, which provided a familiar format for post-processing of the data to apply a 
reporter ion count threshold, isotope purity correction and the calculation of reporter ion ratios. Intensity 
information was subsequently related to their corresponding peptides using the precursor m/z of the peptide. 
Figure 3.18 shows a data workflow of the iTRAQ parser.  
 
 
 
 
 
 
 
 
 Chapter 3    Development of Proteomic Technologies 
106 
 
Figure 3.18. An overview of the data processing workflow for iTRAQ data acquired using a Waters Q-Tof.  
 
The iTRAQ parser provides a basic tool for the extraction of reporter ion information. However, a 
limitation of this software comes from the .pkl peak list format. The only available discriminator in the .pkl 
file to associate reporter ion intensities with their corresponding peptide assignment in the Mascot or PLGS 
output file, is the m/z of the precursor peptide ion, calculated to 4 decimal places. Therefore, if different 
proteins contain a homologous peptide precursor ion with an identical m/z to within 4 decimal places, these 
must be removed, since there is no further discriminator such as spectrum number, retention time, to ensure 
the  correct  set  of  reporter  ion  intensities  are  assigned  to  the  correct  peptide.  However,  for  precise 
quantitation, typically only peptides that are unique to a protein are used for calculating the reporter ion ratio 
and so by default, this weakness is beneficial. Although practically useful, it was clear that the iTRAQ parser 
would require further development. Such improvements needed to include using alternative file formats, 
making use of discriminators such as a spectrum title, or query number for each MS/MS spectrum, so that 
reporter ion intensities can be assigned to their corresponding peptides.  For example, using generic formats 
such  as  mzXML,  mzData,  or  pepXML  would  allow  data  to  be  processed  without  platform  specific 
constraints. Other improvements, such as automated isotopic purity correction, low ion count thresholding 
and reporter ion calculation would all be beneficial. 
 
During  the  development  of  the  iTRAQ  parser,  Shadforth  et  al.  (2005)  reported  an  open  source 
software tool for the extraction of iTRAQ reporter ion ratios using the Mascot .mgf and Sequest .dta formats. 
In  addition  to  improving  the  integration  of  peptide  assignments  with  their  corresponding  reporter  ion 
intensities, the software also performs automated isotope purity correction, applies a user defined low ion Chapter 3    Development of Proteomic Technologies 
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count threshold filter based upon quantisation errors, and calculates a reporter ion ratio for each protein. 
Shortly after, Mascot released an updated version of their software, providing simultaneous identification of 
proteins along with their calculated reporter ion ratios within a single integrated platform. This platform 
offered in addition to the above features, flexibility for different types of peptide and protein normalisation, 
peptide outlier removal and protein ratio calculations. The software also processed iTRAQ data in a range of 
file  formats  (including  the  .pkl  format)  from  the  most  common  MS  vendors.  Since  these  software 
developments were moving so rapidly, continued development of the iTRAQ parser was halted and the 
Mascot platform was adopted for iTRAQ analysis of C. trachomatis L2 presented in Chapter 5. There are 
now a number of alternative freely distributed packages for iTRAQ quantitation available and these are 
shown in Table 3.2.  
 
Table 3.2. Freely available iTRAQ quantitation software 
Software  Format required  Reference 
iTracker  Peak list (*.dta, *.mgf)  Shadforth et al., 2005 
jTraqX  MascotDatFile library  Muth et al., 2010 
Census  mzXML, pepXML, DTAselect  Park et al., 2008 
Libra  mzXML, pepXML  http://tools.proteomecentre.org/Libra.php 
 
 
3.4.2 Absolute quantitation 
The advent of systems biology and biomarker proteomics has created a pressing need for approaches 
that provide absolute measures of protein quantity within cells and biofluids, offering many advantages over 
relative quantitation techniques and representing the gold standard of proteomic analysis (Table 3.3). Based 
upon the well-established technique of stable isotope dilution, the Gygi laboratory demonstrated absolute 
quantitative measurements of horse heart myoglobin and both the phosphorylated and un-phosphorylated 
isoforms  of  human  separase  using  the  AQUA  strategy  (Gerber  et  al.,  2003).  Typically,  these  AQUA 
experiments are performed using LC-MS/MS using selected-reaction monitoring (SRM) or multiple-reaction 
monitoring (MRM) on a triple quadrupole mass spectrometer. Since a triple quadrupole instrument was 
unavailable in our laboratory, the AQUA strategy was developed and implemented using a Q-ToF mass 
spectrometer (Waters) in combination with a CapLC nanoLC system (Waters). An instrument traditionally 
used for untargeted discovery based analyses. 
 
To implement and validate the AQUA strategy, an AQUA experiment was performed measuring the 
expression levels of the regulatory protein BipA during different stages of growth. Using an isotopically 
labelled internal peptide standard corresponding to a tryptic peptide of BipA, changes in the abundance of 
BipA following nutrient upshift of E.Coli cells were monitored using AQUA. The expression of BipA was Chapter 3    Development of Proteomic Technologies 
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maximal in cells in the early exponential phase of growth (>18,000 molecules per cell), but decreased over 
25-fold (<700 molecules per cell) as E.Coli cells progressed into stationary phase. Independent immunoblot 
analysis of the BipA protein showed a good correlation with the AQUA data, showing a similar decrease in 
BipA expression from 15 min to 240 min. These data confirm that the AQUA methodology can be used to 
provide precise quantitative measurements of proteins within complex mixtures and can even provide greater 
sensitivity than traditional antibody based assays, measuring to <700 molecules per cell. The study also 
highlights the usefulness of the AQUA approach to measuring dynamic changes of protein expression over 
multiple time points and without the requirement for antibodies. These types of time-course experiments are 
likely  to  provide  important  clues  about  the  regulation  and  control  of  cellular  systems,  such  as  the 
developmental cycle of Chlamydia.  
 
Using this established AQUA strategy, the endogenous levels of two C. trachomatis L2 proteins, the 
42.4  kDa,  Major  Outer  Membrane  Protein  (MOMP)  and  a  69.2  kDa,  metalloprotease  (CTL0328)  were 
determined (section 2.4.2). Both these proteins were detected in RBs and EBs in the qualitative studies 
presented  in  Chapter  4  and  later  in  the  quantitative  studies  presented  in  Chapter  5.  The  determined 
concentration for the metalloprotease was 693 fmol per 30µg (23 fmol/µg) of protein lysate in RBs and 210 
fmol/30µg (7 fmol/µg) in EBs, representing a 3.3 –fold down-regulation in EBs, a decrease in expression that 
is consistent with the data for this metalloprotease presented in Chapter 5. The measurement of the MOMP 
was unsuccessful in both EB and RB samples and was attributed to poor chromatography. An explanation for 
this was the overloading of the RP column, caused by high concentrations of MOMP. This could be resolved 
by reducing the amount of sample loaded on column, or dilution of the sample prior to loading. However, 
since each AQUA analysis consumes 30 µg of protein lysate from both EB and RB samples, and in light of 
the limited amount of sample available, the remaining sample was retained for the iTRAQ studies presented 
in Chapter 5. Unlike qualitative or relative quantification proteomic studies, obtaining consistent quantitative 
measurements using the AQUA strategy is dependent upon the efficient digestion and recovery of target 
protein peptides from the gel matrix. However, the yield of individual peptides from such in-gel digests have 
been shown to be protein dependent and vary greatly, resulting in error margins of up to 50%, often requiring 
the use of several reference peptides, if accurate quantitation is to be achieved (Havlis and Shevchenko, 
2004). Additionally, and as highlighted by the AQUA studies presented in this Chapter, the approach as it 
stands, where one protein is measured at a time, does not lend itself to large-scale quantitative proteomic 
studies. As such, AQUA methodologies using in-solution digestion followed by LC-MS, without any pre-
fractionation, are now more commonplace (Wolf-Yadlin et al., 2007; Kitteringham et al., 2009; Unwin et al., 
2009). 
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Table 3.3.  Pros and Cons of relative and absolute quantitation 
 
Since the amount of time to perform an AQUA experiment can be significant, multiplexing strategies 
measuring 10’s to 100’s of proteins per analysis are starting to emerge. For example, Kuzyk et al. (2009) 
multiplexed 45 peptide reference standards to measure the endogenous levels of 45 plasma proteins using a 
single LC-MRM assay. Using these multiplexing approaches opens up possibilities for measuring sets of 
proteins  precisely,  under  different  conditions.  For  example,  measuring  the  expression  levels  of  all  the 
glycolytic  enzymes  during  the  developmental  cycle  of  Chlamydia.  Ideally,  each  protein  to  be  measured 
should be quantified using 2-3 reference peptides, since there may be different forms of the protein, i.e., 
degradation products, isoforms. However, the high cost of synthesising, purifying and quantifying AQUA 
peptides has in many studies been restricted to using a single protein per protein target (Cheng et al., 2006; 
Bondar et al., 2007). One cost effective and novel methodology for generating large numbers of reference 
peptides is Q-conCAT (Pratt et al., 2006; Rivers et al., 2007). Here, up to 100 different proteotypic peptides 
from  different  proteins  are  concatenated  to  form  a  synthetic  gene  construct.  The  artificial  proteins  are 
expressed in Escherichia coli and cultured in medium containing stable isotope precursors. The resulting 
synthetic protein is then purified and the concentration determined. The QconCAT proteins are added to 
complex mixtures in know amounts, proteolytically digested to generate reference peptides, which are used 
to  quantify  proteins  using  LC-MRM.  Since  the  QconCATs  are  introduced  at  the  stage  of  digestion, 
systematic errors are minimised, providing precise quantitative measurement. By reducing the limitation of 
generating stable-isotope reference peptides, the possibility of using the AQUA strategy more ambitious 
studies can be realised. 
. 
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PROS  CONS 
High-throughput - providing a relative measure 
of multiple proteins per experiment.  
Only provides a relative measure of quantity 
between individual proteins, restricting analysis to 
comparing 2 to 3 samples (Triplex) or in the case 
of iTRAQ and TMT, the comparison between 6 to 
8 samples. 
Relative quantitation based on multiplexed 
stable-isotope labelling strategies provides an 
internal standard, improving reproducibility 
between experiments. 
Protein amounts are not easily compared across 
experiments. 
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  Proteins are measured as copy number per cell or 
their concentration in either moles or grams.  
Requires an internal standard. 
In the case of AQUA/MRM studies, requires the 
synthesis of a synthetic peptide(s) for each protein 
being measured is required. 
Allows the comparison of protein concentrations 
across experiments. 
AQUA/MRM studies require development time 
for each protein being measured. 
  AQUA/MRM based experiments are relatively low 
throughput. However, new high-throughput 
technologies are emerging (see Chapter 5). Chapter 3    Development of Proteomic Technologies 
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3.4.3 Quantitation using chip-based nanoelectrospray infusion 
The length of sample run time and the usage of expensive machine time required to perform an 
AQUA/LC-MRM  experiment  is  significant.  A  major  component  of  this  time  is  the  chromatographic 
separation  required  prior  to  MS/MS.  Additionally,  for  each  new  reference  peptide  or  set  of  reference 
peptides, chromatographic optimisation must also be performed, often requiring several attempts before an 
optimal separation is achieved. This is further compounded by chromatographic cleaning regimes required to 
minimise chromatographic carry-over effects. These time and cost constraints can limit the application of 
AQUA for larger scale absolute quantification studies in the majority of proteomic laboratories.  
 
Several mass spectrometric assays for the quantitation of small molecule pharmaceutical compounds 
have  been  developed  using  automated  chip-based  nanoelectrospray  infusion  (Nanomate,  Advion 
BioSciences), without the use of chromatography prior to MS/MS (Leuthold et al., 2004; Dethy et al., 2003; 
Corkery et al., 2005). These types of analyses are made possible because of the high selectivity afforded by 
MS/MS, where qualitative and quantitative measurements can be performed without the need to baseline 
resolve components and often achieved without LC separation (Leuthold et al., 2004).  
 
This  Chapter  reports  a  proof-of-concept  application  using  nanoESI-infusion  (Nanomate,  Advion 
Biosciences) for the direct quantitation of proteins in solution, removing the requirement for LC separation. 
This has the potential to reduce run times (typically 60 min for LC-MRM), the cost per sample (columns and 
LC solvents) and eliminate the risk of sample carry-over.  
 
3.4.3.1 Chip-based infusion of simple mixtures 
Using ten different concentrations (from 500 amol to 15 pmol) of a myoglobin digest spiked with a 
myoglobin reference peptide, the sensitivity and linearity of response of the nanoESI infusion approach was 
evaluated. The results showed high linearity across the concentration range measured, from 15 pmol to the 
lower limit of quantitation (LOQ) 500 amol. Even in these simple mixtures, these data suggest that this 
approach  could  have  possible  application  for  the  routine  quantification  of  semi-purified  recombinant 
proteins, where measures of absolute concentration are required. Although acquisition times per sample in 
these studies were 30 minutes, acquisition times of 2-10 min, could easily be achieved depending upon the 
abundance of the protein(s) being measured, providing a rapid precise assay. Alternatively, the ability to 
perform extended periods of infusion could also be used to improve the S/N ratio for low intensity peptides, 
or allow time to perform further analyses such as MS
3 (see later). 
 
3.4.3.2 Chip-based infusion of complex mixtures 
Increased sample complexity presents several issues for quantitative analysis, the first of which is 
selectivity. Chromatographic separation brings an added selectivity to MS analysis, reducing the possibility 
of crosstalk between analytes. Therefore, methodologies such as ESI-infusion, where chromatography is not 
employed, are dependant upon tandem mass spectrometry (MS/MS) to eliminate this crosstalk. Using MRM-
based  experiments  and  measuring  multiple  fragment  ions  of  a  selected  precursor  ion,  can  dramatically 
increase the selectivity, eliminating interferences and improving both linearity and limits of quantitation. Chapter 3    Development of Proteomic Technologies 
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Another important aspect of chromatography is that it provides concentration of the analyte and minimises 
matrix suppression effects. In comparison to the quantification of purified myoglobin, the lower limits of 
quantification (LOQ) for myoglobin in a background of digested human serum was found to be 20-fold less 
[LOQ = 10 fmol] and was not detectable below 10 fmol. Matrix effects causing suppression of the analyte 
signal are the most likely explanation for this reduced limit of quantitation. This is not so surprising when 
considering that ~2000 proteins have been confirmed in human serum (Garbis et al., 2011) and when the 
complexity is increased further by proteolytically digestion. By increasing the selectivity of the analysis, 
these matrix effects can be reduced or eliminated. However, in the absence of chromatographic separation, 
increased selectivity is reliant on the MS methodologies employed. One possibility is to introduce a third 
stage of MS. This has been shown to greatly increase selectivity and thereby reducing matrix effects. Olsen 
and Mann (2004), used MS
3 of C- and N-terminal peptide ions generated from MS/MS (MS
2) to increase 
identification specificity, even at the sub-femtomole level. Similarly, MS
3 has been employed in combination 
with  nanoESI-infusion  to  increase  quantitative  precision  of  a  parent  drug  and  its  metabolites  in  human 
plasma, without the use of LC (Leuthold et al., 2004).  
 
Flow rates in nanoESI display a strong influence on ion signals and the lower flow rates of nanoESI 
have been shown to be more tolerant of salts compared to conventional ESI (Wilm et al., 1996). In ‘true 
nanoESI’, where flow rates are maintained below 50 nL/min, in addition to a higher tolerance towards salts, 
less analyte suppression is observed, with claims that at flow rates of a few nL/min, the signal suppression 
effects totally disappear (Schmidt et al., 2003). Nonetheless, flow rates through the ~10 µM nozzles of the 
Nanomate platform used in this study are between 100-200 nL/min and ion suppression is still observed in 
highly complex matrices, albeit, at lower levels than convention ESI (Chen et al., 2011). Recently, nanoESI-
infusion has been used in combination with FT-ICR-MS to identify proteolytic digests using four narrow 
overlapping mass ranges. Here, ion suppression effects normally observed using a full range scan were 
minimized, improving the number of moderate to low abundance peptides identified. Each analysis was 
performed in 3 min and the results were comparable to LC-MS/MS (Chen et al., 2011). By combining 
different MS strategies, such as MS
3, over-lapping mass ranges or using alternative separation principles such 
as  ion  mobility  (Giles  et  al.,  2011),  increases  in  selectivity  can  be  realised,  offering  the  possibility  of 
achieving absolute quantitation for even low abundance proteins in highly complex mixtures, without the 
requirement for LC. 
 
During  the  final  preparation  of  this  thesis,  Xiang  and  Koomen,  (2012),  evaluated  the  concept  of 
nanoESI-infusion (Nanomate) in combination with MRMs for the absolute quantification of standard proteins 
and the expression of heat shock proteins in digests of whole cell lysates. They concluded that nanoESI-
infusion was comparable to LC-MRM when peak intensities where sufficient or when corrected to eliminate 
interference.  Applied  to  the  measurement  of  abundant  proteins  or  enriched  fractions,  nanoESI-infusion 
provided a fast, high-throughput method for the precise absolute quantitation of proteins. However, they also 
report that measurements for the quantification of low intensity peptides in complex mixtures, were different 
from those obtained using LC-MRM and required further investigation. Extended periods of infusion also Chapter 3    Development of Proteomic Technologies 
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open up the possibility for high-throughput screening, especially when multiplexed. Xiang and Koomen, 
(2012), calculated that up to 6000 transitions could be measured using only 5 µl of sample.  
 
 
3.4.4 Relative and Absolute quantification in Chlamydia 
There are significant barriers to investigating Chlamydial genes and their regulation, For instance, the 
obligate intracellular developmental cycle means there is no host – free system to culture Chlamydia and 
genetic  manipulation  has  historically  been  difficult.  As  a  consequence,  little  molecular  detail  about  the 
biological  function  of  its  gene  products  is  known.  The  precise  quantification  of  proteins  under  specific 
conditions would therefore answer some key questions about chlamydial biology. Such questions are likely 
to include: What are the most abundant proteins during the different stages of the developmental cycle? This 
will be vital if better diagnostic reagents are to be developed. How many hypothetical proteins are actually 
expressed, and at what levels, during the developmental cycle? How does the transcriptomic profile (Belland 
et al., 2003; Nicholson et al., 2003) relate to the proteomic profiles? After measurement of all these proteins 
during  different  stages  of  the  developmental  cycle,  can  they  be  clustered,  providing  clues  about  their 
biological roles in chlamydial biology? 
 
Although relatively modest in size, the qualitative and quantitative analysis of the C. trachomatis 
proteome still presents a challenge. However, with less than 900 proteins, the proposition of relative and 
absolute  quantitation  of  a  complete  chlamydial  proteome  becomes  tangible,  offering  the  prospect  of 
deepening our understanding of how this pathogen mediates the diverse range of pathological outcomes. 
Development  and  implementation  of  the  iTRAQ  approach  in  this  Chapter,  has  paved  the  way  for 
comparisons  of  protein  expression  between  RBs  and  EBs  using  relative  quantitation  (Chapter  5). 
Nevertheless, the approaches for the absolute quantitation of proteins established in this Chapter, are still in 
the majority of proteomic laboratories relatively low throughput (10-20 proteins per day for LC-MRM based 
assays)  and  require  a  considerable  investment  of  resource.  Moreover,  the  amount  of  sample  consumed, 
realistically restricts quantitative measurement to protein subsets when investigating intracellular pathogens 
such as Chlamydia, where protein yields are low. During the course of these studies, a high-throughput label-
free MS approach (LC-MS
E),
 allowing the identification and quantification of up to thousands of proteins 
measured in absolute amounts was described (Silva et al., 2006a; Silva et al., 2006b). Collaborative studies 
with Waters (LifeSciences development laboratory, Manchester, UK) opened up the opportunity to apply this 
MS technology to the measurement of cellular concentrations of chlamydial proteins on a proteome-wide 
scale (Chapter 5). As such, attention was re-focused on using this approach for the comparison of chlamydial 
proteins in RBs and EBs. Whilst, the AQUA and nanoESI-infusion approaches are not easily extended to the 
measurement of an entire proteome, they will be highly useful in future studies. For example, the precise 
measurement of pathway components early in the developmental cycle, before replication begins will require 
highly sensitive assays owing to the limited number of EBs present at this stage. The approach will also be 
invaluable for validation of the data presented in Chapter 5, replacing traditional antibody-based assays. Chapter 4    Shotgun proteomic analysis of C. trachomatis 
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4.0 Shotgun proteomic analysis of C. trachomatis* 
 
4.1 Introduction 
The  availability  of  the  complete  genome  sequence  of  Chlamydia  trachomatis  serovar  D  and 
subsequently  C.  trachomatis,  serovar  L2,  have  facilitated  studies  focused  on  the  protein  components 
expressed  by  chlamydial  genomes.  Given  the  intrinsic  imprecision  of  genome  annotation  software,  the 
validation of genome annotations has become increasingly important. Proteomics provides confirmation that 
predicted  genes  encode  bona  fide  proteins  distinguishing  between  authentic  and  pseudo-genes.  The  vast 
majority of genome annotation efforts now rely on computational methods for gene prediction or comparison 
to homologous proteins in other organsims, but are currently rarely validated experimentally (Jaffe et al., 
2004; Ansong et al., 2008). For example, the error rate in annotation of the 340 genes of Mycoplasma 
genitalium genome has been estimated to be ~8% (Brenner, 1999). Even for extremely well studied species 
such as E. coli strain K-12, substrain JM109, investigations a decade later revealed that many ORFs were 
incorrectly annotated (Maillet et al., 2007). Additionally, studies in the proteomic domain provide biological 
insights, complement quantitative experiments and help to define the limits of the proteome under study. 
 
* This Chapter has been modified from a paper published in Proteomics entitled “Shotgun proteomic analysis 
of Chlamydia trachomatis” (Skipp et al., 2005) 
 
4.1.1 Proteomic analysis of Chlamydia 
2-D gel electrophoresis in combination with MS technology has been extensively used for large-scale 
protein separation and identification experiments and has been applied to the study of chlamydiae. Prior to 
the availability of genome sequences, there have been a number of chlamydial proteomic studies, which are 
reviewed by Vandahl et al. (2002) and which were discussed in section 1.8.1 of this thesis. 
 
Bini et al. (1996) using the improved resolution of Immobilised pH Gradient (IPG) strips, produced 
the first high-resolution 2-D gel electrophoresis map of proteins from the extracellular EB of C. trachomatis 
L2. This map showed up to 600 silver-stained spots, although the vast majority were not identified. Pulse-
labelling and pulse-chase experiments have also been employed to address the protein expression, producing 
definitive maps of EBs for both C. trachomatis (Shaw et al., 2002a) and C. pneumoniae (Vandahl et al., 
2001). However, although many of the protein spots from these maps have been identified, they only provide 
a maximum of 16% coverage of the predicted proteome and do not give data on protein expression in RBs. 
Belland et al. (2003) demonstrated that at the mid point in the infectious cycle of C. trachomatis (15-24 h PI), 
virtually every chromosomal and plasmid gene is transcribed. The remaining 28 genes, corresponding to ~3% 
of the genome were shown to be transcribed during the later stages of the developmental cycle (40 h PI). 
Although several studies report a disparity between the relative expression of mRNAs and the corresponding 
expressed  proteins  (Anderson  and  Seilhamer,  1997;  Gygi  et  al  1999a),  it  is  highly  likely  that  a  large 
percentage of these transcripts are expressed at the protein level and exceed the 16% coverage currently Chapter 4    Shotgun proteomic analysis of C. trachomatis 
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detected. Additionally, the small size of the C. trachomatis genome (serovar D, 894 ORFs; serovar L2, 897) 
makes  it  an  ideal  candidate  for  efforts  aimed  at  achieving  comprehensive  proteome  coverage  and 
understanding the relationship between the transcriptome and proteome. 
 
 
The  limited  proteome  coverage  of  chalmydiae  achieved  so  far,  can,  in  part,  be  attributed  to  the 
necessity  to  culture  Chlamydia  in  a  host  cell  and  difficulties  in  obtaining  good  yields  of  highly  pure 
preparations of EBs and RBs. Additionally, the poor representation of some classes of proteins when using 2-
D gel electrophoresis (Gygi et al., 2000; Rehm, 2006) has also been a contributing factor. Nonetheless, the 
value of the 2-D gel electrophoresis approach should not be under estimated. It has proved useful in the 
identification  of  novel  proteins,  finding  differences  between  preparations,  investigating  the  effects  of 
treatments  on  Chlamydia-infected  cells  and  comparing  Chlamydia  at  different  times  during  the 
developmental cycle (section 1.8.1). However, the majority of the predicted chlamydial components are yet 
to be detected at the protein level, either in EBs or RBs. This suggests that alternative approaches are needed 
to provide increased coverage of the chlamydial proteome  
 
A  particular  method  that  has  generated  a  notable  amount  of  interest  is  multidimensional  liquid 
chromatography in combination with MS/MS for the direct analysis of complex peptide mixtures derived 
from an organism of interest (reviewed by Fournier et al., 2007). One commonly used configuration, termed 
MudPIT (Multidimensional Identification Technology) has proved to be very effective, combining strong 
cation exchange with RP nanocapillary columns arranged in series, to provide high-resolution separation and 
concentration of peptides prior to their identification by MS/MS. (Link et al.,1999; Washburn et al., 2001). 
As a peptide–centric approach, complex mixtures of proteins are first proteolytically digested to produce 
peptides, before loading onto a SCX column. Fractions of these peptides are subsequently eluted from the 
SCX column using successive steps of increasing salt concentration. Each eluted peptide fraction is either 
loaded off-line or directly onto a RPLC column for separation and analysis using tandem mass spectrometry. 
Recently, a modification of MudPIT utilizing on-line SCX in combination with long RP columns and higher 
column  temperatures,  achieved  the  identification  of  53%  and  46%  of  the  predicted  proteomes  for  the 
prokaryotes, Corynebacterium glutamicum and E. coli strain MG1655, respectively. (Fränzel and Wolters, 
2011).  
 
An alternative protein-centric approach, termed GeLC-MS/MS, uses conventional 1D SDS-PAGE for 
protein separation in conjunction with LC-MS/MS analysis (GeLC-MS/MS) of peptides generated by in-gel 
digestion using a site-specific endo-protease such as trypsin (Schirle et al., 2003). Similar to MudPIT, this 
technique boosts peak and load capacity thereby potentially increasing the number of peptides that can be 
identified. It has been applied in a wide range of applications, ranging from extensive proteome coverage of 
different organisms (Jones et al., 2011; Wang et al., 2010), or their sub-celluar compartments (Vaughan et 
al., 2006; Williams et al., 2007), to biofluids and tissues (Nicholas et al., 2006; Albrethsen et al., 2010). 
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In this study, the techniques of MudPIT, GeLC-MS/MS and 2-D gel electrophoresis have been used to 
characterise the expressed proteome of C. trachomatis strain L2 in both the EB and RB forms. At the same 
time, the study provides a comparison of the technologies used to characterise this proteome. At the initiation 
of these studies the genome sequence of C. trachomatis L2 was still being completed at the Wellcome Trust 
Sanger Institute. It was therefore necessary to initially search data against the completed genome sequence of 
C. trachomatis serovar D (Stephens et al., 1998) for protein identification and classification. The data was 
subsequently re-searched against the C. trachomatis L2 genome sequence at a later date (Thomson et al., 
2008). 
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4.2 Results 
 
4.2.1 Purification of EBs and RBs 
EBs contain several proteins in the outer membrane that are synthesised during the late stages of the 
developmental cycle that are not observed in RBs (Hatch et al., 1984; Hatch et al., 1986; Newhall et al., 
1987; Moroni et al., 1996). Additionally, the EB membrane is cross-linked by disulphide bonds and the 
association of the major outer membrane protein (MOMP) and LPS in the membrane is different in EBs and 
RBs (Hackstadt et al., 1985; Birkelund et al., 1988). These characteristics, in combination with the increased 
transcriptional acitivity observed during the mid cycle when RBs are undergoing replication, suggests that 
there will be major differences in the proteomes of RBs and EBs and underscores the importance of defining 
the former. While the methods for purification of infectious EBs are well established, RBs are osmotically 
fragile  and  must  be  purified  from  inclusions,  presenting  difficulties  and  requiring  the  development  of  a 
purification strategy. 
 
C. trachomatis L2 grows well in a range of mammalian cells with a relatively short developmental 
cycle and gives high yields compared to isolates from the trachoma biovar. Additionally, infection of host 
cells is highly efficient, occurring without the need for centrifugation of Chlamydia onto the host cell. These 
features made this strain particularly suitable for this study. In collaboration with Professor Ian Clarke, Dr 
Joanne Spencer and Mrs Leslie Cutliffe (Southampton General Hospital, UK), a purification strategy for EBs 
and RBs was developed.  
  
C. trachomatis L2 were cultured in BGMK cells according to the methods described in Chapter 2. 
Purification of RBs from infected cells was achieved at 15 h PI after replication of RBs by binary fission, but 
before the second stage differentiation of RB to EB within the inclusions. RBs were purified by two cycles of 
density gradient centrifugation in discontinuous Urografin gradients. Yields were typically low, with 1 – 2 
mg of RB cells being obtained for 14 x 175 cm
2 flasks where >95% of host cells were infected. EBs were 
similarly purified and assessment of the purity of both chlamydial forms was achieved using thin section EM. 
Micrographs demonstrated the absence of RB in EB preparations and vice versa (Figure 4.1).  Additionally, 
individual preparations of RBs were verified for translational activity using [
35S] methionine in host free 
protein synthesis reactions as described in section 2.2.8. RBs purified at 15 h were translationally active; by 
contrast, purified EBs were metabolically inert.   Chapter 4    Shotgun proteomic analysis of C. trachomatis 
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Figure 4.1. Thin section EM of gradient-purified EBs (A) and RBs (B) used for subsequent analyses. RBs 
were  purified  from  infected  cells  at  15  h  post-infection  and  EBs  at  48  h  post-infection  The  scale  bar 
represents 0.5 µM. Micrographs were produced by the Southampton Biomedical Imaging Unit (Southampton 
General Hospital, UK). 
 
4.2.2  Two-dimensional  gel  analyses  of  EB  and  RB  whole  cell  lysates  from  C. 
trachomatis 
Having isolated pure preparations of EBs and RBs, proteomic analysis of these preparations was 
performed using the different techniques outlined above. Accordingly, the first technique used was two-
dimensional gel electrophoresis (2-DGE). Protein profiles of EBs and RBs were obtained by solubilisation of 
protein extracts in 2D-GE sample lysis buffer and fractionated by 2-DGE as described in Chapter 2. Figure 
4.2 illustrates the protein profile obtained with whole cell lysates of EBs from C. trachomatis L2. Three 
independent biological preparations were analysed of both EBs and RBs. Despite using a 2-DGE clean-up 
procedure, gels often showed extensive streaking, indicating the presence of interfering chemicals, such as 
salts, lipids and nucleic acids. Reproducibility of RB 2-D gels was extremely poor and alignment with other 
RB 2-D gels and EB 2-D gels for comparison was not possible except for a limited number of highly 
abundant spots. The separation of EB and RB samples using 2-DGE was performed in collaboration with Dr. 
Joanne Spencer (Southampton General Hospital, UK). 
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Figure 4.2. 2-D gel image of protein extracts separated from purified EBs of C. trachomatis L2. The first 
dimension range was pH 4.0 to 7.0. The gel was stained with SYPRO Ruby and the image analysed as 
described in Chapter 2. Identified proteins are indicated by the relevant spot numbers and listed in Table 4.1 
and Table 4.2. 
 
Spots that were reproducibly present in at least three biological replicate gels for each type of sample 
were  excised  and  digested  in  situ  with  trypsin.  Two  approaches  were  used  for  the  identification  of  the 
resulting extracted peptides. Initially, all samples were screened using MALDI-TOF MS to determine the 
presence of peptides. In samples where peptides were observed, nanoLC-MS/MS was used to identify the 
peptides and hence assign the proteins. Table 4.1 provides a list of those proteins identified in EBs and RBs 
using 2-DGE. All proteins identified in RBs were also identified in EBs. Of the 19 proteins identified, the 
majority corresponded to house-keeping components and other previously reported high abundance proteins 
(Shaw et al., 2002a). Only two hitherto hypothetical proteins were found and other classes of protein (e.g., 
integral membrane proteins) were poorly represented (Table 4.1). 
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Table 4.1. A list of identified protein spots from 2D gels of EBs from C. trachomatis L2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Proteins also found in 2-D gels of RBs are indicated by * 
b pI and molecular mass (kDa) were calculated using ProteinLynx Global Server 2.05 (Waters) 
C In the case of exported proteins and integral membrane proteins, the coordinates include the signal sequence region where this is 
known. 
$ The proteins HSP 60 and the 60 kDa cysteine rich OMP were identified within the same gel spot. 
 
 
 
4.2.3 Analysis of the chlamydial proteome by MudPIT 
In light of the results obtained from the 2-D gel electrophoresis experiments, MudPIT was employed 
to increase proteome coverage. ~100 µg of both EB and RB samples were digested in solution with trypsin 
containing Rapigest and the resulting peptides were trapped onto an Optipak SCX column before being 
eluted using seven steps of increasing salt concentration (section 2.3.8). At each step, the peptide fraction was 
Gel spot 
number
a 
UniProt 
accession  Protein Name 
Predicted
b 
MW/pI 
1*  B0B7W6  HSP 70  70/5.0 
2
$
  B0B815  60 kDa Cysteine Rich OMP  59/7.4 
2
$
  B0B9L8  HSP 60  58/5.3 
3  B0B7V0  Arginine Binding Protein  28/5.8 
4  B0B8L2  Aromatic AA Aminotransferase  44/5.7 
5  B0B8Q5  Elongation Factor TS  30/5.4 
6*  B0B7N8  Elongation Factor Tu  43/5.5 
7*  B0B7N8  Elongation Factor Tu  43/5.5 
8*  B0B7N8  Elongation Factor Tu  43/5.5 
9*  B0B8B5  FKBP type peptidyl prolyl cis trans isomerase  26/5.0 
10  B0B9T6  Glucose 6 P Dehydrogenase DevB family  28/5.4 
11*  B0B8F8  hypothetical protein  21/5.9 
12  B0B8B2  hypothetical protein  27/5.2 
13  B0B8F8  hypothetical protein  21/5.9 
14*  B0B8Q7  Major Outer Membrane Protein  42/5.1 
15  B0B8Q7  Major Outer Membrane Protein  42/5.1 
16  B0B8Q7  Major Outer Membrane Protein  42/5.1 
17*  B0B881  RNA Polymerase Alpha  41/5.4 
18*  B0B7N0  RNA Polymerase Beta  140/5.7 
19  B0B9K6  S1 Ribosomal Protein  63/5.22 
20*  B0B7M9  Transaldolase  36/4.98 
21  B0B7N6  Transcriptional termination factor  20/5.31 
22  B0B7P5  Triosephosphate Isomerase  29/5.62 
23*  B0B8D3  Yop proteins translocation lipoprotein J  35/5.66 Chapter 4    Shotgun proteomic analysis of C. trachomatis 
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eluted onto a C18 reverse phase nanoLC column, separated and analysed using tandem mass spectrometry. 
MS/MS data were searched against a protein translation of the C. trachomatis and human genome. The 
human  genome  was  selected  since  this  offered  the  closest  available  genome  sequence  with  significant 
homology to the African green monkey (Cercopithecus aethiops) host cells used for culturing Chlamydia 
(Almeida et al., 2011). 
 
MudPIT  analysis  of  EB  samples  generated  a  total  of  9048  MS/MS  spectra,  resulting  in  the 
identification of 222 unique peptides and 107 proteins. Despite extensive purification of EBs and RBs, host 
cell protein contamination was still observed. Although a similar number of MS/MS spectra were obtained 
(8762 spectra), the total number of chlamydial proteins assigned in RBs using MudPIT was 70. This reduced 
sampling of the predicted RB proteome is likely to reflect greater levels of host cell contamination in RB 
preparations.  Despite  the  contamination  of  preparations  with  host  cell  proteins,  no  homolgous  peptides 
between Chlamydia and the human genome were identified. 
 
Protein identification using the MudPIT approach, in contrast to the poor proteome coverage obtained 
using  2-DGE,  was  relatively  efficient  and  unbiased,  identifying  proteins  across  a  range  of  functional 
categories and encompassing proteins with isoelectric pH values ranging from 4.5 to 11.4; and molecular 
weights from 8.4 to 182.8 kDa. Proteins identified via the MudPIT approach are listed in Table 4.2. 
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Table 4.2. Proteins identified from C. trachomatis L2 by 2-DGE, MudPIT and GeLC-MS/MS. 
Category/Protein name  Gene 
name 
UniProt 
accession 
Primary 
locus 
Serovar D 
locus 
MW 
(kDa)
 a 
pI 
a  No. of 
peptides 
Tech
b  EB/RB 
                   
Amino acid Biosynthesis                   
Leucine Dehydrogenase  ldh  B0B8Z9  CTL0142  CT773  37  5.3  2  G  EB 
Serine Hydroxymethyltransferase  glyA  B0B804  CTL0691  CT432  54  6.6  1  G  EB 
Tryptophan Synthase Alpha Chain  trpA  B0B9S2  CTL0424  CT171  28  4.8  1  G  EB 
                       
Biosynthesis of Cofactors                       
Dihydropteroate Synthase  folP  B0B8I8  CTL0877  CT613  50  5.6  1  M  EB RB 
Geranylgeranyl pyrophosphate synthase  ispA  B0B8K3  CTL0892  CT628  33  4.9  3  G,M  EB 
Ribityllumazine Synthase  ribH  B0B8V8  CTL0101  CT732  16  6.3  2  G  EB 
Thioredoxin Reductase  trxB  B0B9K7  CTL0354  CT099  38  8.0  1  G  EB 
                       
Cell Envelope                       
Putative Outer Membrane Protein A  pmpA  B0B7Y2  CTL0669  CT412  106  8.6  2  G  RB 
Putative outer membrane protein B  pmpB  B0B7Y3  CTL0670  CT413  183  5.7  11  G,M  EB 
Putative outer membrane protein C  pmpC  B0B7Y4  CTL0671  CT414  187  4.5  6  G  EB RB 
Putative Outer Membrane Protein D  pmpD  B0B940  CTL0183  CT812  161  4.8  29  G,M  EB RB 
Putative Outer Membrane Protein E  pmpE  B0B9A1  CTL0248  CT869  105  7.2  3  G  EB 
Putative Outer Membrane Protein F  pmpF  B0B9A2  CTL0249  CT870  112  9.0  5  G  EB 
Putative Outer Membrane Protein G  pmpG  B0B9A3  CTL0250  CT871  107  5.5  7  G,M  EB RB 
Putative Outer Membrane Protein H  pmpH  B0B9A4  CTL0251  CT872  108  6.4  11  G  EB 
Putative Outer Membrane Protein I  pmpI  B0B9A6  CTL0254  CT874  96  6.5  6  G,M  EB RB 
60kDa Cysteine Rich OMP  omcB  B0B815  CTL0702  CT443  59  7.4  14  G,M,2D(2)  EB RB 
60kDa Inner Membrane Protein  oxaA  B0B7G7  CTL0503  CT251  88  9.1  6  G,M  EB RB 
OmpH Like Outer Membrane Protein  ompH  B0B7F8  CTL0494  CT242  19  4.8  2  G  EB 
Major Outer Membrane Protein  ompA  B0B8Q7  CTL0050  CT681  42  5.1  20  G,M,2D(14,
15,16) 
EB RB 
Outer Membrane Protein analog  ompB  B0B8T9  CTL0082  CT713  37  5.2  3  G  EB 
Peptidoglycan-associated lipoprotein  pal  B0B8H4  CTL0863  CT600  22  9.0  3  G  EB 
Omp85 Analog     B0B7F7  CTL0493  CT241  89  9.3  3  G,M  EB RB 
UDP N acetylmuramoylalanylglutamyl DAP 
Ligase 
 
murE  B0B715  CTL0521  CT269  53  5.6  1  M  RB 
UDP 3 O 3hydroxymyristoyl glucosamine N 
acyltransferase 
 
lpxD  B0B7F9  CTL0495  CT243  38  7.6  1  G  EB 
KDO Synthetase  kdsA  B0B8N1  CTL0024  CT655  30  6.0  2  G,M  EB 
                        
Central Intermediary Metabolism                        
Glycogen Phosphorylase  glgP  B0B7G4  CTL0500  CT248  93  5.9  5  G  EB 
Glycogen Synthase  glgA  B0B925  CTL0167  CT798  53  5.7  3  G  EB 
Inorganic Pyrophosphatase  ppa  B0B8Z8  CTL0141  CT772  23  4.8  1  G  EB 
                        
Cellular Processes                        
chromosome partitioning ATPase CHLTR 
plasmid protein homolog GP5D 
 
minD  B0B8F6  CTL0845  CT582  28  7.1  3  G,M  EB RB 
ATP dependent zinc protease  ftsH  B0B970  CTL0213  CT841  102  6.1  10  G,M  EB RB 
HSP 60  groEL  B0B9L8  CTL0365  CT110  58  5.3  15  G,M,2D(2)  EB RB 
HSP 70  dnaK  B0B7W6  CTL0652  CT396  71  5.1  15  G,M,2D(1)  EB RB 
10KDa Chaperonin  groES  B0B9L9  CTL0366  CT111  11  5.0  2  G  EB 
possible Disulfide Bond Chaperone  dsbG  B0B9S7  CTL0429  CT177  27  8.1  1  G  EB 
Heat Shock Protein J  dnaJ  B0B7R0  CTL0595  CT341  42  7.9  3  G,M  EB RB 
HSP 70 Cofactor  grpE  B0B7W5  CTL0651  CT395  22  4.6  1  G  EB 
Leader 60 peptide periplasmic     B0B914  CTL0156  CT788  19  4.8  1  G  EB Chapter 4    Shotgun proteomic analysis of C. trachomatis 
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Thio specific Antioxidant TSA Peroxidase  ahpC  B0B8H7  CTL0866  CT603  22  4.8  2  G,M  EB RB 
Superoxide Dismutase Mn  sodM  B0B7L0  CTL0546  CT294  23  6.2  5  G,M  EB RB 
Secretion Chaperone   scc1  B0B9J6  CTL0343  CT088  16  6.7  1  G  EB 
Translocase  secY  B0B884  CTL0772  CT510  50  10.4  3  G  EB RB 
Trigger Factor peptidyl prolyl isomerase  tig  B0B8T3  CTL0076  CT707  50  5.0  6  G,M  EB RB 
Signal Peptidase I  lepB  B0B9C7  CTL0275  CT020  72  8.6  1  G  EB RB 
GTP Binding Protein  ychF  B0B9K0  CTL0347  CT092  40  5.2  1  M  EB 
Yop proteins translocation lipoprotein J  sctJ  B0B8D3  CTL0822  CT559  35  5.7  8  G,M,2D(22)  EB RB 
Yop proteins translocation protein L  sctL  B0B8D5  CTL0824  CT561  25  5.9  4  G,M  EB RB 
Yops secretion ATPase  sctN  B0B8P5  CTL0038  CT669  48  5.8  3  G  EB 
probable Yop proteins translocation protein 
C general secretion pathway protein 
 
sctC  B0B8Q0  CTL0043  CT674  101  5.7  6  G,M  EB RB 
Low Calcium Response D  lcrD  B0B9J8  CTL0345  CT090  78  8.3  10  G,M  EB 
Low Calcium Response H  scc2  B0B8F0  CTL0839  CT576  26  9.2  2  G  EB 
Yop proteins translocation protein R  sctR  B0B8D6  CTL0825  CT562  34  8.4  1  G  EB 
Protein Export  secF  B0B821  CTL0708  CT448  156  7.7  5  G  RB 
Flagellar Motor Switch Domain YscQ family  sctQ  B0B8P8  CTL0041  CT672  41  4.7  4  G  EB 
                        
Energy Metabolism                        
ATP Synthase Subunit I  atpI  B0B7M1  CTL0557  CT305  73  6.5  1  G  EB 
ATP Synthase Subunit A  atpA  B0B7M4  CTL0560  CT308  65  5.1  1  M  EB 
ATP Synthase Subunit E  atpE  B0B7M6  CTL0562  CT310  23  5.4  1  G  EB 
ATP Synthase Subunit B  atpB  B0B7M3  CTL0559  CT307  49  5.9  1  G  EB 
ATP Synthase Subunit D  atpD  B0B7M2  CTL0558  CT306  23  9.3  1  G  EB 
NADH Ubiquinone Dehydrogenase  nqrB  B0B7J4  CTL0530  CT278  55  8.7  1  G  EB 
NADH Ubiquinone Oxidoreductase Gamma  nqrC  B0B7J5  CTL0531  CT279  34  6.4  2  G,M  EB 
NADH ubiquinone oxidoreductase alpha 
chain 
 
nqrA  B0B8K9  CTL0002  CT634  52  9.1  2  G  EB 
Phenolhydrolase NAD ubiquinone 
oxidoreductase 
 
dmpP  B0B8W6  CTL0109  CT740  48  5.3  2  G  EB 
ADP ATP Translocase  npt1  B0B9H3  CTL0321  CT065  58  8.7  5  G,M  EB RB 
ADP ATP Translocase  npt2  B0B868  CTL0756  CT495  60  9.4  1  G  RB 
Phosphoenolpyruvate Carboxykinase  pckA  B0B8T6  CTL0079  CT710  66  5.7  2  G,M  EB 
Phosphoglycerate Kinase  pgk  B0B8R9  CTL0062  CT693  43  5.9  2  G  EB 
Phosphoglycerate Mutase  pgmA  B0B8U8  CTL0091  CT722  26  7.2  3  G  EB 
Enolase  eno  B0B8G1  CTL0850  CT587  45  4.6  5  G,M  EB RB 
Fructose 6 P Phosphotransferase  pfkA_
2 
B0B9V7  CTL0459  CT207  61  6.7  1  G  EB 
Fructose 6 P Phosphotransferase  pfkA  B0B9V5  CTL0457  CT205  62  6.5  1  G  EB 
Glyceraldehyde 3 P Dehydrogenase  gapA  B0B879  CTL0767  CT505  36  5.8  2  G,M  EB RB 
Pyruvate Kinase  pykF  B0B7Q0  CTL0586  CT332  54  6.3  1  G  EB 
Triosephosphate Isomerase  tpiS  B0B7P5  CTL0582  CT328  30  5.6  2  G,2D(22)  EB 
Malate Dehydrogenase  mdhC  B0B7U5  CTL0630  CT376  36  6.7  6  G  EB 
Phosphomannomutase  mrsA  B0B7L1  CTL0547  CT295  67  5.1  3  G,M  EB 
Predicted 1 6 Fructose biphosphate 
aldolase dehydrin family 
dhnA  B0B9W5  CTL0467  CT215  38  /6.71  3  G  EB 
Cytochrome Oxidase Subunit I  cydA  B0B9C0  CTL0268  CT013  50  9.5  5  G  EB 
Cytochrome Oxidase Subunit II  cydB  B0B9C1  CTL0269  CT014  40  8.9  1  G  EB 
Glucose 6 P Dehydrogenase  zwf  B0B9T5  CTL0437  CT185  51  5.4  2  G  EB 
Glucose 6 P Dehydrogenase DevB family  devB  B0B9T6  CTL0438  CT186  29  5.4  2  G,2D(10)  EB 
Glucose 6 P Isomerase  pgi  B0B7U7  CTL0633  CT378  58  5.8  5  G  EB 
Oxoglutarate Dehydrogenase  sucA  B0B9G2  CTL0310  CT054  103  5.4  1  G  EB 
Transaldolase  tal  B0B7M9  CTL0565  CT313  36  5.0  8  G,M,2D(20)  EB RB 
Transketolase  tktB  B0B8X6  CTL0119  CT750  73  5.4  1  G  EB 
6 Phosphogluconate Dehydrogenase  gnd  B0B9H1  CTL0319  CT063  53  5.4  4  G  EB 
Ribose 5 P Isomerase A  rpiA  B0B9W3  CTL0465  CT213  26  5.5  2  G  EB Chapter 4    Shotgun proteomic analysis of C. trachomatis 
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Pyruvate Dehydrogenase  pdhB  B0B7G2  CTL0498  CT246  36  5.8  1  G  EB 
Dihydrolipoamide Acetyltransferase  pdhC  B0B7G3  CTL0499  CT247  46  5.9  2  G  EB 
Dihydrolipoamide Succinyltransferase  sucB  B0B9G3  CTL0311  CT055  40  5.1  2  G  EB 
Succinyl CoA Synthetase Alpha  sucD  B0B951  CTL0194  CT822  30  5.4  1  G  EB 
Succinyl CoA Synthetase Beta  sucC  B0B950  CTL0193  CT821  42  5.6  5  G  EB 
                        
Fatty Acid and Phospholipid Metabolism                     
Biotin Carboxyl Carrier Protein  accB  B0B9N1  CTL0378  CT123  18  5.1  1  G  EB 
Acyl Carrier Protein Synthase  fabF  B0B8Z6  CTL0139  CT770  45  5.5  5  G,M  EB RB 
Acyl Carrier Protein Synthase  acpS  B0B9K8  CTL0355  CT100  13  9.4  4  G,M  EB 
Glycerol 3 P Acyltransferase  plsC  B0B826  CTL0713  CT453  24  10.0  1  G  EB 
Lipoamide Dehydrogenase  lpdA  B0B8D1  CTL0820  CT557  50  6.7  1  G  EB 
Malonyl CoA Acyl Carrier Transacylase  fabD  B0B7F4  CTL0490  CT238  34  4.9  3  G  EB 
predicted acyltransferase family     B0B9V6  CTL0458  CT206  32  6.0  1  M  RB 
FA Phospholipid Synthesis Protein  plsX  B0B939  CTL0182  CT811  34  6.6  1  G  EB 
Enoyl Acyl Carrier Protein Reductase  fabI  B0B9L2  CTL0359  CT104  32  5.6  7  G,M  EB RB 
Oxoacyl Carrier Protein Reductase  fabG  B0B7F3  CTL0489  CT237  26  8.3  5  G  EB 
Oxoacyl Carrier Protein Synthase III  fabH  B0B7F5  CTL0491  CT239  35  7.6  2  G  EB 
CDP diacylglycerol glycerol 3 phospahte 3 
phoasphatidyltransferase 
 
pgsA  B0B924  CTL0166  CT797  23  8.9  1  G  EB 
predicted Lysophospholipase esterase     B0B9P4  CTL0391  CT136  27  5.5  2  G  EB 
Phosphatidate Cytidylytransferase  cdsA   B0B824  CTL0711  CT451  34  8.9  2  G  EB 
Acyl Carrier UDP GlcNAc O Acyltransferase  ipxA  B0B8A5  CTL0793  CT531  31  6.1  2  G  EB 
AcCoA Carboxylase Transferase Alpha  accA  B0B7I1  CTL0517  CT265  36  5.9  1  G  EB 
Acyl CoA Thioester Hydrolase  vidD  B0B8A9  CTL0797  CT535  19  18.5 
8.75 
1  G  EB 
Acylglycerophosphoethanolamine 
Acyltransferase 
aas  B0B902  CTL0145  CT776  59  7.6  3  G  EB 
                        
Purines, Pyrimidines, Nucleosides and Nucleotides                  
AMP Nucleosidase  amn  B0B8X7  CTL0120  CT751  32  6.6  1  G  EB 
CTP Synthetase  pyrG  B0B9T3  CTL0435  CT183  60  6.2  3  G  EB 
Nucleoside 2 P Kinase  ndk  B0B874  CTL0762  CT500  15  5.3  1  G  EB 
Thymidylate Kinase  tdk  B0B9T8  CTL0440  CT188  23  7.6  1  G  EB 
UMP Kinase  pyrH  B0B8Q4  CTL0047  CT678  26  5.4  3  G  EB 
Ribonucleoside Reductase Large Chain  nrdA  B0B956  CTL0199  CT827  119  6.1  1  G,M  RB 
dUTP Nucleotidohydrolase  dut  B0B7K8  CTL0544  CT292  15  5.3  1  G  EB 
Deoxycytidine triphosphate deaminase 
family protein 
 
dcd  B0B9E6  CTL0294  CT039  21  4.9  1  G  EB 
adenylate kinase  adk  B0B9N6  CTL0383  CT128  28  4.8  1  G  EB 
                        
Regulatory Functions                        
General Stress Protein  rplY  B0B926  CTL0168  CT799  20  9.2  2  G  EB RB 
GTPase  lepA  B0B9H2  CTL0320  CT064  67  6.3  2  G  EB 
HTH Transcriptional Regulatory Protein and 
Receiver Domain 
tctD  B0B8K5  CTL0894  CT630  26  8.9  2  G  EB 
                        
Replication                        
DNA Gyrase Subunit A  gyrA  B0B9T9  CTL0441  CT189  94  6.6  4  G  EB RB 
DNA Gyrase Subunit B  gyrB2  B0B9U0  CTL0442  CT190  90  5.5  9  G,M  EB RB 
DNA Pol III Epsilon chain  dnaQ  B0B7H7  CTL0513  CT261  27  5.8  1  G  EB 
DNA Polymerase I  polA  B0B866  CTL0754  CT493  97  5.4  1  M  EB 
DNA Topoisomerase I Fused to SWI 
Domain 
 
topA  B0B8L8  CTL0011  CT643  97  9.1  2  G  EB 
Endonuclease IV  nfo  B0B8K0  CTL0889  CT625  32  6.0  1  G  EB 
DNA Helicase  uvrD  B0B8I3  CTL0872  CT608  73  6.4  2  G,M  EB Chapter 4    Shotgun proteomic analysis of C. trachomatis 
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ssDNA Exonuclease  recJ  B0B820  CTL0707  CT447  65  9.5  2  G  EB 
                        
Transcription                        
Polyribonucleotide Nucleotidyltransferase  pnp  B0B971  CTL0214  CT842  76  5.7  6  G  EB RB 
Transcription antitermination factor  nusA  B0B9K5  CTL0352  CT097  49  5.3  2  M  EB RB 
RNA Polymerase Alpha  rpoA  B0B881  CTL0769  CT507  42  5.4  6  G,M,2D(17)  EB RB 
RNA Polymerase Beta  rpoB  B0B7N1  CTL0567  CT315  140  5.8  14  G,M  EB RB 
RNA Polymerase Beta  rpoC  B0B7N0  CTL0566  CT314  155  7.5  21  G,M,2D(18)  EB RB 
RNA Polymerase Sigma 66  rpoD  B0B8J0  CTL0879  CT615  66  8.4  3  G  EB RB 
Transcription Elongation Factor G  greA  B0B8L1  CTL0004  CT636  81  5.3  4  G,M  EB 
Transcription Termination Factor  rho  B0B864  CTL0752  CT491  52  7.3  9  G,M  EB RB 
Transcriptional termination protein  nusG  B0B7N6  CTL0572  CT320  21  5.3  2  G,2D(21)  EB 
                        
Translation                        
CLP Protease  clpP  B0B803  CTL0690  CT431  21  5.5  3  G,M  EB RB 
Clp Protease ATPase  clpB  B0B9M1  CTL0368  CT113  96  5.4  11  G,M  EB RB 
ClpC Protease ATPase  clpC  B0B7K2  CTL0538  CT286  95  6.4  12  G,M  EB 
General Stress Protein   ipiY  B0B926  CTL0168  CT799  20  9.0  3  G  EB 
Elongation Factor P  efp  B0B9N0  CTL0377  CT122  21  5.0  2  G  EB 
Elongation Factor P  efp  B0B8X8  CTL0121  CT752  21  5.0  1  G  EB 
Elongation Factor TS  tsf  B0B8Q5  CTL0048  CT679  31  5.4  5  G,M,2D(5)  EB RB 
Elongation Factor Tu  tufA  B0B7N8  CTL0574  CT322  43  5.5  17  G,M,2D(6,7
,8) 
EB RB 
Elongation Factor G  fusA  B0B809  CTL0696  CT437  76  5.3  12  G,M  EB RB 
Arginyl tRNA Transferase  argS  B0B827  CTL0714  CT454  63  6.4  2  G,M  EB 
Aspartyl tRNA Synthetase  aspS  B0B8B6  CTL0804  CT542  66  5.2  3  G,M  EB 
Alanyl tRNA Synthetase  alaS  B0B8X5  CTL0118  CT749  98  5.5  3  G,M  EB RB 
DO Serine Protease  htrA  B0B952  CTL0195  CT823  53  6.8  5  G  EB 
Tryptophanyl tRNA Synthetase  trpS  B0B8F9  CTL0848  CT585  40  6.9  6  G,M  EB RB 
tyrosyl tRNA Synthetase  tyrS  B0B9H0  CTL0318  CT062  45  7.1  2  G  EB 
Initiation Factor 3  infC  B0B962  CTL0205  CT833  20  9.9  1  G  EB 
Initiation Factor IF 1  infA2  B0B7N9  CTL0575  CT323  8  9.4  1  M  EB 
Leucyl Aminopeptidase A  pepA  B0B9F3  CTL0301  CT045  54  5.9  11  G  EB 
Protease  sohB  B0B867  CTL0755  CT494  36  8.4  3  G  EB RB 
Glu tRNA Gln Amidotransferase A subunit  gatA  B0B9B0  CTL0258  CT003  54  6.1  5  G,M  EB RB 
Pet1 12 Glu tRNA Gln Amidotransferase B 
Subunit 
 
gatB  B0B9B1  CTL0259  CT004  55  6.2  4  G,M  EB RB 
Lon ATP dependent protease  lon  B0B7R3  CTL0598  CT344  92  6.9  2  G,M  EB 
Insulinase family Protease III  ptr  B0B933  CTL0175  CT806  108  5.1  14  G,M  EB RB 
Metalloprotease     B0B9I0  CTL0328  CT072  69  6.6  3  G  EB RB 
Metalloprotease  ispH  B0B991  CTL0234  CT859  34  6.1  1  G,M  EB,RB 
Threonyl tRNA Synthetase  thrS  B0B8F5  CTL0844  CT581  73  6.1  1  G,M  EB 
Seryl tRNA Synthetase  serS  B0B8V5  CTL0098  CT729  48  5.9  1  G  EB 
Leucyl tRNA Synthetase  leuS  B0B9V9  CTL0461  CT209  93  5.8  1  M  EB 
Glutamyl tRNA Synthetase  gltX  B0B818  CTL0705  CT445  59  6.5  2  G  EB 
Histidyl tRNA Synthetase  hisS  B0B8B7  CTL0805  CT543  49  7.1  1  G  EB 
Axial Filament Protein  cafE  B0B935  CTL0177  CT808  59  7.1  1  G  EB RB 
Oligoendopeptidase  pepF  B0B9M0  CTL0367  CT112  69  5.6  5  G  EB RB 
Peptidyl tRNA Hydrolase  pth  B0B927  CTL0169  CT800  20  8.3  1  G  EB 
Ribosome Releasing Factor  rrf  B0B8Q3  CTL0046  CT677  20  8.9  1  G  EB 
Thiol: disulfide Interchange Protein  dsdD  B0B8G9  CTL0859  CT595  76  6.7  3  G  EB 
Glycyl tRNA Synthetase  glyQ  B0B923  CTL0165  CT796  113  5.9  1  G  EB 
Lysyl tRNA Synthetase  lysS  B0B907  CTL0150  CT781  60  5.4  1  G  EB 
CLP Protease  clpP  B0B8T2  CTL0075  CT706  22  5.2  2  G  EB 
rRNA methylase  troB  B0B9H6  CTL0324  CT068  29  7.2  2  G,M  EB RB 
Polypeptide Deformylase  def  B0B7S2  CTL0607  CT353  21  5.9  1  G  EB 
L1 Ribosomal Protein  rplA  B0B7N4  CTL0570  CT318  25  9.3  2  G,M  EB RB Chapter 4    Shotgun proteomic analysis of C. trachomatis 
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L10 Ribosomal Protein  rplJ  B0B7N3  CTL0569  CT317  19  6.7  2  G,M  EB RB 
L13 Ribosomal Protein  rplM  B0B9N3  CTL0380  CT125  17  10.5  2  G  EB 
L14 Ribosomal Protein  rplN  B0B892  CTL0780  CT518  13  10.2  2  G  EB 
L15 Ribosomal Protein  rplO  B0B885  CTL0773  CT511  16  10.5  3  G,M  EB RB 
L16 Ribosomal Protein  rplP  B0B895  CTL0783  CT521  16  11.4  2  G  EB 
L17 Ribosomal Protein  rplQ  B0B880  CTL0768  CT506  16  11.4  2  G  EB 
L18 Ribosomal Protein  rplR  B0B887  CTL0775  CT513  13  10.7  2  G,M  EB RB 
L19 Ribosomal Protein  rplS  B0B9D5  CTL0283  CT028  13  10.3  2  G  EB 
L2 Ribosomal Protein  rplB  B0B899  CTL0787  CT525  31  10.8  4  G,M  EB RB 
L21 Ribosomal Protein  rplU  B0B7Z0  CTL0677  CT420  12   9,53  2  G  EB 
L22 Ribosomal Protein  rplV  B0B897  CTL0785  CT523  12  11.4  1  M  EB 
L23 Ribosomal Protein  rplW  B0B8A0  CTL0788  CT526  12  10.3  2  G  EB 
L24 Ribosomal Protein  rplX  B0B891  CTL0779  CT517  13  10.9  2  G,M  EB 
L28 Ribosomal Protein  rpmB  B0B9J4  CTL0341  CT086  10  11.7  2  G  EB 
L29 Ribosomal Protein  rpmC  B0B894  CTL0782  CT520  8  10.3  2  G  EB 
L33 Ribosomal Protein  rpmG  B0B9Q8  CTL0405  CT150  6  10.7  1  G  EB 
L4 Ribosomal Protein  rplD  B0B8A1  CTL0789  CT527  25  10.1  6  G,M  EB RB 
L5 Ribosomal Protein  rplE  B0B890  CTL0778  CT516  21  9.7  3  G  EB 
L6 Ribosomal Protein  rplF  B0B888  CTL0776  CT514  20  10.3  3  G,M  EB RB 
L7 L12 Ribosomal Protein  rplL  B0B7N2  CTL0568  CT316  14  4.9  3  M  EB RB 
L9 Ribosomal Protein  rplI  B0B930  CTL0172  CT803  18  6.5  1  G  EB 
S1 Ribosomal Protein  rpsA  B0B9K6  CTL0353  CT098  64  5.3  8  G,M,2D(19)  EB RB 
S10 Ribosomal Protein  rpsJ  B0B808  CTL0695  CT436  12  10.8  6  G  EB 
S11 Ribosomal Protein  rpsK  B0B882  CTL0770  CT508  14  11.3  2  G,M  EB RB 
S12 Ribosomal  rpsL  B0B811  CTL0698  CT439  15  11.3  1  G  EB 
S13 Ribosomal Protein  rpsM  B0B883  CTL0771  CT509  14  11.2  1  G  EB 
S14 Ribosomal Protein  rpsN  B0B913  CTL0155  CT787  12  11.5  2  G  EB 
S16 Ribosomal Protein  rpsP  B0B9D3  CTL0281  CT026  13  10.6  1  G  EB 
S17 Ribosomal Protein  rpsQ  B0B893  CTL0781  CT519  10  10.7  1  G  EB 
S18 Ribosomal Protein  rpsR  B0B929  CTL0171  CT802  9  11.5  1  G  EB 
S2 Ribosomal Protein  rpsB  B0B8Q6  CTL0049  CT680  31  6.6  3  G,M  EB RB 
S3 Ribosomal Protein  rpsC  B0B896  CTL0784  CT522  24  10.3  4  G,M  EB RB 
S4 Ribosomal Protein  rpsD  B0B8K1  CTL0890  CT626  24  10.3  2  G,M  EB RB 
S5 Ribosomal Protein  rpsE  B0B886  CTL0774  CT512  18  10.2  1  G  EB 
S6 Ribosomal Protein  rpsF  B0B928  CTL0170  CT801  13  9.0  2  G,M  EB,RB 
S7 Ribosomal Protein  rpsG  B0B810  CTL0697  CT438  17  10.1  3  G,M  EB RB 
S8 Ribosomal Protein  rpsH  B0B889  CTL0777  CT515  15  10.5  1  G  EB 
S9 Ribosomal Protein  rpsI  B0B9N4  CTL0381  CT126  15  11.2  3  G,M  EB RB 
Ribosome Binding Factor A  rbfA  B0B9K3  CTL0350  CT095  14  9.3  1  G  EB 
                        
Transport and Binding Proteins                        
ABC Transport ATPase  dppD  B0B8R6  CTL0059  CT690      1  G  EB 
ABC Transporter ATPase  ycfV  B0B9R0  CTL0407  CT152  25  6.9  1  G  EB 
ABC Transporter Protein  yjjK  B0B7R7  CTL0602  CT348  59  5.7  1  G  EB 
PTS IIA Protein HTH DNA Binding Domain  ptsN    B0B7K6  CTL0542  CT290  26  5.3  2  M  RB 
Arginine Binding Protein  artJ  B0B7V0  CTL0636  CT381  29  5.8  8  G,M,2D(3)  EB 
Solute Protein Binding Family   troA    B0B9H5  CTL0323  CT067  37  5.7  3  G,M  EB RB 
Sodium dependent amino acid transporter     B0B9Y2  CTL0483  CT231  55  9.3  1  M  RB 
oligo Binding Lipoprotein  oppA4  B0B853  CTL0741  CT480  80  5.1  1  G  RB 
Protein Translocase  secA  B0B8S7  CTL0070  CT701  110  6.0  7  G,M  EB RB 
Glutamine Binding protein  fliY  B0B859  CTL0747  CT486  29  7.5  6  G  EB RB 
Tyrosine Transport  tyrP  B0B947  CTL0190  CT818  44  9.3  2  G  EB 
Hexosphosphate Transport  uhpC  B0B8B8  CTL0806  CT544  52  8.6  3  G,M  EB RB 
Dicarboxylate Translocator  ybhI  B0B9V4  CTL0456  CT204  51  9.2  1  G  EB 
Amino Acid Transporter  xasA  B0B9W6  CTL0468  CT216  51  9.1  1  G  EB 
Mg Transporter CBS Domain  mgtE  B0B9U4  CTL0446  CT194  51  5.0  1  G  EB 
ABC Amino Acid Transporter ATPase  glnQ  B0B9N8  CTL0385  CT130  26  6.3  1  M  EB Chapter 4    Shotgun proteomic analysis of C. trachomatis 
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Metal Transport P type ATPase  zntA  B0B8V3  CTL0096  CT727  71  7.2  1  G  EB 
                        
Hypothetical Proteins                        
hypothetical protein     B0B7M7  CTL0563  CT311      1  M  EB 
hypothetical protein     B0B9A8  CTL0256  CT001  10  9.0  1  G  EB 
hypothetical protein     B0B9B8  CTL0266  CT011  48  7.3  1  G  EB 
hypothetical protein     B0B9B9  CTL0267  CT012  30  10.0  1  G  EB 
hypothetical protein     B0B9D8  CTL0286  CT031  12  10.0  1  G  EB 
hypothetical protein     B0B9F1  CTL0299  CT043  18  5.1  6  G  EB 
hypothetical protein     B0B9G4  CTL0312  CT056  27  9.5  1  G  EB 
hypothetical protein     B0B9H4  CTL0322  CT066  18  10.3  1  G  EB 
hypothetical protein     B0B9L0  CTL0357  CT102  17  9.9  2  G,M  EB 
hypothetical protein     B0B9R1  CTL0408  CT153  91  6.4  4  G  EB 
hypothetical protein     B0B9T1  CTL0433  CT181  27  5.5  1  G  EB 
hypothetical protein     B0B9W2  CTL0464  CT212  17  5.0  1  G  EB 
hypothetical protein     B0B9X1  CTL0473  CT221  33  7.3  4  G  EB 
hypothetical protein     B0B9X4  CTL0476  CT223  30  8.3  3  G,M  RB 
hypothetical protein     B0B7F0  CTL0486  CT234  106  8.8  1  G  EB 
hypothetical protein     B0B7G9  CTL0505  CT253  24  9.2  5  G,M  EB RB 
hypothetical protein     B0B7H6  CTL0512  CT260  19  4.8  3  M  EB 
hypothetical protein     B0B7K4  CTL0540  CT288  63  8.1  2  G  EB 
hypothetical protein     B0B7M7  CTL0563  CT311  26  9.1  1  M  EB 
hypothetical protein  aaxA  B0B7U1  CTL0626  CT372  49  9.2  2  G  EB 
hypothetical protein     B0B7V7  CTL0643  CT387  77  6.2  1  G  EB 
hypothetical protein     B0B7V8  CTL0644  CT388  13  10.2  1  G  EB 
hypothetical protein     B0B7V9  CTL0645  CT389  47  5.8  1  G  EB 
hypothetical protein     B0B7W8  CTL0655  CT398  30  7.7  6  G,M  EB 
hypothetical protein  nrdR  B0B7X6  CTL0663  CT406  18  9.1  1  G  EB 
hypothetical protein     B0B7Z1  CTL0678  CT421  26  9.4  1  G  EB 
hypothetical protein     B0B7Z7  CTL0684  CT425  70  5.0  2  G,M  EB 
hypothetical protein     B0B801  CTL0688  CT429  39  5.1  1  G  EB 
hypothetical protein     B0B845  CTL0733  CT472  30  5.3  1  G  EB RB 
hypothetical protein     B0B849  CTL0737  CT476  36  8.2  1  M  RB 
hypothetical protein     B0B877  CTL0765  CT503  22  5.7  1  G  EB 
hypothetical protein     B0B8B2  CTL0800  CT538  27  5.2  7  G,M,2D(12)  EB 
hypothetical protein     B0B8D4  CTL0823  CT560  32  7.0  2  G  EB 
hypothetical protein     B0B8F1  CTL0840  CT577  13  7.0  3  G  EB 
hypothetical protein  copB  B0B8F2  CTL0841  CT578  50  9.4  2  G  EB 
hypothetical protein  copD  B0B8F3  CTL0842  CT579  44  9.6  3  G  EB 
hypothetical protein     B0B8F8  CTL0847  CT584  21  5.8  5  G,M,2D(11)  EB RB 
hypothetical protein     B0B8G4  CTL0853  CT590  109  5.8  3  G  EB 
hypothetical protein     B0B8I5  CTL0874  CT610  27  4.9  3  G,M  EB RB 
hypothetical protein     B0B8I6  CTL0875  CT611  27  5.6  2  G  EB 
hypothetical protein     B0B8J3  CTL0882  CT618  28  9.1  2  G,M  RB 
hypothetical protein     B0B8J6  CTL0885  CT621  93  5.0  1  G  EB 
hypothetical protein     B0B8K6  CTL0895  CT631  9  5.3  1  G  EB 
hypothetical protein     B0B8K7  CTL0897  CT632  61  6.0  6  G  EB 
hypothetical protein     B0B8L0  CTL0003  CT635  17  6.5  1  G  EB 
hypothetical protein     B0B8L7  CTL0010  CT642  32  9.4  1  G  EB 
hypothetical protein  recA  B0B8M5  CTL0018  CT650  38  7.6  5  G,M  EB RB 
hypothetical protein     B0B8N5  CTL0028  CT659  88  8.7  4  G  EB 
hypothetical protein     B0B8P2  CTL0035  CT666  92  4.7  2  G  EB 
hypothetical protein     B0B8P7  CTL0040  CT671  31  4.8  2  M  EB 
hypothetical protein     B0B8Q2  CTL0045  CT676  20  5.8  2  M  EB 
hypothetical protein     B0B8R7  CTL0060  CT691  25  5.0  1  G  EB 
hypothetical protein     B0B8S0  CTL0063  CT694  35  5.4  2  G  EB 
hypothetical protein     B0B8S1  CTL0064  CT695  44  5.2  1  G  EB Chapter 4    Shotgun proteomic analysis of C. trachomatis 
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hypothetical protein     B0B8V4  CTL0097  CT728  28  6.2  1  G  EB 
hypothetical protein     B0B8W7  CTL0110  CT741  13  9.5  3  G,M  EB RB 
hypothetical protein     B0B8Y9  CTL0132  CT763  15  4.7  1  G,M  EB RB 
hypothetical protein     B0B8Z4  CTL0137  CT768  64  5.4  1  G  EB 
hypothetical protein     B0B916  CTL0158  CT790  18  4.6  1  G,M  EB RB 
hypothetical protein     B0B932  CTL0174  CT805  52  9.6  1  G  EB 
hypothetical protein     B0B942  CTL0185  CT814  16  11.1  1  G  EB 
hypothetical protein     B0B966  CTL0209  CT837  76  6.1  2  G  EB 
hypothetical protein     B0B975  CTL0218  CT846  27  9.8  1  G  EB 
hypothetical protein     B0B978  CTL0221  CT849  18  5.1  1  G  EB 
hypothetical protein     B0B983  CTL0226  CT853  22  9.0  1  G  EB 
hypothetical protein     B0B9A7  CTL0255  CT875  66  6.2  12  G  EB 
hypothetical protein     B0B9E9  CTL0297  CT041  7  4.0  2  G  EB RB 
hypothetical protein     B0B9Q5  CTL0402  CT147  162  8.6  3  G  RB 
hypothetical protein     B0B9E9  CTL0297  CT041  30  5.0  2  G  EB RB 
                        
Other                        
FHA domain to adenylate cyclase     B0B8P0  CTL0033  CT664  90  4.6  12  G,M  EB RB 
FKBP type peptidyl prolyl cis trans 
isomerase 
 
mip  B0B8B5  CTL0803  CT541  26  5.0  9  G,M,2D(9)  EB RB 
Predicted metal dependent hydrolase     B0B7V6  CTL0642  CT386  33  5.2  2  G  EB 
predicted phosphatase kinase     B0B865  CTL0753  CT492  23  5.7  1  G  EB 
Serine threonine Protein Kinase  pkn1  B0B9Q3  CTL0400  CT145  70  5.1  1  M  EB RB 
SurE like Acid Phosphatase  surE  B0B9W8  CTL0470  CT218  32  5.0  1  G  EB 
Intergration Host Factor Alpha  ihfA  B0B7I3  CTL0519  CT267  11  11.2  4  G  EB 
Histone Like Development Protein  hctA  B0B8W9  CTL0112  CT743  14  11.0  5  G,M  EB 
SWF SNF family helicase  snf   B0B8T4  CTL0077  CT708  133  5.4  2  G,M  EB 
SWIB YM74 complex     B0B833  CTL0720  CT460  10  9.4  1  G  EB 
Yeb C family     B0B830  CTL0717  CT457  27  5.8  3  G  EB 
SuA5 Superfamily related Protein     B0B9P5  CTL0392  CT137  31  6.5  1  G  EB 
CHLPN 76kDa Homolog     B0B8J7  CTL0886  CT622  68  4.8  1  G  EB 
CHLPN 76kDa Homolog     B0B8J8  CTL0887  CT623  48  8.5  16  G,M  EB RB 
hydrolase phosphatase homolog     B0B8Z7  CTL0140  CT771  17  5.1  2  G,M  EB,RB 
Hit Family Hydrolase  hitA      B0B7V5  CTL0641  CT385  12  5.4  1  M  EB 
ACR family  ybgI  B0B9L6  CTL0363  CT108  27  6.0  2  G  EB 
phosphohydrolase  icc   B0B8Y0  CTL0123  CT754  33  7.8  1  G  EB 
HAD superfamily hydrolase phosphatase     B0B9L1  CTL0358  CT103  34  5.1  2  G  EB 
Phosphoglycolate Phosphatase     B0B837  CTL0724  CT464  26  5.2  1  G  EB 
Phosphohydrolase  yaeI  B0B834  CTL0721  CT461  37  9.3  1  G  EB 
a  pI and molecular mass were calculated using ProteinLynx Global Server 2.05 (Waters) 
b The abbreviations for the techniques used are: 
G   = GeLC-MS/MS 
M   = MudPIT 
2D  = 2-DGE 
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4.2.4 Analysis of the chlamydial proteome by GeLC-MS/MS 
To  further  extend  proteome  coverage  of  EBs  and  RBs,  the  technique  GeLC-MS/MS  was 
employed. EB and RB samples were solubilised in final SDS-PAGE sample buffer and fractionated by 
conventional SDS-PAGE. The protein separation profile of EBs and RBs obtained by 1-D SDS-PAGE 
is shown in Figure 4.3. Each track of the gel containing the relevant samples was excised into 25 gel 
bands of equal size and digested in situ using trypsin. Peptides extracted from each gel band were 
identified  using  nanoLC-MS/MS  whereupon  all  spectra  were  processed  and  searched  in  a  similar 
manner to those obtained via the MudPIT approach. 
 
A total of 30,042 spectra were obtained for EB samples, resulting in 824 peptide assignments 
and the identification of 298 unique proteins when searched against the serovar D genome. As found in 
the MudPIT experiments, fewer proteins were identified in RBs, identifying 65 proteins.  
 
The completion of the C. trachomatis L2/434/Bu genome during these studies has offered the 
opportunity to re-search all the MS/MS data obtained from the L2 strain, against the cognate genome 
data. Re-searching of the GeLC-MS/MS data revealed an additional 5 proteins identified with ≥ 2 
peptides,  increasing  the  total  proteome  coverage  of  C.  trachomatis  to  36%.  Although  2-DGE  and 
MudPIT re-searches did not assign any further proteins, protein sequence coverage was significantly 
improved across the dataset, for example, the sequence coverage for MOMP (CTL0050), increased 
from 36% (serovar D) to 83.5% (L2/434/Bu). All protein assignments listed in Table 4.2 are from 
searches against the cognate strain, C. trachomatis L2/434/Bu. 
 
 
Figure  4.3.  Fractionation  of  EB  and  RB  protein  lysates  using  a  NuPAGE  4  –  12%  SDS  – 
polyacrylamide  gel  (Invitrogen,  Paisley,  UK).  Proteins  were  visualised  with  Colloidal  Coomassie 
Brilliant Blue. MW = Broad range protein markers (New England Biolabs, UK); EB = 130 µg of EB 
lysate; RB = 130 µg of RB lysate. 
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4.3 Discussion 
 
This chapter has described the qualitative proteomic analysis of purified EBs and RBs from C. 
trachomatis L2 using the proteomic technologies 2-D gel electrophoresis, MudPIT and GeLC-MS/MS 
(O’Farrell, 1975; Link et al., 1999; Opiteck et al., 1997; Schirle et al., 2003). A comparison of the 
proteomic technologies used in this study, and the roles of some of the identified proteins or groups of 
proteins in the context of Chlamydia biology are now discussed.  
 
4.3.1  Comparison  of  the  sampling  characteristics  of  2-D  gel  electrophoresis, 
MudPIT and GeLC-MS/MS 
The bias of 2-DGE towards high abundance proteins resulted in poor proteome coverage of both 
EB and RB samples. In contrast, protein identification using the MudPIT approach was relatively 
unbiased and provided increases in proteome coverage. For example, it detected over three times as 
many predicted membrane proteins and seven-fold more proteins in the transcription and translation 
categories when compared to 2-D gel electrophoresis (Table 4.2). 
 
Analysis by GeLC-MS/MS provided over a two-fold increase in proteome coverage compared 
to  analysis  by  MudPIT.  GeLC-MS/MS  identified  the  entire  set  of  proteins  identified  by  2D-GE. 
Similarly, all but 26 out of 107 proteins identified by MudPIT were identified in the GeLC-MS/MS 
study. A conclusion drawn from this study is that GeLC-MS/MS is significantly more efficient than the 
two other approaches in detecting components of the chlamydial proteome. 
 
Like  the  MudPIT  approach,  GeLC-MS/MS  sampled  in  a  relatively  unbiased  manner 
representing membrane proteins, low abundance proteins, high molecular weight proteins, and proteins 
with extreme pIs (Table 4.2, Figure 4.4 and Figure 4.5). For example, it detected a 186 kDa outer 
membrane protein (encoded by the CTL0671 gene) as well as a range of inner membrane proteins 
(Table  4.2).  The  procedure  has  allowed  the  identification  of  proteins  with  atypical  codon  biases, 
indicative  of  extremes  of  expression  (Figure  4.4).  Similarly,  the  most  acidic  and  basic  proteins 
identified  by  GeLC-MS/MS  have  pI’s  of  4.01  and  11.7  (Figure  4.5)  respectively,  which  is  in 
reasonable agreement with the predicted pI range of 3.83 to 12.65 for the proteome of serovar L2. Chapter 4    Shotgun proteomic analysis of C. trachomatis 
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Figure 4.4. Experimentally detected chlamydial proteins with atypical codon biases. 
A plot of the codon bias for each gene identified relative to the mean average codon bias for the entire 
genome (solid horizontal Line on graph). Codon bias values that exceed one SD of the average codon bias 
(dashed horizontal lines) are indicative of proteins with atypical levels of expression. Codon bias values were 
calculated by the method of Karlin et al ( 2001). ●, proteins identified by MudPIT or GeLC-MS/MS; ♦, 
proteins identified by 2-D gel electrophoresis. 
 
 
Figure 4.5. pI Distribution plot of the proteins identified from C. trachomatis serovar L2. pI values were 
determined using the database searching package PLGS 2.2 (Waters, Manchester, UK). The dashed line 
indicates the predicted pI range for C. trachomatis L2. 
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4.3.2 Shotgun identification of proteins from C. trachomatis and their 
context in Chlamydia biology 
Generally,  only  tentative  conjectures  about  an  organism’s  cellular  processes  can  be  made  using 
genome sequencing data. Genomic transcriptional analyses have become an important tool in studying gene 
expression especially as prokaryotic gene expression is normally regulated at the transcriptional level. In 
Chlamydia,  the  developmental  cycle  appears  to  be  regulated  by  subsets  of  temporally  expressed  genes 
(Belland et al., 2003; Nicholson et al 2003). However, verification of the presence of a component at the 
protein level significantly strengthens the inferences that can be made. This study has identified protein 
products from all the functional categories of protein-encoding genes and thus provides direct evidence for 
these  processes  and  pathways  (Table  4.2).  The  functional  significance  of  the  identified  components  is 
discussed in the following sections. 
4.3.2.1 Energy metabolism 
Traditionally chlamydiae have been considered ‘energy parasites, unable to synthesise their own ATP 
(Moulder, 1962). Evidence for this was provided by the observation that isolated RBs can transport ATP and 
ADP by an ATP-ADP exchange mechanism (Hatch et al., 1982). In this respect, this study has identified in 
both EBs and RBs, two chlamydial translocases, predicted from the genome sequence and subsequently 
characterised by cloning and expression in E. coli (Tjaden et al., 1999). The gene CTL0024 encodes a protein 
responsible for exchanging ATP and ADP while the protein encoded by CTL0756 catalyses the net import of 
ribonucleoside tri-phosphates. However, the present study also provides evidence to suggest that Chlamydia 
are capable of producing their own energy (Iliffe-Lee and McClarty, 1999) because many of the energy-
generating enzymes of central metabolism are present in both EBs and RBs. The entire complement of 
glycolytic enzymes required to convert glucose-6-phosphate to pyruvate have been detected. Included among 
these enzymes was the recently predicted fructose-bisphosphate aldolase, the product of gene CTL0467, 
where recent controversy over its presence has led to the proposal of an alternative route via the pentose-
phosphate  pathway  to  circumvent  this  enzyme  (Stephens  et  al.,  1998).  Additionally,  all  but  one  of  the 
enzymes associated with the pentose phosphate pathway are present in this proteomic dataset. The fact that 
all of the glycolytic enzymes were readily detectable in the metabolically inert EBs suggest that this pathway 
is preassembled, rather than synthesised de novo in host cells, and suggests that metabolite flux through the 
pathway is only triggered upon infection of the host cell. Also identified in this study were several protein 
subunits encoded by genes of the adenosine triphosphatase (ATPase) operon. However, chlamydiae with 
mammalian hosts appear to have lost genes for the F1 ATPase during evolution (Horn et al., 2004). It is thus, 
unlikely,  that  these  ATPase  components  are  involved  in  energy  generation,  especially  as  most  of  the 
components identified resemble the vacuolar ATPases (McClarty and Stephens, 1999). 
 
In addition to components of the glycolytic and pentose phosphate pathways, the alpha and beta subunits of 
succinyl CoA synthetase from the TCA cycle and pyruvate dehydrogenase, a key linker reaction enzyme 
were found (Table 4.2). Although genetic evidence shows that the TCA cycle is incomplete in Chlamydia Chapter 4    Shotgun proteomic analysis of C. trachomatis 
136 
(Stephens et al., 1998), the presence of these enzymes supports the concept that a modified pathway operates. 
The ability of cells to synthesise glucose is a major requirement and detected in these datasets was the 
gluconeogenesis  enzyme  phosphoenolpyruvate  carboxykinase.  This  enzyme  catalyses  the  conversion  of 
oxaloacetate to phosphoenolpyruvate, bypassing the irreversible glycolytic step of pyruvate kinase (Iliffe-Lee 
and McClarty, 1999). In the absence of a complete TCA cycle phosphoenolpyruvate carboxykinase provides 
the only direct link between the TCA cycle and glycolysis. 
 
One of the properties used to differentiate C. trachomatis from other species of Chlamydia has been 
the detection of glycogen within its inclusions, using the simple and long- established iodine test (Chiappino 
et al., 1995; Iliffe-Lee and McClarty, 2000). This differentiates on the basis that, unlike C. trachomatis, other 
chlamydial species do not synthesise detectable amounts of glycogen. The C. trachomatis genome contains a 
complete  complement  of  genes  for  both  glycogen  biosynthesis  and  metabolism  (Stephens  et  al.,  1998). 
Glycogen  is  usually  stored  under  conditions  of  nitrogen  starvation,  thus  it  would  seem  reasonable  that 
glycogen is synthesised in the later stages of development when EBs are forming. Accordingly, this study 
indicates  the  presence  of  the  biosynthetic  enzyme  glycogen  synthase  in  EBs.  EBs  must  also  be  able  to 
mobilise  glycogen  as  an  energy  source  early  in  the  developmental  cycle  and  presumably  the  glycogen 
phosphorylase detected in EBs is synthesised in preparation for this requirement. 
4.3.2.2 The chlamydial cell envelope 
The chlamydial cell envelope has been the focus of intense study due to its potential significance in 
vaccine development.  An interesting anomaly arising from the genome sequencing project has been the 
discovery of genes for a complete set of peptidoglycan biosynthetic enzymes in the absence of any detectable 
cell wall material (Chopra et al., 1998). Although the expression levels of such components is likely to be 
low (Nicholson et al., 2003), especially in view of the difficulty in detecting chlamydial cell wall material, 
this  study  detected  the  presence  in  RBs  of  UDP-N-acetylmuramoylalanylglutamyl DAP ligase, which is 
encoded by the murE gene. This enzyme is involved in the synthesis of the muramyl-peptide unit, the first 
stage in assembling peptidoglycan (see Chapter 5). The discovery of this enzyme in RBs strongly hints that 
active peptidoglycan biosynthesis occurs during RB growth and cell division, supporting the notion that 
peptidoglycan is essential for progression through the developmental cycle (McCoy et al., 2003; McCoy and 
Maurelli, 2006). In addition, peptides from 17 predicted membrane proteins were detected and many of these 
matched proteins predicted to be located to the C. trachomatis outer membrane (Stephens and Lammel, 
2001), including the major outer membrane protein (OmpA-CTL0050) and its analogue (PorB-CTL0082), 
which are both present in EBs and RBs (Kubo and Stephens, 2000). Consistent with previous studies, the 60 
kDa  cysteine-rich  outer  membrane  protein  (OmcB)  and  the  peptidoglycan  associated  protein  (PaI)  were 
found only in EBs (Hatch et al., 1986). The complete family of ‘Pmp’ proteins, which have no homologs in 
other  bacteria,  were  also  detected.  Strong  evidence  suggests  that  these  proteins  are  autotransporters 
(Henderson and Lam, 2001) and are believed to be located on the chlamydial surface. Interestingly Pmps B, 
F and H have so far only been detected in EBs while Pmps C, D, E, G and I were found in both EBs and RBs. 
By contrast Pmp A was detected only in RBs. These results are in broad agreement with the observation that Chapter 4    Shotgun proteomic analysis of C. trachomatis 
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Pmps E and especially G and H are abundantly expressed late in the developmental cycle (Mygind et al., 
2000; Tanzer et al., 2001). 
 
4.3.2.3 Type III secretion system (TTSS) 
The TTSS in Chalmydia is likely to play a role in modifying the host cell processes that may be 
necessary for host cell invasion, restructuring of the inclusion membrane, or affecting host cell regulatory 
pathways. Seven proteins associated with the chlamydial TTSS were identified and, while their precise roles 
remain to be resolved (Subtil et al, 2000), they are representative of the cellular compartments associated 
with  these  systems.  Thus,  SctR  (CTL0825)  and  LcrD  (CTL0345)  are  believed  to  reside  in  the  inner 
membrane, while SctJ (CTL0822) and SctC (CTL0043) have periplasmic locations and outer membrane 
locations respectively. Additionally, LcrH_1 (CTL0839), which functions as a cytoplasmic chaperone and a 
regulator in the TTSS of other bacteria, was identified as were the cytosolic proteins SctN (CTL0038) and 
SctL (CTL0824). The chlamydial SctJ and SctC proteins were detected in RBs purified at 15 h PI. These 
observations are consistent with evidence that shows transcription of CTL0822 and CTL0043 occurs in C. 
trachomatis L2 as early as 12 h PI and that SctJ is located to RB membranes. Furthermore, all seven proteins 
were found in EBs supporting the proposal that EBs contain a fully assembled and functional TTSS (Fields et 
al., 2003). 
4.3.2.4 Hypothetical proteins 
The  largest  group  of  proteins  identified  in  this  qualitative  study  were  those  designated  as 
‘hypothetical’ within the genome sequence. The detection of peptides representing 68 of these predicted 
proteins substantiates their existence and provides an impetus for more detailed studies to characterise their 
functions. 
 
4.4 Summary 
While the study presented in this chapter has identified proteins from all the major functional classes, 
including predicted low abundance proteins; components secreted from RBs were not detected. These include 
the ‘Inc’ related proteins that have been estimated to constitute up to 12% of the genome coding capacity 
(Rockey et al., 2000). It is likely that such proteins are efficiently exported during infection and hence are 
only present at reduced levels in EBs or RBs, unless present at high abundance during transit. Despite the 
absence  of  these  proteins  from  this  dataset,  the  identification  of  321  proteins  (~36%  of  the  predicted 
proteome)  of  C.  trachomatis  L2  compares  well  with  the  current  proteome  coverage  of  other  obligate 
intracellular pathogens. Examples include, Rickettsia felis, where 11.2% of the proteome was assigned using 
a  combination  of  2-DGE  and  GeLC-MS/MS  (Ogawa  et  al.,  2007);  the  foodbourne  pathogen  Listeria 
monocytogenes, where 245 proteins were identified from 1684 gel spots separated using two dimensional 
differential gel electrophoresis without apparent host cell contamination (Van de Velde et al., 2009); and 
Tucker et al. (2011), who compared Rickettsia prowazekii cultured in different host cells identifying between 
102 to 178 proteins of the 835 proteins encoded by the genome depending upon the host cell background. 
The proteomic data captured in this study complements the genomic data, providing biological insights and Chapter 4    Shotgun proteomic analysis of C. trachomatis 
138 
an  essential  framework  for  quantitative  studies  of  the  chlamydial  developmental  cycle  as  presented  in 
Chapter 5. 
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5.0 Quantitative analysis of C. trachomatis 
 
5.1 Introduction 
While the temporal aspects and morphological changes associated with the chlamydial developmental 
cycle  have  been  well  characterized  using  microscopy  (Ward,  1988;  Matsumoto,  1982),  the  underlying 
mechanisms that regulate and control the transition between the two distinct forms remains unclear. Genome 
sequencing  and  transcriptional  profiling  experiments  with  C.  trachomatis,  suggest  that  the  cycle  is 
coordinated by defined subsets of genes (Nicholson et al., 2003; Belland et al., 2003). The previous chapter 
presented a qualitative analysis of the proteome of C. trachomatis L2 using three different technologies, 
providing protein profiles of both RBs and EBs. Although this information has provided valuable insight into 
various aspects of C. trachomatis, there is a clear need for more quantitative data to obtain information on the 
temporal expression of proteins during the developmental cycle. 
 
Traditionally, quantitative analysis of proteins has been performed using 2D-GE, providing relative 
quantification of proteins between different cellular states. However, as discussed in earlier chapters, there 
are a number of limitations with these gel-based methods, which has in recent years provided an impetus for 
the  development  of  alternative  quantitative  technologies.  These  technologies  can  be  divided  into  two 
different types of approach: (i) labelling, and (ii) non-labelling (label-free). Labelling approaches include 
stable isotope labelling with amino acids in cell culture (SILAC) (Ong et al., 2002), isotope-coded affinity 
tags (ICAT) (Gygi et al., 1999b), tandem mass tags (TMT) (Thompson et al., 2003), isotopically labeled 
peptide standards (AQUA) (Gerber  et al.,  2003)  and  isobaric  tags  for  relative  and  absolute  quantitation 
(iTRAQ) (Ross et al., 2004; Choe et al., 2007). Although these approaches have been widely used, the 
requirement for large amounts of sample, complex sample preparation, non-stoichiometric labeling and the 
high cost of the associated reagents, also limit these approaches. 
 
To address some of these issues, focus has been directed towards label-free approaches. These have 
included the exponentially modified protein abundance index emPAI (Ishihama et al., 2005), which is an 
extension of the protein abundance index (Rappsilber et al., 2002), and provides the measurement of proteins 
in absolute amounts. Other approaches include accurate mass tags (AMT), a method that employs an initial 
qualitative LC-MS/MS analysis to identify peptides and their corresponding retention times, followed by a 
second LC-MS analysis allowing the quantification of those peptides using ion currents (Lipton et al., 2002). 
More recently, a data independent mode of acquisition termed MS
E, similar to the AMT approach, has been 
reported (Silva et al., 2006a). MS
E uses alternating scans of low and elevated collision energies to obtain ion 
intensities  from  both  the  precursor  and  the  product  ions  of  eluting  peptides.  This,  in  combination  with 
reproducible retention times, allows their simultaneous quantitation and identification. An outline of this 
approach is shown in Figure 5.1. Further, the approach also allows the absolute quantification of proteins 
(Silva et al., 2006b). Here, the average intensity of the top three most abundant peptide ions of an internal 
standard is used to calculate a response factor. This in turn can be used to calculate the absolute amount of Chapter 5    Quantitative analysis of C. trachomatis 
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each identified protein by comparison to the mean intensity of the top three most abundant peptide ions from 
each respective identified protein.  
 
5.2 Quantitative proteomic studies of C. trachomatis 
 
There are a limited number of quantitative proteomic studies of Chlamydia and even fewer of the 
LGV  biovars  (see  Proteomics  summary  Table  1.3  in  Chapter  1).  Moreover,  these  studies  can  only  be 
considered  semi-quantitative  at  best  and  the  number  of  proteins  assigned  within  these  studies  is  low. 
Lundemose et al. (1990) characterized the synthesis of early proteins during the intracellular transition from 
EB to RB using 2-DGE in combination with pulse-labeling experiments, and were able to show the synthesis 
of seven proteins during the first 8 h after infection before the detection of MOMP at 10 h. Three of these 
proteins were identified as S1 ribosomal protein, GroEL and DnaK using immunoblotting and were shown to 
decline during 26-30 h PI, the period when RB are undergoing the second stage of differentiation to the 
infectious EB form. The same research group also reported the differential expression of several unidentified 
proteins when investigating the chlamydial response of interferon gamma on C. trachomatis serovars A and 
L2 (Shaw et al.,1999). 
 
A  more  extensive  quantitative  proteomic  analysis  of  the  related  human  respiratory  pathogen 
Chlamydophila pneumonia investigated the global expression changes during the re-differentiation from RB 
to EB (Mukhopadhyay et al., 2006). Although there are distinct differences in the clinical manifestation 
between the C. trachomatis and C. pneumonia species, similarities in their biphasic developmental cycle and 
morphology indicate that there should be core similarities at the molecular level. This study identified 35 
proteins whose expression levels were altered during the transition from RB to EB. 
 
At the time of undertaking this project, all quantitative studies of Chlamydia have employed 2-DGE in 
combination  with  pulse-labeling  and  pulse-chase  experiments.  Although  such  approaches  are  attractive 
because  they  allow  the  detection  of  chlamydial  proteins  in  the  apparent  absence  of  contaminating  host 
proteins, the technique is restricted to the detection of newly synthesized proteins and does not provide a 
direct  quantitative  measure  of  already  existing  proteins.  If  comparisons  are  to  be  made  between  the 
transcriptome and proteome, then it is critical that alternative approaches are implemented that not only 
overcome this limitation, but also those limitations associated with 2-DGE. Further, relative quantitation 
strategies  such  as  2-DGE,  although  useful  for  the  comparison  of  one  or  more  different  experimental 
conditions,  only  offer  information  on  the  direction  of  change  (-up  or  down-regulation),  with  amounts 
expressed as ‘fold’ change. By contrast, absolute quantitation strategies determine the amount of a peptide or 
protein in terms of their precise molar concentration (e.g., fmol per ml of serum, ng per gram of tissue). As 
such,  the  combination  of  samples  that  can  be  compared  using  absolute  quantitation  strategies  is  almost 
limitless and can equally be used to calculate relative measures of protein expression between samples. 
However, costly reagents, time-consuming assay development and the limited number of proteins that can be 
quantified per experiment. Nonetheless, for the integration of proteomic data with other ‘omic’ datasets in the 
context of systems biology, the quantitation of proteins in absolute amounts is an essential prerequisite.   
 
 
Figure 5.1. LC-MS
E 
data acquisition and data processing. 
i) Alternating scans of low and elevated collision energies are used to 
obtain ion intensities from both precursor (low energy) and fragment 
ions  (elevated  energy)  simultaneously.  ii)  Using  ProteinLynx  Global 
Server Ver 2.4, Extracted Ion Chromatograms (XIC) are generated for 
each  ion  from  both  the  low  and  elevated  energy  spectra.  The 
chromatographic  retention  time  maxima  (RT(max))  of  each  eluting 
precursor ion peak is used to extract those fragment ions corresponding 
to the relevant precursor ion by aligning/matching of the RT(max) from 
the fragment ion (elevated energy) spectra. The extracted precursor ion 
and its corresponding fragment ions can then be submitted for searching 
against a protein sequence database. 
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The work in this Chapter describes a quantitative proteomic analysis of EBs and RBs from C. trachomatis L2 
using two different proteomic approaches to address many of these limitations. Qualitative and quantitative 
analysis has been performed using: i) MudPIT incorporating iTRAQ tags and ii) label-free analysis using 
two-dimensional reverse phase chromatography in combination with MS
E with protein expression reported in 
both relative and absolute amounts. 
 
5.3 Experimental design 
 
Culture of C. trachomatis L2 and purification of EBs and RBs 
RBs and EBs were cultured and purified in a similar manner to those prepared for the qualitative 
studies presented in Chapter 4. Four batches of Buffalo Green Monkey Kidney (BGMK) cells were infected 
with C. trachomatis L2/434/Bu as described in section 2.2.6. Infected monolayers were harvested at both 15 
h and 48 h. RBs were purified at 15 h PI and EBs at 48 h PI by density gradient centrifugation (section 2.2.7). 
To minimize potential errors arising from differences in protein concentration between EBs and RBs, and/or 
low-level host cell protein contamination, the data was normalized against the number of bacteria determined 
for each preparation as described in section 2.8.3.1 (where, 1 genome is equivalent to 1 bacterium). The 
number of bacteria determined in a typical preparation of purified EBs and RBs was 1.17 x 10
12 and 1.50 x 
10
12 genomes per ml respectively (as calculated by qPCR, section 2.2.10). 
 
Preparation of EB and RB protein lysates 
Purified EB and RB preparations (~1-2 mg of cells) were re-suspended in 0.5 M triethylammonium 
bicarbonate containing 5 mM dithiothreitol (final concentration) and incubated for 2 h on ice. Addition of the 
reducing agent DTT was found to be necessary for efficient lysis of EBs, but was not required for the 
osmotically  fragile  RBs.  This  requirement  for  DTT  is  likely  to  provide  the  necessary  reduction  of  the 
disulphide  bridges  within  the  highly  cross-linked  outer  membrane  complex  of  EB,  disrupting  the  outer 
membrane and facilitating cell breakage. DTT treated cell suspensions were lysed using a combination of 
ceramic bead maceration and sonication as described in section 2.3.9.1. 
 
5.3.1 iTRAQ analysis 
Tryptic digests of EBs and RBs were labeled using 4-plex iTRAQ reagents as described in section 
2.3.9.3. Biological replicates of EB and RB peptides were labeled as illustrated in Figure 5.2 and sample 
loading normalized based upon their protein concentration (100 µg per replicate). The combined iTRAQ 
labeled sample was fractionated using SCX (section 2.3.9.4) and each fraction separated and analysed using 
nanoLC-MS/MS (section 2.3.9.5). The chromatogram of the SCX fractionation is shown in Figure 5.3. 
 
LC-MS/MS  data  generated  from  the  analysis  of  41  SCX  fractions  were  processed  and  searched 
against a protein translation of the C. trachomatis L2/434/Bu genome and pL2 plasmid sequence using the 
Mascot  software  suite  as  described  in  section  2.7.2  and  2.8.2.  Identification  of  peptides,  extraction  of 
intensity information from the iTRAQ reporter ions and peptide normalization were performed using Mascot Chapter 5    Quantitative analysis of C. trachomatis 
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ver 2.2. Based upon criteria set in Mascot a protein was reported if identified by ≥ 2 unique peptides and 
achieved an identity threshold of p<0.03 (≥98% confidence). To provide an estimate of the false discovery 
rate (FDR) of the experimental dataset, the same MS/MS dataset was also searched against a randomized 
database of the C. trachomatis  L2 translation. The False Discovery Rate of peptides above the identity 
threshold  was  estimated  to  be  3.23%.  For  the  quantification  of  identified  proteins,  peptide  reporter  ion 
intensities were summed and a weighted protein ratio calculated for each identified protein. Protein ratios 
were further normalized according to the number of genomes (1 genome representing 1 bacterium) contained 
within each labelled iTRAQ sample (section 2.8.3.2). The mean protein ratio and standard deviation for each 
protein across the two biological replicates were calculated. Where a ratio was only available for one of the 
two biological replicates, it was excluded from the quantitative dataset. To complement the qualitative study 
in Chapter 4, peptides with two unique peptides, but without quantitative information were also reported 
(supplementary data Table 5.1). 
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Figure 5.2.  Outline workflow for the preparation of EB and RB protein lysates for iTRAQ  analysis. 1 and 2 
refer to biological replicates of each sample. 
 
 
Figure 5.3. SCX fractionation of iTRAQ labeled peptides from C. trachomatis L2. UV absorbance was 
monitored at 235 nm. 
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5.3.2 2D-RP-UPLC -MS
E (label-free analysis) 
Duplicate tryptic digests of two biological preparations (9 µg per replicate) of both EB and RB protein 
lysates (the same preparations used for the iTRAQ analysis) were separated using an 11 step RP gradient of 
increasing  percentages  of  acetonitrile  buffered  at  pH  10  using  ammonium  formate.  Each  of  these  11 
percentage cuts were separated in turn using a conventional linear RP gradient at pH 2.0 and analysed online 
using a Synapt Q-Tof mass spectrometer as described in section 2.6.4. Figure 5.4 provides an outline for the 
label-free experimental workflow.  
 
Figure 5.4. Experimental workflow for the analysis of C. trachomatis L2 using 2D-RP-RP-LC-MS
E label-
free technology. 
 
  Data was processed and normalized using the software IDENTITY
E, part of the ProteinLynx Global 
Server package (sections 2.7.3 and 2.8.3). The database-searching algorithm IDENTITY
E uses an iterative 
process, where several stages of filtering and scoring are applied for protein assignment. Each iterative step 
increases the specificity, selectivity and sensitivity of each search. There are three major steps within this 
search strategy. The ‘1
st pass’ database search uses physiochemical properties of peptides in the gas-liquid 
phase to rank peptides, using parameters such as summed product ion intensities; the correct number of 
product  ions  according  to  length,  charge  state  and  intensity  model;  and  the  presence  of  preferred 
fragmentation sites. For the ‘2
nd  pass’ search, a database based upon the confidently assigned ‘1
st  pass’ 
ranked  peptides  is  generated.  The  remaining  data  is  searched  against  this  database,  taking  into  account 
peptide modifications, missed cleavages and losses associated with in-source fragmentation. The combined 
results from the 1
st pass and 2
nd pass searches are combined. The remaining accurate mass precursor/product 
ion list is searched to identify multiple modifications using the same assignment criteria used for the ‘2
nd 
pass’ search. All three of these consecutive searches are combined to generate a ranked list of assigned 
proteins. A false positive discovery rate filter of 4% was applied to the dataset. It is also important to note Chapter 5    Quantitative analysis of C. trachomatis 
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that only the intensity of the top three most intense peptide ions from the ‘1
st pass’ search are used for the 
quantitative measurement. 
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5.5 Results 
 
5.5.1 Protein identifications 
iTRAQ analyses of EBs and RBs identified 4534 peptides from 85963 MS/MS spectra. There was a 
total of 335 non-redundant C. trachomatis proteins based upon a minimum of two peptides per protein, of 
which 169 revealed quantitative data. 
 
In contrast, the label-free analysis assigned a total of 84,877 different chlamydial peptides with 45,465 
peptides identified in EBs and 60,641 peptides in RBs. The total number of non-redundant C. trachomatis 
proteins identified using label-free acquisition from both EBs and RBs by ≥ 3 peptides was 580, of which 
573 were assigned to the C. trachomatis L2 genome and 7 to the genome of the L2 plasmid. After the 
application of filtering criteria, where a protein must have been assigned in at least two replicates from the 
same developmental form, quantitative data was obtained for 489 proteins. 
 
 To account for possible contaminating homologous host cell peptides, the label-free dataset was also 
searched against a protein translation of the human genome. A total of 459 assigned chlamydial peptides 
were found to have human homologs. Of these, a total of 27 were assigned as ‘1
st pass’ and 432 as ‘2
nd pass’. 
Interestingly,  the  mean  peptide  length  of  the  432  homologous  ‘2
nd  pass’  peptides  was  3.4  amino  acids, 
whereas the mean length of the  remaining  76,015 chlamydial ’2
nd  pass’ peptides was 14.7. These short 
homologous peptides are likely to reflect the increased probability of matching shorter peptides between the 
two  databases.  None  of  the  27  human  ‘1
st  pass’  peptides  overlapped  with  the  ‘top3’  peptides  used  for 
quantitation.  All  overlapping  peptides  were  removed  from  the  chlamydial  dataset.  (The  correlation  and 
removal of homologous peptides between the chlamydial and human datasets was performed using a python 
script written by Dr. Richard Edwards, Southampton University, UK).  
 
Qualitative and quantitative information for both experimental approaches are summarised in Table 
5.1. It is important to note, that when comparing these two approaches, that the minimum number of peptides 
used to assign each protein differ, with a filter of ≥ 2 peptides for iTRAQ and ≥ 3 peptides using the label 
free approach. The validity of assigning proteins based upon single peptide or so-called ‘one hit wonders’ in 
the  absence  of  manually  validated  spectra  has  been  brought  into  question  (Veenstra  et  al.,  2004).  In 
consideration of the large sizes of both datasets, the manual validation of individual spectra was deemed 
unfeasible.  Since  there  is  an  increased  potential  for  false-positive  identifications  when  including  single 
peptides, the criteria for the assignment of a protein in the iTRAQ dataset was established as a minimum of 
two peptides. However, the assignment criteria for the label-free dataset was established as ≥ 3 peptides. This 
threshold  arises  from  the  default  quantification  requirement,  where  the  intensity  of  the  top  three  most 
abundant different peptide ions from each identified protein are required to calculate the concentration of the 
protein. Proteins identified by iTRAQ and the label-free approach are listed in appendix I, Tables 5.1 and Chapter 5    Quantitative analysis of C. trachomatis 
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5.2  respectively.  These  tables  also  provide  information  on  the  molecular  weight, pI  and  the  number  of 
peptides used to assign each protein. 
 
 
Table  5.1.  Total  protein  identifications  and  quantitative  data  obtained  from  both  iTRAQ  and  label-free 
analysis. 
  iTRAQ  Label-free 
Total number of protein identifications  335  580 
Number of assignments with quantitative data  169  489 
 
When  comparing  the  number  of  peptides  used  to  assign  each  protein  using  the  two  different 
experimental approaches, clear differences arise. Figure 5.5 shows the distribution of the number of peptides 
used to assign a protein using the iTRAQ and label-free approach. The number of peptides in the iTRAQ 
dataset ranged from 2 to 53 peptides used to assign a peptide with an average of 10 peptides (median =7 
peptides) compared to the label-free approach, which ranged from a minimum of 3 to 928 unique peptides 
per  protein  assignment  with  an  average  of  143  peptides  (median  =  102  peptides).  Thus,  the  label-free 
approach  resulted  in  consistently  higher  protein  sequence  coverage’s.  For  example,  sequence  coverage 
obtained of the 60 kDa cysteine rich protein (OmcB) using the label-free approach was an average of 67% 
supported  by  380  different  peptides.  In  contrast  the  iTRAQ  approach  yielded  49%  sequence  coverage 
supported by 28 peptides. The higher numbers of peptides and improved sequence coverage obtained through 
the label-free method significantly increased the confidence in protein identifications. 
 
Figure 5.5. The numbers of unique peptides available to assign proteins using the label-free and iTRAQ 
approaches. 
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The overlap of protein identifications obtained using the label-free and iTRAQ methods is shown in 
Figure 5.6. Of the 905 predicted genes encoded by the C. trachomatis L2 genome and its associated cryptic 
plasmid,  630  proteins  were  identified  using  a  combination  of  the  data  obtained  from  the  two  different 
approaches, representing ~70% of the theoretical C. trachomatis L2 proteome. A significant number of these 
proteins (~33%) were uniquely identified using the label-free method, while only 6% of the proteins were 
unique to the iTRAQ approach. The remaining 31% were identified using both technologies. 
 
For comparative purposes, Figure 5.7 shows the overlap between label-free and iTRAQ identified 
proteins, but also includes those proteins identified from C. trachomatis L2 using the qualitative approaches 
GeLC-MS/MS and MudPIT previously presented in Chapter 4. Combination of these four datasets realised 
only an additional 2.0% increase in proteome coverage. Again, in comparison, the label-free method uniquely 
identified a significantly greater proportion of proteins representing ~29% of the 648 proteins identified, 
while iTRAQ, GeLC-MS/MS and MudPIT uniquely identified 6%, 2.3% and <1% respectively. The label-
free also had a significantly higher proportion of proteins in common with the three alternative technologies. 
MudPIT and iTRAQ also had a considerable number of overlapping identified proteins between them. Only 
eleven percent of the proteins were identified using all four technologies. Despite assignment of ~72% of the 
C. trachomatis proteome, ~28% of the proteins encoded by the C. trachomatis genome remain to be detected. 
The possible reasons why these proteins have not been detected using the applied technologies are discussed 
in Chapter 6.  
 
 
Figure  5.6.  Venn  diagram  illustrating  the  overlap  of  proteins  assigned  using  iTRAQ  and  the  label-free 
approaches. Panel a) represents the qualitative data and panel b) represents the quantitative data. Chapter 5    Quantitative analysis of C. trachomatis 
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Figure 5.7. Venn diagram illustrating the qualitative overlap of assigned proteins using MudPIT, GeLC-
MS/MS, iTRAQ and Label-free approaches. 
 
5.5.2 Quantitation of identified proteins 
5.5.2.1 iTRAQ data 
Figure 5.8 shows the differential expression profile of proteins from EBs and RBs of C. trachomatis 
L2 as characterised by iTRAQ. This scaled plot of the mean iTRAQ protein ratio plotted against Protein 
number, highlights the limited range of expression from 0.21 to 1.9. The correlation of the protein ratios 
across the two biological replicates were in good agreement with an R
2 value of 0.81 as shown in Figure 5.9.  
 
Figure 5.8. The combined iTRAQ protein expression profile of RBs (15 h PI) and EBs (48 h PI) from C. 
trachomatis L2. Protein number is defined as the rank of the protein sorted according to expression ratio. 
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Figure  5.9.  Correlation  of  iTRAQ  protein  ratios  from  two  biological  replicates  as  measured  by  the 
abundance of the reporter tags at m/z 114-117. 114:115 = EB:RB protein ratio from biological replicate 1, 
116:117 = EB:RB protein ratio from biological replicate 2. 
 
To illustrate a typical peptide identification and relative quantitation result obtained using iTRAQ, 
Figure  5.10  depicts  a  fragmented  4-plex  iTRAQ  labeled  peptide  from  the  60kDa  cysteine-rich  outer 
membrane  protein  (OmcB).  A  total  of  28  peptides  were  identified  for  OmcB  representing  49%  protein 
coverage. 
 
Figure  5.10.  A  representative  mass  spectrum  from  the  iTRAQ  labelled  peptide  GSAEDTNVSLM*LK, 
(M+2H
+)
+2 = 834.90 m/z, identified as originating from OmcB. The iTRAQ reporter ion intensities in the 
region from 114 – 117 m/z are shown in the inset. * indicates an oxidised methionine. This is indicated in the 
mass spectrum by the loss of CH3SOH (-64 amu) indicating the presence of methionine sulphoxide. 
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iTRAQ is a multiplex technology, i.e. multiple samples are combined within the same experiment, and 
quantification is dependent upon the presence of a reporter ion. Consequently, if a peptide reporter ion is 
absent for one of the replicates within the experiment, a protein ratio cannot be calculated. Even when 
reporter  ion  data  is  available  for  one  out  of  the  two  biological  replicates,  this  is  excluded  under  the 
quantification filtering criteria (i.e. datapoints must be present in both biological replicates). Using these 
criteria, quantitative data were obtained for 169 out of the 335 proteins identified using iTRAQ (Table 5.2). 
These quantitative measurements can be found in Appendix I, Table 5.1, in addition to those proteins only 
fulfilling the identification criteria. Because of the relatively subtle nature of the expression changes shown 
by this experimental dataset, a threshold of 1.4 fold is the cut-off filter for reporting proteins as differentially 
expressed. This cut-off value was based upon previous iTRAQ studies performed in our laboratory where 
technical variation was consistently below 30%. This is also consistent with other published studies (Gan et 
al., 2007; Chen et al., 2007; Choong et al., 2010). A list of these proteins and their expression changes that 
were equal to or greater than this cut-off threshold for both up- and down-regulation can be found in Tables 
5.2 and 5.3, respectively. 
 
Table 5.2. Proteins up-regulated in C. trachomatis L2 EBs using iTRAQ 
Protein name 
Gene 
name 
Primary 
locus 
UniProt 
accession 
number  pI
a) 
Mass 
(kDa)
a) 
Mean 
protein 
ratio 
STD 
dev
b) 
Fold-
change 
Integration Host Factor Alpha   ihfA  CTL0519  B0B7I3  11.0  11.4  1.88  0.02  1.9 
hypothetical protein     CTL0322  B0B9H4  9.9  17.9  1.72  0.10  1.7 
Transcription antitermination factor  nusA  CTL0352  B0B9K5  5.1  48.9  1.56  0.18  1.6 
Glucosamine-Fructose-6-P Aminotransferase   glmS  CTL0188  B0B945  5.3  67.4  1.54  0.03  1.5 
tyrosyl tRNA Synthetase  tyrS  CTL0318  B0B9H0  6.6  45.4  1.52  0.00  1.5 
hypothetical protein     CTL0036  B0B8P3  4.8  16.5  1.50  0.07  1.5 
RECA Protein  recA  CTL0018  B0B8M5  7.0  37.8  1.46  0.02  1.5 
Elongation Factor TS   tsf  CTL0048  B0B8Q5  5.6  30.9  1.46  0.07  1.5 
hypothetical protein      CTL0060  B0B8R7  4.9  25.2  1.46  0.11  1.5 
oligopeptide Binding Lipoprotein  oppA4  CTL0741  B0B853  5.0  77.5  1.46  0.03  1.5 
L13 Ribosomal Protein  rplM  CTL0380  B0B9N3  10.1  16.8  1.45  0.19  1.5 
Thioredoxin Disulfide Isomerase     CTL0149  B0B906  7.9  16.2  1.40  0.07  1.4 
S10 Ribosomal Protein   rpsJ  CTL0695  B0B808  10.4  11.9  1.36  0.07  1.4 
Predicted 1,6-Fructose biphosphate aldolase 
(dehydrin family)   dhnA  CTL0467  B0B9W5  6.3  38.0  1.35  0.03  1.4 
         
  
                        a)  pI and molecular mass were calculated using Mascot server Ver2.2. 
b)  Calculated standard deviation 
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Table 5.3. Proteins down-regulated in C. trachomatis L2 EBs analysed using iTRAQ 
Protein name 
Gene 
name 
Primary 
locus 
UniProt 
accession 
number 
a)pI  
Mass 
(kDa)
a) 
Mean 
protein 
ratio 
STD 
 dev
b) 
Fold-
change 
Solute Protein Binding Family     CTL0323  B0B9H5  5.0  33.3  0.74  0.02  -1.4 
Peptidoglycan-Associated Lipoprotein  pal  CTL0863  B0B8H4  7.9  19.0  0.74  0.02  -1.4 
Acyl-Carrier UDP-GlcNAc O-Acyltransferase   lpxA  CTL0793  B0B8A5  6.0  30.7  0.73  0.02  -1.4 
Lon ATP-dependent protease  lon  CTL0598  B0B7R3  6.9  91.9  0.73  0.01  -1.4 
Putative outer membrane protein B   pmpB  CTL0670  B0B7Y3  8.2  183.0  0.72  0.01  -1.4 
hypothetical protein     CTL0271  B0B9C3  4.7  26.7  0.71  0.04  -1.4 
probable Yop proteins translocation protein C      CTL0043  B0B8Q0  5.4  95.7  0.71  0.01  -1.4 
CLP Protease  clpP  CTL0690  B0B803  5.2  20.9  0.69  0.01  -1.4 
HSP-60  hsp60  CTL0365  B0B9L8  5.2  58.1  0.69  0.01  -1.4 
Acyl Carrier Protein   acpP  CTL0488  B0B7F2  3.8  8.7  0.69  0.03  -1.5 
HSP-70 Cofactor  grpE  CTL0651  B0B7W5  4.6  21.7  0.69  0.04  -1.5 
Candidate inclusion membrane protein     CTL0476  B0B9X4  6.7  29.6  0.67  0.00  -1.5 
hypothetical protein     CTL0238  B0B995  5.2  53.6  0.65  0.03  -1.5 
Polymorphic outer membrane protein      CTL0255  B0B9A7  5.3  65.8  0.62  0.02  -1.6 
hypothetical protein     CTL0272  B0B9C4  6.6  47.7  0.61  0.02  -1.6 
ATP Synthase Subunit E   atpE  CTL0562  B0B7M6  5.4  22.9  0.60  0.01  -1.7 
CHLPN 76kDa Homolog     CTL0886  B0B8J7  4.9  68.9  0.49  0.03  -2.0 
hypothetical protein     CTL0540  B0B7K4  8.3  63.5  0.49  0.00  -2.0 
60kDa Cysteine-Rich OMP  omcB  CTL0702  B0B815  8.0  56.4  0.47  0.02  -2.1 
Histone-Like Developmental Protein   hctA  CTL0112  B0B8W9 
10.
6  13.7  0.41  0.01  -2.4 
hypothetical protein     CTL0840  B0B8F1  6.5  13.3  0.21  0.03  -4.7 
a)  pI and molecular mass were calculated using Mascot server Ver2.2. 
b)  Calculated standard deviation. 
 
5.5.2.2 MS
E label-free data 
In the label-free system, each sample was analysed separately using an 11 step 2D-RP-RP-UPLC 
separation in conjunction with the data-independent MS acquisition MS
E, as described briefly above and 
further in section 2.6.4. Eight samples were analysed in total; two biological replicates of EBs, two biological 
replicates  of  RBs,  all  performed  in  duplicate  to  provide  technical  replicates.  The  excellent  technical 
reproducibility afforded by this approach is highlighted in the scatter plot shown in Figure 5.11. Comparison 
of absolute protein measurements between two technical replicates of an EB protein lysate revealed a close 
correlation with an R
2 value of 0.96 with mean % CVs between replicates ranging from 12.9 to 16.9 across 
the dataset. However, there was significant variation of measurements observed between biological replicates 
with an average coefficient of variation of 45% for RBs and 29% for EBs. 
 
One of the key differences between the two quantitative approaches presented in this thesis is that the 
label-free system provides absolute quantification in addition to relative quantification (Silva et al., 2006b). 
As described in section 2.6.4, the protein alcohol dehydrogenase was spiked into each sample as an internal 
standard. The average intensity of the top three most abundant peptide ions from this internal standard was 
used to calculate a response factor. By comparison of this response factor to the average of the top three most Chapter 5    Quantitative analysis of C. trachomatis 
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abundant peptide ions obtained from each identified protein, the absolute amounts loaded onto the column in 
fmol  and  ng  were  calculated.  Further,  the  number  of  cells  contained  within  each  preparation  was  also 
calculated (see section 2.8.3.1), allowing these absolute amounts to be expressed as molecules per cell. Table 
5.4 lists the top 15 most abundant proteins detected in C. trachomatis L2 RBs and EBs expressed as absolute 
amounts ranging from 2728 to 154 molecules per cell. 
 
 
 
Figure 5.11. Comparison of the absolute protein abundance measurements obtained from the analysis of two 
technical replicates of EBs from C. trachomatis using 2D-LC-MS
E. A correlation coefficient of 0.96 was 
obtained. 
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Table 5.4. The top 15 most abundant proteins in RBs and EBs from C. trachomatis L2 
UniProt 
accession 
Locus  Gene 
name 
Protein description  RB
a)  EB
a)   EB/RB 
ratio 
Category 
 
RB proteins 
B0B7N8  CTL0574  tufA  translation elongation factor Tu   2619  2156  0.82  Translation 
B0B8Q7  CTL0050  ompA  major outer membrane protein  2041  2728  1.34  Cell envelope 
B0B8B5  CTL0803  mip  peptidyl-prolyl cis-trans isomerase   1956  1292  0.66  Other categories 
B0B9L8  CTL0365  hsp60  chaperonin GroEL   1871  1300  0.70  Translation 
B0B815  CTL0702  omcB  60kD cysteine-rich outer membrane 
protein  
1704  518  0.30  Cell Envelope 
B0B8J8  CTL0887     putative exported protein   1464  840  0.57  Exported protein 
B0B7W6  CTL0652  dnaK  chaperone protein   1424  1660  1.17  Translation 
B0B9X4  CTL0476     candidate inclusion membrane 
protein  
968  186  0.19  Cell envelope 
B0B9H5  CTL0323     ABC transport protein_ solute 
binding component  
950  379  0.40  Transport and 
binding proteins 
B0B8P0  CTL0033     phosphopeptide binding protein 
(predicted to be a TTSS protein)  
924  341  0.37  Cellular 
processes 
B0B8F8  CTL0847     conserved hypothetical protein   914  1145  1.25  hypothetical 
protein 
B0B9H3  CTL0321     ADP_ATP carrier protein   828  252  0.30  Energy 
metabolism 
B0B952  CTL0195  htrA  serine protease     774  399  0.52  Translation 
B0B940  CTL0183  pmpD  polymorphic outer membrane 
protein  
685  361  0.53  Cell envelope 
B0B9A3  CTL0250  pmpG  polymorphic outer membrane 
protein  
637  154  0.24  Cell envelope 
 
EB proteins 
B0B8Q7  CTL0050  ompA  major outer membrane protein  2041  2728  1.34  Cell envelope 
B0B7N8  CTL0574  tufA  translation elongation factor Tu   2619  2156  0.82  Translation 
B0B7W6  CTL0652  dnaK  chaperone protein   1424  1660  1.17  Translation 
B0B9L8  CTL0365  hsp60_
1 
chaperonin GroEL   1871  1300  0.70  Translation 
B0B8B5  CTL0803  mip  peptidyl-prolyl cis-trans isomerase   1956  1292  0.66  Other categories 
B0B8F8  CTL0847     conserved hypothetical protein   914  1145  1.25  hypothetical 
protein 
B0B7N2  CTL0568  rplL  LSU ribosomal protein L12P 
(L7/L12)  
626  1006  1.61  Translation 
B0B8J8  CTL0887     putative exported protein   1464  840  0.57  Exported protein 
B0B8I5  CTL0874     conserved hypothetical protein  461  807  1.75  hypothetical 
protein 
B0B7F2  CTL0488  acpP  acyl carrier protein   502  662  1.32  Fatty acid & 
phospholipid 
metabolism 
B0B8Q5  CTL0048  tsf  translation elongation factor TS   453  584  1.29  Translation 
B0B8G1  CTL0850  eno  enolase   525  556  1.06  Energy 
metabolism 
B0B815  CTL0702  omcB  60kD cysteine-rich outer membrane 
protein  
1704  518  0.30  Cell envelope 
B0B9L9  CTL0366  groES  10 kDa chaperonin GroES  622  475  0.76  Translation 
B0B7I3  CTL0519  ihfA  integration host factor alpha-subunit   204  472  2.32  DNA replication  
a) expressed as molecules per cell 
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Since each sample using the label-free system is analysed in turn, each sample generates an individual 
set of protein identifications. After application of filtering criteria; where a protein must be present in EBs or 
RBs in at least two replicates, 48 identified proteins were found to be unique to RBs and 5 unique to EBs. A 
list of these proteins for RBs and EBs are shown in Table 5.5.  
 
Table 5.5. Proteins identified as being unique to a) RBs and b) EBs of C. trachomatis L2 using the label-free 
approach. 
UniProt(
accession(
Locus& Gene(
name(
Protein(description( Average(
molecules/cell(
Replication( Functional(
category(
a)(RB(Proteins(
B0B8Y4% CTL0127% murD% UDP2N2acetylmuramoylalanine22
D2glutamate%ligase%%
19% 3% Cell%Envelope%
B0B980% CTL0223% %% putative%integral%membrane%
protein%%
44% 2% Cell%Envelope%
B0B9W4% CTL0466% %% candidate%inclusion%membrane%
protein%%
41% 2% Cell%Envelope%
B0B7T4% CTL0619% %% putative%integral%membrane%
protein%%
49% 3% Cell%Envelope%
B0B8H5% CTL0864% %% putative%soluble%transglycosylase% 23% 3% Cell%Envelope%
B0B884% CTL0772% secY% protein%translocase%subunit% 31% 2% Cellular%Processes%
B0B9J9% CTL0346% sctU% type%III%secretion%system%inner%
membrane%protein%%
33% 3% Cellular%Processes%
B0B8D6% CTL0825% sctR% type%III%secretion%system_%
membrane%protein%%
32% 3% Cellular%Processes%
B0B8E5% CTL0834% gspE% general%secretion%pathway%
protein%E%%
34% 2% Cellular%Processes%
B0B7P6% CTL0583% xseA% exodeoxyribonuclease%VII%large%
subunit%%
29% 3% DNA%Replication%%
B0B9C0% CTL0268% cydA% cytochrome%d%ubiquinol%oxidase%
subunit%I%%
117% 3% Energy%
Metabolism%
B0B7Q9% CTL0594% %% 22oxoisovalerate%dehydrogenase%
alpha%subunit%%
26% 3% Energy%
Metabolism%
B0B868% CTL0756% %% putative%nucleotide%transport%
protein%%
70% 4% Energy%
Metabolism%
B0B8V9% CTL0102% %% putative%exported%protein%% 33% 2% Exported%protein%
B0B9I1% CTL0329% %% exported%protein%% 14% 2% Exported%protein%Chapter 5    Quantitative analysis of C. trachomatis 
   
160 
B0B7M7% CTL0563% %% putative%exported%protein%% 41% 2% Exported%protein%
B0B7S4% CTL0609% %% putative%exported%protein% 22% 4% Exported%protein%
B0B7V9% CTL0645% %% putative%exported%protein%% 72% 2% Exported%protein%
B0B8E7% CTL0836% %% putative%exported%protein%% 38% 2% Exported%protein%
B0B909% CTL0152% %% putative%exported%protein%% 55% 4% Translation%
B0B9V6% CTL0458% %% conserved%hypothetical%protein%% 1% 2% Fatty%Acid%&%
Phospholipid%
Metabolism%
B0B8U4% CTL0087% %% conserved%hypothetical%protein% 14% 2% hypothetical%
protein%
B0B9Q0% CTL0397% %% conserved%hypothetical%protein%% 80% 4% hypothetical%
protein%
B0B7H1% CTL0507% %% conserved%hypothetical%protein% 8% 2% hypothetical%
protein%
B0B7H9% CTL0515% %% conserved%hypothetical%protein%% 21% 2% hypothetical%
protein%
B0B7J9% CTL0535% %% conserved%hypothetical%protein%% 29% 2% hypothetical%
protein%
B0B9L7% CTL0364% %% conserved%hypothetical%protein%% 30% 2% hypothetical%
protein%
B0B9X3% CTL0475% %% candidate%inclusion%membrane%
protein%
47% 3% Other%Categories%
B0B7H4% CTL0510% %% putative%cysteine%desulfurase%% 17% 3% Other%Categories%
B0B7U4% CTL0629% %% putative%oxidoreductase% 25% 3% Other%Categories%
B0B7U9% CTL0635% phnP% metal2dependent%hydrolase%% 23% 2% Other%Categories%
B0B831% CTL0718% %% ribosomal2protein2alanine%
acetyltransferase%
31% 2% Other%Categories%
B0B835% CTL0722% ispD% 22C2methyl2D2erythritol%42
phosphate%cytidylyltransferase%%
25% 4% Other%Categories%
B0B837% CTL0724% %% hydrolase_%haloacid%
dehalogenase2like%family%%
68% 3% Other%Categories%
B0B860% CTL0748% %% methyltransferase%% 19% 3% Other%Categories%
BOBCM2% pL2204% %% Putative%uncharacterized%protein% 39% 2% Plasmid%
B0B7W4% CTL0650% hrcA% Putative%transcriptional%
regulatory%protein%%
63% 4% Transcription%
B0B7X3% CTL0660% %% 23S%rRNA%methyltransferase%% 8% 2% Transcription%
B0B8T2% CTL0075% clpP% ATP2dependent%Clp%protease%% 58% 3% Translation%Chapter 5    Quantitative analysis of C. trachomatis 
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After further filtering; where a protein was required to be present in at least 3 replicates, 436 proteins 
were found to be common to both EBs and RBs. The relative protein expression ratios for each of these 
proteins were calculated from their respective mean absolute quantity values in > 3 replicates. Figure 5.12 
shows  the  relative  expression  profile  for  these  regulated  proteins.  A  cut-off  value  of  regulation  was 
considered to be 30% fold-change, an average fold-change between -0.30 and 0.30 on a natural log scale 
(±1.3 fold-change), a value that is 2-3 times the estimated error on the intensity measurement (Vissers et al., 
2007). A list of all proteins along with their quantitative information can be found in Appendix 1, Table 5.2. 
 
 
B0B9U7% CTL0449% gcp% O2sialoglycoprotein%
endopeptidase%
20% 2% Translation%
B0B848% CTL0736% pheT% phenylalanyl2tRNA%synthetase%
beta%chain%%
46% 2% Translation%
B0B8R6% CTL0059% dppD% ABC%transport%protein_%ATPase%
component%%
29% 2% Transport%and%
binding%Proteins%
B0B947% CTL0190% %% tyrosine2specific%transport%
protein%%
52% 2% Transport%and%
binding%Proteins%
B0B986% CTL0231% %% sulfate%transporter%% 47% 2% Transport%and%
binding%Proteins%
B0B9E1% CTL0289% %% putative%membrane%
transport/efflux%protein%
15% 3% Transport%and%
binding%Proteins%
B0B7Y5% CTL0672% %% metal%transporter_%metal2
binding%component%%
15% 2% Transport%and%
binding%Proteins%
B0B852% CTL0740% oppB2% oligopeptide%transport%system%
membrane%permease%%
55% 3% Transport%and%
binding%Proteins%
B0B8H3% CTL0862% tolB% outer%membrane%component%of%
membrane%transport%system%
18% 3% Transport%and%
binding%Proteins%
b)%EB%Proteins% %% %% %% %% %% %%
B0B8J5% CTL0884% %% conserved%hypothetical%protein%% 25% 2% hypothetical%
protein%
B0B7Z4% CTL0681% %% conserved%hypothetical%protein%% 46% 2% hypothetical%
protein%
B0B9D4% CTL0282% trmD% tRNA%(guanine2N(1)2)2
methyltransferase%
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B0B9C9% CTL0277% rpmE% LSU%ribosomal%protein%L31P%% 23% 2% Translation%
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Figure 5.12. Label-free protein expression profile of RBs (15 h PI) and EBs (48 h PI) from C. trachomatis 
L2. A log(e) scaled plot of the mean protein ratios from EB to RB. Protein number is defined as the rank of 
the protein sorted according to expression ratio. 
 
Figure 5.6 showed the distribution of quantitative data obtained using the two approaches. In contrast 
to iTRAQ where quantitative information was obtained for only 50% of the proteins assigned (169 out of the 
335 proteins), the Label-free approach provided extensive proteome coverage, with quantitative data for 
~84% of its identified proteins, representing 489 proteins. 
 
A comparison of the expression ratios obtained for the overlapping quantitative data between the two 
different approaches showed a poor correlation with an R
2 value of only 0.060 (Figure 5.13). Interrogation of 
the raw data for the label-free approach showed good correlation between technical replicates as shown 
earlier in Figure 5.11. However, closer examination of the iTRAQ reporter ion ratios obtained for peptides 
assigned to a specific protein often showed disparity. Figures 5.14 and 5.15 represent the distribution of 
peptide reporter ion ratios obtained for a selection of both the up- and down-regulated proteins. These graphs 
highlight the significant variation observed between iTRAQ peptide ratios used to calculate a quantitative 
value for a specific protein. The factors likely to contribute to these variations include; the possible post-
translational modification of a peptide(s), co-fragmentation of peptides or the mis-assignment of a peptide to 
a protein by the Mascot algorithm. For abundant proteins where there are a large number of iTRAQ peptides 
assigned to a protein, there is a general correlation between the iTRAQ and label-free data, although the 
iTRAQ expression changes generally appear lower in magnitude.  
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Figure 5.13. Correlation of protein expression ratios obtained from iTRAQ and the label-free method. Data 
has been transformed onto a log(e) scale. 
 
Figure  5.14.  The  distribution  of  iTRAQ  peptide  ratios  obtained  for  proteins  up-regulated  in  EBs  when 
compared to RBs (Table 5.2). Ratios represented are a mean average of two biological replicates. 
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Figure 5.15.  The distribution of iTRAQ peptide ratios obtained for proteins down-regulated in EBs when 
compared to RBs (see Table 5.3). Ratios represented are a mean average of two biological replicates. 
 
5.5.3 In silico characterisation of proteins 
Identified  proteins  from  both  iTRAQ  and  the  label-free  approach  were  categorized  according  to 
cellular function (Figure 5.16) as described in section 2.8.4. Further comparison of the functional distribution 
between these proteins assigned using label-free, iTRAQ and the qualitative techniques; MudPIT and GeLC-
MS/MS presented in Chapter 4, are also shown in Figure 5.17. The correlation of predicted charge (pI) and 
molecular mass profiles of the predicted chlamydial proteome with the distribution profiles obtained from the 
experimentally  assigned  proteins  for  the  iTRAQ  data  are  shown  in  Figure  5.18a  and  Figure  5.18b 
respectively. The pI profile was typical of the bimodal arrangement observed for other bacterial proteomes, 
with the majority of proteins focused between pI 4-7 and pI 9-11 (Schwartz et al., 2001) (similar profiles 
were  also  obtained  for  the  label-free  approach,  data  not  shown).  These  profiles  and  the  highly  similar 
distribution of proteins across the functional categories between technologies, including those presented in 
Chapter  4,  support  the  idea  that  peptide  sampling  is  relatively  unbiased  using  these  two  quantitative 
approaches. 
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Figure  5.16.  Comparison  of  the  distribution  of  identified  proteins  between  the  label-free  and  iTRAQ 
approaches according to functional category. 
 
 
 
Figure 5.17. Comparison of the distribution of proteins assigned from the label-free, iTRAQ and qualitative 
approaches presented in Chapter 4 according to functional category.  Qualitative data consists of GeLC-
MS/MS, MudPIT and 2-DGE from both EB and RB of C. trachomatis L2. Both qualitative and quantitative 
data was included from both the label-free and iTRAQ approaches. 
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a) iTRAQ experimental data 
 
b) Theoretical data 
 
Figure 5.18. Molecular weight and pI distributions for iTRAQ data from C. trachomatis L2. Graph a) shows 
the molecular weight and pI profile for the experimental iTRAQ data and graph b), the theoretical molecular 
mass and pI distribution for the C. trachomatis L2/434/Bu proteome. 
 
The measurement of protein quantity in absolute amounts (molecules/cell) offered the opportunity to 
calculate, to a first approximation, the total amount of energy expended in synthesizing a specific protein 
within a cell. It has been reported that 60 kcal/mol are required to extend a nascent polypeptide chain by a 
single amino acid (Szaflarski and Nierhaus, 2007). This energy expenditure arises from (i) the synthesis of a 
codon encoding a specific amino acid, (ii) the charging of the tRNA by its synthetase with the cognate amino 
acid, and (iii) the incorporation of the amino acid into the nascent polypeptide chain. The required energy for 
this process is generated from the hydrolysis of 10 energy-rich bonds in the form of either ATP or GTP, each 
with an energy content of about ΔG = -6 kcal/mol. Therefore, by calculating the number of constituent amino 
acids that make-up a specific protein and using the avogadro constant, the amount of energy required to 
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synthesize  a  single  molecule  of  that  protein  can  be  calculated.  Knowing  the  total  number  of  molecules 
synthesised  during  the  transition  from  RB  to  EB  has  permitted  the  amount  of  energy  expended  in 
synthesizing  specific  proteins  to  be  calculated.  This  energy  expenditure  has  been  expressed  in  terms  of 
functional distribution and is shown in Figures 5.19 and 5.20. 
 
Figure 5.19. Energy expended synthesizing proteins in C. trachomatis L2 during the transition from RB to 
EB represented as functional category. The number of proteins for each category are indicated above each 
column. 
 
Figure 5.20. Percentage of the total energy expended synthesizing proteins during the transition from RB to 
EB according to functional category.  Chapter 5    Quantitative analysis of C. trachomatis 
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The energy in kcal/mol required to synthesise the total number of molecules from each different 
protein expressed in C. trachomatis L2 was calculated for each protein that was up-regulated in EBs. Proteins 
were grouped according to functional category and the energy values for each protein within that functional 
category summed. The majority of the energy expended synthesizing new proteins fell into three functional 
categories, cell envelope, hypothetical proteins and protein translation (see Figures 5.19 and 5.20).  
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5.6 Discussion 
 
This chapter presents a quantitative analysis of the C. trachomatis L2 proteome during the late stages 
of  the  developmental  cycle  when  RBs  re-organise  to  EBs.  The  study  has  exploited  two  quantitative 
technologies; the multiplex isobaric labeling technology iTRAQ in combination with multidimensional liquid 
chromatography;  and  a  label-free  approach  combining  2D–RP-RP  UPLC  and  the  data  independent 
acquisition method MS
E. To the best of the author’s knowledge, both captured datasets represent the largest 
quantitative proteomic studies of chlamydiae to date. 
 
5.6.1 Comparison of technologies 
Although iTRAQ and the label-free approach allow qualitative and quantitative data to be collected 
concurrently,  the  multiplex  nature  of  iTRAQ  allowed  the  simultaneous  analysis  of  4  samples,  whereas 
samples using the label-free methodology were analysed consecutively. The demands on MS instrument time 
for  both  technologies  are  high  and  comparable,  with  the  label-free  and  iTRAQ  taking  88  and  82  hrs, 
respectively, for four samples. However, recently, the iTRAQ approach has been extended to allow the 
analysis of up to 8 samples within the same experiment (Choe et al., 2007), doubling the sample throughput 
without increasing MS instrument time. Although the same number of samples could be analysed using the 
label-free approach, this would require double the amount of MS instrument time (176 hrs). But, at the 
expense of MS machine time, there is no limit on the number of samples that can be analysed and compared 
by the MS
E technology per se. 
  
Between the two technologies, the amount of protein required to generate an adequate dataset varied 
considerably, with only 9.0 µg of protein required for the analysis of each label-free sample, compared to 
~100 µg for each individual iTRAQ labelled sample. These lower sample requirements of the label-free 
system  offer  a  clear  advantage,  particularly  when  sample  amounts  are  limiting.  The  lower  sample 
requirements of the label-free approach may allow additional replicate analyses to be performed, thereby 
improving confidence in the collected datasets (Chong et al., 2006) or allowing the analysis of biological 
samples where previously low sample yield would have negated their analysis. 
 
A potential disadvantage of the label-free approach is its reliance on reproducible high-resolution 
chromatographic  separation  and  exact  mass  measurement  of  samples  to  allow  precursor/fragment  ion 
correlation and peak/peptide matching from sample to sample. Nonetheless, the technology showed excellent 
reproducibility between technical replicates, with 87% of identified proteins providing quantitative data. By 
contrast, although the iTRAQ technology showed good peptide replication between samples, a characteristic 
intrinsic  to  multiplex  technologies,  only  ~50%  of  identified  proteins  yielded  quantitative  data  after 
appropriate filtering. 
 Chapter 5    Quantitative analysis of C. trachomatis 
   
170 
This significant difference can be attributed to a number of factors: (i) the number of peptides used to 
assign proteins. The average number of peptides used to assign a protein using iTRAQ was 10, compared to 
an average of 46 for the label-free approach, resulting in significantly lower protein sequence coverage for 
the  former  data.  (ii)  the  number  of  peptides  with  sufficient  reporter  ion  information.  For  example,  the 
confident  assignment  of  the  Cysteine-Rich  protein  (OmcB),  which  was  confidently  assigned  with  28 
peptides, provided only 9 peptides with sufficient iTRAQ reporter ion information to calculate the proteins 
expression ratio. (iii) Further compounding this problem are the observed variations in peptide reporter ion 
ratios, which are particularly variable when the number of peptides used to assign, and hence quantify a 
particular protein, are low. For example, where a protein assignment is based upon only two peptides and 
there  are  significant  differences  between  the  observed  reporter  ion  ratios  for  each,  it  is  not  possible  to 
differentiate which peptide ratio represents the true value of the expression change and which is the outlier. 
As such, those proteins with higher numbers of assigned peptides with sufficient reporter ion information will 
provide a more precise quantitative measurement through improved statistical averaging. However, as shown 
earlier in this chapter, the number of peptides used to assign proteins using iTRAQ, were significantly lower 
than those obtained for the label-free approach and the correlation of the expression changes between the two 
technologies was poor. When comparing the correlation of expression changes between the technologies for 
abundant proteins, the direction of change correlates reasonably well, although the magnitude of the iTRAQ 
change generally appears notably less than the label-free data. As iTRAQ has become more adopted as a 
quantitative proteomic technology, there has been some concern on the accuracy of the relative abundance 
estimates  obtained.  Towards  the  end  of  this  study,  more  in-depth  studies  evaluating  the  precision  and 
accuracy of iTRAQ have been reported (Karp et al., 2010; Ow et al., 2009; Wang et al., 2012). These studies 
demonstrated that iTRAQ could provide quantitative data within two orders of magnitude in simple mixtures, 
but suffers from variance in peptide ion ratios in low signal peptides. As these datasets are dominated by low 
signal  peptides,  there  is  a  propensity  towards  one  ratio,  leading  to  an  under-estimation  of  the  relative 
abundance. This under-estimation arises from contamination in precursor ion selection of the peptides for 
MS/MS. However, since this cross-talk is consistent across the experiment, there is a linear relationship 
between the expected and observed ratios, opening-up the opportunity for the development of a corrective 
software solution.   
 
As shown in this Chapter, the label-free technology provided extensive proteome coverage compared 
to iTRAQ (Table 5.6). These improvements are attributed largely to the LCMS
E mode of data acquisition 
employed. Unlike Data-Directed-Acquisitions used in traditional LC-MS/MS, the limitation on the number of 
peptides that can be isolated by the Q-Tof’s quadrupole for fragmentation during the time frame of an eluting 
chromatographic peak, is essentially removed when performing LC-MS
E. Acquiring exact mass MS data 
using an alternating scan function, switching between low and elevated collision energies, provides a data 
independent mode of acquisition allowing thousands of ions to be de-convoluted into a list of precursor and 
their  associated  time-resolved  fragment  ions  that  can  be  searched  against  an  appropriate  database. 
Additionally, since there is no disruption to MS data collection resulting from switching of the quadrupole 
onto selected ions, the low energy spectra can be used to make multiple precursor ion intensity measurements Chapter 5    Quantitative analysis of C. trachomatis 
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across a chromatographic peak, generating accurate reproducible intensity measurements that can be used for 
quantitation.  
 
One  of  the  most  important  distinguishing  characteristics  between  iTRAQ  and  the  label-free 
technology is the ability to use the latters intensity measurements to provide what is considered the gold-
standard of quantitative proteomics, absolute quantitation. By employing the relationship reported by Silva et 
al. (2006b), the average intensity of the top three peptides from the internal standard alcohol dehydrogenase 
was used as a response factor that was applied to all other proteins within each chlamydial protein lysate, 
thereby allowing an estimate of the number of protein copies per cell to be determined. As discussed in 
Chapter 1, several approaches using stable isotopes in combination with separation and MS analysis have 
been described (Gygi et al.,1999a; Conrads et al., 2001). However, such techniques offer only a targeted 
approach to absolute quantitation because they require the synthesis of one or more isotopically labeled 
peptides per protein to be quantified, a technique that is limited for the analysis of highly complex mixtures 
both in terms of cost and time. The ability of this technology to utilize native proteins as internal standards to 
calculate absolute concentration measurements of any characterized protein within a complex mixture is 
extremely powerful. 
 
Therefore, in the light of the absolute quantitation data generated using the label-free technology and 
because of the poor correlation with the obtained iTRAQ data, further discussion will focus on the data 
obtained using the label-free approach. 
 
Table  5.6.  A comparison of the iTRAQ and Label-free approaches using information from the datasets 
generated.  
  iTRAQ (4-plex)  Label-free 
Sample requirements (µg)  100 µg per iTRAQ label 
(400 µg total loading) 
9.0 µg per sample 
(36 µg for 4 samples/replicates) 
Total analysis time  ~6 days (per 4-plex)  ~4 days (4 samples) 
Total instrument time  82 h (per 4-plex)  88 h(4 samples) 
22 h per sample 
Size of data file  41 fractions x ~272 MB 
(11.15 GB per 4-plex) 
 
11 fractions x ~572 MB 
(6.29 GB per sample; 4 samples 
= 25.2 GB) 
No. of proteins confidently identified  335  580 
No. of proteins with quantitative data  169  489 
Type of quantitation  Relative  Absolute 
Average No. of peptides per protein  10  46 
Average protein sequence coverage  26%  64% Chapter 5    Quantitative analysis of C. trachomatis 
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5.6.2 Biological insights 
Six hundred and fifteen C. trachomatis proteins were identified from 16 functional categories using a 
combination of both iTRAQ and label-free, representing ~68% of the total proteins predicted to be expressed 
by the chlamydial genome. Over-represented categories in both RBs and EBs included functions such as cell 
envelope proteins, cellular processes, energy metabolism, hypothetical proteins, DNA replication and protein 
translation. Using the label-free technology, estimates of the average number of protein copies per cell were 
obtained for ~55% of the proteome in both RBs and EBs. However, the significant variation observed in this 
study  between  biological  replicates  and  in  particular  those  from  RB  preparations,  has  limited  in  certain 
instances, the reporting of precise –fold change to observed trends of differential expression. Purification of 
the osmotically fragile RB is challenging. The variation observed between the two biological replicates of 
RBs, is likely to reflect the difficulties in their isolation and purification. Although time-consuming and 
costly, the analysis of an increased number of biological replicates could help improve the measurement of 
this variation. 
5.6.2.1 Outer membrane proteins 
The  structure  of  the  chlamydial  cell  envelope  is  basically  similar  to  that  of  other  gram-negative 
bacteria  with  an  outer  membrane  containing  lipopolysaccharide,  a  periplasm  and  an  inner  membrane. 
Nonetheless, there are two distinct features that are unique to the chlamydiae. These are the absence or, at the 
very most, low levels of peptidoglycan and the prescence of disulphide-bond-cross-linked-proteins making 
up the outer membrane.  
 
DNA  condensation  and  the  formation  of  this  highly  cross-linked  outer  membrane  complex  are  a 
hallmark event in the transition from RB to EB. Genes previously characterized as being expressed during 
these late stage processes include, an integration host factor (ihfA), recA and the histone-like proteins (hctA 
and hctB), implicated in mediating chromosomal condensation (Brickmann et al., 1993; Barry et al., 1993). 
The  Major  Outer  Membrane  Protein  (MOMP),  the  two  cysteine-rich  proteins  OmcA  and  OmcB  and 
predicted thioredoxin disulphide isomerases are recognizable key proteins associated with the formation of 
the highly cross-linked outer membrane complex. Of the nucleoid-associated proteins detected in this study, 
IfhA  showed  a  significant  up-regulation  of  2.3-fold  which  is  consistent  with  gene  expression  studies 
(Nicholson et al., 2003; Zhong et al., 2001b). The histone-like protein HctB was not detected, however, the 
protein  encoded  by  the  hctA  gene  was  detected  and  surprisingly  showed  a  marked  2.7-fold  decrease  in 
expression. Although the detection of this protein has not been reported in previous proteomic studies, this 
observation is contrary to gene expression data where the transcript has been shown to increase in expression 
from 36 hpi (Nicholson et al., 2003). A possible explanation for this disparity may be attributed to the 
function  of  the  histone-like  proteins.  If  these  proteins  perform  similar  functions  to  those  of  other 
characterized  histones,  HctA  maybe  complexed  with  DNA  forming  a  higher–ordered  structure  like 
chromatin. Such structures may make it inaccessible to proteolysis, thus preventing or reducing the detection Chapter 5    Quantitative analysis of C. trachomatis 
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of HctA derived peptides, resulting in an artfactual decrease of observed protein abundance. Alternatively, it 
is also possible that this dense DNA-histone complex may have been partially depleted during the sample 
preparation process. 
 
The highly abundant major outer membrane protein (MOMP) showed only a marginal increase in 
protein expression between 15 and 48 h PI, suggesting the translation of this protein occurs earlier in the 
developmental cycle. This is consistent with mRNA and other protein studies, where the expression of the 
MOMP transcript was maintained from 15 h to 48 h (Belland et al., 2003; Hatch et al., 1984). The largest 
observed  expression  changes  for  the  COMC  associated  proteins  was  the  60  kDa  cysteine-rich  protein 
(OmcB), which was detected in both RBs and EBs. Surprisingly this protein was only detected in EBs in the 
qualitative studies presented in Chapter 4. Similar to the conflicting results obtained for the histone-like 
protein (HctA), this protein also showed a 3.3-fold decrease, contrary to previous observations of an up-
regulation of mRNA transcripts late in the developmental cycle. Hatch et al. (1986) showed that although 
MOMP monomer could be released from the COMC, the 60 kDa cysteine-rich protein could not be reduced 
to monomers even in the presence of reducing agents such as dithiothreitol. It is therefore plausible that 
peptides from OmcB are inaccessible or not efficiently released from the COMC leading to an apparent 
decrease in OmcB peptide/protein expression. 
5.6.2.2 Polymorphic Outer membrane proteins 
Another  unique  set  of  genes  associated  with  the  chlamydial  outer  membrane,  and  that  have  no 
homologue in other bacteria, are the polymorphic outer membrane proteins (Pmps). This study provides a 
quantitative  measure  of  all  nine  putative  polymorphic  outer  membrane  proteins  encoded  by  the  C. 
trachomatis L2/434/Bu genome. The expression of all nine Pmp proteins was down-regulated from 15 to 48 
h PI, ranging between 1.6 and 4.8–fold. This is in agreement with previous gene expression studies where 
transcripts orthologous to all nine of these pmps in L2 were detected early in the developmental cycle at 8 h 
PI (Lindquist and Stephens., 1998) and more recently by Nunes et al. (2007), who showed that all nine 
transcripts were detected as early as 2 h PI. The expression of these transcripts peaked at ~18 h PI, where 
they were stable until 36/48 h PI when the expression levels decreased. Of all the Pmps, PmpA and PmpF 
showed the lowest level of protein expression at 15 h PI and further decreased at 48 h PI, a result that is 
consistent with the maximal transcript expression of PmpA observed before 12 h PI, supporting a role for this 
protein early in the developmental cycle (Nunes et al., 2007). PmpD showed the highest level of protein 
expression in both developmental forms, albeit lower in EBs. By contrast, pmpF showed the highest mRNA 
levels, but the lowest protein expression levels indicating possible post-transcriptional regulation of this gene, 
an observation that is in accordance with the mRNA expression disparities observed for pmpF and pmpE 
between reference strain L2/434 and clinical strains (Nunes et al., 2007). The role of Pmps in chlamydial 
biology and disease pathogenesis is unknown. However, there are some serovar-specific differences between 
the Pmps that may result in differences in virulence and tissue tropism (Longbottom et al., 1998; Gomes et 
al., 2006; Stothard et al., 2003). They are characterized by a C-terminal phenylalanine, GGAI motifs and 
cleavable signal peptides, suggesting they are located in the outer membrane (Struyve et al., 1991). The Pmps 
are considered to be autotransporter proteins, part of the type V secretion pathway and such a function that Chapter 5    Quantitative analysis of C. trachomatis 
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has been experimentally confirmed for PmpD in C. trachomatis and Pmp21, a C. pneumoniae orthologue of 
PmpD from C. trachomatis (Kiselev et al., 2007). Shaw et al. (2002a), detected peptides mapping to the C-
terminal part of the PmpD sequence, suggesting that this protein had been processed in keeping with their 
role as autotransporters. In contrast, we detected peptides mapping the N-terminal, C-terminal and internal 
fragments, with the exception of the signal sequence (Figure 5.21). Indeed, coverage of the N-terminal, C-
terminal and internal fragments were detected for all the Pmp proteins. However, in keeping with their role as 
autotransporters, they may still be processed and the detection of N-terminal and C-terminal fragments could 
simply  reflect  the  high  sensitivity  of  the  technology  used  and  represent  proteins  yet  unprocessed.  This 
observation highlights an advantage in using 2D gel technology, where isoforms can be easily resolved with 
quantitation at the protein level in comparison to other technologies performing quantitation at the peptide 
level, e.g., label-free and iTRAQ approaches.  
 
 
Figure 5.21. Diagram indicating the peptide coverage obtained for the protein PmpD from C. trachomatis L2 
in EBs and RBs using label-free. The ORF of PmpD is indicated in blue. Regions highlighted in purple and 
orange indicate the detection of PmpD peptides in RBs and EBs, respectively.   
5.6.2.3 The Chlamydial cell wall anomaly 
In most bacteria, the cell wall or peptidoglycan (PG) layer is essential, providing structural strength to 
resist osmotic stresses. Previous attempts to detect PG components such as N-acetylmuramic acid (MurNAc) 
in chlamydiae have been unsuccessful, suggesting that the chlamydial cell wall does not contain PG, or if it 
does, in only small amounts. The osmotic stability of EBs is afforded by the highly cross-linked cysteine–rich 
proteins present in the cell envelope, which likely replaces the requirement for a peptidoglycan layer. The 
osmotically  fragile  RB  possess  fewer  cross-linked  proteins.  However,  they  are  protected  from  osmotic 
stresses by the membrane-bound inclusion within the host cell and so may not require the structural strength 
provided by a PG layer. As discussed in Chapter 1, the discovery of a complete set of biosynthetic genes for 
peptidoglycan synthesis in the genome sequence was therefore a surprise and raised the question whether 
these enzymes and their products are synthesized or are they simply genetic remnants. 
 
Peptidoglycan  biosynthesis  in  other  bacteria  occurs  in  three  compartments.  The  precursor,  UDP-
MurNAc pentapeptide is synthesized in the cytoplasm by six enzymes (MurA to MurF). This precursor is 
subsequently transferred to the lipid carrier undecaprenyl phosphate, catalyzed by MraY, to form the first 
membrane bound intermediate, Lipid I.  Catalysed by MurG, Lipid II is synthesized by the addition of UDP-
GlcNAc to Lipid I, followed by translocation into the peptidoglycan structure (Figure 5.22). Gene expression 
studies have shown the expression of mRNA from this set of genes shows a marked increase at 16-18 h PI Chapter 5    Quantitative analysis of C. trachomatis 
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(Nicholson et al., 2003; Belland et al., 2003). At the translational level, only a few PG synthesis enzymes 
have  been  detected.  Previous  studies  have  detected  MurG  and  MurC  in  EBs  (Montigiani  et  al.,  2002; 
Vandahl et al., 2001) and in the qualitative studies presented in Chapter 4, MurE was detected in RBs only. 
The  datasets  presented  in  this  Chapter  and  summarized  in  Table  5.7  provide  further  evidence  for  the 
translation of these enzymes. Specifically, these include MurA, MurC, MurD, and the two penicillin binding 
proteins, whose expression has previously been detected using radiolabelled penicillin (Barbour et al., 1982). 
 
When chlamydiae–infected cells are treated with inhibitors of cell wall synthesis such as penicillin, 
chlamydial replication is halted with the formation of large aberrant RBs, suggesting a role for PG in RBs. 
Since the RB form is most like other gram-negative bacterium, and undergoes division, the presence of PG 
would require remodeling during division and would therefore be susceptible to penicillin treatment. At the 
same time, the osmotically protective niche of the inclusion may mean that, if PG has a role in maintaining 
structural integrity, it is only minimal. With the exception of one unsuccessful attempt to directly detect PG 
in RBs (Barbour et al., 1982), all others have been in EBs since the osmotic fragility of RBs has previously 
prevented their isolation. This is also true for the detection of enzymes involved in PG. However, evidence 
for a peptidoglycan-like structure in RBs has been obtained using immune detection (Brown & Rockey, 
2000). The quantitative data reported here suggests that these enzymes are detected in RBs, and if detected in 
EBs, their expression levels are low, indicated by their presence in only a single replicate compared to RBs. 
Where  detected  in  the  label-free  dataset,  the  amounts  of  these  enzymes  were  low  (MurC  =  42±28 
molecules/RB  and  20±10  molecules/RB).  Assuming  normal  catalytic  efficiencies,  this  suggests  that  PG 
would only be produced in small amounts. This decrease is concomitant with the maintenance in RBs and 
EBs of the glycoside hydrolase, muramidase, which breaks down PG by hydrolyzing the 1,4 beta-linkages 
between N-acetyl-D-glucosamine and N-acetylmuramic acid.  So what is the role of PG? Chlamydiae have 
reduced  their  genome  size  to  become  an  efficient  intracellular  organism;  therefore,  why  expend  energy 
synthesizing these enzymes unless PG is required? It has previously been proposed that PG plays a role in 
cell division (Chopra et al., 1998) and that PG in the absence of the FtsZ homologue (a conserved tubulin-
like protein that polymerizes into ring-structures at the mid-cell of dividing cells) provides a replacement 
role. The data presented shows that maximal expression of these enzymes occurs in RB at 15 h PI, albeit at 
low levels, supporting an alternative role for PG in RBs such as cell division. 
 
Another possible role for PG may be in host cell signaling. Since PG is unique to bacteria, innate 
immunity systems of the host detect liberated PG fragments via specific receptors and subsequently initiate 
an immune response. The major family of receptors that sense PG and other bacterial components include the 
Toll-like receptors (TLRs) and Nod-like receptors (NLRs) (Chen et al., 2009; Takeda et al., 2003; Girardin et 
al., 2003). As such, bacterial systems have evolved mechanisms to evade or subvert such pathways to allow 
replication and minimize non-advantageous host responses. These mechanisms include additional structures 
on the cell surface, to reduce PG break down, and modification of the PG structure to prevent degradation by 
host cell enzymes. Several studies have also shown that signaling of the NLR receptor, Nod1, can be altered 
by arresting the release of Nod1 signaling ligands by modifying PG and preventing its degradation (Boneca 
et al., 2007; Shimada et al., 2010). There is also some evidence that signaling and initiating a modified host Chapter 5    Quantitative analysis of C. trachomatis 
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response can be beneficial to the bacterium. For example, initiating a response that recruits certain host cells 
to the site of infection can provide a replicative niche for intracellular pathogens (Girardin et al., 2003). 
Could it be that Chlamydiae produce a PG with modified structures that once released, initiates an altered 
immune  response  that  benefits  this  pathogen?  This  could  be  either  through  evading  certain  unfavorable 
pathways or by recruiting host cells to initiate the next round of infection, thereby ensuring the shortest time 
in the harsh environment outside the host cell. The higher expression of the PG enzymes in RBs, compared to 
EBs, could indicate that synthesis of a modified PG structure occurs in RBs. This structure may be prepared 
in readiness for hydrolysis in EBs by muramidase, and the resulting fragments could subsequently initiate a 
modified  host  response  that  is  beneficial  to  chlamydiae.  However,  the  definitive  role(s)  of  PG  and  its 
associated biosynthetic enzymes still remains unclear. The recent development of a genetic transformation 
system  for  C.  trachomatis  (Wang  et  al.,  2011)  provides  the  opportunity  to  resolve  the  role  of  PG  in 
Chlamydia. 
 
 
Table 5.7. Peptidoglycan biosynthetic enzymes expressed in C. trachomatis L2 
Protein  Observed in RB  Observed in EB  Technique 
MurA  Yes*  Yes*  iTRAQ (qualitative) 
MurB  No  No  n/a 
MurC  Yes 
(42 molecules/cell) 
 
 
ND 
Yes 
(22 molecules/cell) 
 
 
Yes 
Label-free 
 
Previously detected 
(Vandahl et al., 2001) 
MurD  Yes 
(20 molecules/cell) 
No  Label free 
iTRAQ (qualitative) 
MurE  Yes  No  Qualitative (chapter 4) 
MurF  No  No  n/a 
MurG  No  No  Detected in Ebs from previous 
study (Montigiani et al., 2002) 
PBP  No  Yes  Label-free(qualitative) 
PBPB  Yes*  Yes*  iTRAQ (qualitative) 
 
* Unable to determine whether detected in EBs or RBs due to multiplex nature of iTRAQ. 
 
 
 
 
      
 
Figure 5.22. A schematic representation of the proposed chlamydial peptidoglycan biosynthesis pathway and related genes. 
The precursor, UDP-MurNAc pentapeptide is synthesized in the cytoplasm by six enzymes (MurA to Mur F). This precursor is subsequently transferred to the lipid carrier 
undecaprenyl phosphate catalyzed by MraY to form the first membrane bound intermediate, Lipid I. Catalysed by MurG, Lipid II is synthesized by the addition of UDP-
GlcNAc to Lipid I, followed by translocation into the peptidoglycan structure.  
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5.6.2.3 Type III secretion 
Chapter 4 identified seven predicted proteins associated with the chlamydial TTSS. An additional 37 
proteins were identified in this quantitative study, providing further support for the idea that this organism 
expresses a functional TTSS. The Chlamydiaceae encode between 20 to 30 genes for structural proteins and 
chaperones of the TTSS depending upon the species. However, the minimal set of proteins that constitutes a 
functional apparatus still remains unclear (Peters et al., 2007; Hefty and Stephens, 2007). Fifteen structural 
proteins (Table 5.8), 4 chaperones and 25 effector proteins of the TTSS were detected and quantified in this 
study. TTSS chlamydial effector proteins unlike in other pathogens are distributed throughout the genome. 
The considerable efforts to determine exactly how many there are and the elucidation of their functions, is 
still ongoing work (Subtil et al., 2001; Fields et al., 2003; Fields et al., 2005; Lugert et al., 2004; Clifton et 
al.,  2005;  Subtil  et  al.,  2005;  Jamison  and  Hackstadt,  2008;  Kleba  and  Stephens,  2008;  reviewed  by 
Beeckman and Vanrompay, 2010). Nonetheless, several elegant studies have demonstrated the secretion and 
localization of predicted effector proteins. These include the inclusion membrane protein IncA, which was 
shown to localize to the cytoplasmic side of the inclusion membrane in both C. trachomatis and C. psittaci 
(Bannatine et al., 1998; Rockey et al., 1997) and the predicted C. pneumoniae proteins IncA, IncB, IncC, 
Cpn0809, Cpn1020, SctN, SctW and LcrH1. These have all been indicated to be secreted into the chlamydial 
inclusion (reviewed by Beeckman and Vanrompay 2010). 
 
Electron microscopic studies revealed a patch of type-III-like structures on the chlamydial surface. In C. 
psittaci, the mean number of these projections was 45 in RB at 10 h PI, decreasing to 20 in late RBs (20 h PI) 
and leveling to about 18 later in EBs at 48 h PI (Matsumoto, 1982). The expression levels of the predicted 
structural TTSS proteins  shown  in  Table 5.8,  with  the  exception  of  SctW,  were generally  expressed  at 
reduced levels in the late stage (48 h PI) of infection and in some cases, were only present in RBs at 15 h PI. 
This observation is consistent with an observed decrease in the type-III-like apparatus later in the cycle. 
Similarly,  the  predicted  effector  proteins,  including  IncA,  IncE,  IncG,  IncC,  and  7  additional  predicted 
inclusion  membrane  proteins  (not  detected  in  the  qualitative  studies  presented  in  Chapter  4)  were  also 
detected and, where quantitative data was available, they showed decreased levels of expression in EBs, 
indicating that they may have been secreted. The exception to this was the effector chaperone Mcsc, which 
was equally abundant in both RBs and EBs and the effector protein CADD, which was more abundant in 
EBs.  
 
A proposed hypothesis consistent with these observations is that these type-III-like projections are 
induced/or activated upon contact of the RBs with the juxtaposed inclusion membrane. Activation during the 
early transition from EB to RB, allows the delivery of effector proteins, until detachment of RBs from the 
inclusion and subsequent deactivation of the type-III apparatus later in the developmental cycle (Bavoil and 
Hsia., 1998). In addition to the Inc proteins, the predicted type III effector proteins CopD, CopB CopN and 
Pkn5 were also expressed in both EBs and RBs, with the exception of Pkn5, which was only detected in RBs. 
The  translocation  of  these  chlamydial  effector  proteins  has  been  demonstrated  by  the  Salmonella Chapter 5    Quantitative analysis of C. trachomatis 
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Typhimurium type III secretion systems (Ho and Starnbach, 2005) and CopD has previously been shown to 
be  abundant  in  EBs  (Fields  et  al.,  2003;  Shaw  et  al.,  2002a).  Interestingly,  the  effector  protein  CADD 
(Chlamydia protein associating with death domains) has previously been shown to be expressed late in the 
developmental cycle and to modulate host cell apoptosis (Stenner-Liewen et al., 2002). In keeping with this, 
an  increased  expression  of  this  TTSS  protein  was  observed  in  EBs  at  48  h  PI.  This  data  confirms  the 
expression of the predicted effector proteins CopD, CopB, CopN, Pkn5 and CADD in Chlamydia.  
 
A functional TTSS is also supported at the initial stages of infection by the presence of a predicted 
type-III effector protein, TARP. This protein is translocated into the host cell and phosphorylated, directly 
nucleating actin filament formation, promoting rapid filament polymerization essential for EB entry (Jewett 
et al., 2006). It is likely that there are many other proteins that are also translocated during the early stages to 
assist in EB entry, avoiding the innate immune responses and modulating maturation of the EB-containing 
endosome. It has been hypothesized that these early stage effector proteins such as TARP are synthesized at 
the later stages of the cycle and are pre-packaged into EBs and ready-to-go for translocation into the host 
upon attachment. Contrary to this, we observed a 2.5 -fold decrease in the levels of TARP from 15 to 48 h PI. 
However, it is unknown whether TARP functions at any other point within the developmental cycle and the 
observed fluctuations could simply reflect a modulation of protein levels according to demand. As discussed 
later in this Chapter, another possible hypothesis is that EBs are not as metabolically inert as originally 
proposed. In addition to certain proteins being synthesized and ready-to-go during the later stages, there may 
be a low level of protein synthesis in the extracellular form. 
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Table 5.8 Structural proteins of the Type III secretion apparatus identified. 
IM: inner membrane; OM: outer membrane; CP: cytoplasmic; MA: membrane associated; HCM: host cell 
membrane; TL: translocon component. Nomenclature adapted from Beeckman and Vanrompay, (2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.6.2.4 Energy metabolism 
Genome  sequencing  has  changed  our  view  of  central  metabolism  in  the  chlamydiae.  Originally 
thought to be energy parasites, incapable of synthesizing their own ATP and dependent on ATP and high-
energy metabolites from the host cell (Moulder et al., 1962), it was a surprise when genes for an intact 
glycolytic pathway were discovered. But, like the peptidoglycan anomaly, it has not been clear whether these 
predicted genes are expressed at the level of translation. Chapter 4 reported the detection of an entire set of 
predicted components of the glycolytic pathway, in addition to the predicted enzymes of a partial TCA cycle 
and a complete pentose phosphate pathway. Vandahl et al. (2001) also reported the detection in EBs of seven 
enzymes involved in glycolysis and three in each of the pentose phosphate pathway and partial TCA cycle. A 
number  of  these  recombinant  chlamydial  enzymes,  including  pyruvate  kinase  (PK),  glyceraldehyde-3-
Locus  Protein name  RB 
molecules/cell 
EB 
molecules/cell 
Location 
CTL0345  SctV/LcrD/CdsV  252±132  65±20  IM 
CTL0344  SctW/LcrE/CopN  54±11  42±18  Secreted 
CTL0038  SctN/CdsN  91±11  45±18  CP:MA 
CTL0041  SctQ/CdsQ  162±68  54±10  IM 
CTL0825  SctR/CdsR  32±16  ND  IM 
CTL0826  SctS/CdS  ND  ND  IM 
CTL0827  ScT/CdsT  ND  ND  IM 
CTL0036  SctU/CdsU  33±10  ND  IM 
CTL0043  SctC/CdsC  260±125  75±12  OM 
CTL0033  SctD/CdsD  924±441  341±7  IM 
CTL0035  SctF/CdsF  ND  ND  Needle 
CTL0822  SctJ/CdsJ  566±249  228±24  IM & OM 
CTL0824  SctL/CdsL  159±35  115±27  CP 
CTL0841  CopB  73±8  31±5  HCM 
CTL0842  CopD  134±21  76±12  HCM   TL 
CTL0238  LcrV  70±14  55±28  HCM   TL Chapter 5    Quantitative analysis of C. trachomatis 
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phosphate dehydrogenase (GAPDH), phosphoglycerate kinase (PK) and glucose-6-phosphate dehydrogenase 
(ZWF) have also been cloned, expressed and shown to be functional in E. coli (Iliffe-Lee and McClarty, 
1999).  The  quantitative  measurements  in  this  study  indicate  that  these  glucose  metabolism  enzymes, 
including the ADP/ATP translocase, are at their most abundant in the metabolically active RB form (15 h PI), 
and show a general trend for decreased levels of expression in EBs (48 h PI). A summary of the expression 
levels of these glycolytic enzymes is shown in Figure 5.23. Despite the higher levels of these enzymes in 
RBs,  the  abundance  of  these  enzymes  in  EBs  is  still  significant,  indicating  that  chlamydiae  have  the 
capability to generate ATP via substrate-level phosphorylation throughout most of their developmental cycle. 
This  is  consistent  with  previous  RT-PCR  results,  which  showed  maximal  expression  of  the  genes  PK, 
GAPDH, PGK and ZWF in RBs (Iliffe-Lee and McClarty, 1999). It has been demonstrated that EBs contain 
large pools of ATP (Tipples and McClarty, 1993) but, unlike RBs, they are unable to obtain ATP from the 
host cell via the ATP/ADP translocase (Hatch et al., 1982). The expression of these enzymes for glucose 
metabolism strongly suggests that both RBs and EBs are capable of producing ATP. This supports the 
hypothesis that chlamydia may build up and store ATP using pre-existing enzymes in the extracellular stage. 
This in turn may aid survival outside the host and/or be of importance during the initial stages of infection 
and subsequent differentiation into RBs. On initiation of infection, chlamydiae begin their transition to the 
metabolically active RB, with a higher energy requirement for replication. ATP demands therefore increase 
and hence the levels of glucose metabolism enzymes increases with further fueling, using host cell ATP 
obtained via the ADP/ATP translocase. While  these  results  still  do  not  answer  whether  chlamydiae  can 
survive independently of host ATP, they question the dogma of a metabolically inert extracellular form. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
  
Figure 5.23. Representation of the glycolytic pathway 
in C. trachomatis L2 and associated expression levels 
of each glycolytic enzyme from 15 to 48 h PI. There is no 
Hexokinase homolog in the C. trachomatis L2 genome.  
Adapted''from'Wikipedia.'Retrieved'10th'August,'2011 
from'http://wikipedia.org/wiki/glycolysis 
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5.6.2.4 Global proteome expression profile 
In light of the clear phenotypic differences between the two transitional forms of C. trachomatis, 
differences in protein expression between the two forms are to be expected. Mukhopadhyay et al. (2006) 
previously  demonstrated  using  2-DGE  combined  with  pulse-labeling,  the  differential  expression  of  35 
proteins in the respiratory pathogen C. pneumoniae during the transition from RB to EB, with a range of 
expression from a 4.6 down- to 14.8 fold up-regulation. By comparison, the range of expression observed for 
C. trachomatis L2 was 8.3 down- to 3.5 fold up-regulation. Although the expression differences between the 
two  experimental  datasets  could  be  attributed  to  strain  variation  between  C.  trachomatis  L2  and  C. 
pneumoniae,  it  is  also  probable  that  they  are  as  a  consequence  of  the  intrinsic  differences  between  the 
technologies  used  in  each  study.  Since  pulse-labeling  2-DGE  techniques  do  not  allow  the  detection  of 
proteins prior to the addition of radiolabel, they are unable to provide a measure of the abundance of any pre-
existing  proteins.  Hence,  in  the  case  of  the  C.  pneumoniae  study,  proteins  synthesized  earlier  in  the 
developmental cycle prior to radiolabeling are not represented. Because of this constraint, if the rates of 
synthesis and degradation for a particular protein are similar, although a pulse-labeling 2-DGE experiment 
may  indicate  an  apparent  increase  in  protein  abundance,  the  net  change  when  taking  into  account  the 
abundance of a protein prior to the pulse may only be subtle. Since the label-free technology is not reliant 
upon  the  metabolic  incorporation  of  a  label,  this  constraint  is  circumvented  and  is  likely  to  be  more 
representative of the protein changes occurring. 
 
As highlighted by the shotgun studies of the two developmental forms presented in Chapter 4, both 
RBs  and  EBs  were  highly  represented  by  proteins  involved  in  protein  metabolism,  transcription  and 
translation. The presence of these functional classes of proteins in the metabolically active replicating RBs 
was not surprising, but their detection in metabolically inert EBs was unexpected. Albeit, in the absence of 
quantitative data, the levels at which they exist could simply reflect low-level residual RB proteins. The 
functional  categories  of  the  proteins  assigned  in  this  quantitative  study  reflect  those  obtained  in  the 
qualitative studies presented in Chapter 4. However, when considering the differential expression or further, 
the proteins that Chlamydia expends energy synthesizing during the transition from RB to EB, the profile is 
quite different. 
 
The availability of absolute quantitation data has allowed, to a first approximation, an estimation of 
the  amount  of  energy  required  to  synthesize  a  specific  protein  within  a  chlamydial  cell.  The  functional 
distribution of this expended energy falls into three main categories, cell envelope formation, hypothetical 
proteins and proteins involved in protein translation. Interestingly, the majority of the energy expended in 
cell envelope formation can be attributed to the Major Outer Membrane Protein. Although the increased 
expression  of  MOMP  in  EBs  is  relatively  low  (1.3  fold),  the  high  abundance  of  MOMP  (≥2000 
molecules/RB and  2700 molecules/EB) equates to a greater number of molecules synthesized per cell, 
representing a significant energy burden upon chlamydia. The infectious EB exists as a tough spore-like 
particle whose role is to provide protection in the harsh conditions outside the host cell. As such, the energy 
expended in synthesizing MOMP to maintain the outer cell envelope is likely to be an essential requirement. Chapter 5    Quantitative analysis of C. trachomatis 
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Previous studies have reported EBs to be metabolically inert (reviewed by Moulder, 1991). The observed 
trend for the down-regulation of proteins in EBs was therefore not surprising and likely reflects the period 
when  chlamydia  begins  shutting  down  its  metabolic  processes  in  preparation  for  survival  in  the  harsh 
environment outside the host cell. However, the synthesis of proteins attributed mainly to protein translation 
(32) and hypothetical proteins (27) were unexpected (Figure 5.19). 
 
The hypothetical proteins showed some of the largest changes in protein expression observed in this 
study, ranging from 3.6 fold down-regulation (CTL0255) to the up-regulation of 27 proteins ranging from 1.3 
to 3.5 fold (CTL0869) in EBs. A number of these proteins were also highly abundant. By the same token that 
energy  expended  synthesizing  MOMP  is  important  for  survival  outside  the  host  cell,  using  energy 
synthesizing these uncharacterized chlamydial proteins also suggests that they too may play an essential role 
in EB maturation, survival outside the host cell and/or infection. Further characterization of these proteins 
will clearly be an important step in understanding the roles they play in chlamydial biology. 
 
The subtle increased  expression  or  maintenance  of  ribosomal  proteins  in  EBs  (Figure 5.20)  also 
presents a significant energy burden. This highlights the necessity for chlamydiae to have an expressed 
protein translation system in EBs. Why? Interestingly, the mRNA expression profiles of C. trachomatis 
indicate  the  expression  and  maintenance  of  nearly  all  transcripts  from  16  h  onwards  to  the  end  of  the 
developmental cycle. Subsets of these transcripts  are  ‘carried over’ into infectious EBs  and others have 
proposed that these “maternal mRNAs” are being stored and are ‘ready-to-go’ with translation initiated upon 
infection (Plaunt & Hatch, 1988). Further support for this proposal comes from the surprisingly low number 
of new genes expressed early in the developmental cycle (<6 h) when EBs reorganize to RBs. The immediate 
translation  of  these  stored  transcripts  would  clearly  be  advantageous  to  chlamydia’s  rapid  and  effective 
invasion of its host cell. However, such a system would require the necessary molecular machinery for the 
immediate translation of these stored transcripts. The data presented in this thesis suggests that EBs contain 
pre-packaged proteins that could provide the necessary molecular machinery for the immediate translation of 
early genes, essentially priming chlamydiae at the mRNA and protein level so that they can quickly capitalize 
on contact with a host cell. 
 
Analogous storage and ‘ready-to-go’ systems have been proposed for other organisms such as those 
reported for spores of the yeast Saccharomyces cerevisiae (Xu and West, 1992). Germinating yeast spores 
were shown to initiate protein synthesis within 20 min and transcription later at 70 min after the addition of 
glucose, indicating the presence of mRNA available for immediate translation. However, a more recent study 
of  mRNA  turnover  during  yeast  sporulation  reported  the  initiation  of  transcription  and  translation  at 
considerably earlier time points than the previously reported 70 min (Brengues et al., 2002). Moreover, 
newly synthesized molecules were detected within spores previously thought to be metabolically inert. They 
postulated that these spores maintained a basal level of transcriptional and translational activity, with low 
levels of turnover, which were highly boosted upon spore germination, a process possibly important for spore Chapter 5    Quantitative analysis of C. trachomatis 
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survival. Like the yeast spores, EBs are considered metabolically inert (Hatch et al., 1985). However, is it 
possible that EBs are not quiescent cells, but maintain a basal level of metabolic activity similar to yeast?  
 
The survival of Chlamydia ultimately depends upon attachment and uptake into the host cell to create 
a niche suitable for replication. As such it requires rapid and efficient mechanisms to effect uptake and to 
subvert host cell defenses. The question therefore remains whether chlamydiae create all their necessary 
molecular machinery for infection de novo or have systems primed and ‘ready-to-go’. Such systems have 
already  been  proposed  for  C.  trachomatis  at  the  level  of  transcription.  However,  the  proteomic  studies 
presented in this thesis provide both qualitative and quantitative evidence that chlamydiae may indeed be 
primed and ‘ready-to-go’ at the protein level. 
 
 
5.6.3 Addendum  
During  the  final  stages  of  preparation  of  this  thesis,  Saka  et  al.  (2011)  reported  a  label-free 
quantitative proteomic analysis of C. trachomatis L2/434/BU, comparing RBs and EBs. This has offered the 
opportunity to compare, where possible, the label-free proteomic dataset presented in this chapter with this 
recently published study. However, it is important to note, as Saka et al. do themselves, that the purified RBs 
and EBs only represent a single time point and may not necessarily reflect RBs and EBs at earlier or later 
stages. As such, a caveat to this comparison is that this thesis compares RBs at 15 h PI and EBs at 48 h PI 
cultured in BGMK cells, whereas, Saka et al. compare the later time point of 18 h PI for RBs and EBs earlier 
at 44 h PI in HeLa cells.  
 
Saka  et  al.  identified  485  (54%  of  the  proteome)  chlamydial  proteins  of  which  they  obtained 
quantitative information for 373. By comparison, the study presented in this chapter identified 580, of which 
489 had quantitative data. These differences in proteome coverage are likely to reflect the differences in the 
separation  methodology  employed.  Both  studies  used  2D-RP-RP-LC-MS/MS,  using  a  high  pH  RP  first 
dimension followed by low pH RP second dimension. Based upon the high complexity of EB and RB lysates 
observed in initial LC-MS
E scoping experiments, an 11 step first dimension fractionation was used in this 
study (Section 2.6.4), compared to 5 steps used by Saka et al.  
 
Interestingly, both studies found RBs were primed for high metabolic activity, with the expression of 
proteins required to address the high demand for nutrients, ATP generation and increases in cellular mass. 
Both studies also showed that the ‘inert’ EB form express the necessary glycolytic enzymes to metabolize 
glucose and generate ATP, independent of the host cell. Although there are many similarities between these 
two datasets, there are also some distinct differences in the observed protein expression profiles. The two 
main differences are associated with energy metabolism and type III secretion (TTS) and these are now 
discussed. 
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5.6.3.1 Type III secretion 
Similar  to  the  data  presented  in  this  thesis,  Saka  et  al.  identified  the  majority  of  the  structural 
components making up the TTSS, 25 predicted TTSS effectors and 7 TTSS chaperones. Surprisingly, they 
found  that  the  majority  of  the  structural  TTSS  proteins  were  either  in  higher  abundance,  or  detected 
exclusively in the EB form. The exception to this was SctD, which was equally abundant in both RBs and 
EBs. The TTSS chaperones were also markedly absent in the RB form and the authors suggest a reduced 
TTSS capacity, or a limited number of active TTSS apparatus in RBs. Notably, the absence of the C-ring 
components of the TTSS basal body, SctQ and the ATPase, SctN in RBs, leads the authors to suggest 
substitutes for these components in the RB form. By contrast, the data presented in this Chapter indicate 
higher expression levels of the TTSS components in RBs with reduced expression in EBs, a trend that is 
consistent with the decrease of the TTS-like projections per bacterium, observed during the transition from 
RB to EB. Additionally, the C-ring components, SctQ and SctN were expressed at 162 ±68 and 91 ±11 
molecules/cell in RBs, respectively, and 54 ±10 and 45 ±18 molecules/cell in EBs, respectively. The authors 
postulate that the expression of SctQ and SctN are ramped-up to pre-pack future EBs, but the results in this 
chapter indicate the expression of these TTS components in RBs at 15 h PI or earlier. 
  
Known  as  the  ‘chlamydial  paradox’,  the  detectable  expression  of  the  TTS-specific  genes  occurs 
between 8-12 h PI, indicating the expression of the TTS apparatus mid-cycle. However, the translocation of 
chlamydial effector proteins are required early after infection, before de-novo synthesis of a TTS apparatus 
(Reviewed by Beeckman and Vanrompay, 2010). Nevertheless, it has been shown in these studies and by 
others, that EBs possess all the components of a TTS apparatus (Vandahl et al., 2001). As such, Fields et al. 
(2003) proposed that EBs have a TTSS which translocate proteins early in the developmental cycle, with the 
TTS apparatuses being replenished mid-cycle in RBs, providing apparatus for the subsequent EB progeny. 
Although the data presented in this thesis supports such a hypothesis, the results of Saka et al. suggests de-
novo  synthesis  of  the  TTS  apparatus  late  in  the  developmental  cycle,  with  a  progressive  reduced  TTS 
capacity  during  the  transformation  from  early  EBs  to  RBs  at  18  h  PI.  This  result  is  surprising  when 
considering the expression of the TTS-specific genes occurs mid-cycle; and is concomitant with an increased 
number  of  type-III  like  projections;  and  at  a  time  when  the  intravacuolar  environment  is  being  heavily 
modified by predicted TTS substrates, such as the Inc proteins. Nevertheless, the data in this thesis does 
confirm  the  expression  of  TTSS  components  in  EBs,  albeit  at  lower  levels  than  RBs,  supporting  the 
hypothesis that EBs are pre-loaded with TTSSs (Peters et al., 2007). These observed differences between the 
TTSS expression profiles in RBs, may reflect the stages when RBs were harvested and purified. However, it 
is clear that further experimental data on the expression levels of these TTSS components at different stages 
throughout the developmental cycle are required.  
5.6.3.2 Energy metabolism 
This thesis identified almost all components encoding enzymes for glycolysis, tricarboxylic acid and 
the pentose phosphate pathway in both RBs and the metabolically inert EBs, suggesting that Chlamydiae are 
capable of utilizing glucose to generate ATP throughout their developmental cycle. ‘Paradoxically’, Saka et Chapter 5    Quantitative analysis of C. trachomatis 
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al. only identify 6 out of the 43 proteins represented in the ‘Energy metabolism’ category in RBs, but 39 in 
EBs. The authors suggest that ATP synthesis occurs via glucose catabolism in EBs, but switches to ATP 
synthesis generated by ion gradients in the RB form. However, the data presented in this Chapter, although 
consistent with glucose catabolism using pre-existing pathways in EBs, also indicates that RBs also have the 
functional capacity to generate ATP via the glycolytic pathway, an observation that is supported by the 
maximal expression of the genes PK, GAPDH, PGK, ZWF in RBs (Iliffe-Lee and McClarty, 1999). 
 
The biological insights acquired from these two studies, highlight the complexity of the chlamydial life cycle 
and  underline  the  need  for  more  proteomic  studies,  at  multiple  stages,  to  further  our  understanding  of 
chlamydial infection at the molecular level.  
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6.0 GENERAL DISCUSSION 
 
6.1 Introduction 
The  study  presented  in  this  thesis  has  provided  a  comprehensive  proteomic  analysis  of  the  two 
distinctive developmental forms of the obligate intracellular pathogen C. trachomatis L2. Using qualitative 
and quantitative mass spectrometry strategies presented in Chapters 4 and 5 has confirmed the expression of  
~72%  of  the  predicted  C.  trachomatis  L2  ORFs.  Further,  using  two-dimensional  reverse-phase 
chromatography in combination with MS
E, estimates of the average copies per cell of ~54% of the proteins 
present in RBs and EBs have been determined. This coverage compares well to other studies in bacteria such 
as those of the spirochete Leptospira interrogans, where estimates of protein copies per cell were obtained 
for 51% of the predicted proteome (Malmstrom et al., 2009). However, it should be noted that the significant 
proteome coverage achieved is not solely attributable to the separation and mass spectrometric strategies 
employed.  
 
Importantly,  the  comprehensive  proteome  analysis  of  an  intracellular  pathogen  requires  the 
purification of the pathogen from the host cell with high purity to avoid the masking of bacterium-derived 
peptides by host cell components. The separation of the spore-like elementary body of Chlamydia from host 
cells, although not without it’s difficulties, can be achieved without lysis of the bacterial cell. However, the 
purification of osmotically fragile RBs has proven more challenging and has previously limited the proteomic 
analysis of RBs in a purified form. In collaboration with Professor Ian Clarke (Microbiology, Southampton 
General Hospital), the development of a purification strategy to obtain RBs in high purity with a low level of 
host cell components has been pivotal to achieving the proteome coverage presented in this thesis. However, 
despite the relatively extensive coverage, ~28% of the predicted proteome of C. trachomatis L2 is as yet 
undetected. A key question therefore still remains as to why it has not yet been possible to identify these 
missing proteins. There are likely to be a number of possible explanations, but does inspection of the proteins 
forming this unidentified dataset allow one to rule out some of these possibilities? Some of these possibilities 
are discussed below. 
 
6.1.1 Pseudogenes 
Non-functional  genes  or  pseudogenes  present  a  problem  in  defining  the  limits  of  an  expressed 
proteome simply because their prediction can be difficult (Rouchka and Cha, 2009). Pseudogenes are thought 
to originate through the same mechanisms as normal protein-coding genes, but have become non-functional 
through  the  accumulation  of  disabling  mutations  such  as  deletions,  stop-codons  and  frameshifts.  The 
frequency of these pseudogenes usually depends upon the rates of gene duplication and loss, but typically, 
the number of pseudogenes present in bacteria is relatively low, i.e. the majority of bacterial genomes encode 
for ~90% protein and structural RNAs. Nonetheless, in some instances it has been shown that bacteria can 
posses high numbers of pseudogenes, e.g. approximately 25% of the Rickettsia prowazekii genome is non-
coding for proteins (Anderson et al., 1998). The intracellular lifestyle of intracellular pathogens such as the Chapter 6    General Discussion 
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chlamydiae  to  some  extent  provides  a  protective  environment  from  mobile  genetic  elements  such  as 
bacteriophage and transposons. Chlamydiae show a remarkable conservation in gene content and gene order; 
and their small genome sizes reflect evolutionary gene loss and genome streamlining (Thomson et al., 2008). 
As  a  consequence,  in  comparison  to  free-living  bacteria,  they  possess  relatively  small  numbers  of 
pseudogenes  (Moran  and  Wernegreen,  2000).  The  availability  of  the  genome  sequence  of  Chlamydia 
trachomatis  L2/434/Bu  has  allowed  whole  genome  comparisons  between  L2  and  other  members  of 
Chlamydiaceae. Consistent with previous findings, they are very similar in genome size, gene content and 
gene order (Thomson et al., 2008). Although there was no apparent gene acquisition, gene loss and small 
mutations  were  a  defining  characteristic  that  may  explain  the  differences  in  host  adaptation  and  tissue 
tropism observed for this LGV strain.  
 
The major region of variation between coding sequences of the different chlamydial species is the 
region termed the plasticity zone (PZ). This is indicated in the circular representation of the C. trachomatis 
L2 genome represented in Figure 6.1. This variant region is principally due to the loss of the cytotoxin 
gene(s), which have almost entirely been deleted from C. trachomatis L2 leaving two remnants CTL0420 
and CTL0421 (Belland et al., 2001); and 4 encoded phospholipase genes, CTL0409, CTL0411, CTL0413 
and CTL0414. However, although CTL0409 and CTL0414 have acquired multiple frameshift mutations and 
deletions,  CTL0411  and  CTL0413  appear  intact  in  UW-3  (serovar  D),  Har-13  (serovar  A)  and  L2. 
Visualising the peptides from RBs and EBs identified in Chapter 5 mapping to the L2 genome, there is a 
striking absence of peptides detected across the PZ. This would be expected for the predicted pseudogenes 
and validates their assignment as pseudogenes. However, the clear and notable absence of peptides mapping 
to other predicted ‘functional’ genes able to encode proteins, such as the phospholipase genes, CTL0411 and 
CTL0413, spanning this same region, does raise the question whether these genes are expressed or whether 
they too are non-coding either at the level of transcription or translation. Additional pseudogenes were also 
assigned outside the PZ and these are shown in Table 6.1 along with those assigned in the PZ.   
 
Of the proteins not identified in this study (Figure 6.2), the hypothetical proteins, or proteins of 
unknown function are quite notable, representing >10% of the predicted C. trachomatis L2 genome. By 
comparison the remaining (~19%) unidentified proteins were fairly evenly distributed across the remaining 
13 functional categories. Interestingly, in a previous study focused on improving psuedogene assignment, 
using 11 genomes from 4 bacterial genera, the number of pseudogenes ranged from 27 in Staphylococcus 
aureus MW2 to 337 in Yersinia pestis CO92. Over half of these pseudogenes identified were previously 
annotated as ‘hypothetical’ (Lerat and Ochman, 2005). Considering the high representation of ‘hypotheticals’ 
within this dataset, could some of these also represent unassigned pseudogenes; or are they characteristically 
atypical preventing their detection; or are they simply not expressed under the conditions of measurement? 
Whatever  the  reason,  it  is  clear  that  accurate  prediction  of  pseudogenes  is  required  in  defining  our 
understanding of what represents a complete proteome.  
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Figure 6.1.  Circular representation of the  C. trachomatis  L2 chromosome and the mapping of peptides 
assigned from both EBs and RBs to their corresponding CDS. The outer scale shows the size in bp. From the 
outside in, circle 1 shows the position of the CDS. Circles 2 (green) and 3 (red) indicate the CDSs of the 
peptides assigned in RBs and EBs respectively. Using the published gene predictions for C. trachomatis 
strains UW-3 and Har-3, the strain L2 CDSs have been colour coded depending on whether the are: (blue) 
predicted and intact in all isolates; (pink) predicted and intact in L2 and UW-3; (green) predicted and intact in 
L2  and  Har-13;  (orange)  defunct  in  L2,  predicted  and  intact  in  Har-13  and  UW-3;  (red)  unique  to  L2; 
(brown) defunct in all isolates. The region spanning the plasticity zone (PZ) is indicated.  
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Table 6.1.  Pseudogenes in C. trachomatis  L2/434/Bu identified by whole genome comparisons with  C. 
trachomatis strains UW-3 (serovar D) and Har-13 (serovar A). 
 
L2 locus  Protein description 
CTL0161  Conserved hypothetical protein 
CTL0228  Fumarate hydratase (FumC) 
CTL0292  Conserved hypothetical protein 
CTL0409  Phospholipase D protein 
CTL0414  Phospholipase D protein 
CTL0415  Conserved hypothetical protein 
CTL0418  Putative membrane protein 
CTL0420  Cytotoxin (adherence) 
CTL0421  Cytotoxin (adherence) 
CTL0426A  Conserved hypothetical protein 
CTL0552  Putative integral membrane protein 
CTL0578  Conserved hypothetical protein 
CTL0612  Inner membrane protein 
CTL0627  Pyruvoyl-dependent arginine decarboxylase 
CTL0856  Succinate dehydrogenase (sdhC) 
 
 
 
Figure 6.2. C. trachomatis L2 proteins not yet identified in this study distributed according to functional 
category. 
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6.1.2 Physio-chemical properties of the non-detected proteins 
Efforts to increase proteome coverage have focused on the development of innovative fractionation 
technologies and improved methods of peptide assignment. However, irrespective of such improvements, 
parts of the proteome have proven to be refractory to detection using the applied technology, either because 
of their physio-chemical properties and/or their low abundance. 
 
At first inspection of the data presented in Chapter 5, the molecular weight, isoelectric point and 
hydrophobicity profiles of the proteins unidentified, do not appear atypical of those already detected ( Figure 
6.3), encompassing molecular weights from 5.2 to 196.7 kDa, isoelectric pH values ranging from 3.93 to 
12.65 and hydrophobicity values (GRAVY) from -1.45 to +1.31. However, closer inspection of these data, 
show some distinct sampling bias. The molecular masses of proteins < 8 kDa (Figure 6.4) represents ~6% of 
the proteins not detected, compared to only ~0.6% of proteins > 8 kDa identified, suggesting a possible 
sampling issue of proteins in this mass range. 
a) 
 
b) 
 
Figure 6.3. Distribution of proteins unidentified in accordance with their a) molecular weight vs. isoelectric 
point (pI) and b) their molecular weight vs. Gravy index. 
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High-throughput proteomics is currently reliant on ‘bottom-up approaches’, where proteins must be 
reduced to more manageably- sized peptides that can be ionised and measured in the mass spectrometer. This 
is  usually  achieved  through  chemical  or  more  often  than  not,  proteolytic  digestion  using  a  site-specific 
protease. In this study, the protease trypsin was employed. Figure 6.5 shows the proportion of proteins 
according to the theoretical number of tryptic peptides they contain for both the identified and unidentified 
proteins in the C. trachomatis proteome. The data points to a clear underrepresentation of small proteins 
containing less than ~10 tryptic peptides. This is probably not surprising, since the likelihood of identifying a 
protein increases with the number of peptides generated from a protein, which tends to be low for small 
proteins and are therefore likely to be underrepresented independent of the method used for analysis. These 
low molecular weight proteins also typically exhibit low levels of expression, reducing their detection (see 
section  6.3,  Low  abundance  and  expression).  Since  the  validation  of  the  theoretical  proteome  and 
understanding an organism at the systems level requires the analysis of all protein classes, methods for 
enriching these low molecular weight proteins will be essential to incorporate into the current experimental 
set-up. This may include using molecular weight membrane filtration devices, gel-filtration and employing 
alternative  proteases  or  even  digestion  using  a  combination  of  different  proteases.  More  recently,  an 
alternative ‘top-down’ strategy has been used to characterise both low and high molecular weight proteins on 
a proteome-wide scale (Tran et al., 2011). Here, intact proteins are separated and identified by subjecting 
intact  protein  molecular  ions  to  gas-phase  fragmentation  and  subsequently  searching/interpreting  their 
fragmentation spectra. However, as a consequence of the highly complex spectra obtained from multiply 
charged product ion species, very effective protein separation and costly high-resolution mass spectrometers 
(i.e., FT-ICR) are required. As such, the uptake of ‘top-down’ strategies has lagged behind ‘bottom-up’ 
proteomic approaches. Nontheless, using such an approach for the identification of low molecular weight 
proteins or large peptide fragments (middle-down proteomics), such as for those not detected in this study, 
could be a very attractive alternative identification strategy. 
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Figure 6.4. Molecular weight profile of proteins identified (blue) and unidentified (red) below 15 kDa. 
 
 
Figure 6.5.  Histogram representing the proportion of proteins in the C. trachomatis predicted proteome 
according to their theoretical tryptic peptide count for both identified and unidentified proteins. 
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6.1.3 Low abundance and expression 
The detection of proteins at low cellular concentrations is challenging and presents a major hurdle in 
the goal of obtaining complete proteome coverage. However, they represent a highly desirable set of proteins, 
not only from the perspective of understanding their role in chlamydial biology, but also their potential as 
therapeutic targets. With low cellular concentrations, they offer the possibility of modulating protein/enzyme 
activity at low therapeutic doses, improving drug efficacy and reducing toxicity dose effects.  
 
Optimization of environmental conditions to ensure that all encoded proteins are expressed under the 
conditions of measurement is also essential. For many microorganisms, such as E. coli, complete proteome 
coverage has been hampered by the lack of a defined set of in-vitro conditions that allows the expression of 
all of its encoded genes (Chang et al., 2004; Conway and Schoolnik, 2003; Tao et al., 1999). However, for 
the  chamydiae,  transcriptomic  studies  would  appear  to  suggest  that  complete  proteome  coverage  is 
achievable,  with  the  expression  of  almost  every  chromosomal  and  plasmid  gene  mid-cycle,  with  the 
exception of a small subset of 28 genes that are expressed late in the developmental cycle (Belland et al., 
2003). 
 
The  detection  limits  of  the  label-free  quantitation  used  in  this  study  provided  lower  limits  of 
quantification at ~ 10-20 copies per cell, based upon the assumption that genome number is equivalent to the 
number of cells. Although the copy number of these unidentified proteins may be below this detection limit, 
there may also be alternative reasons for the absence of these proteins in these data. 
 
One possible explanation is the secretion of these proteins  into  the  host  cell  cytoplasm.  Detailed 
understanding of how and what proteins are secreted remains unclear, but may include the release of pre-
existing proteins from EBs to facilitate chlamydial entry and the secretion of proteins from RBs to support 
chlamydial development and modulate host immune responses. For example, characterised by a bilobed 
hydrophobic motif, there are 46 predicted candidate inclusion membrane proteins of which, at least 10 have 
been reported as being secreted and localised to the inclusion membrane (Bannantine et al., 2000; Bannantine 
et al., 1998a; Bannantine et al., 1998b; Rockey et al., 2002). Additionally, two proteins lacking this motif 
have also been shown to be associated with the inclusion membrane implying there may be many more 
exported (Fields and Hackstadt, 2000; Fling et al., 2001). In this study, the Inc proteins A,C,E and G were 
detected, but in addition to these annotated proteins, six additional putative inclusion membrane proteins, 
CTL0466,  CTL0476,  CTL0478,  CTL0480,  CTL0481  and  CTL0540  were  also  detected.  These  were  all 
detected in RBs, but all showed either a decrease or were below the limit of detection in EBs. Although these 
proteins may be down regulated via cellular protein turnover, the data could also support their predicted 
secretion. The lack of detection of the remaining 40 or more predicted inclusion membrane proteins in either 
RBs (15 h PI) or EBs (48 h PI) may indicate that these proteins are required for early inclusion membrane 
development and are therefore secreted prior to the sampling point at 15 h PI. The undefined secretome of Chapter 6    General Discussion 
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Chlamydia clearly represents a significant proportion of the  ~270 yet undetected proteins and will therefore 
require effective methodologies to allow their detection.  
 
6.1.4 Detection of unidentified proteins 
There  is  a  requirement  for  a  generic,  highly  sensitive  strategy  for  the  detection  and  accurate 
quantitation of proteins that are not easily detected using high-throughput strategies, such as low abundance 
proteins or those present in high protein backgrounds masking their measurement. As discussed and to some 
extent  developed  in  Chapter  3,  the  AQUA  approach  proposed  by  Gerber  et  al.  (2003)  offers  a  highly 
sensitive targeted mass spectrometric methodology, that is able to discriminate between one protein and 
another in highly complex mixtures and provide accurate measurements of quantification. By comparison to 
high-throughput strategies such as the label-free approach presented in Chapter 5, the throughput is relatively 
low and requires the synthesis of isotopically labelled peptides corresponding to each peptide measured. 
However, the approach is highly sensitive and offers excellent quantitative precision. Use of approaches such 
as  AQUA  can  complement  high-throughput  proteomic  strategies,  by  providing  highly  sensitive  targeted 
analyses for the detection and quantitation of proteins not identified using shotgun approaches. However, this 
is of course dependent upon whether these proteins are expressed under the conditions of measurement. 
These  approaches  also  offer  the  opportunity  to  implement  targeted  high-throughput  assays  for  the 
measurement of cellular concentrations of proteins involved in specific pathways and/or processes with high 
sensitivity. A valuable resource generated as part of these studies, is a database of proteotypic peptide data 
for the proteins of C. trachomatis, providing information on the m/z of the observed peptides, their charge 
state,  corresponding  fragment  ions,  collision  energy  and  chromatographic  retention  times.  Utilising  this 
information, methodologies can be devised, based upon these recorded peptide transitions, to provide optimal 
measurement of specific sub-sets of proteins. Because of the specificity and sensitivity of such assays, the 
levels of proteins can potentially be measured in highly complex backgrounds such as a host cell lysate. For 
example,  by  using  several  peptide  transitions  observed  for  each  glycolytic  enzyme  of  chlamydiae, 
quantitative measurement of this pathway could be made from the initial stages of infection, where cellular 
concentrations are likely to be low due to the limited number of chlamydiae, through progressive time points 
in  the  developmental  cycle  without  the  requirement  of  purifying  chlamydiae  from  the  host  cell.  In  the 
absence of a genetic system for C. trachomatis, proteomics has been an essential tool for advancing our 
understanding of Chlamydia at the molecular level. The combination of genetic transformation and proteomic 
technologies offers the potential to advance our molecular understanding of Chlamydiae even further. 
 
6.2 Future Work 
 
Although major advances in characterising the proteome of C. trachomatis L2 have been achieved, the 
assignment of yet undetected proteins and validation experiments falling outside the time limits and scope of 
this study would ideally form the basis of future studies. Three key future experiments are described briefly 
below: 
  Chapter 6    General Discussion 
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6.2.1 Validation of > 5 proteins using MRM technology 
The AQUA (or targeted MRM) approach is currently considered to be the ‘gold standard’ for the 
determination of the absolute concentration of a protein. To provide validation and further confidence in the 
absolute quantitation measurements made for the proteins of C. trachomatis using the high-throughput label-
free technology in this study, a panel of proteins (>5) should be validated using the AQUA approach. This 
selected  panel  of  proteins  should  consist  of  proteins  spanning  the  dynamic  range  of  the  measurements 
obtained in the high-throughput experiments and represent proteins from different functional categories.  
 
6.2.2 Absolute measurement of specific pathways during the developmental cycle 
Using the proteotypic peptide data already obtained, MRM methodologies for specific sub-sets of 
proteins, i.e., glycolytic pathway enzymes, peptidoglycan pathway biosynthetic enzymes, plasmid proteins, 
Pmps, etc, could be developed. These methodologies can subsequently be applied to the routine measurement 
of these protein sub-sets at different stages in the developmental cycle (including the initial stages, where 
there is an absence of proteomic studies because of the limited numbers of developmental forms), under 
different  treatments  and  even  in  cell  lysates  containing  both  chlamydiae  and  host  cell  components, 
eliminating the requirement for purification of RBs and EBs. 
 
6.2.3 Enrichment of proteins associated with the inclusion membrane. 
As discussed above, screening of predicted genome sequences of C. trachomatis and C. pneumoniae 
revealed >40 sequences that contain the characteristic bi-lobed hydrophobic domain that is unique to the 
inclusion membrane proteins (Bannantine et al., 2000). It has also been shown that at least ten of these 
proteins  that  share  this  secondary  motif  are  associated  with  the  inclusion  membrane.  However,  not  all 
proteins containing this motif are necessarily localised to the inclusion membrane (Fields and Hackstadt, 
2000; Fling et al., 2001). Experimental confirmation of which inc proteins and other proteins are localised to 
the inclusion membrane would be a major advance, helping to inform on the interactions with the host cell 
and  environmental  sensing  occurring  along  the  inclusion  membrane.  To  achieve  this,  some  form  of 
enrichment and purification strategy is required to isolate the inclusion membrane from host and pathogen 
cellular components so that proteins associated with the inclusion membrane can be identified. However, the 
isolation of such structures is challenging. 
 
   An elegant approach that uses iTRAQ in combination with analytical density centrifugation described 
by Dunkley et al. (2004), allows the simultaneous assignment of proteins to multiple organelles and even 
sub-cellular compartments within organelles such as the golgi, plasma membrane, mitochondrion, ER and 
vacuolar localisation (Sadowski et al., 2008). This technology termed LOPIT, or Localisation of organelle 
proteins by isotopic tagging has been used to show the distribution of proteins associated with a specific 
organelle. Here, cells are disrupted and their contents layered and centrifuged using self-forming iodixanol 
density gradients to separate out the multiple organelles and subcellular compartments. Fractions from these 
density  gradients  are  extracted,  digested  into  peptides  and  each  fraction  labelled  with  one  of  the  eight Chapter 6    General Discussion 
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possible iTRAQ tags. Once labelled, the fractions are pooled and analysed using LC-MS/MS to obtain the 
identities  and  an  abundance  profile  of  every  assigned  protein  from  each  fractionation  position.  Using 
multivariate  statistical  techniques,  such  as  principal  component  analysis  (PCA)  and  partial  least  squares 
discriminant analysis (PLS-DA), proteins are clustered according to similarities in their protein abundance 
profiles. By comparing the abundance profiles of proteins known to be associated with a particular organelle, 
other proteins associated with that organelle or sub-cellular compartment can be assigned. 
 
The proposed experiment would use this strategy to isolate and assign proteins associated with the 
vacuolar inclusion membrane. However, the success of this experiment would depend on the assumption that 
the intracellular membrane would exist after lysis as a distinct structure that either reforms as a vesicle, or is 
characteristically distinct to allow separation from contaminating components of other host and pathogen 
organelles, etc. If this criterion is met, by using proteins already known to be associated with the inclusion 
membrane as location markers (e.g., IncA), new proteins interacting with the inclusion membrane could be 
assigned.  This  could  provide  an  important  tool  for  elucidating  proteins  associated  with  the  inclusion 
membrane that are likely to play a crucial role in the molecular and cellular interactions that facilitate growth 
and  inclusion  development.  Equally,  it  could  also  potentially  provide  important  information  on 
immunoprotection, translating into potential vaccine targets. 
 
 
6.3 Conclusion           
 
The  study  of  C.  trachomatis  is  challenging  because  of  its  obligate  intracellular  nature  and  until 
recently, the absence of a genetic system for manipulation. As such, alternative molecular techniques such as 
genomics,  transcriptomics  and  proteomics  remain  essential  tools  in  advancing  the  field  of  Chlamydial 
research. This thesis has provided a deep insight into the proteome of the Lymphogranuloma Venereum 
strain of C. trachomatis L2, a serovar that is distinctive in both tissue tropism and pathogenicity from the 
other genital and ocular strains. The study has focused on the development, implementation and application 
of proteomic methodologies to the analysis of the two unique stages of its life cycle, to validate the accuracy 
of the predicted proteome. 
 
Notably,  a  large  proportion  of  the  detected  proteome  was  expressed  at  increased  cellular 
concentrations  in  the  replicative  form,  reflecting  a  time  of  greatest  metabolic  activity.  Challenging  the 
original dogma that chlamydiae are solely energy parasites, the expression of a complete glycolytic pathway 
in both forms suggest they are capable of synthesising their own intracellular ATP, not only in metabolically 
active RBs, but also in extracellular EBs and even possibly in the absence of a host cell.  Despite the absence 
of  any  detectable  cell  wall  material,  the  detection  of  enzymes  for  an  almost  complete  peptidoglycan 
biosynthesis pathway in RBs suggests an alternative role in replication and/or host cell modulation. 
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The secretome of chlamydiae still remains uncharacterised, however, the expression of the type III 
translocation apparatus in both developmental stages supports the translocation of proteins into the host cell 
cytoplasm that may play a role in regulating the developmental cycle. As such, identifying these secreted 
proteins, their interacting partners and their localisation will be key in understanding the importance and 
relationship of signalling between chlamydiae and the host cell. 
   
By contrast, the extracellular stage has a decreased expression of a large proportion of the detected C. 
trachomatis  proteome.  Strikingly,  against  this  background  of  reduced  protein  synthesis,  C.  trachomatis 
expends a considerable amount of energy maintaining the outer cell envelope, protein translational machinery 
and a set of hypothetical proteins. The energy expended in maintaining this functional protein translational 
system implies that this is important for survival and that EBs are primed and ready-to-go upon infection 
and/or even maintain a low level of protein synthesis during this extracellular stage, challenging the dogma 
of the quiescent infectious bacterial cell.  Further support for this hypothesis was recently observed in the 
EBs  of  the  related  organism  Protochlamydia  amoebophila,  where  almost  a  complete  set  of  ribosomal 
proteins was detected (Sixt et al., 2011) and is further supported by the demonstration of extended metabolic 
activity  in  extracellular  EBs  after  release  from  the  host  cell  using  Confocal  Raman  microspectroscopy 
(Haider et al., 2010). The function of the ‘expressed hypothetical proteins’ are unknown, but their expression 
at these late stages are likely to be important in either the formation of EBs; survival in the extracellular stage 
of it’s lifecycle or for initiating infection. 
 
One important legacy of this study is the generation of a database containing proteotypic peptide data 
for the proteome of C. trachomatis L2. This information provides a platform that assists both validation and 
future targeted quantitative proteome studies. It will facilitate the measurement of cellular concentrations of 
proteins  through  the  developmental  cycle.  The  chlamydial  response  to  perturbations,  such  as  immune 
challenges, environmental stimuli, therapeutics and in different cellular states such as persistence can be 
measured against such a database. 
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Appendix I, Table 5.1.  Proteins assigned and quantified by iTRAQ analysis of EBs and RBs from C. trachomatis L2\434\Bu. 
Category/protein name 
Gene  
name 
Primary 
locus 
GenInfo 
identifier 
UniProt 
accession 
number 
Serovar D 
orthologue  pI
a)  
Mass 
(kDa)
a) 
Total 
number of 
peptide 
matches 
Number 
of 
unique 
peptide 
matches 
Reporter 
ion ratios
b) 
114/115 
Reporter 
ion ratios
b) 
116/117  
mean 
protein 
ratio 
Standard 
deviation 
Fold-
change
c) 
Amino acid biosynthesis 
Serine Hydroxymethyltransferase  glyA  CTL0691  166154645  B0B804  CT432  6.04  54.2  13  9  1.32  0.98  1.15  0.24  1.1 
Aromatic AA Aminotransferase  aspC  CTL0005  166153978  B0B8L2  CT637  5.42  44.7  6  5  ND  ND  ND  ND  ND 
Dehyroquinate Synthase  aroB  CTL0623  166154580  B0B7T8  CT369  7.67  41.2  8  7  ND  ND  ND  ND  ND 
Dihydrodipicolinate Synthase  dapA  CTL0615  166154572  B0B7T0  CT361  5.52  31.2  3  3  ND  ND  ND  ND  ND 
   
Biosynthesis of cofactors  
Geranylgeranyl pyrophosphate synthase  ispA  CTL0892  166154843  B0B8K3  CT628  4.88  32.5  6  4  1.10  0.95  1.02  0.10  1.0 
GTP Cyclohydratase and DHBP Synthase  ribA  CTL0100  166154073  B0B8V7  CT731  5.11  46.8  7  3  ND  ND  ND  ND  ND 
Porphobilinogen Synthase  hemB  CTL0001  166153974  B0B8K8  CT633  5.94  37.7  5  4  ND  ND  ND  ND  ND 
Phenylacrylate Decarboxylase     CTL0472  166154430  B0B9X0  CT220  6.64  19.2  4  4  ND  ND  ND  ND  ND 
   
Cell Envelope  
Major Outer Membrane Protein   ompA  CTL0050  166154023  B0B8Q7  CT681  5.06  42.5  449  20  1.10  1.02  1.06  0.05  1.1 
60kDa Cysteine-Rich OMP  omcB  CTL0702  166154656  B0B815  CT443  8.08  56.4  170  28  0.48  0.46  0.47  0.02  -2.1 
Putative outer membrane protein B   pmpB  CTL0670  166154624  B0B7Y3  CT413  8.21  183.0  64  37  0.72  0.72  0.72  0.01  -1.4 
Putative Outer Membrane Protein D   pmpD  CTL0183  166154155  B0B940  CT812  4.75  156.7  69  30  0.80  0.78  0.79  0.02  1.3 
OmpH-Like Outer Membrane Protein  ompH  CTL0494  166154453  B0B7F8  CT242  4.65  17.3  18  8  1.38  1.33  1.35  0.04  +1.4 
Candidate inclusion membrane protein     CTL0476  166154434  B0B9X4  CT223  6.75  29.6  39  13  0.67  0.68  0.67  0.00  -1.5 
Peptidoglycan-Associated Lipoprotein  pal  CTL0863  166154814  B0B8H4  CT600  7.91  19.0  14  3  0.85  0.8  0.82  0.04  1.2 
Putative Outer Membrane Protein G  pmpG  CTL0250  166154217  B0B9A3  CT871  5.66  104.2  22  13  1.13  1.14  1.14  0.01  1.1            
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Putative Outer Membrane Protein I   pmpI  CTL0254  166154220  B0B9A6  CT874  6.07  92.9  36  12  0.87  0.92  0.89  0.03  1.1 
Outer Membrane Protein Analog   ompB  CTL0082  166154055  B0B8T9  CT713  5.18  34.6  11  4  0.91  0.91  0.91  0.00  1.1 
UDP-N-Acetylglucosamine Transferase  murA  CTL0715  166154669  B0B828  CT455  6.15  48.4  15  9  ND  ND  ND  ND  ND 
Putative Outer Membrane Protein H   pmpH  CTL0251  166154218  B0B9A4  CT872  6.6  104.6  20  15  1.01  0.99  1.00  0.02  1.0 
Glucosamine-Fructose-6-P Aminotransferase   glmS  CTL0188  166154160  B0B945  CT816  5.38  67.4  20  14  1.52  1.56  1.54  0.03  +1.5 
Putative outer membrane protein C   pmpC  CTL0671  166154625  B0B7Y4  CT414  4.58  184.9  24  20  0.86  1.04  0.95  0.13  1.1 
Muramidase (invasin repeat family)  nlpD  CTL0128  166154101  B0B8Y5  CT759  9.08  24.1  12  6  ND  ND  ND  ND  ND 
60kDa Inner Membrane Protein  oxaA  CTL0503  166154462  B0B7G7  CT251  8.35  85.0  32  14  1.35  1.26  1.30  0.06  1.3 
Possible Transmembrane Protein     CTL0386  166154352  B0B9N9  CT131  6.59  123.0  34  18  ND  ND  ND  ND  ND 
Inclusion Membrane Protein A   incA  CTL0374  166154340  B0B9M7  CT119  6.15  24.7  13  8  ND  ND  ND  ND  ND 
Omp85 Analog     CTL0493  166154452  B0B7F7  CT241  8.96  85.6  21  14  ND  ND  ND  ND  ND 
PBP2-transglycolase/transpeptidase  pbpB  CTL0051  166154024  B0B8Q8  CT682  6.36  124.0  34  17  ND  ND  ND  ND  ND 
D-alanyl-D-alanine carboxypeptidase  dacC  CTL0813  166154766  B0B8C5  CT551  8.98  46.0  6  5  ND  ND  ND  ND  ND 
UDP-N-acetylmuramoylalanine-D-glutamate 
ligase  murD  CTL0127  166154100  B0B8Y4  CT758  5.48  46.2  13  9  ND  ND  ND  ND  ND 
Membrane Thiol Protease (predicted)     CTL0247  166154214  B0B9A0  CT868  8.24  44.9  3  3  ND  ND  ND  ND  ND 
Polymorphic outer membrane protein      CTL0255  166154221  B0B9A7  CT875  5.39  65.8  34  18  0.64  0.61  0.62  0.02  -1.6 
 
  
Cellular processes  
Thio-specific Antioxidant (TSA) Peroxidase   ahpC  CTL0866  166154817  B0B8H7  CT603  4.78  21.7  66  8  0.99  0.94  0.96  0.04  1.0 
FHA domain; homology to adenylate cyclase     CTL0033  166154006  B0B8P0  CT664  4.53  89.7  49  16  0.75  0.75  0.75  0.00  1.3 
Yop proteins translocation protein L   sctL  CTL0824  166154776  B0B8D5  CT561  5.71  24.8  17  6  0.96  0.88  0.92  0.05  1.1 
Yop proteins translocation lipoprotein J   sctJ  CTL0822  166154774  B0B8D3  CT559  5.24  33.0  23  5  1.24  1.13  1.18  0.07  1.2 
Flagellar Motor Switch Domain/YscQ family  sctQ  CTL0041  166154014  B0B8P8  CT672  4.53  41.2  19  10  1.11  1.09  1.10  0.01  1.1 
Trigger Factor-peptidyl prolyl isomerase   tig  CTL0076  166154049  B0B8T3  CT707  5.02  50.1  28  15  1.14  1.18  1.16  0.03  1.2 
Superoxide Dismutase (Mn)  sodM  CTL0546  166154505  B0B7L0  CT294  6.04  23.4  7  4  1.04  1.06  1.05  0.02  1.0 
probable Yop proteins translocation protein 
C/general secretion pathway protein      CTL0043  166154016  B0B8Q0  CT674  5.43  95.7  30  16  0.87  0.78  0.83  0.06  1.2      
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Protein Translocase  secA  CTL0070  166154043  B0B8S7  CT701  5.65  110.3  33  24  1.11  1.23  1.17  0.08  1.2 
GTP Binding Protein     CTL0347  166154313  B0B9K0  CT092  5.23  40.0  29  10  1.13  1.24  1.18  0.08  1.2 
Low Calcium Response D   lcrD  CTL0345  166154311  B0B9J8  CT090  7.74  77.9  28  17  0.84  0.87  0.86  0.02  1.2 
Signal Recognition Particle GTPase  ffh  CTL0280  166154246  B0B9D2  CT025  8.56  49.7  14  11  ND  ND  ND  ND  ND 
Low Calcium Response E  copN  CTL0344  166154310  B0B9J7  CT089  4.9  45.2  17  7  0.75  0.74  0.74  0.01  1.3 
Yops secretion ATPase  sctN  CTL0038  166154011  B0B8P5  CT669  5.59  48.2  13  9  ND  ND  ND  ND  ND 
GTP Binding Protein     CTL0634  166154589  B0B7U8  CT379  7.09  50.8  12  8  ND  ND  ND  ND  ND 
Low Calcium Response Protein H   scc2  CTL0839  166154791  B0B8F0  CT576  9.1  26.0  16  5  ND  ND  ND  ND  ND 
Gen. Secretion Protein D   gspD  CTL0835  166154787  B0B8E6  CT572  5.24  81.2  42  21  ND  ND  ND  ND  ND 
Protein Translocase     CTL0396  166154362  B0B9P9  CT141  8.61  16.8  6  5  ND  ND  ND  ND  ND 
Signal Peptidase I   lepB  CTL0275  166154241  B0B9C7  CT020  8.42  71.5  13  6  ND  ND  ND  ND  ND 
Flagellum-specific ATP Synthase  fliI  CTL0086  166154059  B0B8U3  CT717  6.55  47.6  7  7  ND  ND  ND  ND  ND 
  
Central intermediary metabolism   
Inorganic Pyrophosphatase   ppa  CTL0141  166154114  B0B8Z8  CT772  4.75  23.4  7  5  0.78  0.81  0.80  0.02  1.3 
Glycogen Synthase  glgA  CTL0167  166154140  B0B925  CT798  5.6  53.4  4  4  ND  ND  ND  ND  ND 
Glycogen Phosphorylase  glgP  CTL0500  166154459  B0B7G4  CT248  5.67  92.7  21  16  ND  ND  ND  ND  ND 
   
Replication   
Molecular chaperone DnaK  DnaK  CTL0653  5858788  B0B7W6  CT652  5.03  70.8  290  32  0.86  0.84  0.85  0.01  1.2 
RECA Protein  recA  CTL0018  166153991  B0B8M5  CT650  7.02  37.8  26  10  1.45  1.48  1.46  0.02  +1.5 
Integration Host Factor Alpha   ihfA  CTL0519  166154478  B0B7I3  CT267  11.07  11.4  60  12  1.89  1.87  1.88  0.02  +1.9 
SWIB (YM74) complex protein      CTL0720  166154674  B0B833  CT460  9.35  9.7  33  12  1.26  1.24  1.25  0.02  1.3 
Histone-Like Developmental Protein   hctA  CTL0112  166154085  B0B8W9  CT743  10.69  13.7  9  5  0.42  0.40  0.41  0.01  -2.4 
DNA Gyrase Subunit B   gyrB2  CTL0442  166154400  B0B9U0  CT190  5.49  89.7  25  17  0.92  0.94  0.93  0.01  1.1 
DNA Pol III (beta chain)  dnaN  CTL0331  166154296  B0B9I3  CT075  5.92  46.5  7  3  ND  ND  ND  ND  ND 
DNA Mismatch Repair   mutS  CTL0160  166154134  B0B918  CT792  6.69  92.1  32  17  ND  ND  ND  ND  ND            
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Exinuclease ABC Subunit B   uvrB  CTL0849  166154801  B0B8G0  CT586  5.43  75.8  16  14  ND  ND  ND  ND  ND 
Holliday Junction Helicase   ruvB  CTL0296  166154261  B0B9E8  CT040  7.03  37.3  16  5  0.86  0.84  0.85  0.02  1.2 
Crossover Junction Endonuclease   ruvC  CTL0764  166154717  B0B876  CT502  9.17  18.7  4  4  ND  ND  ND  ND  ND 
DNA Pol III Alpha  dnaE  CTL0807  166154760  B0B8B9  CT545  5.71  139.4  38  25  ND  ND  ND  ND  ND 
DNA Helicase   uvrD  CTL0872  166154823  B0B8I3  CT608  6.08  72.7  23  10  ND  ND  ND  ND  ND 
DNA Gyrase Subunit A   gyrA  CTL0441  166154399  B0B9T9  CT189  6.27  94.2  38  26  0.90  0.88  0.89  0.02  1.1 
SWF/SNF family helicase     CTL0077  166154050  B0B8T4  CT708  5.4  133.1  17  14  ND  ND  ND  ND  ND 
DNA Pol III Epsilon Chain  dnaQ  CTL0513  166154472  B0B7H7  CT261  5.55  26.5  8  6  1.07  1.02  1.04  0.04  1.0 
DNA Ligase  dnlJ  CTL0401  166154367  B0B9Q4  CT146  6.61  73.5  20  11  ND  ND  ND  ND  ND 
SWI/SNF family helicase     CTL0818  166154770  B0B8C9  CT555  5.67  136.2  22  13  ND  ND  ND  ND  ND 
DNA Pol III Epsilon Chain  dnaQ2  CTL0798  166154751  B0B8B0  CT536  8.9  28.9  25  13  ND  ND  ND  ND  ND 
Primosomal Protein N  priA  CTL0147  166154120  B0B904  CT778  9.1  84.8  34  19  ND  ND  ND  ND  ND 
Replication Initiation Factor   dnaA2  CTL0527  166154486  B0B7J1  CT275  8.67  51.3  21  9  ND  ND  ND  ND  ND 
DNA Gyrase Subunit B   gyrB  CTL0030  166154003  B0B8N7  CT661  8.62  68.2  18  14  ND  ND  ND  ND  ND 
DNA Gyrase Subunit A  gyrA2  CTL0029  166154002  B0B8N6  CT660  6.8  55.2  11  9  ND  ND  ND  ND  ND 
Exodoxyribonuclease VII   xseA  CTL0583  166154539  B0B7P6  CT329  9.58  58.7  12  7  ND  ND  ND  ND  ND 
Holliday Junction Helicase  ruvA  CTL0763  166154716  B0B875  CT501  6.12  22.2  6  5  ND  ND  ND  ND  ND 
DNA Pol III Gamma and Tau   dnaX  CTL0588  166154545  B0B7Q2  CT334  6.35  51.6  13  6  ND  ND  ND  ND  ND 
DNA repair protein  radA  CTL0550  166154509  B0B7L4  CT298  7.18  49.8  12  9  ND  ND  ND  ND  ND 
  
Energy metabolism   
ATP Synthase Subunit E   atpE  CTL0562  166154520  B0B7M6  CT310  5.44  22.9  44  12  0.60  0.59  0.60  0.01  -1.7 
Transaldolase  tal  CTL0565  166154523  B0B7M9  CT313  4.94  36.1  37  11  1.21  1.32  1.27  0.07  1.3 
Triosephosphate Isomerase  tpiS  CTL0582  166154538  B0B7P5  CT328  5.42  29.8  28  7  0.90  0.92  0.91  0.02  1.1 
ATP Synthase Subunit A   atpA  CTL0560  166154518  B0B7M4  CT308  5.12  65.5  18  12  0.87  0.87  0.87  0.00  1.1 
ADP/ATP Translocase     CTL0321  166154286  B0B9H3  CT065  9.31  58.1  23  13  1.06  1.01  1.04  0.04  1.0 
 Enolase   eno  CTL0850  166154802  B0B8G1  CT587  4.65  45.4  10  7  1.10  0.87  0.99  0.16  1.0      
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ATP Synthase Subunit B  atpB  CTL0559  166154517  B0B7M3  CT307  5.45  48.6  14  10  0.97  0.94  0.96  0.02  1.0 
Predicted 1,6-Fructose biphosphate aldolase 
(dehydrin family)   dhnA  CTL0467  166154425  B0B9W5  CT215  6.31  38.0  16  8  1.37  1.33  1.35  0.03  +1.4 
Lipoamide Dehydrogenase   lpdA  CTL0820  166154772  B0B8D1  CT557  6.33  49.4  11  5  0.91  0.98  0.94  0.05  1.1 
Malate Dehydrogenase  mdhC  CTL0630  166154586  B0B7U5  CT376  6.08  35.5  8  4  ND  ND  ND  ND  ND 
NADH-ubiquinone oxidoreductase, alpha 
chain    nqrA  CTL0002  166153975  B0B8K9  CT634  8.91  51.7  13  9  0.91  0.94  0.93  0.02  1.1 
Glucose-6-P Isomerase  pgi  CTL0633  166154588  B0B7U7  CT378  5.49  57.7  3  3  ND  ND  ND  ND  ND 
Phosphoglucomutase     CTL0187  166154159  B0B944  CT815  6.04  49.3  9  7  ND  ND  ND  ND  ND 
Cytochrome Oxidase Subunit I   cydA  CTL0268  166154234  B0B9C0  CT013  9.29  50.2  8  6  ND  ND  ND  ND  ND 
Phosphoglycerate mutase  pgmA  CTL0091  166154064  B0B8U8  CT722  6.66  25.8  13  7  ND  ND  ND  ND  ND 
Dihydrolipoamide Acetyltransferase  pdhC  CTL0499  166154458  B0B7G3  CT247  5.69  46.4  19  13  ND  ND  ND  ND  ND 
Glycerol-3-P Dehydrogenase  gpdA  CTL0083  166154056  B0B8U0  CT714  8.19  36.2  12  7  ND  ND  ND  ND  ND 
ATP Synthase Subunit D   atpD  CTL0558  166154516  B0B7M2  CT306  9.01  23.2  43  10  0.98  1.01  1.00  0.02  1.0 
Succinyl-CoA Synthetase, Alpha   sucD  CTL0194  166154166  B0B951  CT822  5.34  30.2  6  4  ND  ND  ND  ND  ND 
Pyruvate Kinase  pykF  CTL0586  166154543  B0B7Q0  CT332  6  53.6  24  10  ND  ND  ND  ND  ND 
Fructose-6-P Phosphotransferase   pfkA  CTL0457  166154415  B0B9V5  CT205  6.09  61.9  13  8  ND  ND  ND  ND  ND 
6-Phosphogluconate Dehydrogenase   gnd  CTL0319  166154284  B0B9H1  CT063  5.43  52.6  46  14  ND  ND  ND  ND  ND 
Ribulose-P Epimerase  araD  CTL0376  166154342  B0B9M9  CT121  4.85  23.0  9  4  ND  ND  ND  ND  ND 
Succinate Dehydrogenase  sdhB  CTL0854  166154806  B0B8G5  CT591  6.26  25.7  5  3  ND  ND  ND  ND  ND 
(pyruvate) Oxoisovalerate Dehydrogenase 
Alpha and Beta Fusion     CTL0594  166154552  B0B7Q9  CT340  5.47  74.4  5  5  ND  ND  ND  ND  ND 
Lipoate Protein Ligase  lplA  CTL0761  166154714  B0B873  CT499  7.09  26.9  8  4  ND  ND  ND  ND  ND 
Succinate Dehydrogenase  sdhA  CTL0855  166154807  B0B8G6  CT592  6.76  67.7  12  12  ND  ND  ND  ND  ND 
Phosphoglycerate Kinase  pgk  CTL0062  166154035  B0B8R9  CT693  5.65  43.0  10  5  ND  ND  ND  ND  ND 
   
Fatty acid and phospholipid metabolism  
Acyl Carrier Protein   acpP  CTL0488  166154447  B0B7F2  CT236  3.86  8.7  13  2  0.67  0.71  0.69  0.03  -1.5 
Enoyl-Acyl-Carrier Protein Reductase  fabI  CTL0359  166154325  B0B9L2  CT104  5.22  32.0  7  6  1.00  1.12  1.06  0.08  1.1            
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 Biotin Carboxyl Carrier Protein   accB  CTL0378  166154344  B0B9N1  CT123  5.07  18.2  8  4  ND  ND  ND  ND  ND 
Oxoacyl (Carrier Protein) Reductase   fabG  CTL0489  166154448  B0B7F3  CT237  7.7  26.0  14  6  ND  ND  ND  ND  ND 
UDP-3-O-[3-hydroxymyristoyl] glucosamine 
N-acyltransferase  lpxD  CTL0495  166154454  B0B7F9  CT243  7.35  38.4  7  6  0.96  0.94  0.95  0.01  1.0 
Acylglycerophosphoethanolamine 
Acyltransferase  aas  CTL0145  166154118  B0B902  CT776  7.15  59.4  9  6  1.22  1.06  1.14  0.11  1.1 
Acyl Carrier Protein Synthase  fabF  CTL0139  166154112  B0B8Z6  CT770  5.47  44.8  21  9  1.17  1.25  1.21  0.06  1.2 
Biotin Carboxylase 4  accC  CTL0379  166154345  B0B9N2  CT124  6.4  50.1  12  9  ND  ND  ND  ND  ND 
AcCoA Carboxylase/Transferase Alpha   accA  CTL0517  166154476  B0B7I1  CT265  5.91  36.4  17  10  ND  ND  ND  ND  ND 
Lipid A Disaccharide Synthase   lpxB  CTL0668  166154622  B0B7Y1  CT411  9.23  69.1  10  6  ND  ND  ND  ND  ND 
Acyl-Carrier UDP-GlcNAc O-Acyltransferase   lpxA  CTL0793  166154746  B0B8A5  CT531  6.08  30.7  9  7   ND  ND   ND   ND   ND  
AcCoA Carboxylase/Transferase Beta  accD  CTL0545  166154504  B0B7K9  CT293  7.52  33.7  32  9  0.76  0.81  0.78  0.04  1.3 
Hydroxymyristoyl-(acyl carrier protein) 
dehydratase  fabZ  CTL0794  166154747  B0B8A6  CT532  9.19  16.6  5  3  ND  ND  ND  ND  ND 
  
Hypothetical proteins  
hypothetical protein      CTL0847  166154799  B0B8F8  CT584  5.61  21.1  82  7  1.00  1.03  1.02  0.02  1.0 
hypothetical protein      CTL0874  166154825  B0B8I5  CT610  4.94  26.8  62  13  1.02  0.93  0.98  0.06  1.0 
hypothetical protein      CTL0040  166154013  B0B8P7  CT671  4.79  31.0  40  10  0.93  0.94  0.94  0.00  1.1 
hypothetical protein     CTL0028  166154001  B0B8N5  CT659  7.99  8.8  26  5  0.98  0.97  0.97  0.01  1.0 
hypothetical protein      CTL0512  166154471  B0B7H6  CT260  4.76  18.9  44  9  0.85  0.87  0.86  0.01  1.2 
hypothetical protein  copD  CTL0842  166154794  B0B8F3  CT579  9.47  44.0  15  11  0.89  0.91  0.90  0.02  1.1 
hypothetical protein     CTL0322  166154287  B0B9H4  CT066  9.95  17.9  39  9  1.65  1.79  1.72  0.10  +1.7 
hypothetical protein     CTL0034  166154007  B0B8P1  CT665  9.1  9.3  12  4  1.30  1.24  1.27  0.04  1.3 
hypothetical protein     CTL0137  166154110  B0B8Z4  CT768  5.41  64.1  40  18  0.90  0.91  0.90  0.00  1.1 
hypothetical protein     CTL0800  166154753  B0B8B2  CT538  5.33  27.5  12  8  1.03  1.04  1.04  0.01  1.0 
hypothetical protein     CTL0655  166154609  B0B7W8  CT398  7.07  29.5  20  11  1.06  1.09  1.08  0.03  1.1 
hypothetical protein     CTL0688  166154642  B0B801  CT429  5.1  39.2  16  9  0.95  0.93  0.94  0.02  1.1 
hypothetical protein     CTL0299  166154264  B0B9F1  CT043  5.04  18.3  15  7  1.12  1.14  1.13  0.02  1.1      
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hypothetical protein     CTL0840  166154792  B0B8F1  CT577  6.51  13.3  5  3  0.24  0.19  0.21  0.03  -4.7 
hypothetical protein     CTL0036  166154009  B0B8P3  CT667  4.87  16.5  8  3  1.55  1.45  1.50  0.07  +1.5 
hypothetical protein     CTL0110  166154083  B0B8W7  CT741  9.45  10.4  12  4  1.00  1.16  1.08  0.11  1.1 
hypothetical protein     CTL0402  166154368  B0B9Q5  CT147  8.75  162.2  89  53  1.03  0.98  1.01  0.03  1.0 
hypothetical protein      CTL0103  166154076  B0B8W0  CT734  8.47  20.6  11  6  0.91  0.91  0.91  0.00  1.1 
hypothetical protein     CTL0222  166154194  B0B979  CT849.1  4.01  6.8  12  4  0.75  0.75  0.75  0.00  1.3 
hypothetical protein     CTL0272  166154238  B0B9C4  CT017  6.64  47.7  22  14  0.60  0.63  0.61  0.02  -1.6 
hypothetical protein      CTL0626  166154583  B0B7U1  CT372  9.04  49.4  11  5  0.91  0.93  0.92  0.01  1.1 
hypothetical protein      CTL0897  166154847  B0B8K7  CT632  5.83  60.9  18  13  0.90  0.88  0.89  0.01  1.1 
hypothetical protein     CTL0045  166154018  B0B8Q2  CT676  5.54  19.8  6  2  1.05  1.10  1.08  0.03  1.1 
hypothetical protein      CTL0589  166154546  B0B7Q3  CT335  5.16  10.5  5  2  0.78  0.79  0.79  0.01  1.3 
hypothetical protein      CTL0060  166154033  B0B8R7  CT691  4.95  25.2  8  6  1.54  1.38  1.46  0.11  +1.5 
hypothetical protein     CTL0271  166154237  B0B9C3  CT016  4.74  26.7  5  4  ND  ND  ND  ND  ND 
hypothetical protein     CTL0541  166154500  B0B7K5  CT289  9.82  41.8  24  10  1.00  0.97  0.98  0.02  1.0 
 hypothetical protein     CTL0037  166154010  B0B8P4  CT668  4.6  24.4  10  8  0.99  0.87  0.93  0.08  1.1 
hypothetical protein     CTL0238  166154209  B0B995  CT863  5.27  53.6  4  4  0.63  0.67  0.65  0.03  -1.5 
hypothetical protein      CTL0885  166154836  B0B8J6  CT621  4.88  92.6  27  12  ND  ND  ND  ND  ND 
hypothetical protein     CTL0540  166154499  B0B7K4  CT288  8.38  63.5  21  13  0.49  0.49  0.49  0.00  -2.0 
hypothetical protein      CTL0097  166154070  B0B8V4  CT728  6.24  27.9  4  3  ND  ND  ND  ND  ND 
hypothetical protein     CTL0063  166154036  B0B8S0  CT694  5.11  34.7  3  2  ND  ND  ND  ND  ND 
hypothetical protein      CTL0463  166154421  B0B9W1  CT211  4.61  20.8  4  4  ND  ND  ND  ND  ND 
hypothetical protein      CTL0305  166154270  B0B9F7  CT049  5.62  50.8  43  8  ND  ND  ND  ND  ND 
hypothetical protein     CTL0087  166154060  B0B8U4  CT718  5.89  19.6  3  2  ND  ND  ND  ND  ND 
hypothetical protein     CTL0791  166154744  B0B8A3  CT529  9.41  31.2  5  5  0.78  0.76  0.77  0.02  1.3 
hypothetical protein     CTL0297  166154262  B0B9E9  CT041  4.84  27.6  6  4  ND  ND  ND  ND  ND 
hypothetical protein     CTL0266  166154232  B0B9B8  CT011  6.36  44.7  10  10  0.88  0.82  0.85  0.04  1.2 
hypothetical protein     CTL0507  166154466  B0B7H1  CT255  4.79  14.4  4  2  ND  ND  ND  ND  ND            
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hypothetical protein     CTL0643  166154598  B0B7V7  CT387  5.81  77.1  36  13  ND  ND  ND  ND  ND 
hypothetical protein     CTL0102  166154075  B0B8V9  CT733  8.93  47.1  7  7  ND  ND  ND  ND  ND 
hypothetical protein     CTL0293  166154258  B0B9E5  CT038  9.54  13.5  3  3  ND  ND  ND  ND  ND 
hypothetical protein      CTL0605  166154563  B0B7S0  CT351  9.17  78.3  31  11  ND  ND  ND  ND  ND 
hypothetical protein     CTL0563  166154521  B0B7M7  CT311  9.07  23.9  5  5  ND  ND  ND  ND  ND 
hypothetical protein      CTL0609  166154567  B0B7S4  CT355  5.44  37.4  20  10  ND  ND  ND  ND  ND 
hypothetical protein     CTL0314  166154279  B0B9G6  CT058  9.37  39.7  11  4  1.17  1.51  1.34  0.24  1.3 
hypothetical protein     CTL0039  166154012  B0B8P6  CT670  7.83  20.2  21  11  ND  ND  ND  ND  ND 
hypothetical protein     CTL0309  166154274  B0B9G1  CT053  4.41  17.2  10  5  ND  ND  ND  ND  ND 
hypothetical protein     CTL0742  166154695  B0B854  CT481  8.46  27.9  5  3  ND  ND  ND  ND  ND 
hypothetical protein  rmuC  CTL0197  166154169  B0B954  CT825  6.55  48.5  13  9  ND  ND  ND  ND  ND 
hypothetical protein      CTL0891  166154842  B0B8K2  CT627  6.04  37.7  15  6  ND  ND  ND  ND  ND 
hypothetical protein     CTL0477  166154435  B0B9X5  CT224  5.22  15.9  13  5  ND  ND  ND  ND  ND 
hypothetical protein     CTL0853  166154805  B0B8G4  CT590  5.52  109.0  23  14  ND  ND  ND  ND  ND 
hypothetical protein     CTL0065  166154038  B0B8S2  CT696  6.34  45.7  8  6  ND  ND  ND  ND  ND 
hypothetical protein     CTL0433  166154391  B0B9T1  CT181  5.22  24.2  27  10  ND  ND  ND  ND  ND 
hypothetical protein     CTL0010  166153983  B0B8L7  CT642  9.16  32.1  2  2  ND  ND  ND  ND  ND 
hypothetical protein      CTL0577  5858294  B0B7P1  CT326  8.76  16.9  21  5  ND  ND  ND  ND  ND 
hypothetical protein     CTL0408  166154374  B0B9R1  CT153  6.17  90.8  16  11  ND  ND  ND  ND  ND 
hypothetical protein     CTL0883  166154834  B0B8J4  CT619  4.75  96.7  10  10  ND  ND  ND  ND  ND 
hypothetical protein     CTL0003  166153976  B0B8L0  CT635  6.17  16.7  8  5  ND  ND  ND  ND  ND 
hypothetical protein     CTL0369  166154335  B0B9M2  CT114  7.91  55.2  16  13  ND  ND  ND  ND  ND 
hypothetical protein     CTL0561  166154519  B0B7M5  CT309  5.36  32.1  9  6  ND  ND  ND  ND  ND 
hypothetical protein      CTL0496  166154455  B0B7G0  CT244  8.32  45.6  7  6  ND  ND  ND  ND  ND 
hypothetical protein     CTL0640  166154595  B0B7V4  CT384  5.84  59.8  9  4  ND  ND  ND  ND  ND 
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 Other, categories  
FKBP-type peptidyl-prolyl cis-trans isomerase   mip  CTL0803  166154756  B0B8B5  CT541  4.83  24.5  46  13  0.87  0.82  0.85  0.04  1.2 
hydrolase/phosphatase homolog  
hsp60_
1  CTL0140  166154113  B0B8Z7  CT771  5.04  17.4  21  6  0.89  0.86  0.87  0.02  1.1 
CHLPN 76kDa Homolog     CTL0887  166154838  B0B8J8  CT623  6.43  45.8  42  18  0.91  0.91  0.91  0.00  1.1 
CHLPN 76kDa Homolog     CTL0886  166154837  B0B8J7  CT622  4.93  68.9  32  14  0.52  0.47  0.49  0.03  -2.0 
Hit Family Hydrolase     CTL0641  166154596  B0B7V5  CT385  5.43  12.3  16  6  1.28  1.19  1.23  0.07  1.2 
predicted metal dependent hydrolase (histidinic 
triad)   phnP  CTL0635  166154590  B0B7U9  CT380  5.79  30.1  6  4  0.81  0.89  0.85  0.06  1.2 
hypothetical protein   ltuB  CTL0336  166154301  B0B9I8  CT080  9.84  11.3  2  2  ND  ND  ND  ND  ND 
phosphohydrolase     CTL0721  166154675  B0B834  CT461  9.27  37.0  7  6  ND  ND  ND  ND  ND 
ACR family      CTL0363  166154329  B0B9L6  CT108  5.68  27.5  2  2  ND  ND  ND  ND  ND 
SurE-like Acid Phosphatase  surE  CTL0470  166154428  B0B9W8  CT218  4.84  31.5  9  6  1.14  1.23  1.19  0.06  1.2 
Leucine Dehydrogenase   ldh  CTL0142  166154115  B0B8Z9  CT773  5.21  37.3  9  6  ND  ND  ND  ND  ND 
Dpredicted metal dependent hydrolase     CTL0642  166154597  B0B7V6  CT386  5.14  33.1  3  2  ND  ND  ND  ND  ND 
utQ/KpsF Family Sugar-P Isomerase     CTL0656  166154610  B0B7W9  CT399  5.45  36.0  12  4  ND  ND  ND  ND  ND 
Hypothetical protein containing CBS domains     CTL0508  166154467  B0B7H2  CT256  6.44  41.5  6  4  ND  ND  ND  ND  ND 
hypothetical protein     CTL0648  166154603  B0B7W2  CT392  5.26  41.3  9  8  ND  ND  ND  ND  ND 
hypothetical protein   gcpE  CTL0313  166154278  B0B9G5  CT057  5.69  66.5  13  9  ND  ND  ND  ND  ND 
PTS IIA Protein  ptsN_2  CTL0543  166154502  B0B7K7  CT291  4.86  17.1  31  3  0.92  1.27  1.10  0.25  1.1 
predicted polysaccharide hydrolase-invasin 
repeat family      CTL0382  166154348  B0B9N5  CT127  8.75  31.7  5  4  ND  ND  ND  ND  ND 
Methylase      CTL0748  166154701  B0B860  CT487  8.56  20.9  2  2  ND  ND  ND  ND  ND 
Monooxygenase  mhpA  CTL0403  166154369  B0B9Q6  CT148  8.33  57.8  35  14  ND  ND  ND  ND  ND 
YhgN family     CTL0225  166154197  B0B982  CT852  9.87  23.7  2  2  ND  ND  ND  ND  ND 
PTS PEP Phosphotransferase   ptsI  CTL0590  166154547  B0B7Q4  CT336  5.78  63.7  11  7  ND  ND  ND  ND  ND 
Arginine Kinase  aspC  CTL0044  166154017  B0B8Q1  CT675  5.96  40.1  18  5  ND  ND  ND  ND  ND 
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Purines, pyrimidines, nucleosides and nucleotides  
UMP Kinase  pyrH  CTL0047  166154020  B0B8Q4  CT678  5.29  26.1  10  5  0.98  0.89  0.94  0.06  1.1 
Thioredoxin   trxA  CTL0801  166154754  B0B8B3  CT539  5.02  11.2  3  3  ND  ND  ND  ND  ND 
CMP Kinase  cmk  CTL0712  166154666  B0B825  CT452  5.13  24.0  16  7  0.88  0.87  0.87  0.01  1.1 
adenylate kinase  adk  CTL0383  166154349  B0B9N6  CT128  4.85  27.7  15  5  0.94  0.90  0.92  0.02  1.1 
Ribonucleoside Reductase, Large Chain  nrdA  CTL0199  166154171  B0B956  CT827  5.74  119.3  37  20  1.17  1.15  1.16  0.01  1.2 
Thymidylate Kinase  tdk  CTL0440  166154398  B0B9T8  CT188  6.53  22.4  4  3  ND  ND  ND  ND  ND 
CTP Synthetase   pyrG  CTL0435  166154393  B0B9T3  CT183  5.68  58.0  12  11  ND  ND  ND  ND  ND 
dUTP Nucleotidohydrolase  dut  CTL0544  166154503  B0B7K8  CT292  5.18  15.3  3  2  ND  ND  ND  ND  ND 
Ribonucleoside Reductase, Small Chain  nrdB  CTL0200  166154172  B0B957  CT828  5.33  40.5  10  8  ND  ND  ND  ND  ND 
  
Regulatory functions  
General Stress Protein  rplY  CTL0168  166154141  B0B926  CT799  8.99  20.4  4  3  ND  ND  ND  ND  ND 
 
  
Transcription  
RNA Polymerase Alpha  rpoA  CTL0769  166154722  B0B881  CT507  5.34  41.8  44  15  0.99  0.98  0.99  0.01  1.0 
RNA Polymerase Beta  rpoB  CTL0567  166154525  B0B7N1  CT315  5.63  140.0  127  52  1.02  0.98  1.00  0.03  1.0 
RNA Polymerase Beta  rpoC  CTL0566  166154524  B0B7N0  CT314  7.17  154.7  88  52  0.94  0.93  0.93  0.00  1.1 
Transcription antitermination factor  nusA  CTL0352  166154318  B0B9K5  CT097  5.19  48.9  67  15  1.44  1.69  1.56  0.18  +1.6 
RNA Polymerase Sigma-66  rpoD  CTL0879  166154830  B0B8J0  CT615  8.09  66.1  86  26  0.94  0.95  0.95  0.00  1.1 
Sigma Regulatory Factor  rsbV  CTL0683  166154637  B0B7Z6  CT424  5.23  12.5  14  3  0.96  0.96  0.96  0.00  1.0 
Transcription Termination Factor  rho  CTL0752  166154705  B0B864  CT491  6.84  51.6  32  18  0.84  0.82  0.83  0.02  1.2 
Transcription Elongation Factor G   greA  CTL0004  166153977  B0B8L1  CT636  5.28  80.9  38  27  1.18  1.18  1.18  0.00  1.2 
Transcriptional termination protein  nusG  CTL0572  166154530  B0B7N6  CT320  5.26  20.7  9  9  0.89  1.24  1.06  0.25  1.1 
Methionyl tRNA Formyltransferase   fmt  CTL0792  166154745  B0B8A4  CT530  8.87  33.9  20  9  ND  ND  ND  ND  ND      
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Polyribonucleotide Nucleotidyltransferase  pnp  CTL0214  166154186  B0B971  CT842  5.66  75.4  19  11  1.25  1.26  1.25  0.01  1.3 
tRNA (guanine N-1) Methyltransferase  trmD  CTL0282  166154248  B0B9D4  CT027  5.6  39.8  7  4  ND  ND  ND  ND  ND 
rRNA Methyltransferse     CTL0111  166154084  B0B8W8  CT742  6.71  44.6  37  15  ND  ND  ND  ND  ND 
Poly A Polymerase  pcnB  CTL0073  166154046  B0B8T0  CT704  7.76  46.5  7  7  ND  ND  ND  ND  ND 
Ribonuclease III   rnc  CTL0549  166154508  B0B7L3  CT297  6.07  25.6  6  4  ND  ND  ND  ND  ND 
Ribonuclease HII   rnhC  CTL0263  166154229  B0B9B5  CT008  9.07  33.1  2  2  ND  ND  ND  ND  ND 
predicted pseudouridine synthetase family      CTL0361  166154327  B0B9L4  CT106  9.41  31.4  3  2  ND  ND  ND  ND  ND 
Sigma Regulatory Factor  rbsV  CTL0134  166154107  B0B8Z1  CT765  7.69  12.4  6  6  ND  ND  ND  ND  ND 
2-component regulatory system-ATPase  atoC  CTL0728  166154682  B0B841  CT468  6.24  43.1  6  5  ND  ND  ND  ND  ND 
Pseudouridine Synthase  sfhB  CTL0027  166154000  B0B8N4  CT658  6.77  37.8  7  7  ND  ND  ND  ND  ND 
  
  
  
Translation  
HSP-60 
hsp60_
1  CTL0365  166154331  B0B9L8  CT110  5.26  58.1  239  29  0.70  0.69  0.69  0.01  -1.4 
10KDa Chaperonin  groES  CTL0366  166154332  B0B9L9  CT111  4.85  11.2  273  6  0.79  0.69  0.74  0.07  1.3 
Elongation Factor Tu  tufA  CTL0574  166154532  B0B7N8  CT322  5.44  43.3  170  21  1.08  1.05  1.06  0.02  1.1 
DO Serine Protease   htrA  CTL0195  166154167  B0B952  CT823  5.89  51.4  71  21  0.81  0.79  0.80  0.02  1.2 
Molecular chaperone DnaK  dnaK  CTL0652  166154607  B0B7W6  CT396  5.03  70.8  64  11  0.94  0.86  0.90  0.05  1.1 
S15 Ribosomal Protein  rpsO  CTL0215  166154187  B0B972  CT843  9.74  10.4  51  7  1.11  0.99  1.05  0.08  1.1 
ClpC Protease ATPase   clpC  CTL0538  166154497  B0B7K2  CT286  6.03  95.2  76  35  1.06  1.04  1.05  0.02  1.0 
Heat Shock Protein J   dnaJ  CTL0595  166154553  B0B7R0  CT341  7.54  41.9  50  24  0.92  0.88  0.90  0.03  1.1 
Elongation Factor TS   tsf  CTL0048  166154021  B0B8Q5  CT679  5.65  30.9  56  17  1.41  1.51  1.46  0.07  +1.5 
Thioredoxin Disulfide Isomerase     CTL0149  166154122  B0B906  CT780  7.93  16.2  21  5  1.45  1.35  1.40  0.07  +1.4 
Alanyl tRNA Synthetase   alaS  CTL0118  166154091  B0B8X5  CT749  5.53  97.6  41  19  1.05  1.07  1.06  0.01  1.1 
HSP-70 Cofactor  grpE  CTL0651  166154606  B0B7W5  CT395  4.62  21.7  17  5  0.66  0.71  0.69  0.04  -1.5 
Clp Protease ATPase  clpB  CTL0368  166154334  B0B9M1  CT113  5.36  96.6  63  34  1.13  1.14  1.14  0.01  1.1 
L21 Ribosomal Protein  rplU  CTL0677  166154631  B0B7Z0  CT420  9.27  12.2  9  3  0.96  0.90  0.93  0.04  1.1            
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S1 Ribosomal Protein  rpsA  CTL0353  166154319  B0B9K6  CT098  5.2  63.4  22  15  0.79  0.89  0.84  0.07  1.2 
ATP-dependent zinc protease  ftsH  CTL0213  166154185  B0B970  CT841  5.78  98.1  37  25  0.85  0.87  0.86  0.01  1.2 
DnaK Suppressor   dksA  CTL0664  166154618  B0B7X7  CT407  5.1  13.9  13  4  1.04  1.11  1.08  0.05  1.1 
L7/L12 Ribosomal Protein   rplL  CTL0568  166154526  B0B7N2  CT316  4.9  13.6  88  9  1.03  0.98  1.00  0.04  1.0 
S2 Ribosomal Protein   rpsB  CTL0049  166154022  B0B8Q6  CT680  6.55  31.2  42  16  1.11  1.07  1.09  0.03  1.1 
L5 Ribosomal Protein   rplE  CTL0778  166154731  B0B890  CT516  9.44  20.5  18  8  0.82  0.74  0.78  0.06  1.3 
L9 Ribosomal Protein  rplI  CTL0172  166154145  B0B930  CT803  6.11  18.4  15  5  0.91  1.00  0.95  0.07  1.0 
Insulinase family/Protease III  ptr  CTL0175  166154148  B0B933  CT806  5.05  104.4  35  22  1.23  1.16  1.20  0.04  1.2 
Glu-tRNA Gln Amidotransferase (B Subunit)   gatB  CTL0259  166154225  B0B9B1  CT004  5.92  54.9  17  14  1.16  1.37  1.26  0.15  1.3 
L10 Ribosomal Protein  rplJ  CTL0569  166154527  B0B7N3  CT317  5.98  18.9  11  5  0.99  0.95  0.97  0.03  1.0 
L4 Ribosomal Protein  rplD  CTL0789  166154742  B0B8A1  CT527  9.79  24.6  11  5  1.33  1.28  1.31  0.04  1.3 
Protease  sohB  CTL0755  166154708  B0B867  CT494  6.51  31.8  8  4  1.04  0.96  1.00  0.06  1.0 
CLP Protease  clpP  CTL0690  166154644  B0B803  CT431  5.21  20.9  10  5  0.69  0.70  0.69  0.01  -1.4 
L13 Ribosomal Protein  rplM  CTL0380  166154346  B0B9N3  CT125  10.19  16.8  8  3  1.59  1.32  1.45  0.19  +1.5 
L16 Ribosomal Protein  rplP  CTL0783  166154736  B0B895  CT521  11.3  15.8  10  5  0.92  0.95  0.93  0.02  1.1 
L1 Ribosomal Protein  rplA  CTL0570  166154528  B0B7N4  CT318  9.03  24.7  25  10  0.81  0.83  0.82  0.01  1.2 
L11 Ribosomal Protein   rplK  CTL0571  166154529  B0B7N5  CT319  9.68  15.0  7  6  1.10  1.12  1.11  0.01  1.1 
S5 Ribosomal Protein   rpsE  CTL0774  166154727  B0B886  CT512  9.87  17.8  11  6  1.18  1.21  1.19  0.02  1.2 
S3 Ribosomal Protein  rpsC  CTL0784  166154737  B0B896  CT522  10.03  24.3  10  5  1.14  1.12  1.13  0.02  1.1 
Tryptophanyl tRNA Synthetase   trpS  CTL0848  166154800  B0B8F9  CT585  6.51  39.4  10  7  1.02  0.87  0.94  0.10  1.1 
Lon ATP-dependent protease  lon  CTL0598  166154556  B0B7R3  CT344  6.9  91.9  59  31  0.82  0.80  0.81  0.02  1.2 
 Initiation Factor-2   infA  CTL0351  166154317  B0B9K4  CT096  8.21  97.3  41  25  1.31  1.23  1.27  0.06  1.3 
Leucyl Aminopeptidase A      CTL0301  166154266  B0B9F3  CT045  5.73  54.2  43  23  0.99  0.97  0.98  0.02  1.0 
L3 Ribosomal Protein   rplC  CTL0790  166154743  B0B8A2  CT528  9.72  23.5  16  10  1.37  1.23  1.30  0.10  1.3 
Glu-tRNA Gln Amidotransferase (A subunit)   gatA  CTL0258  166154224  B0B9B0  CT003  5.87  53.6  18  14  1.23  1.18  1.20  0.03  1.2 
S9 Ribosomal Protein  rpsI  CTL0381  166154347  B0B9N4  CT126  11.02  14.5  7  4  ND  ND  ND  ND  ND 
Aspartyl tRNA Synthetase  aspS  CTL0804  166154757  B0B8B6  CT542  5.31  66.2  43  21  1.05  1.06  1.06  0.01  1.1      
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Glycyl tRNA Synthetase   glyQ  CTL0165  166154138  B0B923  CT796  5.66  112.4  23  14  0.88  0.95  0.91  0.05  1.1 
Glu-tRNA Gln Amidotransferase (C subunit)   gatC  CTL0257  166154223  B0B9A9  CT002  4.14  11.1  3  2  ND  ND  ND  ND  ND 
 tyrosyl tRNA Synthetase  tyrS  CTL0318  166154283  B0B9H0  CT062  6.62  45.4  25  11  1.51  1.52  1.52  0.00  +1.5 
S8 Ribosomal Protein  rpsH  CTL0777  166154730  B0B889  CT515  10.27  15.1  9  7  ND  ND  ND  ND  ND 
Initiation Factor 3  infC  CTL0205  166154177  B0B962  CT833  9.5  21.1  11  8  ND  ND  ND  ND  ND 
S13 Ribosomal Protein  rpsM  CTL0771  166154724  B0B883  CT509  11.01  13.9  12  4  0.86  0.91  0.88  0.04  1.1 
L19 Ribosomal Protein  rplS  CTL0283  166154249  B0B9D5  CT028  9.95  13.1  9  6  ND  ND  ND  ND  ND 
Ribosome Releasing Factor  rrf  CTL0046  166154019  B0B8Q3  CT677  8.59  20.0  9  7  ND  ND  ND  ND  ND 
Peptide Chain Releasing Factor (RF-1)   prfA  CTL0278  166154244  B0B9D0  CT023  5.29  40.0  7  5  ND  ND  ND  ND  ND 
Elongation Factor P   efp  CTL0121  166154094  B0B8X8  CT752  4.74  20.2  12  6  ND  ND  ND  ND  ND 
L6 Ribosomal Protein   rplF  CTL0776  166154729  B0B888  CT514  9.96  19.8  10  9  0.94  0.87  0.91  0.05  1.1 
S10 Ribosomal Protein   rpsJ  CTL0695  166154649  B0B808  CT436  10.47  11.9  13  6  1.31  1.41  1.36  0.07  +1.4 
L24 Ribosomal Protein  rplX  CTL0779  166154732  B0B891  CT517  10.44  12.6  11  8  ND  ND  ND  ND  ND 
Metalloprotease  ispH  CTL0234  166154205  B0B991  CT859  6.1  34.2  9  7  0.86  0.79  0.83  0.05  1.2 
S6 Ribosomal Protein  rpsF  CTL0170  166154143  B0B928  CT801  8.75  12.9  4  2  ND  ND  ND  ND  ND 
L18 Ribosomal Protein  rplR  CTL0775  166154728  B0B887  CT513  10.32  13.4  3  2  1.13  1.03  1.08  0.07  1.1 
L22 Ribosomal Protein   rplV  CTL0785  166154738  B0B897  CT523  11.34  12.4  3  3  0.98  1.22  1.10  0.17  1.1 
S4 Ribosomal Protein   rpsD  CTL0890  166154841  B0B8K1  CT626  10.01  23.6  13  9  1.00  1.01  1.01  0.01  1.0 
L17 Ribosomal Protein  rplQ  CTL0768  166154721  B0B880  CT506  11.27  16.1  19  9  ND  ND  ND  ND  ND 
Metalloprotease      CTL0328  166154293  B0B9I0  CT072  6.34  66.3  28  14  1.07  1.17  1.12  0.07  1.1 
Histidyl tRNA Synthetase  hisS  CTL0805  166154758  B0B8B7  CT543  6.65  49.1  15  7  ND  ND  ND  ND  ND 
S11 Ribosomal Protein   rpsK  CTL0770  166154723  B0B882  CT508  11.26  13.8  9  5  ND  ND  ND  ND  ND 
Threonyl tRNA Synthetase  thrS  CTL0844  166154796  B0B8F5  CT581  5.68  72.6  10  7  ND  ND  ND  ND  ND 
Leucyl tRNA Synthetase  leuS  CTL0461  166154419  B0B9V9  CT209  5.41  92.8  22  14  ND  ND  ND  ND  ND 
Oligoendopeptidase   pepF  CTL0367  166154333  B0B9M0  CT112  5.6  69.0  25  10  ND  ND  ND  ND  ND 
HSP-60 
groEL
2  CTL0867  166154818  B0B8H8  CT604  5.05  58.8  22  8  ND  ND  ND  ND  ND            
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Lysyl tRNA Synthetase  lysS  CTL0150  166154123  B0B907  CT781  5.33  60.0  19  10  ND  ND  ND  ND  ND 
L28 Ribosomal Protein  rpmB  CTL0341  166154307  B0B9J4  CT086  11.65  10.1  6  4  ND  ND  ND  ND  ND 
Isoleucyl-tRNA Synthetase  ileS  CTL0274  166154240  B0B9C6  CT019  5.36  118.7  9  9  ND  ND  ND  ND  ND 
  
   
Transport and binding proteins  
Solute Protein Binding Family     CTL0323  166154288  B0B9H5  CT067  5.01  33.3  48  11  0.73  0.75  0.74  0.02  -1.4 
ABC Transporter ATPase     CTL0054  166154027  B0B8R1  CT685  5.14  28.4  14  9  0.96  0.99  0.97  0.02  1.0 
oligopeptide Binding Lipoprotein  oppA4  CTL0741  166154694  B0B853  CT480  5  77.5  26  14  1.48  1.44  1.46  0.03  +1.5 
Arginine Binding Protein  artJ  CTL0636  166154591  B0B7V0  CT381  4.89  25.6  12  8  1.17  1.20  1.19  0.02  1.2 
ABC Transporter Membrane Protein      CTL0055  166154028  B0B8R2  CT686  6.03  44.6  8  4  0.83  0.86  0.84  0.03  1.2 
Metal Transport P-type ATPase      CTL0096  166154069  B0B8V3  CT727  6.83  70.4  10  7  ND  ND  ND  ND  ND 
Solute-binding protein     CTL0672  166154626  B0B7Y5  CT415  6.86  29.4  2  2  ND  ND  ND  ND  ND 
ABC Amino Acid Transporter ATPase     CTL0385  166154351  B0B9N8  CT130  5.75  25.5  12  3  ND  ND  ND  ND  ND 
polysaccharide transporter   exbB  CTL0860  166154810  B0B8H0  CT596  9.21  25.9  2  2  ND  ND  ND  ND  ND 
ABC Amino Acid Transporter Permease     CTL0384  166154350  B0B9N7  CT129  9.03  23.6  6  3  ND  ND  ND  ND  ND 
Mg++ Transporter (CBS Domain)  mgtE  CTL0446  166154404  B0B9U4  CT194  4.94  51.4  20  8  ND  ND  ND  ND  ND 
Transport ATP Binding Protein     CTL0516  166154475  B0B7I0  CT264  8.09  68.3  17  10  ND  ND  ND  ND  ND 
Oligopeptide Permease  oppC2  CTL0739  166154692  B0B851  CT478  8.83  61.6  26  11  ND  ND  ND  ND  ND 
ABC Transport ATPase (Nitrate/Fe)      CTL0432  166154390  B0B9T0  CT180  6.6  25.6  28  7  ND  ND  ND  ND  ND 
Oligopeptide Transport ATPase  oppD  CTL0453  166154411  B0B9V1  CT201  6.75  30.7  12  5  ND  ND  ND  ND  ND 
Translocated actin-recruiting phosphoprotein  tarp  CTL0716  166154670  Q6GX35  CT456  4.1  103.2  22  15  0.88  0.98  0.93  0.07  1.1 
   
Plasmid  
Putative uncharacterized protein 
 
pL2-05  5857580  B0BCM1 
 
4.78  27.9  38  7  0.92  0.90  0.91  0.01  1.1 
Putative uncharacterized protein 
 
pL2-07a  5857577  B0BCL9 
 
6.25  14.3  7  4  ND  ND  ND  ND  ND 
Putative uncharacterized protein 
 
pL2-07  5857574  B0BCM7 
 
5.63  15.2  7  2  ND  ND  ND  ND  ND      
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Virulence plasmid integrase pGP8-D 
 
pL2-02  5857576  B0BCM4 
 
10.05  37.8  24  15  ND  ND  ND  ND  ND 
Putative uncharacterized protein 
 
pL2-06  5857575  B0BCM0 
 
9.33  11.8  10  6  ND  ND  ND  ND  ND 
!
a)  pI!&!molecular!mass!were!obtained!using!‘Compute MW/pI ‘ (ExPASy bioinformatics resource portal). 
b)  Reporter!ion!tags!correspond!to!the!following!samples:!114!=!EB,!115=!RB,!116=EB,!117=RB.!
c)  Values!with!(F)!are!downFregulated!below!the!1.4!fold!threshold!and!values!with!(+)!are!upFregulated!above!the!1.4!fold!threshold.!
!
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Appendix I, Table 5.2. Proteins assigned and quantified in EBs and RBs from C. trachomatis L2\434\Bu using the label-free approach. 
 
UniProt 
accession/ 
Category  Locus 
Gene 
name  Protein description 
MW
 
kDa
a  pI
b 
Total 
peptides
c 
Total 
unique 
peptides
d 
Mean RB 
(mol/cell)
e 
RB 
(N)  STDev
f 
Mean EB 
(mol/cell)
e 
EB 
(N)  STDev
f 
EB/RB 
ratio 
                              Amino Acid Biosynthesis 
                        B0B8L2  CTL0005  aspC  Aspartate aminotransferase  44737  5.4  167  22  21  3  11  15  1  ND  0.7 
B0B9S1  CTL0423  trpB  tryptophan synthase beta chain   42618  6.8  71  11  25  1  ND  13  2  2  0.5 
B0B9S2  CTL0424  trpA  tryptophan synthase alpha chain  28101  4.8  112  14  67  4  46  53  4  22  0.8 
B0B7J8  CTL0534  gcsH  glycine cleavage system H protein   13147  4.5  19  4  38  1  ND  17  3  4  0.4 
B0B7T0  CTL0615  dapA  dihydrodipicolinate synthase  31262  5.5  85  13  61  4  32  31  4  7  0.5 
B0B7T1  CTL0616  lysC  aspartokinase  47553  5.1  88  13  26  3  12  21  2  15  0.8 
B0B7T3  CTL0618  dapB  dihydrodipicolinate reductase   27789  5.8  97  12  49  4  22  28  4  8  0.6 
B0B7T8  CTL0623  aroB  3-dehydroquinate synthase  41183  7.7  31  3  0  0  ND  18  1  ND  EB 
B0B7T9  CTL0624  aroE  shikimate 5-dehydrogenase   53252  8.8  84  14  35  1  ND  20  1  ND  0.6 
B0B804  CTL0691  glyA  serine hydroxymethyltransferase   54249  6.0  218  15  65  4  4  48  2  4  0.7 
B0B9Q3  CTL0400  pkn1  serine-threonine-protein kinase  69638  5.1  198  32  70  4  37  34  4  11  0.5 
 
 
 
         
                          
Biosynthesis of Cofactors 
     
                          
B0B8K8  CTL0001  hemB 
delta-aminolevulinic acid 
dehydratase   37726  5.9  39  4  19  1  ND  0  0  ND  RB 
B0B8M4  CTL0017     conserved hypothetical protein  20692  6.2  15  5  8  1  ND  0  0  ND  RB 
B0B8V6  CTL0099  ribD 
Riboflavin biosynthesis protein 
(diaminohydroxyphosphoribosylami
nopyrimidine deaminase)   41104  7.5  69  6  132  1  ND  7  1  ND  0.1 
B0B8V8  CTL0101  ribH 
Riboflavin synthase beta chain (6_7-
dimethyl-8-ribityllumazine synthase)  16412  6.3  48  5  80  4  14  76  1  ND  1.0      
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B0B8X1  CTL0114  hemG  protoporphyrinogen oxidase   47237  9.7  55  5  33  1  ND  27  1  ND  0.8 
B0B8X2  CTL0115  hemN  coproporphyrinogen oxidase (NAD)   52989  7.0  37  12  50  1  ND  0  0  ND  RB 
B0B8X3  CTL0116  hemE  uroporphyrinogen decarboxylase [  37703  5.6  36  3  7  1  ND  0  0  ND  RB 
B0B9W0  CTL0462  hemL 
glutamate-1-semialdehyde 2_1-
aminomutase   45940  6.0  126  16  44  3  16  24  3  6  0.6 
B0B7X5  CTL0662  ribC  riboflavin synthase alpha chain   22123  5.9  24  2  9  1  ND  0  0  ND  RB 
B0B8D2  CTL0821  lipA  lipoic acid synthetase   34695  7.2  126  13  20  3  14  19  3  3  1.0 
B0B8I8  CTL0877  folP 
2-amino-4-hydroxy-6-
hydroxymethyldihydropteridi ne 
pyrophosphokinase  50263  5.4  183  21  61  4  21  19  3  4  0.3 
B0B8I9  CTL0878  folX  dihydroneopterin aldolase   13941  5.2  7  4  0  0  ND  6  1  ND  EB 
B0B8K3  CTL0892  ispA  dimethylallyltransferase   32524  4.9  77  16  37  2  15  20  3  6  0.5 
 
 
 
         
                          
Base & Nucleotide Metabolism 
   
                          
B0B8Q4  CTL0047  pyrH  uridylate kinase   26163  5.3  145  9  95  4  33  63  4  15  0.7 
B0B8X7  CTL0120  amn  AMP nucleosidase   32034  6.6  56  12  20  2  7  20  2  11  1.0 
B0B956  CTL0199  nrdA 
ribonucleoside-diphosphate 
reductase alpha chain   119414  5.7  590  65  117  4  78  70  3  32  0.6 
B0B957  CTL0200  nrdB 
ribonucleoside-diphosphate 
reductase beta chain   40504  5.3  104  14  28  2  6  23  2  2  0.8 
B0B973  CTL0216     Cytosine deaminase  18476  6.2  9  2  0  0  ND  3  1  ND  EB 
B0B9D7  CTL0285  gmk  guanylate kinase  23109  5.6  68  9  26  2  1  25  1  ND  0.9 
B0B9E6  CTL0294  dcd 
deoxycytidine triphosphate 
deaminase   21385  4.8  84  8  34  4  13  21  4  4  0.6 
B0B9K7  CTL0354  trxB  thioredoxin reductase  37868  7.5  128  15  65  3  28  44  3  22  0.7 
B0B9N6  CTL0383  adk  adenylate kinase   27727  4.9  141  15  142  4  28  89  4  25  0.6 
B0B9T3  CTL0435  pyrG  CTP synthase   60189  5.7  165  23  54  3  14  32  4  5  0.6 
B0B9T8  CTL0440  tdk  thymidylate kinase   22457  6.5  64  7  31  3  11  19  3  4  0.6            
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B0B7K6  CTL0542    
PTS-family membrane transport 
protein IIA component   25758  5.3  86  12  59  4  26  42  4  12  0.7 
B0B7K8  CTL0544  dut 
deoxyuridine 5'-triphosphate 
nucleotidohydrolase   15337  5.2  49  6  61  4  22  74  4  2  1.2 
B0B7U8  CTL0634     putative nucleotide-binding protein  50819  7.1  136  19  119  4  102  70  4  27  0.6 
B0B825  CTL0712  cmk  cytidylate kinase   24044  5.1  141  17  62  4  13  55  4  12  0.9 
B0B874  CTL0762  ndk  nucleoside diphosphate kinase   15265  5.4  104  10  59  4  8  28  4  10  0.5 
B0B8B3  CTL0801  trxA  thioredoxin  11197  5.0  5  2  0  0  ND  3  1  ND  EB 
B0B8H7  CTL0866  ahpC  thioredoxin peroxidase   21717  4.8  143  16  549  4  61  445  4  169  0.8 
           
                          
Cell Envelope 
       
                          
B0B9A6  CTL0254  pmpI 
polymorphic outer membrane 
protein   95518  6.1  442  37  241  4  125  82  4  18  0.3 
B0B9A4  CTL0251  pmpH 
polymorphic outer membrane 
protein   107331  6.6  507  41  341  4  191  94  4  18  0.3 
B0B9A3  CTL0250  pmpG 
polymorphic outer membrane 
protein   107244  5.7  537  38  637  4  334  154  4  26  0.2 
B0B9A2  CTL0249  pmpF 
polymorphic outer membrane 
protein   112539  9.1  529  36  123  4  63  30  3  4  0.2 
B0B9A1  CTL0248  pmpE 
polymorphic outer membrane 
protein   104711  6.7  440  37  292  4  164  62  4  20  0.2 
B0B940  CTL0183  pmpD 
polymorphic outer membrane 
protein   160521  4.8  831  77  685  4  291  361  4  80  0.5 
B0B7Y4  CTL0671  pmpC 
polymorphic outer membrane 
protein   187044  4.6  649  66  265  4  167  76  4  4  0.3 
B0B7Y3  CTL0670  pmpB 
polymorphic outer membrane 
protein   183115  8.2  959  77  376  4  48  237  4  14  0.6 
B0B7Y2  CTL0669  pmpA 
polymorphic outer membrane 
protein   105625  8.6  457  40  112  4  123  33  2  1  0.3 
B0B7I6  CTL0522  pbp  penicillin-binding protein   73428  9.3  62  6     0  ND  19  1  ND  EB      
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B0B8H4  CTL0863  pal  peptidoglycan-associated lipoprotein   21532  7.9  112  10  281  4  163  100  4  21  0.4 
B0B7G7  CTL0503  oxaA  inner membrane protein  88024  8.4  417  36  237  4  108  66  4  4  0.3 
B0B7F8  CTL0494  ompH  outer membrane protein   19445  4.7  153  9  475  4  123  328  4  96  0.7 
B0B8T9  CTL0082  ompB  outer membrane protein B   37406  5.2  174  9  459  4  194  215  4  50  0.5 
B0B8Q7  CTL0050  ompA  major outer membrane protein  42550  5.1  414  21  2041  4  1117  2728  4  559  1.3 
B0B815  CTL0702  omcB 
60kD cysteine-rich outer membrane 
protein   59452  8.1  384  34  1704  4  361  518  4  91  0.3 
B0B8Y5  CTL0128  nlpD  muramidase  27234  9.1  94  10  44  4  10  63  2  2  1.4 
B0B8Y4  CTL0127  murD 
UDP-N-acetylmuramoylalanine--D-
glutamate ligase   46183  5.5  109  12  19  3  10  0  0  ND  RB 
B0B8Y8  CTL0131  murC 
UDP-N-acetylmuramate--alanine 
ligase   89204  5.2  189  24  42  4  28  23  1  ND  0.5 
B0B7I8  CTL0524  mraW 
S-adenosyl-L-methionine-dependent 
methyltransferase   34017  8.9  104  16  55  3  38  27  3  11  0.5 
B0B9M6  CTL0373  incG  inclusion membrane protein G  17540  8.3  63  6  161  4  111  19  4  4  0.1 
B0B9M4  CTL0371  incE  inclusion membrane protein E  13594  8.1  59  3  188  4  87  50  4  12  0.3 
B0B7E9  CTL0485  incC  inclusion membrane protein C   18512  8.8  6  2  7  1  ND  0  0  ND  RB 
B0B9M7  CTL0374  incA  inclusion membrane protein A   27489  6.2  160  27  84  4  27  20  2  1  0.2 
B0B945  CTL0188  glmS 
glucosamine--fructose-6-phosphate 
aminotransferase   67471  5.4  250  32  121  4  52  62  4  42  0.5 
B0B814  CTL0701  crpA  cysteine-rich membrane protein  15832  6.2  88  4  174  4  97  33  4  16  0.2 
B0B7I4  CTL0520  amiA 
N-acetylmuramoyl-L-alanine 
amidase  28690  9.8  78  6  24  2  16  12  2  6  0.5 
B0B8L7  CTL0010     putative membrane protein   32122  9.2  17  7  59  1  ND  0  0  ND  RB 
B0B941  CTL0184    
candidate inclusion membrane 
protein  29429  5.4  31  5  94  1  ND  0  0  ND  RB 
B0B942  CTL0185     putative membrane protein   11421  10.7  54  4  242  4  112  32  4  23  0.1 
B0B980  CTL0223     putative integral membrane protein   45891  5.2  92  7  44  2  2  0  0  ND  RB 
B0B999  CTL0246     putative membrane protein   38368  4.6  14  4  17  1  ND  0  0  ND  RB 
B0B9A0  CTL0247     putative membrane protein   44978  8.2  222  17  112  4  75  29  4  9  0.3            
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B0B9B2  CTL0260     putative membrane protein   39562  9.2  17  4  30  1  ND  0  0  ND  RB 
B0B9B9  CTL0267     putative integral membrane protein   29973  9.5  56  7  34  4  20  13  2  3  0.4 
B0B9C5  CTL0273     putative membrane protein   17817  9.2  71  9  25  4  9  7  3  3  0.3 
B0B9L0  CTL0357     putative membrane protein  17289  9.6  21  5  44  1  ND  0  0  ND  RB 
B0B9Q2  CTL0399     putative membrane protein   31355  8.9  160  15  96  4  30  31  2  7  0.3 
B0B9Q5  CTL0402     putative integral membrane protein  162274  8.8  813  80  132  4  61  42  4  9  0.3 
B0B9Q9  CTL0406    
lipoprotein releasing system_ inner 
membrane component   56294  5.2  52  3  30  1  ND  0  0  ND  RB 
B0B9R1  CTL0408     MAC/perforin family protein   90871  6.2  300  44  96  4  46  85  4  43  0.9 
B0B9W4  CTL0466    
candidate inclusion membrane 
protein   59776  9.2  72  12  41  2  21  0  0  ND  RB 
B0B9X4  CTL0476    
candidate inclusion membrane 
protein   29592  6.8  212  17  968  4  432  186  4  68  0.2 
B0B9X7  CTL0478    
candidate inclusion membrane 
protein   18263  5.5  9  4  3  1  ND  0  0  ND  RB 
B0B9X9  CTL0480    
candidate inclusion membrane 
protein   20777  5.1  104  8  46  4  34  13  3  7  0.3 
B0B9Y0  CTL0481    
candidate inclusion membrane 
protein   23534  9.2  88  6  75  4  52  18  4  7  0.2 
B0B7F7  CTL0493    
outer membrane protein (variable 
surface antigen)   88771  9.0  389  38  309  4  161  91  4  11  0.3 
B0B7H0  CTL0506     inner membrane protein   28293  9.2  21  1  13  1  ND  0  0  ND  RB 
B0B7K4  CTL0540  omp85 
candidate inclusion membrane 
protein  63512  8.4  214  26  85  4  11  23  2  2  0.3 
B0B7K5  CTL0541    
putative membrane protein 
[Chlamydia trachomatis 434/Bu]  41811  9.8  122  20  115  3  26  109  4  29  0.9 
B0B7T4  CTL0619     putative integral membrane protein   61073  9.4  90  14  49  3  11  0  0  ND  RB 
B0B7Z1  CTL0678     putative inner membrane protein   25762  9.1  127  5  89  4  43  47  4  8  0.5 
B0B812  CTL0699     putative membrane protein   12667  9.6  5  1  26  1  ND  0  0  ND  RB 
B0B8A3  CTL0791     putative membrane protein   31250  9.4  133  11  329  4  166  45  2  16  0.1      
 
 
2
6
5
 
B0B8E2  CTL0831     putative membrane protein  17110  7.5  20  3  14  1  ND  0  0  ND  RB 
B0B8H5  CTL0864     putative soluble transglycosylase  22467  8.8  104  7  23  3  2  0  0  ND  RB 
B0B8J1  CTL0880     putative integral membrane protein   49923  8.6  157  17  11  2  18  22  1  ND  0.5 
B0B8J3  CTL0882     putative membrane protein  27913  9.6  109  10  340  4  172  48  4  36  0.1 
B0B9U5  CTL0447 
 
putative integral membrane protein  40800  9.5  26  3  0  0  ND  22  1  ND  EB 
B0B983  CTL0226 
 
putative integral membrane protein  21180  9.0  15  1  0  0  ND  10  1  ND  EB 
           
                          
Cellular Processes 
       
                          
B0B8T3  CTL0076  tig  trigger factor (chaperone)   50098  5.0  304  39  279  4  101  283  4  80  1.0 
B0B7L0  CTL0546  sodM  superoxide dismutase   23396  6.0  129  8  85  4  10  58  4  33  0.7 
B0B884  CTL0772  secY  protein translocase subunit  50227  10.1  32  3  31  2  16  0  0  ND  RB 
B0B821  CTL0708  secF 
protein translocase (secFG fusion 
protein)  156503  7.4  #N/A  64  47  4  19  49  2  24  1.0 
B0B7N7  CTL0573  secE  protein translocase subunit   9542  10.1  25  3  56  3  18  47  4  28  0.8 
B0B8S7  CTL0070  secA  preprotein translocase subunit  110403  5.7  491  68  136  4  49  51  4  4  0.4 
B0B9J9  CTL0346  sctU 
type III secretion system inner 
membrane protein   40453  9.3  91  8  33  3  10  0  0  ND  RB 
B0B8D6  CTL0825  sctR 
type III secretion system_ membrane 
protein   33799  7.0  77  4  32  3  16  0  0  ND  RB 
B0B8P8  CTL0041  sctQ 
Type III secretion component_ basal 
body   41198  4.5  157  16  162  4  68  54  4  10  0.3 
B0B8P5  CTL0038  sctN 
ATP synthase (predicted TTSS 
protein)  48217  5.6  245  28  91  4  11  45  3  18  0.5 
B0B8D5  CTL0824  sctL  type III secretion system protein  24767  5.7  139  14  159  4  35  115  4  27  0.7 
B0B8D3  CTL0822  sctJ 
type III secretion system protein_ 
membrane component   35512  5.2  242  15  566  4  249  228  4  24  0.4 
B0B8F0  CTL0839  scc2 
type III secretion chaperone (low 
calcium response protein H)  26053  9.1  89  10  60  4  25  27  2  8  0.5 
B0B8F3  CTL0842  copD 
putative type III secretion system 
protein  44066  9.5  305  14  134  4  21  76  4  12  0.6            
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B0B8F2  CTL0841  copB 
putative type III secretion system 
membrane protein ]  50321  9.2  300  23  73  4  8  31  4  5  0.4 
B0B9J7  CTL0344  copN 
low calcium response protein E 
(TTSS effector protein)   45195  4.9  250  24  54  4  11  42  4  18  0.8 
B0B8Q0  CTL0043  SctC 
Type III secretion structural protein 
(outer membrane ring)  100237  5.4  377  35  260  4  125  75  4  12  0.3 
B0B9F1  CTL0299    
putative type III secretion system 
chaperone  18356  5.0  149  11  192  4  49  98  4  47 
0.5 
 
B0B8P9  CTL0042  pkn5 
putative serine/threonine-protein 
kinase (TTSS effector protein)   55968  6.3  30  7  8  1  ND  0  0  ND  RB 
B0B8R4  CTL0057  parB 
putative chromosome partitioning 
protein   31524  8.7  160  19  27  4  7  27  3  9  1.0 
B0B8T5  CTL0078  mreB  Cell shape determining protein   39510  8.7  119  13  46  4  33  27  4  6  0.6 
B0B8F6  CTL0845  minD 
Chromosome partitioning ATPase 
(ParA family)  28208  6.7  67  8  44  4  28  16  3  2  0.4 
B0B9C7  CTL0275  lepB  signal peptidase I   71535  8.4  281  27  137  4  95  47  4  28  0.3 
B0B9H2  CTL0320  lepA  GTP-binding protein   67408  6.0  218  25  54  4  32  32  4  11  0.6 
B0B9J8  CTL0345  SctV 
low calcium response protein D 
(predicted to be part of the TTSS 
apparatus) [  77974  7.7  407  33  252  4  132  65  4  20  0.3 
B0B8E3  CTL0832  gspG  general secretion pathway protein G   12169  7.7  83  8  69  4  35  35  4  8  0.5 
B0B8E5  CTL0834  gspE  general secretion pathway protein E   55754  6.6  93  10  34  2  5  0  0  ND  RB 
B0B8E6  CTL0835  gspD  general secretion pathway protein D   83768  5.2  334  45  46  4  21  17  3  2  0.4 
B0B949  CTL0192  ftsY  Cell Division Protein  31455  7.7  42  5  22  3  10  15  1  ND  0.7 
B0B8Y6  CTL0129  ftsW  Cell division protein   41994  9.5  15  3  64  1  ND  0  0  ND  RB 
B0B9D2  CTL0280  ffh 
signal recognition particle_ subunit 
FFH/SRP54   49705  8.6  268  28  41  3  14  39  4  12  1.0 
B0B8S9  CTL0072  engA  GTP-binding protein   55606  8.6  96  14  28  2  8  10  1     0.3 
B0B935  CTL0177  cafE  ribonuclease E  59365  6.5  279  34  112  4  43  65  4  26  0.6 
B0B8P0  CTL0033     phosphopeptide binding protein   89739  4.5  496  44  924  4  441  341  4  7  0.4      
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B0B8Q9  CTL0052     tetratricopeptide repeat protein   38333  4.9  93  13  14  4  4  10  1  ND  0.7 
B0B9K0  CTL0347     GTP-binding protein   39990  5.2  189  18  88  4  54  67  4  33  0.8 
B0B9P9  CTL0396     protein translocase   16791  8.6  38  5  18  2  1  17  3  10  1.0 
B0B7H5  CTL0511 
 
protein phosphatase 2C  28051  5.9  20  2  0  0  ND  0  1  ND  EB 
           
                          
Central Intermediary Metabolism 
   
                          
B0B8T6  CTL0079  pckA 
phosphoenolpyruvate carboxykinase 
(GTP)   66117  5.6  212  24  70  4  16  54  2  0  0.8 
B0B8Z8  CTL0141  ppa  inorganic pyrophosphatase   23391  4.8  64  11  108  3  22  81  3  36  0.8 
B0B925  CTL0167  glgA  glycogen synthase   53394  5.6  182  20  100  4  61  50  4  14  0.5 
B0B7G4  CTL0500  glgP  glycogen phosphorylase   92767  5.7  375  47  39  4  2  41  2  10  1.1 
B0B7R5  CTL0600     Ribonuclease Z  34662  6.6  94  12  48  1  ND  21  2  13  0.4 
B0B807  CTL0694     Putative oxidoreductase   39884  7.6  38  11  28  1  ND  0  0  ND  RB 
B0B862  CTL0750  glgC 
glucose-1-phosphate 
adenylyltransferase   49935  6.2  61  12  17  1  ND  0  0  ND  RB 
           
                          
DNA Replication 
       
                          
B0B8L8  CTL0011  topA  DNA topoisomerase I  96705  8.8  173  24  32  1  ND  18  1  ND  0.6 
B0B8M5  CTL0018  recA  recombinase A   37818  7.0  213  22  311  4  159  255  4  34  0.8 
B0B8N6  CTL0029  gyrA2  DNA gyrase subunit A   55250  6.8  66  16  26  2  6  18  2  6  0.7 
B0B8T4  CTL0077     putative helicase   133190  5.4  513  66  113  4  71  50  4  14  0.4 
B0B8W9  CTL0112  hctA 
histone H1--like developmental 
protein   13699  10.7  28  1  162  2  49  61  1  ND  0.4 
B0B8X4  CTL0117  mfd  transcription-repair coupling factor   121163  6.1  412  56  45  4  5  76  2  74  1.7 
B0B918  CTL0160  mutS  DNA mismatch repair protein  92131  6.7  429  41  67  4  21  40  4  17  0.6 
B0B954  CTL0197  rmuC  DNA recombination protein  48522  6.6  189  20  48  4  17  34  3  10  0.7 
B0B9D1  CTL0279    
peptide release factor-glutamine N5-
methyltransferase   32772  6.3  23  4  12  1  ND  0  0  ND  RB 
B0B9E8  CTL0296  ruvB 
Holliday junction ATP-dependent 
DNA helicase   37289  7.0  63  10  22  2  11  16  1  ND  0.7            
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B0B9F2  CTL0300  ssb  single-strand DNA binding protein   17147  4.8  44  9  36  4  19  26  2  17  0.7 
B0B9I3  CTL0331  dnaN  DNA polymerase III_ beta chain   46530  5.9  195  19  85  4  53  49  4  4  0.6 
B0B9Q4  CTL0401  dnlJ  NAD-dependent DNA ligase   73498  6.6  59  8  34  1  ND  0  0  ND  RB 
B0B9T9  CTL0441  gyrA  DNA gyrase subunit A   94235  6.3  478  52  176  4  66  82  4  7  0.5 
B0B9U0  CTL0442  gyrB2  DNA gyrase subunit B   89761  5.5  458  53  143  4  53  103  4  2  0.7 
B0B7G6  CTL0501  dnaA 
Chromosomal replication initiation 
protein   51929  6.5  179  17  30  3  13  28  2  11  0.9 
B0B7H7  CTL0513  dnaQ  DNA polymerase III_ epsilon chain   26559  5.6  126  13  37  4  16  55  4  12  1.5 
B0B7I3  CTL0519  ihfA  integration host factor alpha-subunit   11411  11.1  101  7  204  4  62  472  4  86  2.3 
B0B7J1  CTL0527  dnaA2 
Chromosomal replication initiation 
protein  51348  8.7  205  22  46  4  20  31  4  9  0.7 
B0B7L4  CTL0550  radA  DNA repair protein   49811  7.2  27  3  47  1  ND  0  0  ND  RB 
B0B7P6  CTL0583  xseA 
exodeoxyribonuclease VII large 
subunit   58704  9.6  127  16  29  3  12  0  0  ND  RB 
B0B7P7  CTL0583A  xseB 
exodeoxyribonuclease VII small 
subunit   8358  4.8  12  3  49  1  ND  61  1  ND  1.2 
B0B7Q2  CTL0588  dnaX 
DNA polymerase III subunit 
gamma/tau   51622  6.4  84  11  72  2  44  11  1  ND  0.1 
B0B820  CTL0707  recJ 
single-stranded-DNA-specific 
exonuclease  64550  9.4  173  22  35  3  23  35  1  ND  1.0 
B0B850  CTL0738     putative DNA methyltransferase   19174  7.6  29  6  8  1  ND  16  2  11  2.1 
B0B866  CTL0754  polA  DNA polymerase I   96663  5.3  312  35  45  3  29  27  2  5  0.6 
B0B871  CTL0759  dnaB  replicative DNA helicase   53366  6.0  193  24  36  4  20  24  2  5  0.7 
B0B875  CTL0763  ruvA  holliday junction DNA helicase [  22222  6.1  84  8  13  3  4  9  4  2  0.7 
B0B8B0  CTL0798  dnaQ2  DNA polymerase III_ epsilon chain   28960  8.9  85  10  50  2  55  10  2  2  0.2 
B0B8B9  CTL0807  dnaE  DNA polymerase III alpha subunit   139474  5.7  243  31  84  1  ND  47  1  ND  0.6 
B0B8C9  CTL0818     putative helicase (SWF/SNF family)  136257  5.7  76  13  25  1  ND  0  0  ND  RB 
B0B8G0  CTL0849  uvrB  excinuclease ABC subunit B   75854  5.4  195  23  60  3  46  17  1  ND  0.3 
B0B8I3  CTL0872  uvrD  DNA helicase   72751  6.1  318  35  135  4  88  55  4  10  0.4 
B0B8K0  CTL0889  nfo  endonuclease IV   31648  5.7  49  4  18  1  ND  18  1  ND  1.0      
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B0B876  CTL0764  ruvC  Holliday junction resolvase  18715  9.2  6  3  0  0  ND  3  1  ND  EB 
B0B7Q1  CTL0587  urvA  excinuclease ABC subunit A  196870  6.3  81  14  0  0  ND  11  1  ND  EB 
           
                          
Energy Metabolism 
     
                          
B0B8K9  CTL0002  nqrA 
Na(+)-translocating NADH-quinone 
reductase subunit A  51757  8.9  127  26  108  4  56  29  3  3  0.3 
B0B8R9  CTL0062  pgk  phosphoglycerate kinase   43071  5.7  111  18  71  4  30  49  3  1  0.7 
B0B8U0  CTL0083  gpdA  glycerol-3-phosphate dehydrogenase   36229  8.2  136  11  38  4  10  26  4  7  0.7 
B0B8U8  CTL0091  pgmA  phosphoglycerate mutase   25832  6.7  269  14  64  4  12  43  4  11  0.7 
B0B8W6  CTL0109  dmpP 
Na(+)-translocating NADH-quinone 
reductase subunit F  48518  5.2  147  13  75  4  44  40  3  20  0.5 
B0B8X6  CTL0119  tktB  transketolase  73164  5.3  142  21  72  3  35  33  2  5  0.5 
B0B944  CTL0187  glmM  phosphoglucosamine mutase   49288  6.0  193  24  50  4  20  51  4  9  1.0 
B0B950  CTL0193  sucC  succinyl-CoA synthetase beta chain   41762  5.4  196  15  59  4  10  46  2  10  0.8 
B0B951  CTL0194  sucD  succinyl-CoA synthetase alpha chain   30239  5.3  95  12  53  4  12  36  3  12  0.7 
B0B9C0  CTL0268  cydA 
cytochrome d ubiquinol oxidase 
subunit I   50223  9.3  54  10  117  3  41  0  0  ND  RB 
B0B9C1  CTL0269  cydB 
cytochrome d ubiquinol oxidase 
subunit II  39567  8.8  80  2  103  1  ND  10  1  ND  0.1 
B0B9G2  CTL0310  sucA 
2-oxoglutarate dehydrogenase E1 
component   102586  5.3  199  29  67  3  37  20  1  ND  0.3 
B0B9G3  CTL0311  sucB 
dihydrolipoamide 
succinyltransferase component (E2) 
of 2-oxoglutarate dehydrogenase 
complex   40344  5.1  133  14  98  4  36  43  3  11  0.4 
B0B9H1  CTL0319  gnd  6-phosphogluconate dehydrogenase   52619  5.4  79  14  38  1  ND  30  1  ND  0.8 
B0B9H3  CTL0321   npt1  ADP_ATP carrier protein   58100  9.3  145  19  828  4  490  252  4  45  0.3 
B0B9M9  CTL0376  araD  ribulose-phosphate 3-epimerase   24848  4.9  21  5  0  0  ND  14  1  ND  EB 
B0B9T5  CTL0437  zwf 
glucose-6-phosphate 1-
dehydrogenase   58597  5.4  253  23  42  4  24  20  2  2  0.5            
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B0B9T6  CTL0438  devB  6-phosphogluconolactonase  29005  5.2  159  16  46  4  9  29  4  6  0.6 
B0B9V5  CTL0457  pfkA 
pyrophosphate--fructose 6-
phosphate 1-phosphotransferase   61986  6.1  131  18  36  4  15  30  2  13  0.8 
B0B9V7  CTL0459  pfkA_2 
pyrophosphate--fructose 6-
phosphate 1-phosphotransferase   61186  6.0  117  20  37  3  18  17  1  ND  0.5 
B0B9W3  CTL0465  rpiA  ribose 5-phosphate isomerase   26673  5.4  45  10  15  2  7  8  1  ND  0.5 
B0B9W5  CTL0467  dhnA  fructose-bisphosphate aldolase   38020  6.3  177  17  185  4  25  104  4  66  0.6 
B0B7G1  CTL0497  pdhA 
pyruvate dehydrogenase E1 
component alpha subunit   37204  5.6  113  14  35  4  17  31  4  9  0.9 
B0B7G2  CTL0498  pdhB 
pyruvate dehydrogenase E1 
component beta subunit  36168  5.6  117  14  53  4  24  23  3  3  0.4 
B0B7G3  CTL0499  pdhC 
dihydrolipoamide acetyltransferase 
component of pyruvate 
dehydrogenase complex [  46400  5.7  173  18  59  4  18  64  4  5  1.1 
B0B7J4  CTL0530  nqrB 
Na(+)-translocating NADH-quinone 
reductase subunit B   54947  8.7  79  9  49  3  18  11  1  ND  0.2 
B0B7J5  CTL0531  nqrC 
Na(+)-translocating NADH-quinone 
reductase subunit C   34412  5.6  113  9  53  4  23  17  1  ND  0.3 
B0B7L1  CTL0547  mrsA  phosphoglucomutase   67411  5.1  315  38  74  4  24  36  4  25  0.5 
B0B7M1  CTL0557  atpI 
V-type sodium ATP synthase 
subunit I   73285  6.5  88  13  62  4  41  31  1  ND  0.5 
B0B7M2  CTL0558  atpD  V-type ATP synthase subunit D   23182  9.0  97  11  63  4  28  31  4  8  0.5 
B0B7M3  CTL0559  atpB 
V-type sodium ATP synthase 
subunit B   48645  5.5  196  17  84  4  21  34  3  5  0.4 
B0B7M4  CTL0560  atpA  V-type ATP synthase alpha chain   65495  5.1  317  36  123  4  51  56  4  11  0.5 
B0B7M6  CTL0562  atpE  V-type ATP synthase subunit E   22946  5.4  104  17  169  4  40  85  4  32  0.5 
B0B7M9  CTL0565  tal  transaldolase   36161  4.9  212  21  369  4  163  242  4  45  0.7 
B0B7P5  CTL0582  tpiS  triosephosphate isomerase   29776  5.4  61  9  36  2  9  54  1  ND  1.5 
B0B7Q0  CTL0586  pykF  pyruvate kinase   53631  6.0  297  27  111  4  49  55  4  10  0.5 
B0B7Q9  CTL0594     2-oxoisovalerate dehydrogenase   74457  5.5  111  17  26  3  12  0  0  ND  RB      
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B0B7U5  CTL0630  mdhC  malate dehydrogenase   35561  6.1  175  13  120  4  53  52  3  19  0.4 
B0B7U7  CTL0633  pgi  glucose-6-phosphate isomerase   57700  5.5  245  24  65  4  32  36  4  12  0.6 
B0B7X0  CTL0657  sucB 
lipoamide acyltransferase 
component (E2) of branched-chain 
alpha-keto acid dehydrogenase 
complex   42535  5.6  93  15  43  2  8  13  1  ND  0.3 
B0B868  CTL0756   npt2  putative nucleotide transport protein   59620  9.3  96  16  70  4  16  0  0  ND  RB 
B0B879  CTL0767  gapA 
glyceraldehyde 3-phosphate 
dehydrogenase   36294  5.6  123  17  115  4  9  73  4  37  0.6 
B0B8D1  CTL0820  lpdA  dihydrolipoamide dehydrogenase  49477  6.3  261  21  88  4  20  84  4  13  1.0 
B0B8G1  CTL0850  eno  enolase   45434  4.7  208  20  525  4  250  556  4  152  1.1 
B0B873  CTL0761  lplA  lipoate-protein ligase A  26908  7.1  27  4  0  0  ND  7  1  ND  EB 
           
     
              Exported protein 
       
                          
B0B8L3  CTL0006     exported protein   37184  5.0  36  3  25  1  ND  0  0  ND  RB 
B0B8M2  CTL0015     putative exported protein   22071  8.6  81  7  38  3  25  6  1  ND  0.2 
B0B8M6  CTL0019     putative exported lipoprotein   70454  5.9  50  10  36  1  ND  0  0  ND  RB 
B0B8V9  CTL0102     putative exported protein   49899  8.9  82  12  33  2  14  0  0  ND  RB 
B0B914  CTL0156     putative exported protein   19063  4.8  52  6  78  4  24  27  4  2  0.3 
B0B9B8  CTL0266     putative exported protein   48112  6.4  282  22  155  4  90  46  4  5  0.3 
B0B9E9  CTL0297     putative exported protein   29852  4.8  134  19  201  4  112  49  4  2  0.2 
B0B9I1  CTL0329     exported protein   36478  9.3  92  9  14  2  9  0  0  ND  RB 
B0B9T1  CTL0433     putative exported protein   26979  5.2  80  7  50  3  18  17  2  2  0.3 
B0B9X1  CTL0473     putative exported protein   33080  6.1  101  11  187  4  86  62  4  5  0.3 
B0B7M7  CTL0563     putative exported protein   26290  9.1  19  4  41  2  21  0  0  ND  RB 
B0B7S4  CTL0609     putative exported protein  39968  5.4  167  13  22  4  7  0  0  ND  RB 
B0B7V9  CTL0645     putative exported protein   47018  5.3  56  9  72  2  7  0  0  ND  RB 
B0B849  CTL0737     putative exported protein  36313  8.3  139  17  60  4  36  10  1  ND  0.2 
B0B855  CTL0743     putative exported protein  24846  8.0  57  10  17  2  1  9  2  4  0.5 
B0B8C1  CTL0809     putative exported protein   36307  8.8  133  18  72  4  48  16  3  4  0.2            
 
2
7
2
 
B0B8E7  CTL0836     putative exported protein   45849  5.5  64  12  38  2  2  0  0  ND  RB 
B0B8J8  CTL0887     putative exported protein   48477  6.4  389  28  1464  4  577  840  4  261  0.6 
B0B909  CTL0152     putative exported protein   39630  4.6  123  13  55  4  23  0  0  ND  RB 
           
     
   
  
   
  
  Fatty Acid & Phospholipid Metabolism 
   
                          
B0B8N1  CTL0024  kdsA 
2-dehydro-3-deoxyphosphooctonate 
aldolase   29645  5.7  158  17  51  4  21  47  4  9  0.9 
B0B8W2  CTL0105     conserved hyporthetical protein  16508  4.6  54  3  33  4  7  37  2  15  1.1 
B0B8Z6  CTL0139  fabF 
3-oxoacyl-[acyl-carrier-protein] 
synthase  44874  5.5  156  17  284  4  109  185  4  23  0.7 
B0B901  CTL0144    
1-acyl-sn-glycerol-3-phosphate 
acyltransferase   29187  9.3  83  10  56  4  18  26  2  2  0.5 
B0B902  CTL0145  aas 
2-acylglycerophosphoethanolamine 
acyltransferase   59393  7.2  194  22  106  4  64  25  3  5  0.2 
B0B924  CTL0166  pgsA 
CDP-diacylglycerol--glycerol-3-
phosphate 3-phosphatidyltransferase   22753  8.8  76  3  71  4  64  26  3  15  0.4 
B0B934  CTL0176  plsB  glycerol-3-phosphate acyltransferase  38125  5.7  134  17  50  4  24  40  3  11  0.8 
B0B939  CTL0182  plsX  Fatty acid/phospholipid synthase   34439  6.2  66  5  29  1  ND  14  2  8  0.5 
B0B9L2  CTL0359  fabI  enoyl-acyl-carrier protein reductase  32012  5.2  152  14  121  4  39  63  4  19  0.5 
B0B9N1  CTL0378  accB 
biotin carboxyl carrier protein of 
acetyl-CoA carboxylase   18198  5.1  98  7  52  4  47  33  3  19  0.6 
B0B9N2  CTL0379  accC  biotin carboxylase  50106  6.4  222  23  112  4  65  48  4  3  0.4 
B0B9P4  CTL0391    
putative phospholipase-
carboxylesterase family protein   26823  5.3  77  5  55  3  20  36  1  ND  0.6 
B0B9V6  CTL0458     conserved hypothetical protein   31610  6.0  40  3  12  2  2  0  0  ND  RB 
B0B7F2  CTL0488  acpP  acyl carrier protein   8702  3.9  59  5  502  4  120  662  4  202  1.3 
B0B7F3  CTL0489  fabG 
3-oxoacyl-[acyl-carrier protein] 
reductase  26036  7.7  138  12  115  4  25  66  4  30  0.6 
B0B7F4  CTL0490  fabD 
malonyl-CoA-[acyl-carrier-protein] 
transacylase   33489  4.9  87  9  27  4  9  18  2  3  0.7      
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B0B7F5  CTL0491  fabH 
3-oxoacyl-[acyl-carrier-protein] 
synthase III   35327  7.0  122  15  53  3  19  42  4  10  0.8 
B0B7F9  CTL0495  lpxD 
UDP-3-O-[3-hydroxymyristoyl] 
glucosamine N-acyltransferase   38403  7.4  168  8  105  4  77  46  3  7  0.4 
B0B7I1  CTL0517  accA 
acetyl-coenzyme A carboxylase 
carboxyl transferase subunit alpha   36374  5.9  156  18  91  4  57  49  4  16  0.5 
                             
B0B7K9  CTL0545  accD 
acetyl-coenzyme A carboxylase 
carboxyl transferase subunit beta   33688  7.5  130  12  81  4  27  65  4  23  0.8 
B0B826  CTL0713  plsC 
1-acyl-sn-glycerol-3-phosphate 
acyltransferase   23825  10.0  86  13  41  4  20  38  1  ND  0.9 
B0B8A5  CTL0793  lpxA 
acyl-[acyl-carrier-protein]--UDP-N-
acetylglucos amine O-
acyltransferase   30724  6.1  120  14  61  4  31  35  4  8  0.6 
B0B8A6  CTL0794  fabZ 
(3R)-hydroxymyristoyl-[acyl carrier 
protein] dehydratase   16624  9.2  20  3  27  1  ND  20  1  ND  0.7 
B0B8A7  CTL0795  lpxC 
UDP-3-O-[3-hydroxymyristoyl] N-
acetylglucosamine deacetylase   31298  5.7  56  8  26  2  25  46  3  20  1.8 
B0B8A9  CTL0797     acyl-CoA hydrolase  18526  8.6  36  5  20  2  17  9  1  ND  0.5 
           
                          
hypothetical proteins 
     
                          
B0B8L0  CTL0003     conserved hypothetical protein   16754  6.2  122  9  109  4  35  64  4  47  0.6 
B0B8M1  CTL0014     conserved hypothetical protein   51478  6.7  23  5  22  1  ND  0  0  ND  RB 
B0B8N5  CTL0028     conserved hypothetical protein   8783  8.0  60  7  343  4  14  268  4  53  0.8 
B0B8P1  CTL0034     conserved hypothetical protein   9326  9.1  85  7  113  4  3  144  4  32  1.3 
B0B8P3  CTL0036     conserved hypothetical protein   16465  4.9  61  7  103  4  39  88  4  4  0.8 
B0B8P4  CTL0037     conserved hypothetical protein   24444  4.6  169  12  190  4  69  162  4  18  0.9 
B0B8P7  CTL0040     conserved hypothetical protein   31030  4.8  62  12  130  4  40  150  4  21  1.1 
B0B8Q2  CTL0045     conserved hypothetical protein   19858  5.5  149  10  47  4  11  42  4  6  0.9 
B0B8R7  CTL0060     conserved hypothetical protein   25176  5.0  110  11  78  4  6  69  3  30  0.9            
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B0B8S0  CTL0063     conserved hypothetical protein   34744  5.1  229  16  97  4  18  44  4  5  0.5 
B0B8S1  CTL0064     conserved hypothetical protein   44310  5.2  199  20  42  4  15  25  4  10  0.6 
B0B8S8  CTL0071     conserved hypothetical protein   20483  4.6  75  5  37  3  13  19  3  7  0.5 
B0B8T7  CTL0080     conserved hypothetical protein   86301  4.9  107  11  57  1  ND  0  0  ND  RB 
B0B8T8  CTL0081     conserved hypothetical protein   44048  5.3  72  11  9  1  ND  25  1  ND  2.6 
B0B8U4  CTL0087     conserved hypothetical protein  19602  5.9  25  5  14  2  2  0  0  ND  RB 
B0B8X9  CTL0122     hypothetical protein   8617  9.1  11  2  9  1  ND  0  0  ND  RB 
B0B8Y9  CTL0132     conserved hypothetical protein   15082  4.8  80  5  178  4  96  289  4  188  1.6 
B0B8Z4  CTL0137     conserved hypothetical protein   64095  5.4  430  37  222  4  85  158  4  52  0.7 
B0B916  CTL0158     hypothetical protein   18416  4.6  48  9  391  4  240  416  4  78  1.1 
B0B937  CTL0179     conserved hypothetical protein   12470  10.2  6  3  0  0  ND  4  1  ND  EB 
B0B974  CTL0217     conserved hypothetical protein   7992  3.9  24  5  7  2  2  15  3  10  2.0 
B0B978  CTL0221     conserved hypothetical protein   17539  5.0  66  7  13  4  7  16  1  ND  1.3 
B0B979  CTL0222     conserved hypothetical protein   6843  4.0  39  3  143  4  78  206  4  78  1.4 
B0B995  CTL0238     conserved hypothetical protein  53614  5.3  261  22  70  4  14  55  4  28  0.8 
B0B997  CTL0244     conserved hypothetical protein   37483  9.2  100  12  45  4  28  18  1  ND  0.4 
B0B9A7  CTL0255     conserved hypothetical protein   65820  5.4  510  40  574  4  148  163  4  4  0.3 
B0B9B4  CTL0262     conserved hypothetical protein   35549  6.1  138  10  45  4  28  16  1  ND  0.4 
B0B9C3  CTL0271     conserved hypothetical protein   26737  4.7  115  9  127  4  22  27  4  13  0.2 
B0B9C4  CTL0272     conserved hypothetical protein   47726  6.6  259  30  129  4  58  46  4  13  0.4 
B0B9D8  CTL0286     conserved hypothetical protein  11680  9.8  25  8  12  2  3  10  1  ND  0.9 
B0B9E7  CTL0295     conserved hypothetical protein   5675  5.1  19  3  3  1  ND  2  1  ND  0.6 
B0B9F5  CTL0303     conserved hypothetical protein   35794  6.3  36  3  23  1  ND  0  0  ND  RB 
B0B9F7  CTL0305     conserved hypothetical protein   50786  5.6  130  12  94  3  83  21  2  5  0.2 
B0B9F8  CTL0306     conserved hypothetical protein   58928  4.9  103  13  36  1  ND  31  2  2  0.9 
B0B9F9  CTL0307     conserved hypothetical protein   60546  5.3  160  18  38  3  13  35  2  11  0.9 
B0B9G1  CTL0309     conserved hypothetical protein   17204  4.4  36  6  35  4  17  35  4  8  1.0 
B0B9H4  CTL0322     conserved hypothetical protein   17948  10.0  137  11  186  4  74  349  4  59  1.9 
B0B9J0  CTL0338     conserved hypothetical protein   59568  4.8  259  18  68  4  6  33  4  3  0.5 
B0B9J1  CTL0338A     conserved hypothetical protein   18320  9.9  28  5  19  1  ND  0  0  ND  RB      
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B0B9Q0  CTL0397     conserved hypothetical protein   31449  8.5  117  10  80  4  57  0  0  ND  RB 
B0B9Q1  CTL0398     conserved hypothetical protein   31497  5.8  160  16  88  4  48  37  4  43  0.4 
B0B9V3  CTL0455     conserved hypothetical protein   28263  4.5  37  6  19  4  3  21  2  4  1.1 
B0B9W1  CTL0463     conserved hypothetical protein   20814  4.6  49  5  74  4  33  53  2  0  0.7 
B0B9W2  CTL0464     conserved hypothetical protein   17082  5.0  55  10  27  4  11  8  2  3  0.3 
B0B7H1  CTL0507     conserved hypothetical protein  14372  4.8  9  3  8  2  3  0  0  ND  RB 
B0B7H6  CTL0512     conserved hypothetical protein   18876  4.8  132  11  421  4  96  450  4  71  1.1 
B0B7H8  CTL0514     conserved hypothetical protein   28754  6.4  109  11  30  4  16  24  3  7  0.8 
B0B7H9  CTL0515     conserved hypothetical protein   21942  5.6  19  4  21  2  1  0  0  ND  RB 
B0B7I9  CTL0525     conserved hypothetical protein   21558  9.1  68  6  25  2  4  66  1  ND  2.7 
B0B7J0  CTL0526     conserved hypothetical protein   15607  4.6  59  5  48  4  15  17  4  5  0.3 
B0B7J2  CTL0528     conserved hypothetical protein   21294  4.5  72  8  52  4  34  24  2  9  0.5 
B0B7J9  CTL0535     conserved hypothetical protein   79885  7.3  113  14  29  2  1  0  0  ND  RB 
B0B7M5  CTL0561     conserved hypothetical protein   32129  5.4  184  17  121  4  88  35  4  11  0.3 
B0B7P8  CTL0584     conserved hypothetical protein   9953  4.3  26  2  36  2  12  33  3  8  0.9 
B0B7Q3  CTL0589     conserved hypothetical protein   10537  5.2  68  5  50  4  5  59  4  10  1.2 
B0B7U1  CTL0626  aaxA  conserved hypothetical protein   49447  9.0  235  15  368  4  119  159  4  17  0.4 
B0B7V7  CTL0643     conserved hypothetical protein   77101  5.8  182  21  79  4  19  56  3  28  0.7 
B0B7V8  CTL0644     conserved hypothetical protein   12867  9.9  39  5  39  3  20  28  4  12  0.7 
B0B7W8  CTL0655     conserved hypothetical protein  29552  7.1  229  19  154  4  51  227  4  88  1.5 
B0B7Z7  CTL0684     conserved hypothetical protein   70066  4.9  196  28  69  4  25  35  3  6  0.5 
B0B801  CTL0688     conserved hypothetical protein   39227  5.1  171  22  92  4  19  84  3  15  0.9 
B0B830  CTL0717     conserved hypothetical protein   26532  5.5  105  8  57  4  11  100  4  49  1.7 
B0B839  CTL0726     conserved hypothetical protein   12782  9.4  51  8  26  4  11  19  4  4  0.7 
B0B845  CTL0733     conserved hypothetical protein   30147  5.3  58  7  59  4  49  24  1  ND  0.4 
B0B854  CTL0742     conserved hypothetical protein   27889  8.5  22  5  33  1  ND  0  0  ND  RB 
B0B877  CTL0765     conserved hypothetical protein  17709  5.0  164  11  29  4  26  21  3  12  0.7 
B0B878  CTL0766     conserved hypothetical protein   32034  4.7  99  12  217  4  25  351  4  109  1.6 
B0B8B2  CTL0800     conserved hypothetical protein   27481  5.3  177  19  239  4  44  253  4  25  1.1 
B0B8C0  CTL0808     conserved hypothetical protein  32658  9.2  134  9  23  3  6  9  1  ND  0.4            
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B0B8C4  CTL0812     conserved hypothetical protein   15804  4.3  48  7  12  4  6  7  3  4  0.6 
B0B8D4  CTL0823     conserved hypothetical protein   32051  6.6  78  7  44  3  7  21  1  ND  0.5 
B0B8F1  CTL0840     conserved hypothetical protein   13291  6.5  38  4  117  2  88  10  1  ND  0.3 
B0B8F8  CTL0847     conserved hypothetical protein   21142  5.6  268  11  914  4  115  1145  4  208  1.3 
B0B8G4  CTL0853     conserved hypothetical protein   109092  5.5  175  29  31  2  9  22  1  ND  0.7 
B0B8H6  CTL0865     conserved hypothetical protein   14407  4.6  7  2  3  1  ND  0  0  ND  RB 
B0B8I0  CTL0869     conserved hypothetical protein   23278  7.0  84  11  19  3  7  66  3  5  3.5 
B0B8I1  CTL0870     conserved hypothetical protein  8896  4.8  60  5  23  2  8  12  4  6  0.5 
B0B8I5  CTL0874     conserved hypothetical protein  26833  4.9  168  14  461  4  161  807  4  267  1.8 
B0B8I6  CTL0875     conserved hypothetical protein   27141  5.5  28  4  11  1  ND  0  0  ND  RB 
B0B8J4  CTL0883     conserved hypothetical protein  96809  4.8  92  13  32  1  ND  0  0  ND  RB 
B0B8J5  CTL0884     conserved hypothetical protein   93181  4.8  75  5  0  0  ND  25  2  8  EB 
B0B8J6  CTL0885     conserved hypothetical protein   92625  4.9  354  28  55  4  20  44  3  13  0.8 
B0B8K6  CTL0895     conserved hypothetical protein  9245  5.3  45  3  48  3  25  58  3  53  1.2 
B0B8K7  CTL0897     conserved hypothetical protein  60901  5.8  280  36  113  4  32  41  3  10  0.4 
B0B8Y0  CTL0123     conserved hypothetical protein  32717  7.3  65  9  30  4  10  17  2  9  0.6 
B0B8Z7  CTL0140     conserved hypothetical protein   17374  5.0  87  12  106  4  27  62  4  25  0.6 
B0B9L1  CTL0358     conserved hypothetical protein   34188  5.1  184  14  74  4  40  45  4  5  0.6 
B0B9L7  CTL0364     conserved hypothetical protein   29671  8.9  41  7  30  2  12  0  0  ND  RB 
B0B9F6  CTL0304     conserved hypothetical protein   26452  7.6  36  5  20  2  6  16  1  ND  0.8 
B0B7V5  CTL0641     conserved hypothetical protein   12319  5.4  81  5  111  3  24  207  4  88  1.9 
B0B7W2  CTL0648     conserved hypothetical protein   41295  5.3  119  14  19  4  4  19  3  18  1.0 
B0B7Z4  CTL0681     conserved hypothetical protein   18456  4.4  21  5  0  0  ND  46  2  33  EB 
B0B7Z8  CTL0685     conserved hypothetical protein   41372  7.2  93  7  27  3  11  20  3  6  0.7 
B0B819  CTL0706  euo  conserved hypothetical protein   20930  7.8  76  8  10  4  2  14  2  4  1.3 
B0B8J7  CTL0886     conserved hypothetical protein   68969  4.9  530  39  87  4  24  83  4  52  1.0 
B0B833  CTL0720     conserved hypothetical protein   9736  9.4  117  7  82  4  52  136  4  102  1.7 
B0B7S9  CTL0614 
 
conserved hypothetical protein   21845  4.7  34  6  0  0  ND  4  1  ND  EB 
B0B9L6  CTL0363 
 
conserved hypothetical protein   27514  5.7  46  6  0  0  ND  7  1  ND  EB 
B0B9C2  CTL0270 
 
conserved hypothetical protein   48830  8.7  33  7  0  0  ND  4  1  ND  EB      
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B0B8P6  CTL0039 
 
conserved hypothetical protein   20247  7.8  16  2  0  0  ND  5  1  ND  EB 
B0B966  CTL0209 
 
conserved hypothetical protein   76407  6.0  121  17  0  0  ND  30  1  ND  EB 
B0B8M3  CTL0016 
 
conserved hypothetical protein   47796  7.5  30  7  0  0  ND  4  1  ND  EB 
B0B8R0  CTL0053     conserved hypothetical protein   53946  5.7  182  23  47  4  12  39  4  25  0.8 
                             
Other Categories 
       
                          
B0B8L9  CTL0012     putative oxidoreductase   37055  5.4  148  16  29  4  20  16  2  8  0.6 
B0B8W0  CTL0103     putative lipoprotein  23967  8.5  89  11  79  2  19  90  4  29  1.1 
B0B8Z9  CTL0142  ldh  leucine dehydrogenase   37349  5.2  183  17  91  4  17  43  4  21  0.5 
B0B9H9  CTL0327  dxr 
1-deoxy-D-xylulose 5-phosphate 
reductoisomerase   41758  5.8  120  19  31  4  12  22  2  11  0.7 
B0B9Q6  CTL0403  mhpA  FAD-dependent monooxygenase   57859  8.3  60  11  24  1  ND  15  1  ND  0.6 
B0B9W8  CTL0470  surE  5'-nucleotidase   31516  4.8  140  16  101  4  55  42  4  3  0.4 
B0B9X3  CTL0475    
candidate inclusion membrane 
protein  13879  9.0  37  2  47  3  26  0  0  ND  RB 
B0B7G9  CTL0505     putative lipoprotein   24041  8.7  167  7  382  4  290  104  4  25  0.3 
B0B7H4  CTL0510     putative cysteine desulfurase   40245  6.2  66  7  17  3  10  0  0  ND  RB 
B0B7K3  CTL0539  trmU 
tRNA (5-methylaminomethyl-2-
thiouridylate)-methyltransferase  40174  6.6  81  7  18  1  ND  16  1  ND  0.9 
B0B7Q4  CTL0590  ptsI 
phosphoenolpyruvate-protein 
phosphotransferase   63718  5.8  35  3  79  1  ND  0  0  ND  RB 
B0B7U4  CTL0629     putative oxidoreductase  38037  5.3  80  8  25  3  5  0  0  ND  RB 
B0B7U9  CTL0635  phnP  metal-dependent hydrolase   30143  5.8  34  5  23  2  5  0  0  ND  RB 
B0B7W9  CTL0656     carbohydrate isomerase  36020  5.5  96  9  17  3  6  14  2  3  0.8 
B0B7X2  CTL0659     Tetraacyldisaccharide-1-P 4'-kinase   40882  9.3  35  9  29  1  ND  0  0  ND  RB 
B0B831  CTL0718    
ribosomal-protein-alanine 
acetyltransferase  19281  8.9  27  5  31  2  1  0  0  ND  RB 
B0B834  CTL0721     putative metallo-phosphoesterase   37056  9.3  100  13  51  4  12  27  1  ND  0.5 
B0B835  CTL0722  ispD 
2-C-methyl-D-erythritol 4-phosphate 
cytidylyltransferase   24228  5.4  49  7  25  4  10  0  0  ND  RB            
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B0B837  CTL0724    
hydrolase_ haloacid dehalogenase-
like family   26188  5.0  72  10  68  3  48  0  0  ND  RB 
B0B860  CTL0748     methyltransferase   20887  8.6  30  2  19  3  6  0  0  ND  RB 
B0B8B5  CTL0803  mip  peptidyl-prolyl cis-trans isomerase   26648  4.8  301  16  1956  4  853  1292  4  295  0.7 
B0B8C7  CTL0815     putative methyltransferase   42100  9.5  29  9  46  1  ND  0  0  ND  RB 
B0B8G8  CTL0858 
 
putative hydrolase  29798  5.0  22  3 
 
0  ND  3  1  ND  EB 
B0B865  CTL0753  yacE  dephospho-CoA kinase  22982  5.5  15  4  0  0  ND  5  1  ND  EB 
B0B8F7  CTL0846  gp6D 
virulence plasmid protein pGP6-D-
related protein   30733  9.4  110  11  21  1  ND  19  3  8  0.9 
B0B8U7  CTL0090 
 
cysteine desulfurase  41793  6.2  32  3  0  0  ND  3  1  ND  EB 
           
                          
Plasmid 
         
                          
B0BCL9  pL2-07a     Putative uncharacterized protein  14281  6.3  95  7  45  4  33  18  4  6  0.4 
B0BCM1  pL2-05     Putative uncharacterized protein  27923  4.8  172  14  320  4  48  153  4  80  0.5 
B0BCM2  pL2-04     Putative uncharacterized protein  41425  9.5  54  11  39  2  5  0  0  ND  RB 
B0BCM3  pL2-03     Virulence plasmid helicase  51457  8.6  127  20  52  3  6  12  1  ND  0.2 
B0BCM6  pL2-08     Putative uncharacterized protein  28307  8.8  60  9  26  1  ND  25  2  12  1.0 
B0BCM7  pL2-07     Putative uncharacterized protein  15217  5.6  30  7  26  2  2  7  1  ND  0.3 
           
                          
Transcription 
       
                          
B0B8L1  CTL0004  greA  Transcription elongation factor   80997  5.3  465  59  139  4  70  105  4  17  0.8 
B0B8T0  CTL0073  pcnB  polyA polymerase   46553  7.8  80  13  31  2  19  19  2  1  0.6 
B0B8U9  CTL0092    
ribosomal large subunit 
pseudouridine synthase B  26425  9.6  17  5  16  1  ND  0  0  ND  RB 
B0B8Z1  CTL0134  rbsV  anti-sigma F factor antagonist  12412  7.7  54  7  23  3  6  29  2  18  1.2 
B0B959  CTL0202    
putative SAM-dependent 
methyltransferase   21559  5.7  24  1  0  0  ND  68  1  ND  EB 
B0B971  CTL0214  pnp 
polyribonucleotide 
nucleotidyltransferase   75403  5.7  408  42  117  4  48  62  4  17  0.5 
B0B9B6  CTL0264     conserved hypothetical protein   16226  5.7  66  8  39  4  24  52  3  18  1.3      
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B0B9D4  CTL0282  trmD 
tRNA (guanine-N(1)-)-
methyltransferase  39780  5.6  36  10  0  0  ND  28  2  19  EB 
B0B9D6  CTL0284  rnhB  ribonuclease HII   23975  6.1  87  15  19  3  3  17  4  4  0.9 
B0B9K5  CTL0352  nusA  N utilization substance protein A  48885  5.2  284  26  147  4  44  163  4  47  1.1 
B0B9S0  CTL0422  trpR  trp operon repressor   10875  7.9  30  5  8  1  ND  20  1  ND  2.7 
B0B7L3  CTL0549  rnc  ribonuclease III   25595  6.1  14  2  33  1  ND  0  0  ND  RB 
B0B7N0  CTL0566  rpoC 
DNA-directed RNA polymerase 
beta-prime chain   154814  7.2  900  103  396  4  186  287  4  82  0.7 
B0B7N1  CTL0567  rpoB 
DNA-directed RNA polymerase beta 
chain   140058  5.6  802  88  406  4  176  339  4  146  0.8 
B0B7N6  CTL0572  nusG  transcription antitermination protein   20760  5.3  188  14  155  4  88  93  4  22  0.6 
B0B7S3  CTL0608  ksgA  dimethyladenosine transferase   31462  7.7  28  3  22  1  ND  0  0  ND  RB 
B0B7W4  CTL0650  hrcA 
Putative transcriptional regulatory 
protein   44979  5.9  128  19  63  4  37  0  0  ND  RB 
B0B7W7  CTL0654  vacB  exoribonuclease II   77957  9.3  188  24  76  4  50  34  2  15  0.4 
B0B7X3  CTL0660     23S rRNA methyltransferase   30136  5.8  35  4  8  2  2  0  0  ND  RB 
B0B7X6  CTL0663  nrdR  transcriptional repressor  17660  9.1  110  6  43  4  28  37  4  10  0.9 
B0B7Y0  CTL0667  pcnB  polyA polymerase   49446  9.1  163  21  49  4  14  20  4  2  0.4 
B0B7Z6  CTL0683  rsbV  anti-sigma F factor antagonist   12530  5.2  117  9  59  4  24  71  4  41  1.2 
B0B864  CTL0752  rho  transcription termination factor rho   51666  6.8  280  32  180  4  85  133  4  36  0.7 
B0B881  CTL0769  rpoA 
DNA-directed RNA polymerase 
alpha chain   41810  5.3  226  21  486  4  254  364  4  68  0.7 
B0B8B4  CTL0802    
putatve rRNA methylase (SpoU 
family)   16747  5.8  24  3  7  1  ND  4  1  ND  0.5 
B0B8C3  CTL0811  rsbW 
sigma regulatory factor-histidine 
kinase  16424  5.8  37  7  32  2  32  20  2  6  0.6 
B0B8J0  CTL0879  rpoD  RNA polymerase sigma factor   66133  8.1  330  36  107  4  46  104  4  30  1.0 
B0B8K5  CTL0894     transcriptional regulatory protein  25835  8.4  76  10  39  4  13  25  1  ND  0.7 
B0B9L4  CTL0361 
 
tRNA pseudouridine synthase A  31465  9.4  16  4  0  0  ND  4  1  ND  EB 
           
                                     
 
2
8
0
 
Translation 
       
                          
B0B8Q3  CTL0046  rrf  ribosome recycling factor   20054  8.6  90  15  62  3  13  83  4  15  1.3 
B0B8Q5  CTL0048  tsf  translation elongation factor TS   30953  5.7  299  20  453  4  189  584  4  169  1.3 
B0B8Q6  CTL0049  rpsB  SSU ribosomal protein S2   31220  6.6  203  22  395  4  165  317  4  135  0.8 
B0B8T1  CTL0074  clpX 
ATP-dependent Clp protease_ ATP-
binding component  46183  5.6  159  23  113  4  45  86  4  45  0.8 
B0B8T2  CTL0075  clpP 
ATP-dependent Clp protease 
proteolytic component   22050  5.1  49  6  58  3  31  0  0  ND  RB 
B0B8V5  CTL0098  serS  seryl-tRNA synthetase   48406  5.7  169  19  109  4  28  87  4  37  0.8 
B0B8X5  CTL0118  alaS  alanyl-tRNA synthetase  97639  5.5  514  48  180  4  84  121  4  28  0.7 
B0B8X8  CTL0121  efp  translation elongation factor P  20190  4.7  55  6  126  4  12  109  4  4  0.9 
B0B906  CTL0149     protein disulfide isomerase   18586  7.9  141  11  102  4  32  84  4  5  0.8 
B0B907  CTL0150  lysS  lysyl-tRNA synthetase   60076  5.3  231  24  72  4  67  40  4  19  0.6 
B0B908  CTL0151  cysS  cysteinyl-tRNA synthetase   57210  6.0  54  12  26  1  ND  11  1  ND  0.4 
B0B913  CTL0155  rpsN  SSU ribosomal protein S14P   11716  11.4  53  6  40  4  10  66  4  13  1.6 
B0B923  CTL0165  glyQ  glycyl-tRNA synthetase   112503  5.7  398  44  60  4  23  37  4  4  0.6 
B0B926  CTL0168  rplY  LSU ribosomal protein L25   20425  9.0  99  10  131  4  67  88  4  24  0.7 
B0B927  CTL0169  pth  peptidyl-tRNA hydrolase   19963  7.8  28  6  7  2  3  16  1  ND  2.5 
B0B928  CTL0170  rpsF  SSU ribosomal protein S6P   12907  8.8  67  7  194  4  94  163  4  54  0.8 
B0B929  CTL0171  rpsR  SSU ribosomal protein S18   9402  11.4  44  5  65  4  2  91  4  33  1.4 
B0B930  CTL0172  rplI  LSU ribosomal protein L9   18437  6.1  125  11  159  4  59  227  4  82  1.4 
B0B933  CTL0175  ptr  exported insulinase/protease   108365  5.1  442  39  443  4  232  176  4  25  0.4 
B0B952  CTL0195  htrA  serine protease   53270  5.9  460  26  774  4  293  399  4  91  0.5 
B0B953  CTL0196     metalloprotease-insulinase  109245  5.3  359  35  87  4  35  30  2  10  0.3 
B0B962  CTL0205  infC 
bacterial protein translation initiation 
factor 3 (IF-3)   21067  9.5  71  9  33  3  17  41  4  5  1.3 
B0B964  CTL0207  rplT  LSU ribosomal protein L20P  13936  11.9  82  7  77  4  42  65  4  35  0.9 
B0B965  CTL0208  pheS 
phenylalanyl-tRNA synthetase alpha 
chain  38677  5.8  153  22  30  4  6  19  4  4  0.6 
B0B970  CTL0213  ftsH  Cell division protein   101816  5.8  543  55  257  4  91  119  4  36  0.5      
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B0B972  CTL0215  rpsO  SSU ribosomal protein S15P   10400  9.7  27  3  119  4  38  129  4  69  1.1 
B0B981  CTL0224  map  methionine aminopeptidase   32641  6.1  105  9  47  4  6  45  4  17  1.0 
B0B990  CTL0233  cpa  putative exported protease  67281  5.5  220  20  87  4  51  40  4  18  0.5 
B0B991  CTL0234  ispH 
4-hydroxy-3-methylbut-2-enyl 
diphosphate reductase   34250  6.1  129  11  187  4  60  135  4  25  0.7 
B0B9A9  CTL0257  gatC 
glutamyl-tRNA(Gln) 
amidotransferase subunit C  11074  4.1  48  2  434  4  219  268  4  184  0.6 
B0B9B0  CTL0258  gatA 
aspartyl-glutamyl-tRNA(Asn-Gln) 
amidotransferase subunit A  53602  5.9  224  31  188  4  106  145  4  32  0.8 
B0B9B1  CTL0259  gatB 
aspartyl/glutamyl-tRNA(Asn/Gln) 
amidotransferase subunit B   54964  5.9  316  26  306  4  163  220  4  45  0.7 
B0B9C6  CTL0274  ileS 
isoleucyl-tRNA synthetase_ 
mupirocin resistant   118804  5.4  383  48  57  4  22  33  3  4  0.6 
B0B9C9  CTL0277  rpmE  LSU ribosomal protein L31P   12188  9.6  13  3  0  0  ND  23  2  24  EB 
B0B9D0  CTL0278  prfA 
bacterial peptide chain release factor 
1   40022  5.3  226  24  101  4  38  109  4  35  1.1 
B0B9D3  CTL0281  rpsP  SSU ribosomal protein S16P   13410  10.4  67  6  171  4  109  198  4  102  1.2 
B0B9D5  CTL0283  rplS  LSU ribosomal protein L19P   13142  10.0  107  12  129  4  62  130  4  72  1.0 
B0B9D9  CTL0287  metG  methionyl-tRNA synthetase  62749  5.1  238  24  35  4  4  24  3  5  0.7 
B0B9F3  CTL0301  pepA  putative aminopeptidase   54186  5.7  295  28  193  4  39  78  4  22  0.4 
B0B9H0  CTL0318  tyrS  tyrosyl-tRNA synthetase   45435  6.6  208  24  118  4  59  82  4  14  0.7 
B0B9I0  CTL0328     putative protease   69272  6.3  284  26  284  4  149  89  4  11  0.3 
B0B9J4  CTL0341  rpmB  LSU ribosomal protein L28P   10145  11.7  29  4  47  3  24  43  3  11  0.9 
B0B9K4  CTL0351  infA 
bacterial protein translation initiation 
factor 2 (IF-2)   97378  8.2  431  46  118  4  8  165  4  4  1.4 
B0B9K6  CTL0353  rpsA  SSU ribosomal protein S1P   63474  5.2  283  36  418  4  184  363  4  182  0.9 
B0B9L8  CTL0365  hsp60_1  chaperonin GroEL   58091  5.3  549  35  1871  4  186  1300  4  194  0.7 
B0B9L9  CTL0366  groES  10 kDa chaperonin GroES  11169  4.9  94  7  622  4  183  475  4  197  0.8 
B0B9M0  CTL0367  pepF  oligoendopeptidase F   69030  5.6  207  29  130  4  18  59  3  19  0.5 
B0B9M1  CTL0368  clpB  chaperone-protease ClpB   96631  5.4  481  58  270  4  98  150  4  22  0.6            
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B0B9N0  CTL0377  efp  translation elongation factor P   20529  5.0  75  9  53  2  35  26  2  6  0.5 
B0B9N3  CTL0380  rplM  LSU ribosomal protein L13P   16850  10.2  78  6  118  4  60  146  4  60  1.2 
B0B9N4  CTL0381  rpsI  SSU ribosomal protein S9P  14542  11.0  91  10  176  4  83  203  4  86  1.2 
B0B9Q8  CTL0405  rpmG  LSU ribosomal protein L33P   6285  10.3  5  1  58  3  35  56  3  12  1.0 
B0B9S7  CTL0429  dsbG  disulfide bond chaperone   26822  7.7  122  8  38  4  17  17  3  4  0.5 
B0B9U7  CTL0449  gcp  O-sialoglycoprotein endopeptidase  35892  6.1  34  7  20  2  1  0  0  ND  RB 
B0B9V9  CTL0461  leuS  leucyl-tRNA synthetase   92846  5.4  253  36  59  3  31  33  4  8  0.6 
B0B7K2  CTL0538  clpC  ATP-dependent Clp protease   95239  6.0  476  50  307  4  139  206  4  29  0.7 
B0B7L8  CTL0554  valS  valyl-tRNA synthetase  107103  5.6  126  18  21  1  ND  15  1  ND  0.7 
B0B7N2  CTL0568  rplL 
LSU ribosomal protein L12P 
(L7/L12)   13571  4.9  71  10  626  4  342  1006  4  284  1.6 
B0B7N3  CTL0569  rplJ  LSU ribosomal protein L10P   18875  6.0  112  11  152  4  131  129  4  68  0.8 
B0B7N4  CTL0570  rplA  LSU ribosomal protein L1P   24742  9.0  158  16  157  4  30  384  4  62  2.4 
B0B7N5  CTL0571  rplK  LSU ribosomal protein L11P   15054  9.7  102  8  94  4  10  113  4  27  1.2 
B0B7N8  CTL0574  tufA  translation elongation factor Tu   43309  5.4  404  32  2619  4  1474  2156  4  701  0.8 
B0B7N9  CTL0575  infA2 
bacterial protein translation initiation 
factor 1 (IF-1)   8413  9.4  51  5  29  4  15  17  2  14  0.6 
B0B7R0  CTL0595  dnaJ  heat shock chaperone protein   41916  7.5  226  28  389  4  99  316  4  79  0.8 
B0B7R3  CTL0598  lon  ATP-dependent protease La   91949  6.9  459  56  134  4  59  89  4  28  0.7 
B0B7S2  CTL0607  def  peptide deformylase   20523  5.7  92  11  108  4  25  52  4  4  0.5 
B0B7W3  CTL0649  proS  prolyl-tRNA synthetase   65676  5.6  118  17  39  4  15  18  1  ND  0.4 
B0B7W5  CTL0651  grpE  HSP-70 Cofactor   21668  4.6  151  9  211  4  48  190  4  142  0.9 
B0B7W6  CTL0652  dnaK  chaperone protein   70843  5.0  718  54  1424  4  274  1660  4  654  1.2 
B0B7X7  CTL0664  dksA  dnaK suppressor protein   13938  5.1  91  7  140  4  14  184  4  22  1.3 
B0B7Y9  CTL0676  rpmA  LSU ribosomal protein L27P    8916  11.0  37  4  34  4  28  32  3  22  0.9 
B0B7Z0  CTL0677  rplU  LSU ribosomal protein L21P   12163  9.3  91  5  112  4  23  118  4  30  1.1 
B0B803  CTL0690  clpP 
ATP-dependent Clp protease 
proteolytic subunit   21073  5.2  94  6  284  4  119  245  4  70  0.9 
B0B808  CTL0695  rpsJ  SSU ribosomal protein S10P   11869  10.5  59  7  50  4  22  75  4  29  1.5 
B0B809  CTL0696  fusA  translation elongation factor G   76493  5.3  536  46  623  4  257  451  4  37  0.7      
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B0B810  CTL0697  rpsG  SSU ribosomal protein S7P  17799  9.9  100  5  239  4  71  252  4  92  1.1 
B0B811  CTL0698  rpsL  SSU ribosomal protein S12P   14524  11.1  47  2  24  2  13  27  1  ND  1.2 
B0B818  CTL0705  gltX  glutamyl-tRNA synthetase  58563  6.6  242  33  81  4  32  54  2  7  0.7 
B0B827  CTL0714  argS  arginyl-tRNA synthetase  63029  6.1  256  25  81  4  28  42  4  12  0.5 
B0B832  CTL0719  prfB 
bacterial peptide chain release factor 
2   42402  5.4  254  29  28  4  18  19  4  3  0.7 
B0B848  CTL0736  pheT 
phenylalanyl-tRNA synthetase beta 
chain   87115  6.1  70  20  46  2  5  0  0  ND  RB 
B0B867  CTL0755  sohB  exported protease IV   35771  6.5  204  14  105  4  35  48  4  3  0.5 
B0B880  CTL0768  rplQ  LSU ribosomal protein L17P   16152  11.3  49  5  0  0  ND  57  4  26  EB 
B0B882  CTL0770  rpsK  SSU ribosomal protein S11P   13822  11.3  75  10  53  4  21  35  4  9  0.7 
B0B883  CTL0771  rpsM  SSU ribosomal protein S13P   13895  11.0  66  8  142  4  42  174  4  86  1.2 
B0B885  CTL0773  rplO  LSU ribosomal protein L15P   16114  10.2  60  8  100  4  47  97  4  34  1.0 
B0B886  CTL0774  rpsE  SSU ribosomal protein S5P   17762  9.9  123  7  175  4  48  150  4  36  0.9 
B0B887  CTL0775  rplR  LSU ribosomal protein L18P  13379  10.3  48  4  37  4  7  19  3  19  0.5 
B0B888  CTL0776  rplF  LSU ribosomal protein L6P   19839  10.0  121  14  151  4  75  170  4  75  1.1 
B0B889  CTL0777  rpsH  SSU ribosomal protein S8P  15070  10.3  42  4  35  3  34  7  2  2  0.2 
B0B890  CTL0778  rplE  LSU ribosomal protein L5P   20489  9.4  103  12  152  4  69  118  4  49  0.8 
B0B891  CTL0779  rplX  LSU ribosomal protein L24P   12608  10.4  67  6  90  4  25  83  4  19  0.9 
B0B892  CTL0780  rplN  LSU ribosomal protein L14P   13443  9.8  108  11  97  4  10  85  4  56  0.9 
B0B893  CTL0781  rpsQ  SSU ribosomal protein S17P   9645  10.5  12  4  9  1  ND  6  1  ND  0.7 
B0B894  CTL0782  rpmC  LSU ribosomal protein L29P   8295  9.9  20  5  52  1  ND  16  3  5  0.3 
B0B895  CTL0783  rplP  LSU ribosomal protein L16P   15775  11.3  62  6  152  4  27  111  4  14  0.7 
B0B896  CTL0784  rpsC  SSU ribosomal protein S3P   24343  10.0  166  15  293  4  151  167  4  40  0.6 
B0B897  CTL0785  rplV  LSU ribosomal protein L22P   12455  11.3  164  7  60  4  22  63  4  26  1.1 
B0B898  CTL0786  rpsS  SSU ribosomal protein S19P   10233  10.8  40  5  41  1  ND  47  3  10  1.1 
B0B899  CTL0787  rplB  LSU ribosomal protein L2P   31473  10.6  155  17  180  4  71  158  4  72  0.9 
B0B8A0  CTL0788  rplW  LSU ribosomal protein L23P   12223  9.9  62  6  55  4  24  87  4  52  1.6 
B0B8A1  CTL0789  rplD  LSU ribosomal protein L1E   24590  9.8  150  17  202  4  116  169  4  68  0.8 
B0B8A2  CTL0790  rplC  LSU ribosomal protein L3P   23480  9.7  106  10  115  4  55  99  4  43  0.9            
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B0B8B6  CTL0804  aspS  aspartyl-tRNA synthetase   66272  5.3  326  34  117  4  40  93  4  20  0.8 
B0B8B7  CTL0805  hisS  histidyl-tRNA synthetase   49093  6.7  215  25  93  4  82  43  3  11  0.5 
B0B8E8  CTL0837  pepP  proline dipeptidase   39330  5.4  138  22  81  4  49  30  3  13  0.4 
B0B8F5  CTL0844  thrS  threonyl-tRNA synthetase  72630  5.7  413  31  102  4  24  114  4  125  1.1 
B0B8F9  CTL0848  trpS  tryptophanyl-tRNA synthetase   39380  6.5  181  24  197  4  59  247  4  76  1.3 
B0B8G9  CTL0859  dsdD  thiol:disulfide interchange protein  76171  5.8  174  23  93  4  41  40  3  13  0.4 
B0B8H8  CTL0867  groEL2  60 kDa chaperonin GroEL2   58869  5.1  50  4  59  1  ND  0  0  ND  RB 
B0B8K1  CTL0890  rpsD  SSU ribosomal protein S4P   23660  10.0  203  15  102  4  54  97  4  32  0.9 
B0B8J2  CTL0881  rpsT  SSU ribosomal protein S20P  10826  11.2  3  2  0  0  ND  ND  1  ND  EB 
B0B7R1  CTL0596  rpsU  SSU ribosomal protein S21P  6666  10.9  5  2  0  0  0  16  1  ND  EB 
           
     
                                           
Transport and binding Proteins 
   
                          
B0B8R1  CTL0054    
ABC transporter ATP-binding 
protein   28450  5.1  163  12  149  4  78  176  4  85  1.2 
B0B8R2  CTL0055     conserved hypothetical protein   44583  6.0  151  18  45  4  28  22  2  0  0.5 
B0B8R5  CTL0058  dppF 
ABC transport protein_ ATPase 
component   31012  9.6  122  12  69  4  42  22  3  6  0.3 
B0B8R6  CTL0059  dppD 
ABC transport protein_ ATPase 
component   35998  6.4  62  6  29  2  13  0  0  ND  RB 
B0B8V3  CTL0096     cation transporting ATPase   70483  6.8  229  20  269  4  162  98  4  4  0.4 
B0B8W1  CTL0104  dagA 
Na(+)-linked D-alanine glycine 
permease  48147  9.0  22  4  20  1  ND  0  0  ND  RB 
B0B8W7  CTL0110     preprotein translocase  12814  9.5  56  5  74  4  9  39  3  18  0.5 
B0B947  CTL0190     tyrosine-specific transport protein   43975  9.2  37  3  52  2  32  0  0  ND  RB 
B0B968  CTL0211     putative membrane transport protein   40022  9.2  19  3  13  1  ND  0  0  ND  RB 
B0B986  CTL0231     sulfate transporter   61653  8.5  45  5  47  2  34  0  0  ND  RB 
B0B9E1  CTL0289    
putative membrane transport/efflux 
protein  36145  7.0  22  3  15  3  13  0  0  ND  RB 
B0B9H5  CTL0323     ABC transport protein  37063  5.0  304  19  950  4  209  379  4  102  0.4      
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B0B9H6  CTL0324    
ABC transport protein_ ATP-
binding component   28948  6.7  137  8  126  4  80  37  2  5  0.3 
B0B9N7  CTL0384    
putative ABC-membrane transport 
protein_ inner membrane component   23602  9.0  69  5  29  4  6  10  2  6  0.4 
B0B9N8  CTL0385    
ABC transporter_ ATP-binding 
component   25536  5.8  82  7  26  3  7  20  2  0  0.7 
B0B9P7  CTL0394  oppA 
oligopeptide transport system 
binding protein   48310  6.3  121  13  68  3  35  18  1  ND  0.3 
B0B9R0  CTL0407    
lipoprotein release ATP-binding 
component   25028  6.5  95  7  28  4  12  16  4  1  0.6 
B0B9S5  CTL0427  oppA2 
Oligopeptide transport system 
binding protein   60307  6.2  62  7  21  1  ND  0  0  ND  RB 
B0B9U4  CTL0446  mgtE  magnesium transport protein   51411  4.9  142  12  69  4  54  15  2  0  0.2 
B0B9Y1  CTL0482    
putative sodium:dicarboxylate 
symport protein   45049  8.4  37  4  96  3  50  20  1  ND  0.2 
B0B7R7  CTL0602    
ABC transporter_ ATP-binding 
component   58876  5.3  239  24  89  4  46  46  4  3  0.5 
B0B7R9  CTL0604     putative lipoprotein   63471  6.0  40  3  0  0  ND  33  1  ND  EB 
B0B7S1  CTL0606  secG  preprotein translocase   11088  4.3  79  4  195  4  195  27  4  14  0.1 
B0B7V0  CTL0636  artJ 
arginine transport substrate-binding 
protein   28570  4.9  127  16  234  4  138  94  4  22  0.4 
B0B7Y5  CTL0672    
metal transporter_ metal-binding 
component   31462  6.9  49  4  15  2  15  0  0  ND  RB 
Q6GX35  CTL0716  tarp 
Translocated actin-recruiting 
phosphoprotein  103252  4.1  339  35  134  4  13  55  3  5  0.4 
B0B852  CTL0740  oppB2 
oligopeptide transport system 
membrane permease   53123  7.2  90  13  55  3  32  0  0  ND  RB 
B0B853  CTL0741  oppA4 
oligopeptide transport system_ 
binding protein   79929  5.0  270  37  97  4  59  22  1  ND  0.2 
B0B859  CTL0747  fliY  glutamine-binding protein   28974  6.9  96  10  209  4  83  97  4  22  0.5            
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B0B8B8  CTL0806  uhpC  putative sugar phosphate permease   51668  8.6  107  16  143  4  98  29  1  ND  0.2 
B0B8H3  CTL0862  tolB 
outer membrane component of 
membrane transport system  47567  9.0  122  12  18  3  5  0  0  ND  RB 
 
a = Molecular mass (kDa) were calculated using ProteinLynx Global Server Ver 2.3. 
b= Isoelectric points were calculated using ‘Compute pI ‘ (ExPASy bioinformatics resource portal) 
c= Total number of peptides used to assign a protein. 
d= Total number of unique peptides used to assign a protein. 
e= Quantity of each assigned protein in EBs or RBs expressed as molecules per cell. 
f= Calculated standard deviation of biological and technical replicates for each developmental form. 
 
 